CA2103059C - Method for making humanized antibodies - Google Patents

Method for making humanized antibodies Download PDF

Info

Publication number
CA2103059C
CA2103059C CA002103059A CA2103059A CA2103059C CA 2103059 C CA2103059 C CA 2103059C CA 002103059 A CA002103059 A CA 002103059A CA 2103059 A CA2103059 A CA 2103059A CA 2103059 C CA2103059 C CA 2103059C
Authority
CA
Canada
Prior art keywords
antibody
residue
variable domain
human
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002103059A
Other languages
French (fr)
Other versions
CA2103059A1 (en
Inventor
Paul J. Carter
Leonard G. Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24873346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2103059(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to CA002481259A priority Critical patent/CA2481259A1/en
Publication of CA2103059A1 publication Critical patent/CA2103059A1/en
Application granted granted Critical
Publication of CA2103059C publication Critical patent/CA2103059C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F15/00Digital computers in general; Data processing equipment in general
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Computer Hardware Design (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

Description

W~ 92/22653 ~ ~ Q ~ ~ ~ ~ PCI'/US92/U5126 METHOD FOIL h9Ai~ING-HUMANIZED ANTIBODIES.
i Field of the Invention This invention relates to methods for the preparation and use of variant antibodies and 1o finds application particularly in the fields of immunology and cancer diagnosis and therapy.
t3~kg_r~~ of the Inven~i~n Naturally occurring antibodies (immunogfobulins) comprise two heavy chains linked Z5 'together by disulfide bonds and two light chains, one light chain being linked to each of the heavy chains by disulfide bonds. Each heavy chain has at one end a variable domain (V,~) followed by a number of constant domains. Each light chain has a variabie domain 4~J~) at one end and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is 2o aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light end heavy chain variable domains, see e.g.
Chothia et al., J lNol. Biol. 186:651-868 (1985); Novotny and Naber, 'roc.
Matt. Aca~f Sci.
USA 8:4592-4596 (1985).
The constant domains are not involved directly in binding the antibody to an antigen, 25 but are involved in various effector functions, such as participation of the antibody in antibody-dependent ~ellufar cytotoxicity. The variabl~ domains of each pair of tight and heavy chains are involved directly pn binding the antibody to the antigen. The domains of natural light and heavy chains have the sarcie general structure, and each domain comprises four framework (FR) regions, whose sequences are somewhat conserved, connected by three hyper-variable 30 or complementarity determining regions tCDRs) (see tCabat, E. A. et al., See~s~errces of Pr~teens of Imenunoldgecal lnte~est, National institutes of He~9th, Bethesda, ~!I~, (198?)). The four framework regions largely adopt a ~-sheet conformation and the CCRs form loops connecting, and in some cases forming part of, the ~-sheet structure. The CDRs in each chain are held ire close proximity by the framework regions and, with the CDRs from the other chain, contribute z ~c-rlu~~~eom26 W~ 92!22653 to the formation of the antigen binding site.
Widespread use has been made of monoclonal antibodies, particularly those derived from radents including mice, however they are frequently antigenic in human clinical use. For example, a major limitation in the clinical use of rodent monoclonal antibodies is an anti-globulin response during therapy (Miller, R. A. et al., Blood 62:988-995 (1983); Schroff, R. W. et al., Cancer Res. 45:879-885 41985)).
The art has attempted to overcome this problem by constructing "chimeric"
antibodies in which an animal antigen-binding variable domain is coupled to a human constant domain (Cabilly et al., U.a. patent No. 4,816,56?; IVlorri~on, S. L. et al., Proc.
Natl. .~lcad. Sci. UBA
81:6851-6855 41984); Boutianne, G. L. et al., Nature 312:643-646 (1984);
Neuberger, M. S.
et al., Nature 314:268-270 (1985)). The term "chimeric" antibody is used herein to describe a polypeptide comprising at least the antigen binding portion of an antibody molecule linked to at least part of another protein (typically an immunogiobuiin constant domain).
The isotype of the human constant domain may be selected to tailor the chimeric °~ antibody for participation in antibody-dependent cellular cytotaxicity (ADCC) and complement-dependent cytotoxicity (see e.g. Bruggemann, l~If. et al., J. Exp.
IVled.
186:1351-1361 (1987); Riechmann, L. et al., Nature 332:323-327 (1988); Love et al., IVlethods in Enzymology 178:515-527 (1989): Bindon et al., J. Exp. MecJ.
168:127-142 1988).
2o In the typical embodiment, such chimeric antibodies contain about one third rodent 4or other non-human species) sequence and thus are capable of eliciting a significant anti-globulin response in humans. For example, in the case of the murine anti-CD3 antibody, ~KT3, much of the resulting anti-globulin response is directed against the variable region rather than the constant region tJaffers, G. J. et al., transplantation 41:572-578 11986)).
In a further eff~art to resolve the antigen binding functions of antibodies and to minimize the us~ of h~terologous sequences in human antibodies, Winter and colleagues (Jones, P. T.
et al., Nature 321:5'22-525 (1986): Riechmann, L. et al., Nature 332:323-327 11988);
Verhoeyen, iVi. etal., Science 239:1534-1536 (1988)) have substituted rodent CDRs or CDR
sequences for the corresponding segments of a human antibody. As used herein, the term 30 ''humanized" antibody is an embodiment of chimeric antibodies wherein substantiaNy less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, hdmanized antibodies are typically human antibodies in which some CDR residues and possib6y some FR residues are substituted by residues from analogous sites in rodent antibodies.

,..,..r. '',, . . . ;'~, . . : .~ . ~', W092/2265~ 3 ~ ~ ~'~ ~~ ~ ~ PCT/US92/OS126 The therapeutic promise of this approach is supported by the clinical efficacy of a hs..~nanized antibody specific for the CAMPATH-1 antigen with two non-Hodgkin lymphoma patients, one of whom had previously developed an anti-globulin response to the parental rat antibody tRiechmann, L. et al., Nature 332:323-327 (1988); Hale, G. et ai., Lancet 1:1394-1399 (1988)). A murine antibody to the interfeukin 2 receptor has also recently been.
humanized (Queen, C. et ai., Prac. Nath Acad. Sci. USA 8f:10029-10033 (1989)) as a potential immunosuppressive reagent. Additional references related to humanization of antibodies include Co et al., Prac. Nat/. Acad. Sci. USA 88:2869-2873 11991 );
Gorman et al., Prac. Nat/. Acad. Sci. USA 88:4181-4185 (1991 ); Daugherty et al., G1/uc%ic Acids Research 19(9):2471-2476 t 1991 ); Brown et al., Proc. Nat/. Acad Sci. USA 88:2663-2667 t 1991 );
,lunghans et al., Cancer Research 50:1495-1502 11990).
In some cases; substituting CDRs from rodent antibodies for the human CDRs in human frameworks is sufficient to transfer high antigen binding affinity (Jones, P.
T, et al., Nature 321:522-525 t 1986): Verhoeyen, M. etal.; Science 239:1534-153611988)), whereas in other -cases it has been necessary to additionally replace one tRiechmann, L. et al"
Nature 332:323-327 t1988D? or several (Queen, C. et ai., Proc. Natl. Acad, Sci. USA
86:10029-10033 (1989)) framework region tFR1 residues. See also Co et al., supra.
For a given antibody a small number of FR residues are anticipated to be important for antigen binding. Firstly for example, certain antibodies have been shown to contain a few FR
residues which directly contact antigen in crystal structures of antibody-antigen complexes te:g:; reviewed in Davies, D. R: et al., Ann. Rev. Biochem. 59:439-473 11990)). Secondly, a number of FR residues have been proposed by Chothia, Lesk and colleagues lChothia, C. &
Lesk, A. M.; J. Mol. Bi~l. 196:901-917 11987); Chothia, C. et al.~, Nature 342:877-883 ti 989); Tramontano, A. et al.; J. Mol. Biol. 215:175-182 (1990)) as critically affecting the cpnformation of particular tDRs and thus their contribution to antigen binding. See also Margolies ef al.; Proc. lVatl. ~8cad. Sci. USA 72:2180-2184 11975).
It is also known that; in a few instances, an antibody variable domain (either V" or V~) may contain glycosylation sites; and that this glycosylation may improve or abolish antigen binding, Pluclcthun, Biotechnology 9:545-51 (1991 ); Spiegelberg etal., Biochemistry 9:4217-4223 (1970); Wal)ic ef al., J: Exp. Med. 168:1099-1109 11988); Sox etal., Prac. Nat/. Acad.
Sci: USA 66:975-982' (19701; Margni et al:, Ann. Rev. lmmunol. 6:535-554 (1988).
Ordinarily, however, glycosyl-. ion has: no influence on the antigen-binding properties of an antibody. Pluckthun, supra, t : a91 ).
The three-dimensional structure of irnmunoglobulin chains has been studied, and crystal Pi.'T/US92/05126 ~f structures for intact immunoglobulins, for a variety of immunoglobulin fragments, and for antibody-antigen complexes have been published (see e.g., Saul et al., Journal of Biological Chemistry 25:585-97 (1978); Sheriff etal., Prac. Nat/. Acad Sci. USA 84:8075-79 11987);
Segal et al,, Proc. Nat/. Acad. Sci. USA 71:4298-4302 11974); Epp et al., Biochemistry 14(22):4943-4952 (1975); Marquart et al., J. Mol. Biol. 141:369-391 11980);
Furey et al., J. Mol. Biol. 167:661-692 (1983); Snaw and Amzel, Protein: Structure, Function, and Genetics 1:267-279, Alan R. Liss, Inc. pubs. 11986): Chothia and Lesk, J. Mal.
Biol. 196:901-917 (1987); Chothia et al., Nature 342:877-883 (1989); Chothia et al., Science 233:755-58 (1986); Huber et al., Nature 264:415-420 11976); Bruccaleri et al., Nature 335:564-568 11988) and Nature 336:266 (1988): Sherman etal., JournalofBiological Chemistry 263:4064-4074(1988); Amzel and Pa)jak, Ann. Rev. Biochem. 48:961-67 (1979); Silverton etal., Proc.
Nat/. Acad Sci. USA ?4:5140-5144 11977); and Gregory et al., Molecular Immunology 24:821-829 (1987). It is known that the function of an antibody is dependent on its three dimensional structure, and that amino acid substitutions can change the three-dimensional ''structure of an antibody, Snow and Amzel, supra. It has previously been shown that the antigen binding affinity of a humanized antibody can be increased by mutagenesis based upon molecular modelling (Riechmann; L. etal., Nature 332:323-327 (1988): Queen, C.
etal., Proc.
Natl. Acad. Sci. USA 86:10029-10033 (1989)).
Humanizing an antibody with retention of high affinity for antigen and other desired biological activities is at present difficult to achieve using currently available procedures.
Methods are needed for ratibrralizing the selection of sites for substitution in preparing such antib~dies and thereby increasing, the efficiency of antibody humanization.
The proto-onco~ene HER,2 (human epidermal growth factor receptor 2) encodes a protein tyrosine kinase tp'185HER2'that is related to and somewhat homologous to the human epidermal growth factor receptor lsee CoussenS, L. et al., Science 230:1132-1139 (1985);
Yamamoto; T. et al., Nature 319:230-234 (1986); King, C. R, et al., Science 229:974-976 1985)). HER2 is also known in the field as c-erbB-2, and sometimes by the name of the rat homolog, neu. AmpiifiGation and/or overexpression of HER2 is associated with multiple human malignancies and appears to be integrally involved in progression of 25-30°~ of human breast ' 30 and ovarian cancers tSP'amon, D. J. et al.; Science 235:177-182 (1987), Siamon, D. J. et al., Science 244:707-712 E 1989)): Furthermore, the extent of amplification is inversely correlated with the observed median patient survival time (Slamon, supra, Science 1989).
The murine monoclonal antibody known as muMAb4D5 tFendly, 13. M. et al., Cancer Res. 50:1550-1558 t1 X90)), directed against the extracellular domain, (ECD) of p185HER2, WO 92/22653 . ~ .i ~ ~ ~ ~ ~ PCT/US92/~512G
specifically inhibits the growth of tumor cell lines overexpressing p185RER2 in monolayer culture or in soft agar (Hudziak, R. M. et al., Molec. Cell. Biol. 9:1165-1172 (1989D; Lupu, R.
et al., Science 243:1552-1555 (1990)). MuMAb4D5 also has the potential of enhancing tumor cell sensitivity to tumor necrosis factor, an important effector molecule in 5 macrophage-mediated tumor ce!! cytotaxicity (Hudziak, supra, 1989; Shepard, H. M. and t_ewis, G. D. J. Clinical Immunology 8:333-395 (1988)). Thus muMAb4D5 has potential far . clinical intervention in and imaging of carcinomas in which p185H~R2 is averexpressed. The muMAb4D5 and its uses are described in PGT application WO 89/06692 published 27 July 1989. This murine antibody was deposited with the ATCC and designated ATCC CRL
10463.
However, this antibody may be immunogenic in humans.
tt is therefore an object of this invention to provide methods for the preparation of antibodies which are less antigenic in humans than non-human antibodies but have desired antigen binding and other characteristics and activities.
It is a further object of this irwention to provide methods for the efficient humanization ~of antibodies; i.e. selecting non-human amino acid residues for importation into a human antibody background sequence in such a fashion as to retain or improve the affinity of the non human donor antibody for a given antigen.
It is another object of this invention to provide humanized antibodies capable of binding pIB~HER2 2o C?ther objects; features, and characteristics of the present invention will became apparent upon consideration of the following description and the appended claims.
~ummaw of the invention The objects of this invention are accomplished by a method for making a humanized antibody comprising amino acid sequence of an import, non-human antibody and a human antibody, c~mprising the steps of:
a. obtaining the amino acid sequences of at least a portion of an import antibody variable darnain and of a consensus variable domain;
b. identifying Complementarily Determining Region (CDR) amino acid sequences in the import and the human variable domain sequences;
c. substituting an impart CDFi amino-acid sequence far the corresponding human CDR amino acid sequence;
d. aligning the ameno acid sequences of a Framework Region (FR) of the import ".': -'. .'. , .n'. . , "' ; .;~ ,:.. . :.. ~', ... ;;
.. ... ,.,, .,-.,;... ..... ,:.. > "...; .. ,.,..... ~ , ...' :.!.~: . , ,.;
~...,.. . . ' : .. ~ ~ . .. . a W~ 92/22653 ; ', . 6 PGT/US921~5126 antibody and the corresponding FR of the consensus antibody;
e. identifying impart antibody FR residues in the aligned FR sequences that are non-homologous to the corresponding consensus antibody residues;
f. determining if the non-homologous import amino acid residue is reasonably expected to have at least one of the following effects:
1. non-covalantly binds antigen directly, 2. interacts with a CDR; or 3. participates in the VL - VH interface: and g, for any non-homologous import antibody amino acid residue which is reasonably expected to have at least one of these effects, substituting that residue for the corresponding amino acid residue in the consensus antibody I~R sequence.
f3ptionally, the method of this invention comprises the additional steps of determining if any non-homologous residues identified in step te) are exposed on the surface of the domain or buried within it, and if the residue is exposed but has none of the effects identified in step r 15 rtf), retaining the consensus residue.
Additionally; in certain embodiments the method of this invention comprises the feature wherein the corresponding consensus antibody residues identified in step (e) above are salect~d from the group consisting of 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, COL; 71 L, ?3L, 85L; 8?L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 20 45H, 49H, 58H, 60H; 67H, 68H; 69H, ?~DH, ?3H, ?4H, 75H, 76H, ?8H, 91 H, 92H, 93H, and t03H tutilizing the numbering system set forth in Rabat, E. A. et al., SeQuences of Proteins of trrrmunologica! Inter~~t (National Institutes of Health, Bethesda, MD, 1987)).
in certain embodiments; the method of this invention comprises the additional steps of searching either or both of the import, non-human end the consensus variable domain 25 sequences for glycosylation sites, deternnining if the glycosytation is reasonably expected to be irnportarvt for the desired antigen binding and biological activity of the antibody (i.e., determinincd if the glycosyiation site binds to antigen or changes a side chain of an amino acid residue that binds to antigen, or if the glycosytation bnhanees or weakens antigen binding, or is important for maintaining antibody affiriityD: If the import sequence bears the glycosylation 3p site, it is preferred to Substitute that site for the corresponding residues in the consensus human if the glycosyiation site is re~sonat~ly expeoted to be important. if only the consensus sequence, end hot the import; bears the gtycosyfati~n site, it is preferred to eliminate that glycosyiation site or substitute therefor'ths corresponding amino acid residues from the import s~q~ience:

,.' .. :s: ;..,.,. . ... ., ::; ,;~' .. . 'v . . '.': :v..-; .,::'.' ,;: ~: ,:
v.
W~ X2/22653 ~ ~, o ~ ~ PLT/US92/05126 Another embodiment of this invention comprises aligning import antibody and the consensus antibody FR sequences, identifying import antibody FR residues which are non-homologous with the aligned consensus FR sequence, and far each such non-homologous import antibody FR residue, determining if the corresponding consensus antibody residue represents a residue which is highly conserved across all species at that site, and if it is so conserved, preparing a humanized antibody which comprises the consensus antibody amino acid residue at that site.
Certain alternate embodiments of the methods of this invention comprise obtaining the amino acid sequence of at feast a portion of an import, non-human antibody variable domain 1o having a CDR and a FR, obtaining the amino acid sequence of at least a portion of a consensus antibody variable domain having a CDR and a FR, substituting the non-human CDR
for the human CDR in the consensus antibody variable domain, and then substituting an amino acid residue for the consensus amino acid residue at at least one of the following sites:
a, tin the FR of the variable domain of the tight chain) 4L, 35L, 36L, 38L, 43L, '~ ~ 44L, 58L, 46L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, ?OL, 71 L, 73L, 85L, 87L, 98L, or b. tin the FR,of the variable domain of the heavy chain) 2H, 4H, 24H, 36H, 37H, 39H; 43H, 45H; 49H, 58H, 60H, 67H, 68H, 69H, 70H, ?3H, 74H, 75H, 76H, ?8H, 91 H, 92H, 93H, and 103H.
In preferred embodiments, the non-CDR residue substituted at the consensus FR
site is the residue found at the corresponding location of the non-human antibody.
Dptionally, this just-recited embodiment comprises the additional steps of following the method steps appearing at the beginning of this summary and determining whether a particular amino acid residue can reasonably be expected to have undesirable effects.
This invention also relates to a humanized antibody comprising the CDR
sequence of an irnp~rt, non-human antibody and the FR sequence of a human antibody, wherein an amino acid residue within the human FR sequence located at any one of the sites 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L64L, 65L; 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H; 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91 H92H, 93H, and 103H has been substituted by another residue.
In preferred embodiments, the residuq substituted at the human FR site is the residue found at the corresponding location of the non-human antibody from which the non-human CDR was obtaified. In other embodiments, no human FR residue other than those set forth in this group has been substituted.

1 and SEQ. 1D NO. 3, respectively). FIGURE 1 B shows the comparison between the VH
domain amino acid residues of the muMAb4d5, huMAb4D5, and a consensus sequence (Fig_ 1 B, SEQ. ID N0. 6, SEO. 1D N0. 2 and SEQ. ID NO. 4, respeciively)_ Both Figs 1 A and 1 B
use the generally accepted numbering scheme from Kabat, E. A., et al , Sequences of Proteins of Immunologicallnterest (National Institutes of Health, Bethesda; MD
(1987)). !n both Fig_ 1 A and Fig. i B, tfie CDR residues determined according to a standard sequence definition (as in Kabat, E. A. et al., Sequences of Proteins oflmmunologicallnterest (National Institutes of Health, Bethesda, MD, 1987)) are indicated by the first underlining beneath the sequences, and the CnR residues determined according to a structur<~I
definition (as in Choihia, C. & Lesk, A. M., J. MoL Biol. 19fi:901-917 (1987)) are indicated by the second, lower underlines. The mismatches between genes are shown by the vertical lines.
FIGURE 2 shows a scheme for humanization of muMAb4D5 Vt. and Vti by gene conversion mutagenesis.
FIGURE 3 shows the inhibition of SK-BR-3 proliferation by MAb4D5 variants.
Relative i 5 cell proliferation was determined as described (Hudziak, R. N1. et al., Molec. Cell. Biol.
9:1165-1172 (1989)) and data (average of triplicate determinations) are presented as a percentage of results with untreated cultures for muMAb4D5 (I), huMAb4D5-8 (n) and huMAb4D5-1 (I).
FIGURE 4 shows a stereo view of a-carbon tracing for a model of huMAb4D5-8 V~
and VH _ The CDR residues (Kabat, E. A. et al., Sequences of Proteins of ImmunologicaJ Interest (National Institutes of Health, Bethesda, MD, 1987)) are shown in bold and side chains of VH
residues A?1, T73, A78. S93, Y102 and V~ residues Y55 plus R66 (see Table 3) are shown.
FIGURE 5 shows an amino acid sequence comparison of V~ (top panel) and VH
(tower pane!) domains of the murine anti-CD3 monoclonal Ab UCHT1 (muxCD3, Shalaby et al., J.
Exp. Med. 175, 217-225 (1992) with a humanized variant of this;antibody (ImxC:1).sv I Also shown are consensus sequences (most commonly occurring residue or pair of residues) of the most abundant human subgroups, namely V~ K i and VH III upon which the humanized sequences are based (Kabat, E. A. et aL, Sequences of Proteins of ImmunolopicaJ Interest, 5'" edition, National Institutes of Health, Bethesda, MD, USA (1991)). The light chain sequences--muxCD3, )~tlxCD3 v 1 and huKl--correspond to SEQ.ID.NOs 16, 17, and i 8, respectively. 'The heavy chain sequences muxCD3, huxCD3v1 and hutd correspond to SEQ.
ID. NOs 19, 20, and 21 respectively. Residues which differ between muxCD3 and huxCD3v1 are identified by an asterisk ('), whereas those which differ between humanized and consensus sequences are identified by a sharp sign (ll). A bullet (°) denotes that a residue at this position has been found to contact antigen in one or more crystallographic structures of antibodylantigen complexes (Kabat et al., 1991; Mian, i_ S. et al , J. Mol_ Biol.
217, 133-151 (1991)). The location of CDR residues according to a sequence definition SUBSTITUTE SHEET

2/22653 ~ ~ ~ ~ ~ 'a ~ pCT/US92/0512b 'WU 9 amino acid residues of the muMAb4d5, huMAb4D5, and a consensus sequence (Fig.
1 B, SEQ
ID NO. 6, SEO.. ID NO. 2 and SECT. ID NO. 4, respectively). Both Figs 1 A and 1 B use the generally accepted numbering scheme from Kabat, E. A., et ai., Sequences of Proteins of lmmunological Interest (National Institutes of Health, Bethesda, MD (1987)).
In both Fig. 1A
and Fig. 1 B, the CDR residues determined according to a standard sequence definition tas in Kabat, E. A. et al" Sequences of Proteins of lmmunolagical Interest (National Institutes of Health, Bethesda, MD, 1987)) are indicated by the first underlining beneath tha sequences, and the CDR residues determined according to a structural definition (as in Chothia, C. & Lesk, A.
M., J, Mol. Biol. 996:901-917 (198?I) are indicated by the second, Lower underlines. The to mismatches between genes are shown by the vertical lines.
FIGURE 2 shows a scheme for humanization of muMAb4D5 VE and VH by gene conversion mutagenesis.
FIGURE 3 shows the inhibition of SK-BR-3 proliferation by MAb4D5 variants.
Relative cell proliferation was determined as described tHudziak, R. M. et al., Mo%c.
Cell. Biol.
'9 1165-1172 ( 1989)) and data (average of triplicate determinations) are presented as a percentage of results with untreated cultures for muMAb4D5 (I), huMAb4D5-8 (n) and huMAb4D5-1 (I).
FIGURE 4 shows ~ stereo view of a-carbon tracing for a model of huMAb4D5-8 V~
and VH . The CDR residues (Kabat, E. A: et aL, Sequences of Proteins of Immunological Interest (NationaE Institutes of Health, Bethesda, MD, 1987)) are shown in bold and side chains of VH
residues A71, T 73, A78, S93: Y 102 and VL residues Y55 plus R66 (s~e Table 3) are shown.
FIGURE 5 shows an amino acid Sequence comparison of V~ (top panel) and VH
(lower panel) domains of the murine anti-CD3 monoclonal Ab UCHT1 (muxCD3, Shalaby et al., J.
Exp. Med. 175, 217-225 ( 1992) with a humanized variant of this antibody (huxCD3v9). Also shown are consensus sequences (most commonly occurring residue or pair of residues) of the most abundant human subgroups, namely VL K 1 and VH II) upon which the humanized sequences are based (Kabat, E. A. et al.; Sequences of Proteins of Immuno%gical Interest, 5'"
edition; National institutes of Health; Bethesda, MD, USA (1991 )). The light chain sequences--muxCD3, huxCD3v9 and huKl--correspond to SEQ.ID.NOs 16, 17, and 18, respectively. The hea~ey chain sequences--muxCD3; huxCD3v9 and huKt--correspond to SEa.ID.NOs 19, 20, and 21; respectively: Residues which differ between muxCD3 and huxCD3v9 are identified by an asterisk ('" ), whereas those which differ between humanized and consensus sequences are identified by a sharp sign (#). A b~rllet (a) denotes that a residue at this position has been found to contact antigen in- one or more crystallographic structures of antibodyiantigen °nf, ,~'.~;r~~rt~:~~.a~y 7,~' a.'i%ji4rr~..~,~i&5il~su :~~'~d~~t~r ~
n,s~!~~r~t~.:al~a;. . <.u',~i~":x:..~,.~~r.~i<. ..":rk;sso.,:<:.a ; .tea., .:~..

17V0 92/22653 , . , complexes iKabat et al., 1991; Mian, t. S. et al., J. Mol. Biol. 217, 133-151 (1991 )). The location of CDR residues according to a sequence definition (Kabat et al., 1991 ) and a structural definition tChothia and t-esk, supra 1987) are shown by a line and carats t") beneath the sequences, respectively.
FIGURE 6A compares marine and humanized amino acid sequences for the heavy chain of an anti-CD18 antibody. H52H4-160 tSEa. ID. NO. 22) is the marine sequence, and pH52-8.0 tSECI. ID. N0. 23) is the humanized heavy chain sequence, pH52-8.0 residue 143S is the final amino acid in the variable heavy chain domain VH, and residue 144A is the first amino acid in the constant heavy chain domain CH1.
FIGURE 6s compares marine and humanized amino acid sequences for the light chain of an anti-CD18 antibody. H52L6-158 tSEQ. ID. NO. 24> is the marine sequence, and pH52-9.0 tSEQ. ID. NO. 25) is the Humanized light chain sequence. pH52-9.0 residue 128T is the final amino acid in the light chain variable domain VL, and residue 129V is the first amino acid in the light chain constant domain CL, ' Defiled Descrio~on of the Invention pefinition~
In general, the following words or phrases have the indicated definitions when used in the description, examples, and claims:
The mutine monoclonal antibody known as muMAb4D5 tFendly, B. M. et al., Cancer Res. 50:1550-1558 119901) is directed against the extracellular domain tECD) of p185HER2, The muMAb4D5 and its uses are described in PCT application W0 89/06692 published 27 July 1989. This marine antibody was deposited with the ATCC and designated ATCC CRt-10463.
Inthis description and claims, the terms muMAb4D5~ chMAb4D5 and huMAb4D5 represent marine, chimerized and humanized versions pf the mor~oclonai antibody 4D5, respectively.
A humanized antibody- for the purposes herein is an immunoglobulin amino acid sequence variant ar fragment thereof which is capable, of binding to a predetermined antigen and which comprises a FR region having substantially the amino acid sequence of a human immunoglobulin and a 'CDR having substantially the amino acid sequence of a non-human imenunogtobulirr.
'Generally, a humanized antibody has one ~r more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are referred to hereirt as "impbrt" residues, which are typically taken from an "import°' antibody domain, W~ 92/22653 ~ ~ ~ ~ ~ ~ ~ P~/vS92/05126 particularly a variable domain. An import residue, sequence, or antibody has a desired affinity and/or specificity, or other oesirable antibody biological activity as discussed herein.
In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains (Fob, Fab', F(ab')z, Fabc, Fv) in which all or substantially all of the CDR regions correspond to these of a non-human immunoglobulin and all ar substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
The humanized antibody optimally also will comprise at Least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Ordinarily, the antibody will contain both the light chain as well as at least the variable domain of a heavy chain. The i0 antibody also may include the CH1, hinge, CH2, CH3, and CH4 regions of the heavy chain.
The humanized antibody will be selected from any class of tmmunoglobufins, including IgM, IgG, IgD, IgA and Ig~, and any isotype, including IgG 1, IgG2, IgG3 and IgG~4. Usually the constant domain is a complement fixing constant domain where it is desired that the humanized antibody exhibit cytotoxic activity, and the class is typically IgG,. Where such ''cytotoxic activity is not desirable, the constant domain may be of the IgGz class. The humanized antibody may comprise sequences from mare than one class or isotype, and selecting particular constant domains to optimize desired effector functions is within the ordinary skill in the art.
The FR and CDR regions of the humanized antibody need not correspond precisely to the parent~t sequences, e.g., the import CDR or the consensus FR may be mutagenized by substitution, insertion or deletion of at least one residue so that the CDR or FR residue at that site does not correspond to either the consensus or the import antibody. Such mutations, however, wilt not be extensive. Usually, at least 75°~ of the humanized antibody,residues will correspond to those of the pareritat FR and CDR sequences, more often 90%, and mast preferably greater than 95,%.
In general, humanized antibodies prepared by the method of this invention are produced by a procoss of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences. Three dimensional immunoglabulin models are commonly available and are familiar to those skilled in the art.
Computer programs are available which illustrate and display probable three dimensional conformational structures of selected candidate immunoglobulin sequences.
Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunogtobulin to bind its antigen.

PC1'/US92/05126 Iz Residues that influence antigen binding are defined to be residues that are substantially responsible for the antigen affinity or antigen specificity of a candidate immunoglobulin, in a positive or a negative sense. The invention is directed to the selection and combination of FR
residues from the consensus and import sequence so that the desired immunoglobutin characteristic is achieved. Such desired characteristics include increases in affinity and greater specificity for the target antigen, although it is conceivable that in some circumstances the opposite effects might be desired. In general, the CDR residues are directly and most substantially involved in influencing antigen binding talthough not all CDR
residues are so involved and therefore need not be substituted into the consensus sequence).
However, FR
to residues also have a significant effect and can exert their influence in at least three ways:
They may noncovalently directly bind to antigen, they may interact with CDR
residues and they may affect the interface between the heavy and light chains.
A residue that nancovalently directly binds to antigen is one that, by three dimensional analysis, is reasonably expected to noncovalently directly bind to antigen.
Typically, it is a necessary to impute the position of antigen from the spatial location of neighboring CDRs and the dimensions and structure of the target antigen. In general, only those humanized antibody residues that are capable of forming salt bridges, hydrogen bands, or hydrophobic interactions are likely to be involved in non-covalent antigen binding, however residues which have atoms which are separated from antigen spatially by 3.2 Angstroms or less may also non-covalently 2p interact with antigen. Such residues typically are the relatively larger amino acids having the side chains with the greatest bulk; such as tyrosine, arginine, and lysine.
Antigen-binding FR
residues also typically will have side chains that are oriented into an envelope surrounding the solvent oriented face of a CDR which extends about 7 Angstroms into the solvent from the CDR domain and about 7 Angstroms on either side of the CDR domain, again as visualized by three dimensional modeling.
A residue that interacts with a CDR generally is a residue that either affects the conformation of the CDR polypeptide backbon~ ar forms a noncovalent bond with a CDR
residue side chain: Conformation-affecting residues ordinarily are those that change the spatial position of any CDR backbone atom IN; Ca, C, 0, C,B') by more than about 0.2 Angstroms.
' 30 ' Backbone atoms of CDR sequences are displaced far example by residues that interrupt or modify organized structures such as beta sheets, helices or loops. Residues that can exert a profound affect on the conformation of neighboring sequences include proline and giycine, both of which are capable of introducing bends into the backbone. Other residues that can displace backbone atoms are those that are capable of participating in salt bridges and hydrogen bonds.

WO ~Z/2~653 _ I~ ~ ~ ~ ~ ~ J ~~ . ~ ~ f'~/US92/05126 A residue that interacts with a CDR side chain is one that is reasonably expected to form a noncovalent bond with a CDR side chain, generally either a salt bridge or hydrogen bond. Such residues are identified by three dimensional positioning of their side chains. A salt or ion bridge could be expected to form between two side chains positioned within about 2.5 -3.2 Angstroms of one another that bear opposite charges, for example a lysinyl and a.
giutamyl pairing. A hydrogen bond could be expected to form between the side chains of residue pairs such as Beryl or threonyl with aspartyl or glutamyl for other hydrogen accepting residues). Such pairings are well known in the protein chemistry art and will be apparent to the artisan upon three dimensional modeling of the candidate immunoglobulin.
1o lmmunoglobulin residues that affect the interface between heavy and light chain variable regions t"the V~ - V" interface") are those that affect the proximity or orientation of the fiwo chains with respect to ane another. Certain residues involved in interchain interactions are already known and include V~ residues 34, 36, 38, 44, 46, 87, 89, 91, 96, and 98 and V" residues 35, 37, 39, 45, 47, 91, 93; 95, 100, and 103 (utilizing the nomenclature set forth '' n Kabat et al.; Sequences of Proteins of lmmunological Interest (National Institutes of Health, Bethesda, MD, 1987)1. Additional residues are newly identified by the inventors herein, and include 43t., 85L, 43H and 60H. While these residues are indicated for IgG
only, they are applicable across species: In the practice of this invention, import antibody residues that are reasonably expected to be involved in interchain interactions are selected for substitution into 20' the consensus sequence: It is believed that heretofore no humanized antibody has been prepared-with an intrachain-a>fecting residue selected from an import antibody sequence.
Since it is not entirely possible to predict in advance what the exact impact of a given substitution will be it may be necessary to make the substitution and assay the candidate antibody for the desired characteristic. These steps, however, are per se routine and welt within the ordinary skill of the art.
CDR and FR residues are deternnined according to a standard sequence definition tKabat et al. , Sequences of Proteins of lmmcen~lagical Interest, National institutes of Health, Bethesda MD (1987), and a structural definition tas in Chothia and Lesk, J. Mol. Bi~l.
196:901-917 (1987). Where these two methods result' in slightly different identifications of a CDR, the 3o structural definition is preferred, but the residues identified by the sepuence definition method are considered important FR residues for determination of which framework residues to import into a consensus ~equence.
Throughout this description; reference is made to the numbering scheme from Kabat, E. A., et el., Sequences of Proteins of lmmunological Interest (National Institutes of Health, WO 92/22653 ~ ~ ~ ~ ~ ~ ~ ~' I P(.'T/US92/OS126 ''i Bethesda, MD 11987) and (1991 ). In these compendiums, Kabat lists many amino acid sequences for antibodies for each subclass, and lists the most commonly occurring amino acid for each residue position in that subclass. Kabat uses a mefihod for assigning a residue number to each amino acid in a Listed sequence, and this method for assigning residue numbers has become standard in the field. The Kabat numbering scheme is followed in this description.
For purposes of this invention, to assign residue numbers to a candidate antibody amino acid sequence which is not included in the Kabat compendium, one follows the following steps. Generally, the candidate sequence is aligned with any immunoglobulin sequence or any consensus sequence in Kabat. Alignment may' be done by hand, or by computer using commonly accepted computer programs; an example of such a program is the Align 2 program discussed in this description. Alignment may be facilitated by using some amino acid residues which are common to mast Fab sequences. For example, the light and heavy chains each typically have two cysteines which have the same residue numbers; in V~ domain the two cysteines are typically at residue numbers 23 and 38, and in the VH domain the two cysteine residues are typically numbered 22 and 92. Framework residues generally, but not always, have approximately the same number of residues, however the CDRs will vary in size. For example, in the case of a CDR from a candidate sequence which is longer than the CDR in the sequence in Kabat to which it is aligned, typically suffixes are added to the residue number to indicate the insertion of additional residues (see, e.g. residues 'i OOabcde in Fig. 5). For candidate sequences which, for example, align with a Kabat sequence for residues 34 and 3f but have no residue betv~reen ther~n to align with residue 35, the number 35 is simply not assigned to a residue.
Thus, in humanization of an import variable sequence, where one cuts out an entire human or consensus CDR and r~places it with an import CDR sequence, (a) the exact number z5 of residues may be swapped, leaving the numbering the same, Ib) fewer import amine acid residues may be introduced than are cut, in w~Oich ease there will be a gap in the residue numbers, or (c) a larger number of'amino acid residues may be introduced then were cut, in which case the numbering will involve the use of suffixes such as 100abcde.
The terms "consensus sequence°' and "consensus antibody" as used herein refers to ' 30 ' an amine acid sequence which comprises the most frequently occurring amino acid residues at each location in ail immunoglobulins of any particular subclass or subunit structure. The consensus sequence may be based on immunogiobulins of a particular species or of many species. A "consensus" sequence, structure, or antibody is understood to encompass a consensus human sequence as described in certain embodiments of this invention, and to refer P~'1US92/0512G
'NVO 92/22653 ' 15 to an amino acid sequence which comprises the most frequently occurring amino acid residues at each location in all human immunoglobulins of any particular subclass or subunit structure.
This invention provides consensus human structures and consensus structures which consider other species in addition to human.
The subunit structures of the five immunogiobulin classes in humans are as follows:
IgG Y Y1, Y2, Y~, Y4 x or ~l (Y~2) (Ya~a) IgA a a1, a2 x or A (a~rz)" , (~2JI2)~

IgM ~ none ~ x or e1 (~.~zx~)s , G~.~z~z)s IgD a none x or /I (c3ax2) , (d~Jlz) IgE a none x or ~l (e~re2) , (E~12) (" may equal 1, 2, or 3) Pn preferred embodiments of an IgGY1 human c~nserysus sequence, the consensus variable domain sequences are derived from the most abundant subclasses in the sequence compilation of Kabat etal., Sequencesnf~roteins oflmmuncl~gicalfnterest, National Institutes of Health, Bethesda MD (1987), namely V~ x Subgroup I and Vy group Ill. In such preferred embodiments, the V~ consensus domain has the amino acid sequence:

SGSGTDFTLTISSLQPEDFATYYCQQYNSLPYTFGQGTKVEIKRT (SEQ. ID NO. S);
the VH consensus domain has the amino acid sequence:
EV~1LVESGGGLVQPGGSLRLSCAA~GFTFSf~YAMSWVRQAPGKGLEWVAVISENGGYTRYAD
SVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGTLVTVSS (SEQ.
ID NC. 4).
These sequences include consensus CDRs as well as consensus FR residues (see for eacample irk Fig. 1 ).
While not wishing to be limited to any particular theories, it may be that these preferred embodiments are less likely to be imrnunogenic ire an individuaa than less abundant subclasses.
however, in other embodiments, the consensus sequence is derived from other subclasses of human immunogiobulin variable domains: In yet other embodiments, the consensus sequence is derived from human constant domains.
Identity or homology with respect to a specified amino acid sequence of this invention is defined herein as the percentage of amino acid residues in a candidate sequence that are ' PCTlUS92/U5126 WO 92/22653 - , . ' , identical with the specified residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. None of N-terminal, C-terminal or internal extensions, deletions, or insertions into the specified sequence shall be construed as affecting homology. All sequence alignments called for in this invention are such maximal homology alignments. While such alignments may be done by hand using conventional methods, a suitable computer program is the "Align 2°' program far which protection is being sought from the U.S. Register of Copyrights (Align 2, by Genentech, Inc., application filed 9 December 1991 ).
"Non-homologous" import antibody residues are those residues which are not identical to the amino acid residue at the analogous or corresponding location in a consensus sequence, after the import and consensds sequences are aligned.
The term °'computer representation" refers to information which is in a form that can be manipulated by a computer. The act of staring a computer representation refers to the act ~ of placing the information in a form suitable for manipulation by a computer.
This invention is also directed to novel polypeptides, and in certain aspects, isolated novel humanized anti-p185HER2 antibodies are provided. These novel anti-p185HER2 antibodies are sometimes collectively referred to herein as huMAb4D5, and also sometimes as the light or heavy chain variable domains of huMAb4D5, and are defined herein to be any 2o polypeptide sequence which possesses a biological property of a polypeptide comprising the following polypeptide sequence:
DIO.MTt~SPSSLSASVGDRVTITCRASaDVNTAVAWYQQKPGKAPKLLIYSASFLESGVP
SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGO,GTKVEIKRT (SEQ. ID NO. 1, which is the light chain variable domain of huMAb4.D5); or EVQLVESGGGLV~PGGSLRLSCAASGFNIKDTYiHWVRQAPGKGLEWVARIYPTNGYTR
YADSVKGRFTfSADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDVWGQGTLV
TVSS (SECT. ID NO. 2, which is the heavy chain variable domain of huMAb4D5?.
30 "Biological property", as relates for example to anti-p185RER2, for the purposes herein means an in a~ivo effector or antigen-binding function or activity that is directly or indirectly performed by huMAb4D5 (whether in its native or denatured conformation).
Effector functions include p185HER2 binding, any hormonal or hormonal antagonist activity, any mitogenic or agonist or antagonist activity, any cytotoxic activity. An antigenic function means possession WO 92/22653 ~ ~ '~ ~ I . , PCT~US92/05126 I~
of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against t.::polypeptide sequence of huMAb4D5.
Biologically active huMAb4D5 is defined herein as a polypeptide that shares an effectar function of huMAb4D5. A principal known effector function of huMAb4D5 is its ability to bind to p185HERZ_ Thus, the biologically active and antigenically active huMAb4D5 palypeptides that are the subject of certain embodiments of this invention include the sequence of the entire translated nucleotide sequence of huMAb4D5; mature huMAb4D5; fragments thereof having a consecutive sequence of at Least 5, 10, 15, 20, 25, 30 or 40 amino acid residues comprising sequences from muMAb4D5 plus residues from the human FR of huMAb4D5; amino acid sequence variants of huMAb4D5 wherein an amino acid residue has been inserted N- or C-terminat ta, ar within, huMAb4D5 ar its fragment as defined above; amino acid sequence variants of huMAb4D5 or its fragment as defined above wherein an amino acid residue of huMAb4D5 or its fragment as defined above has been substituted by another residue, including ~~predetermined mutations by, e.g., site-directed or PCR mutagenesis;
derivatives of huMAb4D5 or its fragments as defined above wherein huMAb4D5 or its fragments have been covalent modified, by substitution, chemical, enzymatic, or other appropriate means, with a moiety other than a naturally occurring amino acid: and gtycosylation variants of huMAb4D5 tinsertion s~f a gtycosytation site or dehtion of any glycosylation site by deletion, insertion or substitution of suitable residues). Such fragments and variants exclude any potypeptide heretofore identified, includir~g~muMAb4D5 or any known polypeptide fragment, which are anticipatory order 35 U.S.C.102 as well as polypeptides obvious thereaver under 35 U.S.C.
103.
An "isolated" polypeptide means polypeptide which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous salutes. In preferred embodiments, far example, a polypeptide product comprising huMAb4D5 wilt be purified from a cell culture or other synthetic environment t1 to greater than 95% by weight of protein as determined by the Lowry method, and most preferably mare than 99°~ by weight, i2) to a degree sufficient to obtain at least 15 residues of N-terminal ar internal amino acid sectuence by use of a gas- ar liquid-phase sequenator tsuch as a commercially availabt~, Applied Biasystems sequenator Model 470, 477, or 4731, or t3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. isolated huMAb4D5 includes huMAb4D5 in,~tu within recombinant P~GT/US9~/OS1Z5 WO 92/2653 ' -t$
Gcll$ since at least or~~ component of the huMAb4D5 natural envirorlrr~ent will not be present.
Drdinarity, however, Isolated huMAb4I~5 will be prepared by at least one purification step.
in accordance with this invention. huMAb4D5 nucteiC acid is I~NA or DNA
containing greater than ten bases that encodes a biologically or antigenically active huMAb4D5, is complementarlr to nucleic acid sequence encoding such huMAb4D5. or hybridizCS
tb nuCIeiC
acid sequence encoding such huMAb~t05 and remains sfabty bound to it under stringent conditions, and comprises nuClt~ic acid from s muMAb4D5 CDR and a human FR
region.
Preferably. the huMAb4a5 riucleic~f~cid ~sncodes a palypeptida sharing ax least 75°~6 sequenaa idantixy, more preferably at least BO°/s, still more praf8tably at l6ast 8596, oven more i0 preferably at 90%, and most prCfarabty 959b, with the huMAb4D5 amino acid sos~uance.
Preferably, a nucleic acid molecule that hybridizes to the huMAb4D5 nucleic said contains at . least 20, more proferably.. Vin, and most preferably 9D bases. Such hybridizing or comrilementary nucleic acid, however, is further defined as being novel under 35 U-S.C. 10~
and unobvious under 35 U:S.~. t 03 over any prior art nuCleiC acid.
is ~' ~ Stringent conditions era those that f 1 i employ law ionic svength and high temperature for washing, for exempts, O.Oi S M NaC110.00t 5 M sodium citratel0/1 %
NaDodSO; at 80° G:
t2) employ during hybridixatlon a ,denaturing agent such as formamide, for example, &096 lvol/vol) .formamide with 0:9 96~ bavina serum albuminl0ll °.6 ~colh~l9 °~ polyvinylpyrrolidona150 mM sodium~phosphate. buffer at pH 6.,6 with 75o rnM NaGI, T5 mM sodium citrate at 42° G:
D' v w or: (3) employ 5096 form>~mida, 6.x';SSC 10.76 M, NeCI, 0.0'Y5 M sodium Gitratef, 50 mM
sodiury phosphate lphl f.$i. O-t °.~ sQdlum pyrophosphate, 5 x D$nhardt's solution, sonicaxed .. $atmowsperm DNA I50.g1m11, 0.1:% SDS. and 1096 dextran sulfate at 4~ C, with washes at - . ~,~ C in 0.2 x SSC arid 0.~1.% S~S..
w . ~ Tha~term .'cant~ol sequerzc~s" refers to UNA soquertces necessary for the expression ~f:':an~operabty linkqdycoding. sequence yin a.parti.uuler host organism. The Contr4l Setluencss ' , that era suitable for-~~prokaryotes, for example; include a promoter.
aptionaliy an operattrr $equence,~ a ribosome binding site; and possibly, other as yet poorly understood sequences.
Eukaryotic cells. are knows to utiliaa promoters, polyadenylation signals and enhancers.
Nucleic acid is "oparably linked." when it is placed into a functional relationship with ~' so ancrthar nucleic acrd sequence: °FCir example, 17NA for a presaqu~nce or secretory leader is Qperpbly,lihked to DNA for a polypeptide if it is expressed as $ grpprptein that participates in the. secretion' of the ~ potypeptide; a promoter ~or enhanaor is aperably linked to a Coding sequence if It affects the transcription of the seguence; ar a ribosome binding site is aperably linked ~to a ,coding ~ sequersce ii it is positioned. so as to facilitate translation. Generally, *-trademark _WO 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT%US92/05126 1 '~
"operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.
An "exogenous" element is defined herein to mean nucleic acid sequence that is foreign to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is ordinarily not found.
As used herein, the expressions "cell,"~ "cell line," and "cell culture" are used 1o interchangeably and all such designations include progeny. Thus, the words "transformants"
and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that alt progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell '"'are included. Where distinct designations are intended, it will be clear from the context.
"Oiigonucleotides" are short-length, single- or double-stranded polydeoxynucleotides that are chemically synthesized by known methods (such as phosphotriester, phosphate, or phosphoramidite chemistry, using solid phase techniques such as described in EP 266,432 published 4 May 1988, o~ via deoxynucleoside H-phosphonate intermediates as described by Froehler et a6.; Nu_cl__ Acids Res., 14: 5399-5407 ( 19861). They are then purified on polyacrylamide gels:
The technique of "polymerase bhain reaction," or "PCR," as used herein generally refers to a procedure wherein minute amounts of a specific piece of nucleic acid, RNA
and/or DNA, are amplified as described in U.S. Pat. No. 4;683,195 issued 28 July 1987.
Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences; specific DNA sequences from total genomic DNA, and cDNA
3o transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally Mullis et aL, Cold Sarinca Harbor- Symn. Quant. Biol., ,~: 263 (1987); Erlich, ed., P R
Technoioav: tStockton f~ress, NY; 1989). As used herein, PCR is considered to be one, but not the only, example of a nucleic acid polyrryerase reaction method for amplifying a nucleic acid 'test sample, comprising he use of ~ known nucleic acid (DNA or RNA) as a primer and ~:~U~~J~
WO 92/22$53 ~ PGT/US92/0~126 ,, zo utilizes a nucleic acid polymerise to amplify or generate a specific piece of nucleic acid or to amplify or generate a specific piece of nucleic acid which is complementary to a particular nucleic acid.
Su~able Metho~i~ for Practicing ~h~ Invention Some aspects of this invention include obtaining an import, non-human antibody variable domain, producing a desired humanized antibody sequence and for humanizing an antibody gene sequence are described below. !~ particularly preferred method of changing a to gene sequence, such as gene conversion from a non-human or cons~nsus sequence into a humanized nucleic acid sequence, is the cassette mutagenesis procedure described in ~xampl8 1. Additionally, methods are given for obtaining and producing antibodies generally, which apply equally to native non-human antibodies as well as to humanized antibodies.
Generally, the antibodies and antibody variable domains of t6rois invention are i5 'conventionally prepared in recombinant cell culture, as described in more detail below.
Recombinant synthesis is preferred for reasons of safety and economy, but it is known to prepare peptides by chemical synthesis and to purify them from natural sources; such preparations are included within the definition of antibodies herein.
2o Molecular Modeling An integral step in our approach to antibody humanization is construction of computer graphics models of the import and humanized antibodies. These models are used to determine if the six complementarity-determining regions (CDRs? can be successfully transplanted from the import framework to a human one and to determine which framework residues from the 25 import antibody: if any, need-to be incorporated into the humanized antibody in order to maintain CDR conformation. In addition, analysis of the sequences of the import and humanized antibodies and reference to the- models can help to discern which framework residues are unusual and hereby might be involved in antigen binding or maintenance of proper antibody structure.
30 All of the humanized antibody models of this invention are based ~an a single three-dimensional'computer graphics structure hereafter referred to as the consensus structure. This consensus structure is ~ key distinction from the qpproach of previous workers in the field, who ty~icalty begin by selecting a human antibody structure which has an amino acid sequence which is similar to tl~e sequence of their import antibody.

WO 92/22653 . ~ ~ ~ ~ ~ ~ PC"f/US92/05126 z~
The consensus structure of one embodiment of this invention was built in five steps as described below.
Step 1: Seven Fab X-ray crystal structures from the Brookhaven Protein Data Bank were used (entries ZFB4, 2RHE, 3FAB, and 1 REI which are human structures, and 2MCP, 1 FBJ, and 2HFL which are murine structures). For each structure, protein mainchain geometry and hydrogen bonding patterns were used to assign each residue to one of three secondary structure types: alpha-helix, beta-strand or other (i.e. non-helix and non-strand). The immunoglobutin residues used in superpositioning and those included in the consensus structure are shown in Table 1.

aWWO 9WZ26s3 PCT/'U~'~2/OS126 ~Z
Table I
Immunoglobulin Residues in Superpositioningand Those Used Included in the Consensus Structure ~l,t~ domain Iga 2FB4 2RIiE 2MCP 3FAB iFBJ 2I~'~. 11tE1 Consensush 60-56 62-58 57-72 53-65 60=65 50-55 61-66 59-77 RMSe 0.40 0.60 0.53 0.54 0.48 0.50 VB domain Iga 2hB4 2MCP 3FAB 1FBJ 2I~r. Consensusb ~~- 3-8 58-71 70-73 57-?0 58-71 58-71 66-?1 78-84 80-86 77-8~ 78-84 78-84 75-82 82_99 94-101 91-98 92-99 92-99 88-94 RMSe 0.43 0.85 0.62 0.91 RMSd 0.91 0.73 0.77 0.92 a Four-letter code Bank file.
for Protein Data b Residue numbers the crystalstructures ire from the Protein Data for taken Bank files. Residuenumbers f~r the consensus structure are according to Kabat et al.

c Root-mean-s9uare ation for (N,Ca;C) superimposed 2FB4.
devi in ~ atoms on d Root~aean-square atioa~ for (Id,Ca;C) superira~poscd2IIFL.
devi in ;~ atones on W(~ 92/22653 '~ ~ 0 ~ ~ j ~ PCT/US92/05126 z~
Step 2: Having identified the alpha-helices and beta-strands in each of the seven structures, the structures were superimposed on one another using the INSIGHT
computer program (Biosym Technologies, San Diego, CA) as follows: The 2FB4 structure was arbitrarily chosen as the template (or reference? structure. The ~FB4 was held fixed in space and the S other six structures rotted and translated in space so that their common secondary structural elements ti.e. alpha-helices and beta-strands) were oriented such that these common elements ware as close in position to one another as possible. (This superpositioning was performed using accepted mathematical formulae rather than actually physically moving the structures by hand.) t0 Step 3: With the seven structures thus superimposed, for each residue in the template (ZFB41 Fab one calpulates the distance from the template alpha-carbon atom (Ca) to the analogous Ca atom in each of th~ other six superimposed structures. This results in a table of Ca Ca distances for each residue pdsition in the sepuence. Such a table is necessary in order to determine which residue positions will be included in the consensus model. Generally, 15 '~if all Ca-Ca distances for a given residue position were ~ 1.0~, that position was included in the consensus structure. If for a given position only one Fab crystal structure was > 1.0~, the position was included but the outlying crystal structure was not included in the next step (for this position anlyl. In gene~al~ the seven ~B-strands were included in the consensus structure while some of the loops connecting the ~B-.strands, e.g.
complementarity-determining 20 regions (CDRs?, were not included in view of Ca divergence.
Step 4: For each residue which was included in the consensus structure after step 3, the average of the coordinates for individual mainchain N, Ca, C, O and C~
atoms were calculated. D~ae to the averaging procedure,- as well as variation in bond Isngth, band angle and dihedral angle among the crystal structures, this "average" structure contained some bond 25 lengths and angles which deviated from standard geometry. For purposes of this invention, "standard geometry" is understood to include geometries commonly accepted as typical, such as the compilation of bond lengths and angles from small molecule structures in Weiner, S.J.
et, al.; J. Artier. Chem. Soc., 106: ?65-784'(1984).
Step 5: In order to correct these deviations; the final step was to subject the 30 "average" structure t'o 50 cyc6e~ of energy minimization (DISCOVER program, Biosym Technologies) using the AMBER fllVeiner, S.J. er: al., J. Amer. Chem. S~c., 106: 765-784 (1984.x? parameter set with only the Ca coordinates fixed (i:e. all other atoms are allowed to mtDVe) (energy minimization is described belowl. This allowed any deviant bond lengths and angles to assume a standard (chemically acceptable) geometry. See Table It.

PCT/US92/OSl2G

2 'i Table II
Average Bond Lengths and Angles for "Average" (Before) and Energy-Minimized Consensus (After SO Cycles) Structures VLK V1,K Vg VH Standard before after before after Geometry (~) (A> (~) (~) (~) N-Ca 1.459(0.012)1.451(0.004)1.451(0.023)1.452(0.004)1.449 Ca-C 1.515(0.012)1.523(0.005)1.507(0.033)1.542(0.005)1.522 ~C 1.208(0.082)1.229(0.003)1.160(0.1??)1.231(0.003)1.229 C-N 1.288(0.049)1.33?(0.002)1.282(0.065)1.335(0.004)1.335 Ca-C~ 1.508(0.026)1.530(0.002)1.499(0.039)1.530(0.002)1.526 b C-N-Ca 123.5(4.2) 123.8(1.1) 125.3(4.6) 124.0(1.1) 121.9 N-Ca-C 110.0(4.0) 109.5(1.9) 110.3(2.8) 109.5(1.6) 110.1 Ca-C-N 116.6(4.0) 116.6(1.2) 11?.6(5.2) 116.6(0.8) 116.6 C~C 123.1 (4.1 123.4(0.6) 122.2(4.9) 123.3(0.4) 122.9 N ) N-Ca-C~110.3(2.1) 109.8(0.?) 110.6(2.5) 109.8(0.6) 109.5 C~-Ca-C111.4(2.4) 111.1(0.?) 111.2(2.2) .111.1(0.6)111.1 ~ialues in parentheses are standard deviations. Note that while some bond length and angle averages did not change appreciably after energy-minimization, the corresponding standard deviations arc reduced due to deviant geometries assuming standard values after energy-minimization. standard geometry values are from the AMBER forcefield as implennented in I)ISCOVEFt (Biosym Technologies).

~r:s::. -_-_"._,_ __,__ _..
.WO 92/22653 ~ ~ ~ ~ ~ ~ ~ P~/US9zio~1z6 zs The consensus structure might conceivably be dependent upon which crystal structure was chosen as the template an which the others were superimposed. As a zest, the entire procedure was repeated using the crystal structure with the worst superposition versus 2Ft34, i.e. the 2HFL Fab structure, as the new template Ireference). The two consensus structures corlnp8re favorably (root-mean-squared deviation of x.11 ~ for alt N, Ca and C
atoms).
Note that the consensus structure only includes mainchain IN, Co. C. a. CB
atoms) coordinates far only those residues which are part of a conformation common to all seven X
' ray cryøtal structures. Fvr iha Fob structures, these include the common ~
strands Iwhich comprisB two ~-shoat$1 and a few non-~DFi lobes which connect these -strands.
The >.o consensus structure does not include GDRs yr sidachains, both of which vary in their conformation. among the seven structures. Also, note that the consensus structure includes only the VL and VH domains.
This aansansus structure is u$ed as the archetype. It is not particular to any species.
aryd has only the basic sh~p~ without side chains. starting with this consensus structure the is ~-rinodal of any import, human, or humanized Fab can be constructed as follows. lJsing the amino said seQuence of tha..particular antibody VL and VH domains of interest, a computer graphics prv~ram iau~b as INSIGHT*Bio$ym Technologies) is used to add sidechains and CDRs to the congarysus strirctura. When a 'sidechatn is added, its conformation is chosen on the basis of knbwn Fab erystal structures lsee the Background acotian fw publications of such . Zo . ~ crystal struaturesl and rotamer libraries (Ponder. J.W. & Richards, F. M.. J. Mwi. Biol. 1g3:
77~-791 (t sa$7I1. The modet also. is constructed so that the atoms of the sidechain are positioned s4. as to not collid,a with other atoms in the s=ob. , CDRS are coifed to fthe model Inow having the backbone plus 5ida chains) as follows.
The- size Ii.e. number-.of amino acids? of each import GDR is compared to canonical CDR
as structuras.~tabuiated by Chothia et al., Nature, 342:877-883 ('I 9B9)1 and which ware derived from. Fab cnistals. Each CDR svquanca is also reviewed for the prssancs or absence of certain specific arinino acid rasiduas v~ihich era identified by Chathia as structurally important: e.g. light chain residues 29 (CCiR1 i and' 95' (GDR3), dnd heavy chain residues 26. 27.
29 IGDR1 f and 55 ICDR2?. For light chain .CpR2, and heavy chain CDR3, only the size of the GDR i5 3o compered to~the Chvtliia. canonical structure. if the size and sequence li_e. inctusiar< of the specific, structurally impartant~.residuas as denoted by Chothia et al.l of the import CdR agrees in size and ha$ the same structurally. important residues asr those of a canonical CPR, than the mainchsiwconfonnation of the irnpoft CDR in the model is taken to be the same as that of the canonical CDR- This means that the import seduance is assigned the structural configuration *-trademark _ ,, . ~v,.-,. -.;~:
,,, r ': ~: r..~.. ~:.; x, , . /,'~.~ZS:":' 7, ~~\ e.h.
~.~'1'~.":.' _1i :': .~,..,.. ., ... .
f..:rwl:~ ~~ , . .. ... ..
S ~.~' L. f '~,~iy,,' ' y..,ffS ~.~:,,~1,~; ~~~.
~ . ,S.~'n':~:~:~lf:n 7 .... ... 'f~.
5...: ..
wa gxiz~~~ ~ ~ ~ ~ Pcr~us9zro~rzra of the canonical ~(?R, which is then incorporated in the evolving model.
Wowevar, if no matcriing canonical CDR can be assigned far the import CDR, than one of two options can bs exercised. First, using a program such as INSIGHT
iRiosym Technologie$), the 8rookhavan protein Data Bank can bs searched far loops with a similar size to that of the import CDR and these loops can be evaluated as possible conformations for the .
import CDR in thn model. Minimally. such loops must sxhibtt a conformation in which na loop atom overlaps with other protein atoms. Second, one can use available Programs which calculate possible laop~ conformations. assuming a given loop size, using methods such as tiescribsd by ~r~coleri et at , Natwe 335: b6a-ggg t'1988).
Wh~n all CDRS and sidechains have been added to the aonsansus structure to give the final rrvodal timport. human or, humanixad), the model is preferably subjected to energy minimization using programs which era available commerCi811Y (a-g~ Ci~CaVpR;
BioBym Tpchnolog)as)'. This technique .uses complex mathematical formulae to refine the model by performing such tasks as ohecking.that ail atoms ors within appropriate distances from cue ~, 15 'another and checking that band lengths and angles are within chemically acceptable limits.
nnodels of ~a humanized, import, or human antibody sequence era used in the practice of thi3 invent;on to understand the impact' of selected amino acid re$idues of tire activity of the seqwanca being modet~d. For exarhple, such a model can show residues which may be important in antigen binding. br for ma)ntaining the conformation of the $ntit~ody, as discussed _ in mare detail below. Modeling can also be used to explore the potential impact of Gharlgin$
. sny amino~acid residue in the antibody sequence.
M ini tn the praatJce~ af,. tills : invention, the first stop in humanizing an irnPort antibody is deriving a aonsensirs amine acid. sequence into which to incorporate the import sequences.
HBO ~ ~Qdel. is.'gdnera~tad far.these sequences using the methods described above. in certain ~~b~imqnts of this lnvenxian~ the consensus human sequences are derived from the mast $bundant~ ~~~)assas- iri the' seqWenca ccmp)lation of Kabat et al. IKabat. !!.
A. et al..
Sd4uences of Proteins of lri~rmuriological interest National Institutes of Health: Etethesda. MD, 3p ~ 1987)1,, namely V4 K subgroup 1 arid VM group III, and have th$
setluances indicated in the ~
. . definitions above.. , . . Whileahese steps may. ba. takbn in different order, typically a structure for the Candidate h~ariized antibod~r is~'crpated by transfsrring~ the at least one GOR from the non-human.
import sequence into thd consensus human structure, after the entire corresponding human . *--trademark i .t~' ~ ...' ,. ~_,..~... .. . .;~.,' ' ...:.:.: , ':_~'_;... ... -.;....~
.~..~:.~ . ...:. , :~;' . ;-,,~.. .. ~:r:. ' . .,:, . ~, ~',,.;..' .::... ,.' ,:..; ,...,...:~ ..: w~...~.~. '....,,. .. ; .''. .
.:..:.~v . ~.~.~':.... ~,:. ~:.~ . '. ... ,.. ., , ....
WO 92/22653 ~ ~ ~ 1 Q j ~ ~ ~ PC'T/US921U512~b CDR has been removed. The humanized antibody may contain human replacements of the non-human import residues at positions within CDRs as defined by sequence variability (Kabat, E. A. et al., Seguences of Proteins of Immunoiagica! Interest (National Institutes of Health, Bethesda, MD, 1987)) or as defined by structural variability (Chothia, C. & t-esk, A. M., J. Mol.
Biol. 196:901-917 (1987)). For example, huMAb4D5 contains human replacements of the muMAb4D5 residues at three positions within CDRs as defined by sequence variability (Kabat, E. A. et al., Seguences of Proteins of lmmunoiogical Interest tNational Institutes of Health, Bethesda, MD, 1987)) but not as defined by structural variability (Chothia, C.
& Lesk, A. M., J. Mol. Biol. 196:901-917 (1987)): V~-CDR1 K24R, V~-CDR2 R54L and V~-CDR2 T56S.
Differences between the non-human import and the human consensus framework residues are individually investigated to determine their possible influence on CDR conformation and/or binding to antigen. Investigation of such possible influences is desirably performed through modeling, by examination of the characteristics of the amino acids at particular locations, or determined experimentally through evaluating the effects of substitution or t5 '"mutagenesis of particular amino acids.
In certain preferred embodiments of this invention, a humanised antibody is made comprising amino acid sequence of an import, non-human antibody and a human antibody, utilizing the steps of:
a. obtaining the amino acid sequences of at least a portion of an import antibody variable domain and of a consensus human variable domain;
b. identifying Complementarily Determining Region (CDR) amino acid sequences in the import and the human variable domain sequences;
c. substituting an import CDR amino acid sequence for the corresponding human CDR amino acid sequence;
d. aligning the amino acid sequences of a Framework Region (FR) of the import antibody and the corresponding FR of the consensus antibody;
e. identifying import antibody FR residues in the aligned FR sequences that are non-homologous to the corresponding consensus antibody residues;
f. determining if the non-homologous import amino acid residue is reasonably 3o expected to have at least one of the following effects:
1. r9on-covalently binds antigen directly, 2. interacts with a CDR; or 3. participates in the V~ - VH interface; and g. far any'non-homologous import antibody amino said residue which is reasonably ~~.03~~j WO 92l226S3 ~CT/US92/05126 2$
expected to have at feast one of these effects, substituting that residue for the corresponding amino acid residue in the consensus antibody FR sequence.
aptionally, one determines if any non-homologous residues identified in step te) are exposed on the surface of the domain or buried within it, and if the residue is exposed but has none of the effects identified in step tf), one may retain the consensus residue.
Additionally, in certain embodiments the corresponding consensus antibody residues identified in step te) above are selected from the group consisting of 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 6?L, 68L, 69L, ?4L, ?1 L, ?3L, 85L, 8?L, 98L, 2H, 4H, 24H, 36H, 3?H, 39H, 43H, 45H, 49H, 58H, 6tJH, 6?H, 68H, 69H, ?OH, ?3H, ?4H, ?5H, io ?6H, 78H, 91 H, 92H, 93H, and 1 ~D3H (utilizing the numbering system set forth in Rabat, E.
A. et al., SeQuences of Proteins of lmmunologica! Interest (National Institutes of Health, 8ethesda, nIID, 19871).
In preferred embodiments, the method of this invention comprises the additional steps of searching either or both of the import, non-human bnd the consensus variable domain ~~sequences for glycosylatian sites, determining if the glycosylation is reasonably expected to be important for the desired antigen binding and biological activity of the antibody ti.e., determining if the glycosylation site binds to antigen or changes a side chain of an amino acid residue that binds to antigen, or if the glycosyiation enhances or weakens antigen binding, or is important for maintaining antibody affinity). If the import sequence bears the glycosylation site, it is preferred to substitute that site for the corresponding residues in the consensus human sequence if the glycosylation site is reasonably expected to be important. if only the consensus sequence; and not the import, bears the glycosylation site, it is preferred to eliminate that glycosylation site or substitute therefor the corresponding amino acid residues from the import sequence.
Another preferred embodiment of the methods of this invention comprises aligning import antibody and the consensus antibody FR sequences, identifying import antibody FR
residues which are non-homologous with the aligned consensus FR sequence, and for each such non-homologous import antibody FR residue, determining if the corresponding consensus antibody residue represents a residue which is highly conserved across all species at that site, 3o and if it is so conserved, preparing a humanized antibody which comprises the consensus antibody amino acid residue at that site.
tn certain alternate embodiments, one need not utilize the modeling and evaluation steps described above, and may instead proceed with the steps of obtaining the amino acid sequence of ~t least a portion of an import, non-human antibody variable domain having a GDR and a FR, WC? X2/22653 ~ ~ ~ PCT/US92/~5126 obtaining the amino acid sequence of at least a portion of a consensus human antibody variable domain having a CDR and a FR, substituting the non-human CDR for the human CDR
in the consensus human antibody variable domain, and then substituting an amino acid residue for the consensus amino acid residue at at least one of the following sites:
a. tin the FR of the variable domain of the light chain) 4L, 35L, 36L, 38L, 43L, 44L, 58L, 46L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71 L, 73L, 85L, 87L, 98Lr or b. !in the FR of the variable domain of the heavy chain) 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60Hr 67H, 68H, 69H, 70H, 73H, 74Hr 75H, 76H, l0 78H, 91 H, 92H, 93H, and 103H.
Preferably, the non-C~R residue substituted at the consensus FR site is the residue found at the corresppnding location of the non-human antibody» If desired, one may utilize the other method steps described above for determining whether a particular amino acid residue can reasonably be expected to have undesirable effects, and remedying those effects.
' f if after making a humanized antibody according to the steps above and testing its activity one is not satisfied with . the humanized antibody, one preferably reexamines the potential effects of the amino acids at the specific locations recited above.
Additionally, it is desirable to reinvestigate any buried residues which are reasonably expected to affect the ~h -V" interface but may not directly affect CDR conformation. It is also desirable to reevaluate the humanized antibody utilizing the steps of the methods claimed herein.
In certain embodiments of this invention, amino acid residues in the consensus human sequence are substituted for by other amino acid residues. In preferred embodiments, residues from a particular non-human import sequence are su~st~tute~i, however there are circumstances where it is desired to evaluate the effects of other amino acids. For example, if after making a humanized antibody according to the steps above and testing its activity one is hot satisfied with the humanized antibody, one may compare the sequences of other classes or subgroups of human antibodies, or classes or subgroups of antibodies from the particular non-human species, and determine which other amino acid side chains and amino acid residues are found at particular locations and substituting such other residues.
Antibodies Certain aspects of this invention are directed to natural antibodies and to monoclonal antibodies, as illustrated in the Examples below and by antibody hybridomas deposited with the ATCC tae described below). Thus, the references throughout this description to the use ~~Q ~~ ~~ , V~IG 92/22653 PCT/US92/0512b of monoclonal antibodies are intended to include the use of natural or native antibodies as well as humanized and chimeric antibodies. As used herein, the term "'antibody"
includes the antibody variable domain and other separable antibody domains unless specifically excluded.
In accordance with certain aspects of this invention, antibodies to be humanized timport 5 antibodies) are isolated from continuous hybrid cell tines formed by the fusion of antigen-primed immune lymphocytes with myeloma cells.
in certain embodiments, the antibodies of this invention are obtained by rautine screening. Polyclonat antibodies to an antigen generally are raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections'of the antigen and an adjuvant. It may be 1o useful to conjugate the antigen or a fragment containing the target amino acid sequence to a protein that is immunogenib in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sultosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide tthrough lysine'residuesl, glutaraldehyde, succinic ~r iS anhydride, SOC12, or R'N = C = NR; where R and R' are different alkyl groups.
The raute and schedule of the host animal or cultured antibody-producing cells therefrom are generally in keeping with established and conventional techniques for antibody stimulation and production. While rnice are frequently employed as the test madel° it is contemplated that any mammalian subjECt including human subjects or antibody-producing 20 cells obtained therefrom can be manipulated according to the processes of this invention to serve as the basis for production of mammalian, including human, hybrid cell lines.
Animals are typically immunized against the immunogenic conjugates or derivatives by combining 1 mg or 1 ,ug of conjugate (for rabbits or mice, respectively) with 3 volumes of Freund°s complete adjuvant and injecting the solution intradermally at multiple sites. One 25 month later the animals are boosted with 1 /5 to 1 /10 the original amount of conjugate in Freund's complete adjuvant for other suitable adjuvant) by subcutaneous injection at multiple sites. 7 to 14 days later animals are-bled and the serum is assayed for antigen titer. Animals erg boosted until the titer plateaus. Preferably; the animal is boasted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking 30 agent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.
After immunization; monoclonal antibodies are prepared by recovering immune lymphoid cells--typically spleen cells or lymphocytes from lymph node tissue--from immunized animals and immortalizing the ceps in con~rentional fashion, e.g. by fusion with myeloma cells or by f .,r ~. . ~ .~.. , ~.~~ ~, ~ .. ... . . ,.,..,. ~~ ' .. ., . . ,." y WO 92/22653 ~ ~ ~ '~ ~ '~ '~ PCT/US92/U5126 3!
Epstein-Barr tEB)-virus transformation and screening for clones expressing the desired antibody.
The hybridoma technique described originally by ICohler and Milstein, Eur. J.
Irrrmunol. 6:51 1 ( 1976) has been widely applied to produce hybrid cell lines that secrete high levels of monoclonal antibodies against many specific antigens.
It is possible to fuse cells of one species with another. However, it is preferable that .
the source of the immunized antibody producing cells and the myeloma be from the same species.
The hybrid call lines can be maintained in culture in rritrp in cell culture media. The cell lines of this invention can be selected and/or maintained in a composition comprising the to continuous cell line in hypoxanthin~-aminapterin thymidine tMAT) medium. In fact, once the hybridoma cell line is established, it can be maintained on a variety of nutritionally adequate media. Moreover, the hybrid cell lines can be stored and preserved in any number of conventional ways. including freezing and storage under liquid nitrogen.
Frozen calf lines can be revived and cuttured indefinitely with resumed synthesis and secretion of monoclonal antibody. The secreted antibody is recovered from tissue culture supernatant by conventional methods such as precipitation, ton exchange chromatography, affinity chromatography, or the like. The antibodies described herein are also recovered from hybridoma celP
cultures by conventional methods for purification of IgG or IgM as the case may bs that heretofore have been used to purify these irnmunoglobulins from pooled plasma, e.g. ethanol or polyethylene 2o glycol precipitation procedures. ~'he purified antibodies are sterile filtered, and optionally are conjugated to a detectable marker such as an enzyme or spin label for use in diagnostic assays of the antigen in test samples.
While routinely rodent monoclonal antibodies are used as the source of the import antibody, the invention is not limited to any species. Additionally, techniques developed for the production of chirneric antibodies ~Morrison etal., Froc. Nall. cad. Sci., 81:6851 t1984);
Neuberger ef al., Nature 312:6~4 (1984); Takeda at al., Nature 314:452 t1985)) by splicing the genes from a mouse antipody molecule of appropriate antigen specificity together with ga3nes from a human antibody molecule o~f appropriate biological activity tsuch as ability to activate human complement and mediate ADCC) can be used; such antibodies are within the scope of this invention.
Techniques for creating recombinant DNA versions of the antigen-binding regions of antibody molecules (known ae Fab fragments) which bypass the generation of monoclonal antibt~dies are encornpassed within the practice of this invention. One extracts antibody-specific messenger RW 0. molecules from immune system cells taken from an immunized animal, .. :,.'... ;..; .... . ,w.., ' :, .. ,.. .'' ..:.: , :,; ;.: ,. .,'; ; ;;.:, .,..;; ,, . . :... , ,, . ...
WO 92/22653 , . PC1'/US92/05126 .
3z transcribes these into complementary DNA (cDNA), and clones the ,DNA into a bacterial expressions system. One example of such a technique suitable for the practice of this invention was developed by researchers at Scripps/Stratagene, and incorporates a proprietary bacteriophage lambda vector system which contains a leader sequence that causes the expressed Fab protein to migrate to the periplasmic space (between the bacterial cell membrane and the cell watt) or to be secreted. One can rapidly generate and screen great numbers of functional FAb fragments for those which bind the antigen. Such FAb fragments with specificity for the antigen are specifically encompassed within the term "antibody" as it is defined, discussed, and claimed herein. ' Aming Acid Seauence Variants Amino acid sequence variants of the antibodies and polypeptides of this invention (referred to in herein as the target polypeptidel are prepared by introducing appropriate nucleotide changes into the DNA encoding thb target polypeptide, or by in vitro synthesis of the desired target polypeptide. Such variants include, for example, humanized variants of non-human antibodies, as well as deletions from, or insertions or substitutions of, residues within particular amino acid sequences. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the target po[ypeptide; such as changing he number ar position of glycosylation sites, altering any membrane anchoring characteristics, and/or altering the intro-cellular location of the target polypeptid~ by inserting, deleting, ;or otherwise affecting any leader sequence of the native target polypeptide.
in designing, amino acid sequence variants of target polypeptides, the location of the mutation site and th~ nature of ' the mutation will depend an the target polypeptide Gharacteristicts) to' be modified. The sites for mutation can be modified individually or in series, e.g.; by t 1 ) substituting first v~ith conservative amine acid choices and then with more radical selections depending upon the results achieved, d2) deleting the target residue, or f3) inserting residues of the same'or a different class adjacent to the located site, ar combinations of options 1-3. tn certain embodiments, these choices are guided by the methods far creating humanized sequences set forth above.
A useful method for identification of certain residues or regions of the target polype~rtide that are preferred locafians far mutagenesis i~ called "alanine scanning mutagenesis" as described by Cunningham and Wells tS~,ience, 244: 1081-1085 (19891).

WU 92!22653 3 3~ ~ I~ ~ ~ j ~ PCT/t1S92/05126 Here, a residue or group of target residues are identified (e.g., charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably ~tanine or polyalanine) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensetivity to the substitutions then are refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, ala scanning or random mutagenesis may be conducted at the target codon ar region and the expressed target polypeptide variants are screened for the optimal combination of desired activity.
There are two principal variables in the construction of amino acid sequence variants:
the location of the mutation site and the nature of the mutation. In general, the location and nature of the mutation chosen will depend upon the target polypeptide characteristic to be -modified.
Amino acid sequence deletions of antibodies are generally not preferred, as maintaining the generally configuration of an antibody is believed to be necessary for its activity. Any deletions will be selected so as to preserve the structure of the target antibody.
Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging zo in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of singte or multiple amino acid residues.
Intrasequence insertions li.e., insertions within the target polypeptide sequence) may range generally from about 1 to 't 0 residues, more preferably 1 to 5, mast preferably 1 to 3, Examples of terminal insertions include the target polypeptide with an N-terminal methionyl residue, an artifact of the direct expression of target potypeptide in bacterial recombinant cell culture, and fusion of a heterologous N-terminal signal sequence to the N-terminus of the target polypeptide molecule to facilitate the secretion of the mature target polypeptide from recombinant host cells. Such signal sequences generally will; be otitair~ed from, and thus homologous to, the intended host cell species: Suitable sequences include STIt or Ipp for ~ call, alpha factor for yeast, and viral ssgnals such 'as herpes, gD for mammalian cells.
Other insertional variants of 'the target polypeptide include the fusion to the N- or C-tecminus of the target polypeptide of immunogenic polypeptides, e.g., bacterial polypeptides such as beta~lactamase ar an enzyme encoded by the E: coli trp locus, or yeast protein, and C-terminal fusions with proteins having a tong half-fife such as immunogiobulin constant ~~ 92/22653 ~ ~ ~ '~ ~ ') ~ ~ PCT/US92/05126 3 ~9 regions Ior other immunoglobulin regions), albumin, or ferritin, as described in WO 89/02922 published 6 April 1989.
Another group of variants are amino acid substitution variants. These variants have at least one amino acid residue in the target polypeptide molecule removed and a different residue inserted in its place. The sites of greatest interest for substitutional mutagenesis include sites identified as the active sites) of the target polypeptide, and sites where the amino acids found in the target poiypeptide from various species are substantially different in terms of side-chain bulk, charge, and/or hydrophobicity. Other sites for substitution are described infra, considering the effect of the substitution of ' the antigen binding, affinity and other characteristics of a particular target antibody.
Other sites of interest are those in which particular residues of the target polypeptides obtained from various species ara identical. These positions may be important for the biological activity of the target polypeptide. These sites, especially those falling within a sequence of at least three other identicalty conserved sites, are substituted in s relatively conservative manner. If such substitutions result in a change in biological activity, then other changes are introduced and the products screened until the desired effect is obtained.
Substantial modifications ire furictian or immunolagical identity of the target polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the palypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or tcl the bulk of th~ side chain. Naturally occurring residues are divided into groups based on common side chain properties:
t1 ) hydrophobic: norfeucine, met, ala> val, leu; ile; , t2) neutral hydrophilic: cys, ser, thr;
t3) acidic: asp, glu;
t4) basic: a5n, gln, his:' lys, arg;
(5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp; tyr, phe.
Non-conservative substitutions will entail exchanging a member of one of these classes ' 30 for another. Such substituted residues may be introduced into regions of the target polypeptide that are homologous with other antibodies of the same class or subclass, or, more preferably, into the non-homologous regions of the molecule.
any cysteine residues not involved' in maintaining the proper conformation of target polypeptide also may be substituted, generally with serine, to improve the oxidative stability ' ,;.. ...
WO 92/22653 . ~ ~ ~ J ~ ~ ~ PCg'/US92/U5126 3s of the molecule and prevent aberrant crasslinking.
DNA encoding amino acid sequence variants of the target polypeptide is prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source tin the case of naturally occurring amino acid sequence variants) or preparation by oligonucleatide-mediated (or site-directed) mutagenesis, PCR
mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of the target polypeptide. A particularly preferred method of gene conversion mutagenesis is described below in Example 1. These techniques may utilized target potypeptide nucleic acid tDNA or RNA), or nucleic acid complementary to the target polypeptide nucleic acid.
to Otigonucleotide-mediated mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of target polypeptide DNA. This technique is well known in the art as described by Adetman et al., _D_N~A, ~: 183 (1983). Briefly, the target polypeptide DNA
is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the target potypeptide. After hybridization, a DNA
potymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the otigonucleotide primer, and wilt code for the selected alteration in the target polypeptide DNA:
Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucteotide wilt have 12 to 15 nucleotides that are camptetely complementary to the template on either side of the nucleotidets) coding for the mutation. This ensures that the otigonucteotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crew et al. tProg: Na~rl. Acad. Sci. USA, ~: 6765 (19781).
Single-stranded DNA template may also be generated by denaturing doubts-stranded plasmid for other) DNA usirfg standard techniques.
For alteration of the native DNA sequence tto generate amino acid sequence variants, fer example), the oligonucteotide is hybridized to the single-stranded template under suitable hybridization conditions: A DNA polymerizing enzyme, usually the Ktenow fragment of DNA
polymerase t, is then added to synthesize the complementary strand of the template using the otigonucleotide as a primer for synthesis. A heteroduptex molecule is thus formed such that one stand of DNA encodes he mutated form of the target polypeptide, and the other strand tthe original template) encodes the native, unaltered sequence of the target potypeptide. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote such :,';~: .; ,'.'.,,.,., ': .~.... . . '..:,~... ..
WO 92/22653 ~ ~ ~ '~ ~ '~ ~ 1'CT/1JS92/05126 3~
as E, coil ,lM101. After the cells are grown, they are plated onto agarase plates and screened using the oliganucleotide primer radiolabeled with 32-phosphate to identify the bacterial colonies that contain the mutated DNA. The mutated region is then removed and placed in an appropriate vector for protein production, generally an expression vector of the type typically employed for transformation of an appropriate host.
The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the ptasmid contain the mutation(s). The modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosins tdATP); deoxyriboguanosine tdGTP), and deoxyribothymidine tdTTP), is combined with a modified thin-deoxyribocytosine called dCTP-taS) twhich can be obtained from Amersham Corporation). This mixture is added to the template-oligonucieotide complex.
Uport addition of DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. ln~ addition, this new strand Ot UNA wul contain dCTP-taS) instead of dCTP, which serves to protect it from restriction endonuclease digestion.
After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme; the template strand can be digested with VIII
nuclease or another appropriate nuclease past the region that contains the sitets) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA tigase. This homoduplex molecule can then be transformed into a suitable host cell such as E. coil JM10'6, as described above.
DNA encoding target polypeptide variants with more than one amino acid to be substituted may be generated i~ one of several ways. If the amino acids are located close tog~ther in the polypep~tide chain, they may be mutated simultaneously using one o6igonuctdotide that podes for alt of the desired amino acid substitutions.
If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to 'generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.
tn the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA
simultaneously, and the second strand of DNA that is synthesized from the template will encode alt of the desired amino acid substitutions.

WU 92/22653 ~ ~ ~ ~ ~ J ~ PCTlUS92lOSf26 3 '~
The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid substitutions) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitutions) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be used as a template in a third round Zo of mutagenesis, and so on.
PCR mutagenesis is also suitable for making amino acid variants of target polypeptide.
While the following discussion refers to DNA, it is understaad that the technique also finds application with RNA. The PCR technique generally refers to the following procedure (see Erlich, supra, the chapter by R. Higuchi, p. 61-70): When small amounts of template DNA are ~5 Bused as starting material in a PCR, primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions whore the primers differ from the template. Far introduction of a mutation into a plasmid DNA, one of the primers is designed to overlap the position of the mutation and to contain the mutation;
20 the sequence of th~ other primer must be identical to a stretch of sequence of the apposite strand of the ptasmid, but this sequence can be Located anywhere along the plasmid DNA. It is preferred, however, that the sequence of the second primer is located within 2~0 nucleotides from that of the first, such that in the end the entire amplified region of DNA
bounded by the primers can be easily sequenced. PCR amplification using a primer pair like 25 the one just described results in a population of DNA fragments that differ at the position of the mutation specified by the primer, and possibly at other positions, as template copying is somewhat error-prone.
If the ratio of template to product material is extremely low, the vast majority of product DNA fragments incorporate the desired mutation(s). This product material is used to 30 replace the corresponding region in the plasmid that served as PCR template using standard DNA technology. Mutations at separate positions can be introduced simultaneously by either using a mutant second primer, or performing a second PCR with different mutant primers and ligating the two resulting PCR fragments simultaneously to the vector fragment in a three (or rreore?-part ligation.

,v, n ' ~:. , ,.,~~.", ~.,...., ..~ ,~,~,~'~~~v~. ;~... ; .., ,.,~:.' ~.:w,, .
. .~...;.,:,. ;.-i,~~..~~ ~~.,;:
PCTlUS92l05126 WO 92!22653 In a specific example of PCR mutagenesis, template plasmid DNA (1 ,ug) is lineariaed by digestion with a restriction endonuclease that has a unique recognition site in the plasmid DNA outside of the region to be amplified. Of this material, 100 ng is added to a PCR mixture containing PCR buffer, which contains the four deoxynucleotide tri-phosphates and is included in the GeneAmp'~ kits (obtained from Perkin-Elmer Cetus, Norwalk, CT and Emeryville, CA), and 25 pmole of each aligonuclsotide primer, to a final volume of 50 Nl. The reaction mixture is overlayed with 35 NI mineral oil. The reaction is denatured for 5 minutes at 100~C, placed briefly an ice, and then 1 NI Thermus aquaticus (Taql DNA polymerise t5 unitslNl, purchased from Perkin-Elmer Cetus, Norwalk, CT and Emeryvilie, CA) is added below the mineral oil layer.
to The reaction mixture is then inserted into a DNA Thermal Cycler (purchased from Perkin-Eimer Cetus) programmed as fol!~ws: 2 min. at 55~C, then 30 sec. at 72~C, then 19 cycles of the following: 30 sec. at 94~C, 30 sec. at 55~C, and 30 sec. at 72~C.
At the end of the program, the reaction vial is removed from the thermal cycler and the aqueous phase transferred to a new vial, extracted with phenol/chlorafarm t50:50:vo1), and 'ethanol precipitated, and the DNA is recovered by standard procedures. This material is subsequently subjected to the appropriate treatments for insertion into a vector.
Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells etal. tGen_e,~4: 315 (19851). The starting material is the plasmid for other vector? comprising the target polypeptide DNA to be mutated. The cadants) in the target polypeptide DNA to be mutated are identified. There must be a unique restriction endonuclease site an each side of the identified mutation sitets). If no such restriction sites exist, they may be generated using the above-described oliganucleatide-mediated mutagenesis method to introduce them at appropri to locations in the target polypeptide DNA. After the restriction sites have been introduced into the plasmid, the piasmid is cut at these sites to finearize it. A double-stranded oligonucleatide encoding the sequence of the DNA between the restriction sites but containing tho desired mutatiants) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have3' and 5' ends that are compatible with the ends of the linearized plasmid, such that it can be ditectiy ligated to the plasmid. This plasmid now contains the mutoted target polypeptide DNA sequence.
Insertion of DNA into a Cloning 'Vehicle The cDNA or gertomic DNA encoding the target palypeptide is inserted into a replicable ,.
.., . . "e~. ...
. . . " . ,. . ,,,. ~ , .'. , . .:. . . .,. . ,. ,. ,..
:,.::. ,.~' '.'.~~ ~~..;~, . ',. .. .. ~...; , ~ 7, .. r..., .' :.,, .,..,.
.., . . . .. . . . . ~ ~
~_~.~ ~~~J~
'WO 92!22653 PCT/US92105126 vector for further cloning tamplification of the DNA) or for expression. Many vectors are available, and selection of the appropriate vector will depend on 1 ) whether it is to be used for DNA amplification or for DNA expression, 2) the size of the DNA to be inserted into the vector, and 3) the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNAI and the bast cell for which it is compatible. The vector components generally include, but are not limited to, one or mare of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.
(a) ,signal Se uenc~ Component In general, the signal sequence may be a component of the vector, or it may be a part of the target polypeptide DNA that is inserted into the vector.
The target poiypeptides of this invention may be expressed not only directly, but also i5 gas a fusion with a heteraiagous polypeptide, preferably a signal sequence or ether polypeptide having a specific cleavage site at the N~terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the target polypeptide DNA that is inserted into the vector. Included within the scope of this invention are target paiypeptides with any native signal sequence deleted and replaced with a heterotogaus signs! sequence. The heterologaus signal sequence selected should be one that is recognized and processed (i.e. cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not reGOgnize and process the native target paiypeptide signet sequence, the signal sequence is substituted by a prokaryotic signal sequence Selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stable 'enterotoxin If leaders, For yeast seG~etion the native target polypeptide signal sequence may be substituted by the yeast invprtase, dlpha,factor, or acid phasphatase leaders. in mammalian cell expression the native signal sequence is satisfactory, although ether mammalian signal sequences may be suitable.
(b) ~?rigin of Replication Comaonent Both expressiart and cloning vectors contain s nucleic acid sequence that enables the vector to replicate in one or more 'selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomal ,,;, ;., . , . :, ,,:
~ ~;.,. . .. . ,. . ,~, , ~; .. .'' , . , ...,' , ..y( .y' ,. !.. ..~.~. ..., ':. ' ..,' ~ ,. . .. . . y" . , ~..
PC'f'JUS92/OSI z6 wo 9zJZZ~s3 2 ~ ~ ~ ~ '~ ~
~0 DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2N
plasmid origin is suitable for yeast, and various viral origins tSV40, polyoma, adenovirus, VSV
or BPV) are useful for cloning vectors'in' mammalian cells. Generally, the origin of replication component is not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoters.
Most expression vectors are "shuttle" vectors, i.e. they are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For io example, a vector is cloned in E. coli and then the same vector is transfected into yeast or mammalian cells for expression even though it is not capable of replicating independently of the host cell chromosome.
DNA may also be amplified by insertion' into the host genome. This is readily accomplished using Bacillus species as hosts, for example, by including in the vector a DNA
sequence that is complementary to a sequence found in Bacillus genomic DNA.
Transfection of Bacillus with this vector results in homologous recombination with the genome and insertion of the target poiypeptide DNA. However, the recovery of genomic DNA encoding the target polypeptide i~ more complex than that of an exogenously replicated vector because restriction enzyme digestion is required to excise the target poiypeptide DNA.
tc) ~~ c.t~~ene Component Expression and cloning vectors should contain a selection gene, also termed a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown 'in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that ta) confer resistance to antibiotics or other toxins, e.g. ampiciltin, neomycin, methotrexate; or tetracycline; tb) complement auxotrophic deficiencies, or tc) supply critical nutrients not available frorro complex media, e.g. the gene encoding D-alanine racemase for Bacilli.
One example of a selection scheme utilizes a drug to arrest growth of a host cell.
Those calls that are successfully-transformed with a heterologous gene express a protein conferring drug resistance and thus survive the selection regimen. Examples of such dominant selection use the drugs neomycin (Southern et al., ~. Motec. Appl. Genet., 1:
S27 (19821), Frtt/ ,~ 9Q ';. S V .III ;Yr''~,2~W~P .ir.'P(j~.a=.,..
~nt,"','.~."
~~a~~JJ
''YO 92/2265 P~1'/US921o5126 '-I I
mycophenolic acid (Mulligan et al., cien~_e., 209: 1422 [ 19801) or hygromycin (Sugden et al. , Mol. Cell. Biol., 5_: 410-413 (19851). The three examples given above employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug 6418 or neomycin (geneticin), xgpt (mycophenolic acid), or hygromycin, respectively.
Another example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the target polypeptide nucleic acid, such as dihydrofolate reductase (DHFR) or thymidine kinase. The mammalian cell transformants are placed under selection pressure which only the transformants are uniquely adapted to survive by virtue of having taken up the marker. Selection pressure is imposed by culturing the transformants under conditions in which the concentration of selection agent in the medium is successively changed; thereby leading to amplification of both the selection gene and the DNA that encodes the target polypeptide. Amplification is the process by which genes in greater demand for the production of a protein critical for growth are reiterated in tandem ~vyithin the chromosomes of successive generations of recombinant cells.
Increased quantities 15 of the target polypeptide are synthesized from the amplified DNA.
For example, cells transformed with the DHFR selection gene are first identified by cultdring all of the transformants in a culture medium that contains methotrexate (Mtx), a competitive antagonist of Di~FR. An appropriate host cell when wild-type DHFR
is employed is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared and 20 propagated as described by Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77: 4216 ~1980~.
Tne transfocrned cells are then exposed to increased levels of methotrexate.
This leads to the synthesis of multiple copies of the DHFR gene, and, concomitantly, multiple copies of other DNA comprising thd expression vectors, such as the DNA encoding the target polypeptide.
This amplification technique can be used with any otherwise suitable host, e.g., ATCC No.
CCL61 CHO-K1, notwithstanding the presence of endogenous DHFR if, for example, a mutant DHFR gene that is highly resistant to Mtx is employed (EP 117,060?.
Alternatively, host cells (particularly wild-type hosts that contain endogenous DHFR) transformed or co-transformed with DNA sequendes encoding the target polypeptide, wild-type DHFR protein, and another selectable marker such as arninoglycoside 3' phosphotransferase (APH) can be selected by cell growth in medium containing a selection agent for the selectable marker such as an aminoglycosidic antibibtic, e:g., kanamycin, neomycin, or 6418. See U.S. Pat.
No.
4,965;199.
A suitable s~iection gene for use in yeast is the trill gene present in the yeast plasmid YRp7 (Stinchcc~mb et al:; Na ure, 282: 39 (19791; Kingsman et al., Gene, 7:
141 [1979D; or '.. r.;.; , ~
~r,..~ ~.5',. b . .1.~~. ' r ~1.7: . ~~i:9,.. , r . .. . ' .. . '~ . . s... .

~I Z
Tschemper et al., Gene, 10: 157 [1980]?. 'The trp1 gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 (Jones, Genetics, 85: 12 [19771). The presence of the trp1 lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2-deficient yeast strains tATCC
20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.
td) Promoter ramoonent Io Expression and cloning vectors usually contain a promoter that is recognized by the host organism and is operably linked to the target polypeptide nucleic acid.
Promoters are untranslated sequences located upstream t5') to the start codon of a structural gene (generally within about 100 to 1000 bpl that control the transcription and translation of a particular nucleic acid sequence, such as that encoding the target polypeptide, to which they are ~operably linked. Such promoters typically fall into two classes, inducible and constitutive.
Inducible promoters ere promoters that initiate increased levels of transcription from DNA
under their control in response to some change in culture conditions, e.g. the presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known. These promoters are operably 2Q linked to DNA encoding the target polypeptide by removing the promoter from the source ANA
by restriction enzyme digestion and inserting the isolated promoter sequence into the vector.
Both the native target polypeptide promoter sequence and many heterologous promoters may be used to direct amplification andlor expression of the target polypeptide DNA. However, heterologous promoters are preferred, as they generally permit greater transcription and higher yields of expressed target polypeptide as compared to the native target polypeptide promoter.
Promoters suitable for use with prokaryotic haste include the ~B-lactamase and lactose promoter systems tChang et al., _Naturg, 275: 615 [1978]; and Goeddel et al., Nature, 2 1:
544 [ 19791), alkaline phosphatase, a tryptophan ttrp) promoter system (Goeddel, Nu,~leic Aids Res., 8: 4057 119801 and ER 36,761 and hybrid promoters such as the tac promoter tdeBoer ' 3o et al., Proc. Natl. Acad: Sci. USA; ,$Q: 21-25 [19831). However, other known bacterial pr~moters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably: to ligate them to DNA encoding the target polypeptide tSiebenlist et al.Ceii; 20: 269 (1980)) using linkers or adaptors to supply any required restriction sites.
Promoters lot use in bacterial systems also generally will contain a Shine-Dalgarno tS.D.) d1'O 92122653 . ~ ~ ~ ~ ~~ ~ ~ PC.'T/US92105126 ~I 3 sequence operably linked to the DNA encoding the target polypeptide.
Suitable promoting sequences for use with yeast hosts include the promoters for 3-phasphoglycerate kinase (Hitzeman et al., J. Biol. Chem., 2~~'5: 2073 [1980)) or other glyco)ytic -enzymes (Hess et al., J Adv. Enzyme Reg~., 7: 149 (19681; and Holland, Biochemistrv,17: 4900119781), such asenolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarbaxylase, phosphafructakinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isamerase, phasphoglucase isomerase, and glucakinase.
Other yeast promoters, which are inducib)e' promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallathianein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and gafactose utilization. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman et al., EP 73,857A.
Yeast enhancers also are advantageously used with yeast promoters.
Promoter sequences are known for eukaryotes. Virtually ail eukaryotic genes have an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated. Another sequence found 70 to 80 bases upstream from the start of transcription of many genes is a CXCAAT region where X may be any nucleotide.
At the 3' end of mast eukaryatic genes is an AATAAA sequence that may be the signal for addition of the poly A tail to the 3' end of the coding seauence. All of these sequences are suitably inserted into mammalian expression vectors.
Target polypeptide transcription from vectors in mammalian host cells is controlled by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (Ul~
z5 2,211,504 published S July 1989), adenovirus (such as Adenovirus 2), bovine papit)oma virus, avian sarcoma virus, cytamegatovirus, a retrovirus, hepatitis-B virus and mast preferably Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g. the actin promoter ar an immunogl~bulin promoter, from heat-shock promoters, and from the promoter normally associated with the target palypeptide sequence, provided such promoters are compatible with the host cell systems.
The early and late promoters of the SV40 virus are conveniently obtained as an restriction fragment that also contains the SV40 viral origin of replication.
Fiers et al" Na ure, 27:113 11978); Mulligan and Berg, fence, 2~9: 1422-1427 (1980): Pavlakis et al., Proc.
N~,~1 Acad Sci USA, 78: 7398-7402 (1981 ). The immediate early promoter of the human .'.~. , ~ . ~~. . .::. ~,....,. u,... ...w, n:' ..."' .,:....,.,. . ~['~.",.
~.' ,... '..:.. ' . .. . . ' ... ... .~ . ..
~ r. ,. . ~.~. ~~ ~ '. . .' '.i ne , -'.:.. . , : ~ , f',.'., :. ... . .. ...
~..'.~ ..'.. :. ' : ? , n,;,. ..;~ n . ~ :'. .' . ' .. . '. : . .. . .
sd.~~Jil:~~~
W~ 92/22653 PCT/US92/05126 cytomegalovirus is conveniently obtained as a Hindlll E restriction fragment.
Greenaway et al. , Gene, 18: 355-360 (198Z). A system for expressing DNA in mairnmalian hosts using the bovine papilloma virus as a vector is disclosed in U.S. 4,419,446. A
modification of this system is described in U.S. 4,601,978. See also Gray et al,, Nature, ~: 503-508 (1982) on expressing cDNA encoding immune interferon in monkey cetts; , Reyes et al., N ure, 297: ~
598-601 (1982) on expression of human ~-interferon cDNA in mouse cells under the control of a thymidine kinase promoter from herpes simplex virus, Canaani and Berg, Pr2q,. Natl. Acad.
~;i. USA, 79: 5166-5170 (1982) on expression of the human interferon,81 gene in cultured mouse and rabbit cells, and Gorman et al., Plc. N~tl. Acad. S~;i. USA, ,~Q:
6777-6781 ( 1982) 1o on expression of bacterial CAT sequences in CV-1 monkey kidney cells, chicken embryo fibroblasts, Chinese hamster ovary cells, HeLa cells, and mouse NIH-3T3 cells using the ffious sarcoma virus long terminal repeat as a promoter. ~
(e) Enhan~er Element Camnonent ' Transcription of DNA encoding the target polypeptide of this invention by higher eukaryotes is often increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10-300 bp, that act on a promoter to increase its transcription. Enhancers are relatively orientation and position independent having 2p been found 5' tLaimins et al., Per ~. Natt. Acad. Sri- USA, 7$: 993 ( 19811) and 3' (Lusky et a/..; Mol: Cell Bio., ~: 1108 t1983)t to the transcription unit, within an intron (Banerji et al., Cell, ,~: 729 f 19t~31) as well as within the coding sequence itself (Osborne et al., M I. ell Bio., 4: 1233 [1984)). Many enhancer sequences are now known from mammalian genes (globin, etastase; albumin, o-fetoprotein and insulin). Typically, however, one will use an enhancer frt~m s eukaryotic cell virus: Examples include the SV40 enhancer on the late side of the replication origin (bp '100-270), the cytpmegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. See also Yaniv, N_ature_, 297:' 17-18 11982) on enhancing elements for activation of eukaryotic promoters. The enharycer may be spliced into the vector at a position 5' or 3' to the target potypeptide DNA, but is preferably located at a site 5' from the promoter.
(f) Transcription 'termination ComQOnent Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, WO X2/22653 ~ ~ ~ ~ ~ a ~ PCTlUS92/05126 human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA.
Such sequences are commonly available from the 5' and, occasionally 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the target polypepride. The 3' untranslated regions also include transcription termination sites.
Construction of suitable vectors containing one or more of the above listed components the desired coding and control sequences employs standard ligation techniques.
Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required.
For analysis to confirm correct sequences in plasmids constructed, the ligation mixtures are used to transform E, coli K12 strain 294 tATCC 31,446) and successful transformants selected by ampicillin or tetracycline resistance where appropriate. Plasmids from the transformants are prepared; analyzed by restriction endonuclease digestion, and/or sequenced °lay the method of Messing e# a/., Nucleic Acids Res., ~,: 309 11981 ) or by the method of Maxam et al., Methods in Enzvmoloqv_, ,~5_: 499 11980).
Particularly useful in the practice of this invention are expression vectors that provide for the transient expression in mammalian cells of DNA encoding the target polypeptide. in general; trarvsient expression involves the use of an expression vector that is able to replicate efficiently in a host cell; such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector. Transient expression systems, comprising a suitable expression vector and a host cell, allow for the convenient positive identification of polypeptides encoded by cloned DNAs, as well as for the; rapid screening of such .polypeptides for desired biological or physiological properties. Thus: transient expression systems are particularly useful in the invention for purposes of identifying analogs and variants of the target polypeptide that have target polypsptide-like activity:
~ther methods, vectors; and host cells suitable for adaptation to the synthesis of the target poiypeptide in recombinant vertebrate cell culture are described in Gething etal., N re, ' 3o ' 2."~,~: 620-625 (19811; Mantel et al.-, N re, 2 1: 40-46 [19791;
Levinson et al.; EP 117,060;
and EP 117,058. A particularly useful plasmid for mammalian cell culture expression of the target poiypeptide is pRKS tEP-pub. no. 307,247) or pSVi6B.
Seie~tsrt~ and Transformation of Host Cells v ~I ~P
Suitable host cells for cloning or expressing the vectors herein are the prokaryote, yeast, or higher eukaryote cells described above. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, E. toll, Bacilli such as B. subtilis, Pseudomonas species such as P. aeruginosa, Salmonella typhimurium, or Serratia marcescans.
One preferred E. toll cloning host is E. toll 294 (ATCC 31,446), although other strains such as E, cofi B, ,E. toll X1776 (ATCC 31,537), and E. toll W3110 (ATCC 27,325) are suitable.
These examples are illustrative rather than limiting. Preferably the host cell should secrete minimal amounts of proteoPytic enzymes. ,A(ternatively, in vitro methods of cloning, e.g. PCR
or other nucleic acid polymerase reactions, are suitable.
1o In addition to prokaryotes, eukaryotic microbes such as filamsntous fungi or yeast are suitable hosts for target polypeptids-encoding vectors. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms.
However, a number of other genera, species, and strains are commonly auaiiable and useful herein, such as Schizosaccharomyces pombe (Beach and Nurse, Na ur , ,2~Q: 140 (1981 ); EP
1S P139,383 published May 2, 19851, Kluyveromyces hosts (U.S. 4,943,529) such as, e.g., K.
lactis (Louvencourt et al., ~. B~~teriol., 737 (1983)), K. arragilis, K.
bulgaricus, K.
thern~otolerans, and K. marxianus, yarrowia tEP 402,2261, Pichia pastoris IEP
183,070;
Sreekrishna et al., J. Basic Microbiol., 28: 265-278 (1988)1, Candida, Trichoderma reesia fEP
244,2341, Neurospora crassa (Case et al., Proc,, Natl. Asad. Sci. USA, ~: 5259-52(3 20 (1979)1, and filamentous fungi such as, e.g, Neurospora, Penicillium, Tolypocladium [WO
91100357 published 10 January 19911, and Aspergillus hosts such as A. nidulans (l3allance etal., Biochem. Bi~phvs. Res. Commun., 112_: 284-289 (1983); Tilburn et al., en , ~6: 205-221 (1983); Yelton et al., Proc. Natl. e4cad. Sci. USA, ~1: 1470-1474 (1984)) and A. niger (Kelly and Hynes, EMBO J., 4: 475-479 (1985)x.
25 Suitable host cells for the expression of glycosylated target polypeptide are derived from multicellular organisms. Such host calls are capable of complex processing and glycosylation activities. Pn principle; any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture. Examples of invertebrate cells include plant and insect cells.
Numerous baculoviral strains and variants and corresponding permissive insect host cells from 30 hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori host cells have been identified. See, e.g., Luckow et al., B~,Ttechnologv. _6: 47-55 (1988); Miller et al., in ~n Ericlineerine. Setlow, J.K. et al., eds., Vol. 8 (Plenum Publishing, 1986), pp. 277-279; and Maeda et al., Nature, 315: 592-594 (1985). A variety of such viral strains are publicly J .~, ~ . . , .
'~ , f ~ ~f~r . ~... .~. .... ,... . ." . ... . . . , . ,. . ..
WtJ 92!22653 ~ ~ ~ ~ ~ ~ f'CT/US92105126 available, e.g, the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of Spodoptera frugiperda cells. Plant cell cutrtres of cotton, corn, potato, soybean, petunia, tomato, and tobacco can be utilized as hosts.
Typically, plant cells are transfected by incubatian with certain strains of the bacterium Agrobacterium tumefaciens, which has been previously manipulated to contain the target polypeptide DNA. During incubation of the plant cell culture with A, tumefaciens, the DNA
encoding target polypeptide is transferred to the plant cell host such that it is transfected, and will, under appropriate conditions, express the target polypeptide DNA. In addition, regulatory and signal sequences compatible with plant cells are available, such as the nopaline synthase promoter and polyadenylation signal sequences. Depicker et aO , ~. Mol. Aopl.
Gen., 1_: 561 ! 1982). In addition, DNA segments isolated from the upstream region of the T-DNA 780 gene are capable of activating or increasing transcription levels of plant-expressible genes in recombinant DNA-containing plant tissue: See EP 321,196 published 21 June 1989.
'"~ However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue cultural has become a routine procedure in recent years (Tissue Culture, Academic Press, Kruse and Patterson, editors 11973)1. Examples of useful mammalian host cell tines are monkey kidney CV 1 line transformed by SV40 (COS-7, ATCC CRL
1651 ); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham etal., J~Gen Virol., ~: 59 (19771): baby hamster kidney cells (BHK, ATCC CCL
10); Chinese hamster ovary cells/-D!-:FR tCHO, Urtaub and Chasin, PrQc. Natl. Acad. ci.
USA, 77: 4216 (19801): mouse settoli cells tTM4, Mather, Biol: Reorod., 23: 243-251 (19801);
monkey kidney cells tCV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587);
human cervical carcinoma cells tHELA, ATCC CCL 2): canine kidney cells (MDCK, ATCC CCL
34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells tW138, ATCC CCL
75); human liver cells tHep G2, HB 80651; mouse mammary tumor (MMT 060562, ATCC
CCL51); TRI cells (blather et ~1., Annals N:Y. Acad. Sci., ,: 44-68 (19821):
MRC 5 cells;
FS4 cells; and a human hepatoma cell line tHep G2). Preferred host cells are human embryonic kidney 293 and Chinese hamster ovary cells.
Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this 'invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desiied sequences.
Transfection refers to the taking up of an expression vector by a host cell whether or Wo ~zm.~~ ~ 3 U j ~ . »crms9vosizs not any COdin9 sequences are in fact eXpr~ssed. Numerous methods of transfeetion are known to the ordinarily skilled artisan, far example, CaPO, and electroporarion.
Successful transfeCtion is generally recognized whorl any indication of the oporati4n of this vector occurs within the host Cell.
Transformation means introducing DIVA into an organism so that the L7NA is replicable, either as an extrachromosbmai element or by chromosomal integrant. Depending on the host cell used, transformation iS done using Standard techniques appropriate to such oeus. The Calcium treatment employing calcium chloride, as described ire section 9.8? of Sambrook et aL, supra, is generally used for prokaryotes or other cells that contain substanGat colt-wall io bar~l8rs. tnfaction with Agrobacteritrm tVmefaciens is used for transformation of certain plant coils, as described by Shaw et al., Gene. 2~' : 315 (19831 and WO 89/Q5859 published 2S
June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method described in sections 16.33--t 8,37 of Samhrook et arl, supra, is prefarrgd. General aspects of mammalian cell host system transforrnations have been described bY
Axa1 in U.S. .
15 '4,399.216 issued 16 August '1983. Transformations into yeast are typically carried out according to the method of Van Solingen et at-, .,,1,~t3act., .1~: 946 11977) and Hsiaa et al., Prod. Natl_ A dad. Sci...CUSAL.~: 3829 ~~ 9791. tfawaver, other methods for introducing DNA
into cells such as by nuclear injection, alflctfOp4fatiOn. or protoplast fusion may also be used.
., 20 Culturing the Hpst Cells Prokaryotic tails used.ta produce th9 target polypeptide of thisvnventtan are cu~tured in.suitable media as described gerraraliy in Sambrodk et al., ~utrra.
The mammalian host tails used to produce the target polypeptide of this invention 25 ~ may be'cultured in a variety of media. Corrzme~cially available media such as Ham's F10.
(Sigma). Minimal Essential Medium tIMEnn), Sigma), f;PMI-16~i0 tSigma), and Dulbecco's Modified iragle'$ Medium t(DMEM3, Sigma) are suitable for culturing the host celis_ in addition, any of the media,describ~d-in Harri arid Walface. Meth. Erix.; ~$: 44 (1979), Barnes and Sato, Anal;~BiOCrlem.. ~: 255 11980),; U.S. 4;7fi7;704; 4,857,866; 4.927.762: or 4.580.655:
3o Wp gpl03430; WO 87/~Da195; may be used as culture media for the host cells.
Any of these media may be supplemented as necessary with hormones andlor other growth factors (such as insulin, tr2~nsferring or epidermal growth flGtor), salts (such as sodium ohlaride, calcium, magnesium, and phosphate), buffers (such as HOPES), nucleosides (such a5 adenosine and thymidine), antibiotics (such as GentamycinT"' drug), trace elements ...
I~YO 92l22S53 ~ ~ ~ ~ ~ ~ ~ PCflfJS92/4S126 (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
The culture conditions, such as temperature, pFi, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
The host cells referred to in this disclosure encompass cells in in vitro culture as well as cells that are within a host animal.
It is further envisioned that the target polypeptides of this invention may be produced by homologous recombination, or with recombinant production methods utilizing control io elements introduced into cells already containing DNA encoding the target poiypeptide currently in use in the field. For example, a powerful promoter/enhancer element, a suppressor, or an exogenous transcription modulatory element is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA
encoding the desired target potypeptide. The control element does not encode the target ~~olypeptide of this invention, but the DNA is present in the host cell genome. One next screens for cells making the target polypeptide of this invention, or increased or decreased levels of expression, as desired:
DetPCting Gene Amnlifi,~tion/Ex_pression Gene amplification and/or expression may be measured in a sample directly; for exampld, by conventional Southern blotting, northern blotting to quantitate the transcription of mRNA-tThomas; Prod; Natl. Acad. Sci. USA, 77: 5201-5205 (1980j), dot blotting tDNA
analysis), or in situ hybridization; using an appropriately labeled probe, based on the sequences provided herein, Various labels may be employed, most commonly radioisotopes, particularly 32P~ however, other techniques may also be employed, such as using biotin-modified nucleotides'for introduction into a polynucleotide. The biotin then serves as the site for binding to avidin or antibodies, which may b~ labeled with a wide variety of labels, such as radionuctides, fluo~escers, enzymes, or the tike. Alternatively, antibodies may be employed that can recognize specific duplexes; including DNA duplexes, RNA duplexes, and DNA-RNA
hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of dd~iex an the surface, the presence of antibody bound to the duplex can be detected.
Gene expression, atternatively, may be measured by immunological methods, such as r~.t i~ ~ ~ ~C't/US91~45126 wo 92izz~~3 so immunohistoehgmicat staining of tissue sectibns and asset' of cell CUItUr9 Or ksadY fluids, to quantitate directly th~ expression of gene product. With immunohistochemical staining techniques, a cell sample is prepared, tYPically by dehydration and fixation, followed try reaction with labeled antlb4dies specific far the gene product coupled, where the labels are u$uafly visually detectable, such as enzymatic labels. fluorescorrt labels.
luminescent labals~
and the like. A particularly sensitive staining technique Suitable for use in the present invention is described by Hsu et a~ , ~~.' . W 7~4-X38 11980).
Antibodies useful for immunohistochemicat staining andlor assay of sample fluids may ba either monoclonal or palyclonal, and may be prepared in any mammal.
~o~weniantly, the to antibodies may be prepared ageinst,a native target~patypeptide yr against a synthetic peptide based on the 4~NA sequences, provided herein as described further in Section 4 below-D,urifir.~tinr'~ a ThB~noIyoeDtidB
. The target palypaptid~.pref~arably is racovsred fr~n the culture medium as a secreted '~olypeptide, although it also may be recovered from host call lysatss when directly expressed without a secretory signal.
WfYen the tgrgmt pQIYPePtide is expressed in a recombinant cell other than one of human .origin, the target polypepti~e is completely frees of proteins or polypeptides of human origin.
However, it i$ necessary tc purify the target polypeptide from recombinant cell proteins or Z.p. . ~ polypaptides to obtain preparations that ar,e substantially homogeneous ass to the target pol~rpeptide. As.a first step; ths-cultu~a rnedium or lysate is centrifuged to remove particulate celi~dabris. The membfene ahd soluble protein fraotians are then separated.
The target . paiypeptide maY then be purified frorriahe soluble protein fraction and from the membrane fraction of the ~ cultur~. iysate, depending on whether the target polypeptida is membrane b. The ialt~awing: , proceduies ~ are exemplary of suitable purification procedures:
fractionation.on immuriQaffiiiity ~or iori-exchange columns; ethanol precipitation; reverse phase ~. Hpl:C: , ahromatograptiy: ' an silica, ~ or on a ration exchange resin such as D>"AE;
chrom$tafocusing: 5DS-i'~GE;. ~mvinanium sulfate precipitation: gel filtration using. for example. Sephadex G~75; and.protein A 6aphsrase*columns to remove contaminants such as ;- 30 ~ IQG. ; .
~, ~ :Target palypeptide wariar<ts iii:which residues have been deleted, inserted or substituted are recovered in the.sa~np. ;fashion, taking account of any substantial changes in properties . ac~asiprved by the variation_ Few example, preparation,af a target polypaptide fusion with another,ptatein or polYpeDtide, e.g,a,bacterial or vita! antigen, facilitates purification; an *_trademark ' '' , ... '~' ~ . ' .
VlrO 92f226S3 ~ ~ ~ ~ PCT/gJS92fOS126 immur~oaffinity column containing antibody to the antigen (or containing antigen, where the target polypeptide is an antibody) can be used to adsorb the fusion.
Immunoaffinity columns such as a rabbit polyclonat anti-target polypeptide column can be employed to absorb the target polypeptide variant by binding it to at least one remaining immune epitope. A protease S inhibitor such as phenyl methyl sutfonyl fluoride (~MSF) also may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants. One skilled in the art wile appreciate that purification methods suitable for native target polypeptide may require modification to account for changes in the character of the target polypeptide or its variants upon expression in recombinant cell culture.
Covalent ~llodifica~ions of Tara~e~"F'otvDeptides Covalent modifications of target polypeptides are included within the scope of this invention. One type of covalent modification included within the scope of this invention is a target potypeptide fragment. Target polypeptide fragments having up to about 4O amino acid residues may be conveniently prepared by chemical synthesis, or by enzymatic or chemical cleavage of the full-length target polypeptide or variant target polypeptide.
Other types of covalent modifications of the target polypeptide or fragments thereof are introduced into the molecule by reacting specific amino acid residues of the target polypeptide or fragments thereof with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues.
Cysteinyl residues most commonly are reacted with a-haloacetates (and corresponding amines), such as chBe~roacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Gysteinyl residues also are derivatized by reactitm with bromotrifluoroacetone, a-bromo,8-(a-imidozoyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-vitro-Z-pyridyl disulfide, methyl 2-pyridyl disutfid~, p-chloromercuribenzoate, ~-chtoromercuri-4-nitrophenol, or chloro-?-nitrobenzo-2-oxa-1,3-diazole.
Histidyt residues are derivatized by reaction with diethylpyrocarbonate at pH
5.5-?.0 because this agent is relatively specific for the histidyl side chain. pare-bromophenacyl 3,0 bromide also is useful; the reaction is preferably performed in 0.1 M
sodium cacodytate at pH
fiØ
bysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. C~erivatization with these agents has the effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing Q-amino-containing residues include . ... . .., ~'~~~~ . , :~ .'~~ . o:~:' : ;. r ' , . ~ . ' ~. _ : _~ . , ~.,,.
.. ,,~._:.. . ~.;:. . .
W~ 92/22653 ~ ~ ~ ~ ~ ,'~ ~ )PC°A'/US92/05r26 ,..~ .
Z
imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal;
chloroborohydride;
trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; and transaminase-catalyzed reaction with glyoxylate.
Arginyl residues are modified by reaction with one or several conventional reagents, 5 among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin.
Derivatization of arginine residues requiros that the reactian be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.
Th~ specific modification of tyrosyl residues may be made, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidizole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosyl residues are iodinated using'z51 or'3'I to prepare labeled proteins for use in radioimmunoassay, the chloramine T method described above being suitable.
Carboxyl side groups taspartyl or glutamyl) are selectively modified by reaction with carbodiimides tR'-N = C = N-R'), where R and R' are different alkyl groups, sash as 1-cyclohexyt-3-(2-morpholinyl-4-ethyl) carbadiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginyl and glutarninyl residues by reaction with ammonium ions., Derivatization with bifunctional agents is useful for crosslinking target palypeptide to a water-insoluble support matrix ar surface for use in the method for purifying anti-target paiyp~ptids antibodies, and vice versa. Commonly used crosslinking agents include, e.g., 1,1-bisidiazoacetyl)-2-phenylethane, glutaraldehyd~, N-hydroxysuccinimide esters, for example, esters with ~-azidosalicylic acid; homobifunctional imidaesters, including disuccinimidyl esters such as 3,3'-dithicrbistsuccinimidylpropionate), and bifunctional maleimides such as bis-N-rnaleimido-1,8-octane. Derivatizing agents such as methyl-3-tIp-azidophenyl)dithiolpropioimi-date yield photoactivatable intermediates that are capable of farming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. 3,969,28?;
3,691,016;
4,195,128; 4,247,642; 4,229.53?; and 4,330,440 are employed far protein immobilization.
Glutaminyl and asp~araginyl residues are frequent6y deamidated to the carresponding glutamyl and aspartyl residues, respectively. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this inventian.

.,''VO92/22653 ~ ~ ~ ~ P~;f/f.JS92/05i26 Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of Beryl or threonyl residues, methylation of the a-amino groups of lysine, arginine, and histidine side chains tT.E. Creighton, Pr ins: Structure and Molecular Pranerj~i, es, W.H. Freeman & Co., San Francisco, pp. 79-86 f 1983)), acetylation of th~ N-terminal amine, and amidation of any C-terminal carboxyl group.
Another type of covalent modification of the target polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide.
By altering is meant deleting one or more carbohydrate moieties found in the native target polypeptide, andlor adding one or more glycosylation sites that are not present in the native target pofypeptide.
Clycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. The tri-peptide sequences asparagine-X-serine and asparagine-X-threonine, where X
is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to th~ asparagir~e side chain. Thus, the presence of either of these tri-peptide sequences in a polypeptide creates a potential glycosylation site. O-finked glycosylation refers to the attadhment of one of the sugars N-acetylgalactosamine, galactose, or xytose; to a hydroxyamino acid, most commonly serine or threonine, although hydroxyproline or 5-hydroxylysine may also' be used.
Addition of g[ycosylation sites to the target polypeptide is conveniently accomplished by altering the amino acid sequence such hat it contains one or more of the above-described tri-peptide sequences (for N-linked glycosylation sites). The alteration may also be made by the addition of; or substitution by, one or more serine or threonine residues to the native target s''' polypeptide sequence tfor O-linked glycosylation sites?. Fat ease, the target polypeptide amino acid sequencb is prgferabl~ altered throughchanges at the DNA level, particularly by mutating the DNA encodieg the target polypeptide at p~esalected bases such that codons are generated than will translate into the desired amino acids. The DNA mutationtsl may be made using methods described above under the heading of "Amino Acid Sequenc8 Variants of Target 'Potypeptide".
Another means of ' increasing the number of carbohydrate moieties on the target polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. These procedures are advantageous in that they do not require production of the polypeptide in a host cell that has glycosyiation capabilities for N- and O- linked glycosylation.
Depending on the coupling mode used, the sugartsf may be attached to ta? arginine and histidine, tb? free ~i'T..,..,.',~ , ~ ,' a :.~... .. ~ .-,. ~ ,:.': .. :..,. .::, ~ . . ~. ~.
.'.~~. ~. ,.:. ;'; _, . ,~. ..' . .,'.,,.'~~. , wo ~z>zz~s3 2 ~. ~ ~ ~ ~ ~ FCT/US9zl05126 carboxyl groups, tc) free sulfhydryl groups such as those of cysteine, td) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, te) aromatic residues such as those of phenytalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine.
These methods are described in WO 87/05330 published 11 September 1987, and in Aplin and Wriston (CF1C_ Crit Rev Biochem., pp. 259-306 (1981]).
Removal of carbohydrate moieties present on the native target polypeptide may be accomplished chemically or enzymatically. Chemical deglycosylation requires exposure of the polypeptide to the compound trifluoromethanesulfonic acid, or an equivalent compound. This treatment results in the cleavage of most or' ail sugars except the linking sugar (N-acetylglucosamine or N-acetylgalactosamine), while leaving the polypeptide intact. Chemical deglycosytation is described by Hakimuddin et al. (Arch Biochem. Bionhys., 259:52 (198?]) and by Edge et al. (Anal. Biachem., 11 :131 ( 19811). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-giycosidases as described by Thatakura et al. (fVleth. Enzvmol., 18:350 (1987]).
Glycosylation at potential ~lycosbtation sites may be prevented by the use of the compound tunicamycin as describ~d by Duskin et al. (J. Bial. them.. 2_x:3105 ( 19821).
Tunicamycin blocks the formation of protein-N-glycoside linkages.
Another type of covalent modification of the target polypeptide comprises linking the target poiypeptide to various nonproteinaceous polymers, e.g. polyethylene glycol, _ polypropylene glycol or polyoxyalkylenes, in the manner set forth in U.S.
4,640,835;
4:496,689; 4,301;144; 4;670,417; 4,791,192 ar 4,179,337.
The target polypeptide also may, be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization Ifor example, hydroxymethylcellulase o~ getatir~-microcapsules and poly-(methytmethacylateD
microcapsufes, ~S ' respectively), in colloidal drug delivery systems tfor example, tiposomes, albumin microspheres, microemutsionsnano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Reminaton's Pharmaceutical Sciences, 16th edition, Osol, A., Ed., (1980).
Target polypeptide preparations are also useful in generating antibodies, for screening #or binding partners, as standards in assays for the target polypeptide te.g.
by labeling the target polypeptide for use as a standard in a radioimmunoassay, enzyme-linked immunoassay, or radioreceptar assay), in affinity purification techniques, and in competitive-type receptor binding' assays when labeled with radioiodine, enzymes, fluorophores, spin labels, and the like.
Since it is often difficult to predict in advance the characteristics of a variant target potypeptide, it will be appreciated that some screening of the recovered variant will be needed ~~~~,a : .:F: ;. :' .. .: . .. : . ~ w.r: . ..:.; . ",; , ... ..,, ::; . : ;;
: .
~~t..
,.,~ WO 92/22653 ~ ~ ~ ~ ~ ~ PL'I'/US92/OS126 S S' to select the optimal variant. For example, a change in the immunologicai character of the target polypeptide molecule, such as affinity for a given antigen or antibody, is measured by a competitive-type immunoassay. The variant is assayed for changes in the suppression or enhancement of its activity by comparison to the activity observed for the target polypeptide in the same assay. Other patential modifications of protein or palypeptide properties such as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation, stability in recombinant calf culture or in plasma, or the tendency to aggregate with carriers or into multimers are assayed by methods well known in the art.
la Diac~na_~ i~,~nd Relatee~~l~,g_s of the Anti odies The antibodies of this invention are useful in diagnostic assays for antigen expression in specific cells or tissues. The antibodies are detectably labeled andJor are immobilized on an insoluble matrix.
The antibodies of this invention find further use far the affinity purification of the - 15 antigen from recombinant cell cult~rre or natural sources. Suitable diagnostic assays for the antigen and its antibodies depend on the particular antigen or antibody.
Generally, such assays include competitive and sandwich assays, and steric inhibition assays.
Competitive and sandwich methods employ a phase-separation step as an integral part of the method white steric inhibition assays are conducted in a single reaction mixture.
Fundamentally, the same 20 procedures are used for the assay of the antigen and for substances that bind the antigen, although certain methods wilt be fav~red depending upon the molecular weight of the substance being assayed: ' Therefore, the substance to be tested is referred to herein as an ar~alyte, irrespective of its status otherwise as an antigen or antibody, and proteins,$hat bind to the analyte, are denominated binding partners, whether they be antibodies, cell surface 25 ' receptors, or antigens.
Analyxical methods far he antigen or its antibodies all use one or more of the following reagents: labeled anaiyte analogue; immobilized ana)yte analogue, labeled binding partner, immobilized bindiryg partner and steric conjugates. The labeled reagents also are known as "tracers."
The label used _tand this is also useful to label antigen nucleic acid for use as a probe) is any detectable functionality 'that dogs not interfere with the binding of ana)yte and its binding partner. Numerous labels are known for use in immunoassay, examples including moieties that gay be detected directly, such as fluorochrome, chemiluminescent, and radioactive labels, as well as moieties, such as enzymes, that must be reacted or derivatized r?,~r k , ., ,.. ,. . ',.
PCT/ US92/0512b W~ 92/22653 5~
to be detected. Examples of such labels include the radioisotopes 3ZP, '4C, '25i, 3H, and '3'I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterbal luciferase tU.S. Pat. No. 4,737,456);.luciferin, 2,3-dihydrophthalazinedianes, horseradish peroxidase 5' tHRP), alkaline phasphatase, ~-galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose axidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or micraperoxidase, biotin/avidin, spin labels, bacterrophage labels, stable free radicals, and the like.
Conventional methods are available to bind these labels covalently to proteins or polypeptides. For instance, coupling agents such as dialdehydes, carbadiimides, dimaleimides, bis-imidates, bis-diazotized benzidine, and the like may be used to tag the antibodies with the above-described fluorescent, chemiiuminescent, and enzyme labels. See, for example, U.S.
Pat. Nos. 3,940,475 tfluarimetry) and 3,645,090 (enzymes); Hunter et al., Nature, 144: 945 (1962); L?avid etal., Biach~mistry, 1~: 1014-1021 (1974); Pain etal., ~
Immunol. Methods, 40: 219-230 (1981); and Nygren, J. Histochem. and Cvtochem., ~0: 407-412 (1982).
Preferred labels herein are enzymes such as horseradish peroxidase and alkaline phosphatase.
The cpnjugation of such label; including the enzymes, to the antibody is a standard manipulative procedure far one of ordinary skill in immunoassay techniques.
See, for example, O'Sultivan et a/., "Methods for the Preparation of Enzyme-antibody Conjugates for Use in Enzyme Imrnunoassay." in Methods in Enzvmolaav, ed. J.J. Langone and H. Van Vunakis, Vol.
73 (Academic Press, New: Yprk; New York, 1981 ), pp. 147-166. Such bonding methods are suitable for use with the antibodies and polypeptides of this invention.
Immobilization of reagents is required for certain assay methods.
Immobilization entails separating the binding partner from any anatyte that remains Eras in solution.
This conventionally is accomplished by either insoiubilizing the binding partner or analyte analogue before the assay procedure, as by adsorption to a water-insoluble matrix or surface (Bennich etal.., U.S. 3,710,760), by covalent coupling (for example, using glutaraldehyde cross-finking), or by insolubilizing the partner or analogue afterward, e.g., by immunoprecipitation.
Other assay methods, known as competitive or sandwich assays, are well established and widely used in thd commercial diagnostics industry.
Competitive assays rely on the ability of a tracer analogue to compete with the test sample anaiyte for a limited number of binding sites on a common binding partner. The binding ry~,:~,;~.:v" ,. . ., ,.., wo ~2i226~~ ~ ~. ~ ~ ~ J ~~ ~orius~2i~5~z6 S~
partner generally is insolubilized before or after the competition and then the tracer and analyte bound Lo the binding partner are separated from the unbound tracer and analyte. This separation is accomplished by decanting (where the binding partner was preinsoiubilized? or by centrifuging (where the binding partner was precipitated after the competitive reactiony.
The amount of test sample analyte is inversely proportional to the amount of bound tracer as measured by the amount of marker substance. Dose-response curves with known amounts of analyte are prepared and compared with the test results to quantitatively determine the amount of analyte present in the test sample. These assays are called ELISA
systems when enzymes are used as the detectable markers. ' to Another species of competitive assay, called a "homogeneous" assay, doss not require a phase separation. Here, a conjugate of an enzyme with the analyte is prepared and used such that when anti-analyte binds to the analyte the presence of the anti-analyte modifies the enzyme activity. In this case, the antigen or its immunologically active fragments are conjugated with a bifunctional organic bridge to an enzyme such as peroxidase.
Conjugates are selected for use with antibody so that binding of the antibody inhibits or potentiates the enzyme activity of the label. This method per se is widely practiced under the name of EMIT.
Steric conjugates are used in steric hindrance methods for homogeneous assay.
These conjugates are synthesized by covalently linking a low-molecular-weight hapten to a small analyte so that antibody to hapten substantially is unable to bind the conjugate at the same 2o time as anti-analyte. Under this assay procedure the analyte present in the test sample wilt bind anti-analyte, thereby allowing anti-hapten to bind the conjugate, resulting in a change in the character of the conjugate hapten, e.g., a change in fluorescence when the hapten is a fluorophore.
., Sandwich assays particularly are useful for the determination of antigen or antibodies.
In sequential sandwich assays an immobilized binding partner is used to adsorb test sample analyte, the tdst sample is removed as by washing, the bound analyte is used to adsorb labeled binding partner, and bound nnaterial is then separated from residual tracer.
The amount of bound tracer is directly proportional to test sample analyte. In "simultaneous'° sandwich assays the test sample is not separated before adding the labeled binding partner. A sequential sandwich assay using an anti-antigen monoclonal antibody as one antibody and a polyclonal anti-antigen antibody ass he other is,useful in testing samples for particular antigen activity.
The foregoing aye merely exemplary diagnostic assays for the import and humanized antibodies of this inventibn. other methods now or hereafter developed for the determination of these analytes are included within the scope hereof, including the bioassays described -_._ ~ ~'.~ ~ 1 S.f, Y.mrr v.,-r.r WO 9Z/~2653 S$
above.
~mmunotoxins This invention is also directed to immunochamica) derivatives of the antibodies of this invention such as immunatoxins fconjug3tes at the antibody and a cytotoxic moiety).
A_rrtfbodies which carry the apprapriato effector functit5ns, such as with-their constant domains, are also used to induce lysis;thirough the natural complement process, and to interact with antibody dependent cytotoxic cells normally present-For example, purified, sterile filtered antibodies are optionally conjugated to a 1a cytotoxin such as ricin for use in AIDS therapy. 'The methods of this invention, for example, era 'suitable for obtaining humanized antibodies for use as immunotoxins for use in AIDS therapy, The cytotoxic moiety. of the immunatoxin may be a aYtotoxic drug or an enzymaticaNy active toxin of bacterial, fungal, plant or animal origin, or an enzymatically active fragment Qt such a toxin. i:nzymatically active toxins and fragments thereof used are diphtheria A chain, nonbinding active fragments of diprithoria~ .toxin. exotoxin A drain (from Psetrrlamo~as aemginosa), ~ricin A chain, abrin A chain, modaccin A chain, alpha-s9rcin, Aleurites fordii proteins,.dianthin fxoteins;.~hyiclacaamericana proteins iF'APi; PAPI1, and PAF-S), momordica ~.: zo charantia inhibitor, curcirr. . crotin, sapaonaria afficinalis inhibitor, gelonin, mitogellin, restrictocin, phor<omycin. enomycin and the tricothecenes. In another embodiment, the antibod'ses ire conjugated to small molecule anticancer drugs such as cis-platin or 5FU.
. Conjugates of the monoclonal antibody and'such cYtotoxic moieties are made using a variety of bifunotional protein coupling agents. Examples of such reagents are SPDP, IT , bifunctional derivatives af. imidoesters : such . as dimethyl ~ adipimidate HCI, active esters such as . ~ disuccinimidyl ,suberate, aldehydes.such as ~tutaraidehyde. his-azido compounds such as bis fp-azidobenzoyll hekanediamina, bis-diaz4riium-derivatives such as his- tp-diazonium4enzoyll w ~ethylenediamine, .diisocyanates such, as tolylene 2,6-diisocyanate and bis-active fluorine compounds such ~as l,~-difluoro 2;4-dinitrobenzer~e. The (YSing portion of s toxin may be joined to the Fob fragment of the antib6dies.
Imrrmnoioxins can be cnada gin, a variety of ways; as discussed heroin.
Gommoniy . .known crosslinking reager~ta can.be used~to yield stable conjugates.
Advantageously. rE'~onocional antibodies specifically binding the domain of the antigen which is exposed tiry the infected cell 'surface, are con9ugated to ricin A
chain. Most . VVO 92/22653 2 ~ ~ ~ 0 ~ ~ PCT/US92/OS1Z6 advantageously the ricin A chain is deglycosylated and produced through recombinant means.
An advantageous method of making the ricin immunotoxin is described in Vitetta et al., Science 238:1D98 11987).
When used to kill infected human cells in vitro for diagnostic purposes, the conjugates will typically be added to the cell culture medium at a concentration of at least about 10 nM.
The formulation and mode of administration for in vitro use are not critical.
Aqueous formulations that are compatible with the culture or perfusion medium will normally be used.
Cytotoxicity may be read by conventional techniques.
Cytotoxic radiopharmaceuticals for treating infected cells may be made by conjugating radioactive isotopes te.g. l, Y, Pr) to the antibodies. Advantageously alpha particle-emitting isotopes are used. The term 'cytotoxic moiety" as used herein is intended to include such isotopes.
in a preferred embodiment, ricin A chain is deglycosylated or produced without oligosaccharides, to decrease its clearance by irrelevant clearance mechanisms (e.g., the liver).
in another embodiment. whale ricin tA chain plus B chain) is conjugated to antibody if the gatactose binding property of B-chain can be blocked t"blocked ricin").
In a further embodiment toxin-conjugates are made with Fab or Ftab')2 fragments.
Because of their relatively small size these fragments can better penetrate tissue to reach infected cells. -In another embodiment, fusogenic liposomes are filled with a cytotoxic drug and the liposom~s are coated with antibodies specifically binding the particular antigen.
Antibody Denenden~ Cellular Cvtotoxicitv ".w/
Certain aspects of this invention involve antibodies which are ta) directed against a particular antigen acrd tb) belong to a subclass or i~otype that is capable of mediating the lysis of cells to which the antibody molecule 'binds. IVlore specifically, these antibodies should belong to a subclass or isotype than upon c~mplexing with cell surface proteins, activates serum complement and/or mediates antibody dependent cellular cytotoxicity tADCC) by activating effector cells such as natural kilter cells or macrophages.
90 Bioto~ical activity of antibodies is known to be determined, to a large extent, by the constant domains or Fd region of the antibody molecule tUananue and t3enacerraf, Textbook of Jmmuno%gy; 2nd i=dition, Williams & Wilkinsp. 218 11984)). This includes their ability to activate complement and to mediate antibody-dependent cellular cytotoxicity tADCC) as effected by leukocytes. Antibodies of different classes and subclasses differ in this respect, wo ~ziza~s3 ~ ~. ~ ~~ ~ ~~ ~ ~crius9a/asiab coo as do antibodies from the same subclass but different species; according to the present invention, antibodies of, those classes having the desired biological activity are prepared.
Preparation of these antibodies involves the selection of antibody constant domains are their incorporation in the humanized antibody by known technique. For example, mouse immunoglobulins of the IgG3 and IgG2a class are capable of activating serum complement upon binding to the target cells which express the cognate antigen, and therefore humanized antibodies which incorporate IgG~ and IgG2a effector functions are desirable for certain therapeutic applications.
In general, mouse antibodies of the IgG2a and IgG3 subclass and occasionally IgG 1 can to mediate ADCC, and antibodies of the IgG3, IgG2a, and IgM subclasses bind and activate serum complement. Complement activation generally requires the binding of at least two IgG
molecules in close proximity on the target cell. However, the binding of only one IgM molecule activates serum complement.
The ability of any particular antibody to mediate lysis of the target cell by complement activation and/or ADCC can be assayed. The cells of interest are grown and labeled in vitro;
the antibody is added to the cell culture in combination with either serum complement or immune cells which may be activated by the antigen antibody complexes.
Cytolysis of the target cells is detected by the release of label from the lysed cells. 6n fact, antibodies can be screened using the patient's own serum as a source of complement and/or immune cells. The antibody that is capable of activating complement or mediating ADCC in the in vitro test can then be used therapeutically in that particular patient.
This invention specifically encompasses consensus Fc antibody domains prepared and used according to the teachings of this invention.
-a Thera,~eutic and~ther Uses of the Antibodies When used in ~ivo for therapy, tha antibodies of the subject invention are administered to the patient in therapeutically effective amounts (i.e. amounts that have desired therapeutic effect?. They will normally be administered parenterally. The dose and dosage regimen will depend upon the degree of the infecti~n, the characteristics of the particular antibody or 3o immunotoxin used, e.g., its therapeutic index, the patient, and the patient's history.
Advantageously the antibody or immunotoxin is administered continuously over a period of 1 ~2 weeks, intravenously to treat cells in the vasculature and subcutaneously and intraperitoneally to treat regional lymph nodes. Optionally, the administration is made during the course of adjunct therapy such as combined cycles of radiation, chemotherapeutic treatment, or . W4 92/22653 ~ ~ ~ ~ ~ ~ v PC'd'lUS92>05126 (0 4 administration of tumor necrosis factor, interferon or other cytoprotective or immunomodulatory agent.
For parentera! administration the antibodies will be formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vehicle. Such vehicles are inherently nontoxic, and non-therapeutic. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5~~
human serum albumin. Nonaqueous vehicles such as fixed oils and ethyl oleate can aBso be used. Liposomes shay be used as carriers. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, e.g., buffers and preservatives.
to The antibodies will typically be farmulated in such vehicles at concentrations of about 1 mgiml to 10 mgiml.
Use of lgAl1 antibodies may be preferred for certain applications, however !gG
molecules by being smaller may be more abte than IgM molecules to localize to certain types of infected cells.
There is evidence that complement activation in vivo~leads to a variety of biological effects, including the induction of an inflammatory response and the activation of macrophages tUananue and l3enecerraf, Textbook of lmmunalogy, 2nd Edition, Williams &
Wilkins, p. 218 (1984)). The increased vasodilation accompanying inflammation may increase the ability of various agents to localize in infected cells. Therefore, antigen-antibody combinations of the . 20 type specified by this invention can b~ used therapeutically in many ways. Additionally, purified antigens tHakomori, Ann. Rev, lmmunol. 2:103 (1984)) or anti-idiotypic antibodies (Nepom et aP., Proc. Nat/. Acad. Sci. 81:2864 (1985); Koprowski et al., Proc.
lUatl. Acad. Sci.
81:216 ( 1984)) relating to such antigens could be used to induce an active immune response in human patients. Such a response includes the formation of antibodies capable of activating human complement and mediating ADCC and by such mechanisms cause infected cell destruction.
Optionally, the antibodies of this invention are useful in passively immunizing patients, as exemplified by the administration of humanized anti-HlV antibodies.
The antibody compositions used in therapy are formulated and dosages established in 3o a fashion consistent with good medics! practice taking into account the disorder to be treated, the condition of the individual patient, the site of delivery of the composition, the method of administration and other factors known to practitioners. The antibody compositions are prepared for administration according to the description of preparation of polypeptides for administration, infra.

W~ 92/22653 ~ ~ ~ ~ ~ j ~ PCTlUS92/0512t~
(0 2 Deposit of Materials As described above, cultures of the muMAb4D5 have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA
(ATCC).
This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest.Tr~aty). This assures maintenance of viable cultures for 30 years from the date of the deposit. The organisms will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures l0 to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 38 USC ~ 122 and the Commissioner's rules pursuant thereto (including 37 CFR ~ 1.12 with particular reference to 886 OG 638).
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPCD
The assignee of the present application has agreed that if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a viable specimen of the same culture.
Availability of the deposited strain is not to be construed as a license to practice the invention in contravention ,~ s of the rights granted under the authority of any government in accordance with its patent Isws.
The foregoing written spepification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the constructs deposited, since the deposited embodiments are intended to illustrate only certain aspects of the invention and any constructs that are functionally equivalent are within the ,, scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode (hereof, nor is it to be construed as limiting the scope of the Maims to the specific illustrations that they represent. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those ~.,:..;, ,. ..; ~ ..-.. ...,;..:.;: .,.:.: . ;;. :... .....:".,. .. ._ .. .
~~.~~f~ )~
..,W~ 92/22653 4 ~ PC~'/USl2/05126 skilled in the art from the foregoing description and fall within the scope of the appended claims.
It is understood that the application of the teachings of the present invention to a specific problem or situation will be within the capabilities of one having ordinary skill in the art in light of the teachings contained herein. Examples of the products of the present invention and representative processes for their isolation, use, and manufacture appear below, but should not be construed to limit the invention.
EXAMPLES
EXAMPLE 1. HUMANIZATION OF muMAb4D5 Here we report the chimerization of muMAb4D5 tchMAb4D5> and the rapid and simultaneous humanization of heavy tVM) and light tV~) chain variable region genes using a novel "gene conversion mutagenesis" strategy. Eight humanized variants thuMAb4D5) were constructed to probe the importance of several FR residues identified by our molecular modeling or previously proposed to be critical to the conformation of particular CDRs tees Chothia, C. & Lesk, A. M., J. Mol. Biol. '196:901-917 (19871; Chothia, C. et al., Nature 342:877-883 11989); Tramontano, A. et al., J Mol. 6~ial. 215:175-182 11990)).
Efficient 2p transient expression of humanized variants in non-myeloma cells allowed us to rapidly inv~stigate the relationship between binding affinity for p185HEgz ECD.and anti-proliferative activity against p185HER2 ~verexpressing carcinoma cells.
flliATERIALS and tUIETHOD9 ,;
Cloning of ilariobte l~egi~ro Genes: The muMAb4D5 VH and VL genes were isolated by potymerase chain reaction (PCR) arnptific~tion of mRNA from the corresponding hybridoma iFer~dly, ~. M. et al., Cancor Res. 5~:1550-1558 11990)) as described by Orlandi et al.
tOrtandi; R. et ~P.; Proc: '!Nato Acid. Sci. LISA 86:3833-3837 11989)). Amino terminal sequencing of muMA64D5 V~ and V~ was used to design the sense strand PCR
primers, whereas the anti-sense PCR primers were based upon consensus sequences of murine framework residues dOrtandi, R. et al., Proc. lUarl. Acad. Sci. USA 86:3833-3837 11989);
Kabat, E. A.' et al., Sequences'of ProPeins of Ira~murrologica! Interest tPlational Institutes of Health, 8ethesda; MD; 1987)) incorporating restriction sites for directional cloning shown by underlining ahd listed after the sequences: V L sense, 5'-TCCGATATCCAGCTGACCCAG~'CTCCA-3' tSEQ. 1D NO. 7), EcoRV; VL anti-sense, 5'-Wo 9zn~s53 ~ ~, ~ ~ ~ ~ ~ P~G'1'/US92/0512b GT'iTGATCTCCAGCTT~~t~iSCDCCGAA-S' (SEO. IQ NO. 8). Asp77 B; vH sense, 5'-AGGTSMARSe.TSAGTGWGGw3' ISEa~ iQ NO- 9f~ Pstl and YH anti-sense, 5'-TGAGGAGAC~~.GTGG~'CCCTTGGCCCCAG-3' (SECZ. ID NO. 10), BstEll; where H =
A or C or T. 8 - C or G. D = A or G or T, M ~ A ar C. R = A or G and W = A or T. The PCR products were cloned iota pli'C11,9 tVielra..f~ & Messing. J., Methods En~ymol. '153:3-1.1 , (19871) and five cibnes for each variakFla domain sequenced bY the dideoxy method (5anger.
F. ei .al., Prac. Natl. Aced. Saj. LISA 74:6463-5487 ! ~ 977)).
Molecular Modelling. Modats for muMAb4D5 VH and VL domains were c~structed separately from oonsensws coordinates based upon seven Fob structures from the Brookhavan 1o protein dad bank (entries 1 F~~ 2RHt~, 2MCP. 31=AB, 1 FBJ, 2HFL and 1 REI).
The pab fragment KCAL lMarquart, M. et al., J. Mal. Bial. '141:3$9-391 (1980)) was first Chosen as a template for V~ and VH domains and additional structures were then superimposed upon this structure using their main chain atom coordinates 11NSIGH~'iprogram. Biosym Techwlogies).
The distance from the template Catv the analvgaus Ca in each of thg superirnposad structures 15. was calculated for each residue position. If alt for nearly all? Ccr-Ca distances far a given residue were 5 1 R, then that position .was included in the aansensus structure. In most cases the ~-sheet framework.rssidues satisfied tflese criteria whereas the CDR loops did not. For each of these selected 'rasidu'as the average coordinates fvr individual N, Ca. C, O and CB
atoms were calGUl~ted and then corrected far resultant deviations from non-standard bond ' geormetry >;y 50 cycles of energy minimization using the DISCOVER"program (Biosym Technologies) .with the yAM,B>'Rk:fotcefield (Weiner, s. J. et al., J. Amer.
Chem. 5oc.
106:766-?84 (1984)) and Cccoordir~ates fixed. The side chains of highly conserved residues, ' , such as the disul8de-bridseii b~lstdine reaidues~ ware then incorporated into the .resultant consensus structure. . Next the saqu~ncBS of muMAb4D6 V~ and VH ware incorporated 5sxartin~ with the CDR fes'idues and using the tabulations of CDR
conformations from Chotnia ex a!: (Chothia:.C~.'et al,, IVatLre' 342:8?7-883 (1989)1 as a guide. Side-chain conformations - were chosen on.the~ basis.of I=ab crystal structures, rotemer libraries (Ponder, ,!. W. ~ Richards.
F. nn,; .1.; Mah viol 193:?75-.791 (19$7)i and pac.kir~g considerations. Since VR-CDR3 could not be assigned a definite #ackbone; conformation from these criteria, two modals were created '~o ~ frpm a search of similar,sized leaps using the INSIGHT program. A third rnadal was derived using packing and solvent expusurd considerations. Each modal was then subjected to 5000 cybles of energy minimization: , In humanizing mulVIAb4D~.''aanssnsUS human sequences were first derived from the mdst~abundant sutxlasses in. he sequence caniliilation of Kabat et al. (Kabat.
E. A. et al_, *-trademarks W4 92122653 ~ ~ ~ J ~ J ~ PC1'/LJ592/0512G
!~ S
SeQuences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD, 1987)), namely V~ x subgroup I and VH group III, and a molecular model generated for these sequences using the methods described above. A structure for huMAb4D5 was created by transferring the CDRs from the muMAb4D5 model into the consensus human structure. All huMAb4D5 variants contain human replacements of muMAb4D5 residues at three positions within CDRs as defined by sequence variability (Kabat, E. A. et al., Sequences of Proteins of lmmuno%gicallnterest (National Institutes of Health, Bethesda, MD, 1987)) but not as defined by structural variability (Chothia, C. & Lesk, A. M., J. Mol. Biol. 196:901-917 (1987)):
VL-CDR1 K24R, VL-CDR2 R54L and VL-CDR2 TSfS. Differences between muMAb4D5 and l0 the human consensus framework residues (Fig. 1 ) were individually modeled to investigate their possible influence on CDR conformation and/or binding to the p185HER2 ECD.
Construction of Chimeric Genes. Genes encoding chMAb4D5 light and heavy chains were separately assembled in previously described phagemid vectors containing the human cytomegalovirus enhancer and promoter, a 5' intron and SV40 polyadenylation signal (Gorman, 1~ C. M, et al., DNA & Prot. Engin. Tech. 2:3-10 (1990)). Briefly, gene segments encoding muMAb4D5 VL (Fig. 1 A) and REI human K1 light chain CL (Palm, W. & Hilschmann, N., Z.
Physiol. Chem. 356:167-191 (1975)~ were precisely joined as were genes for muMAb4D5 VH
(Fig. i B) and human y1 constant region (Capon, D. J. et al., Nature 337:525-531 (1989)) by simple subcloning (Boyle, A.; in Current Protocols in Molecular Biology, Chapter 3 (F. A.
20 Ausubel et al., eds., Greene Publishing & Wiley-Interscience, New York, 1990)) and site-directed mutagenesis (Carter; P., in Mutagenesis: A Practical Approach, Chapter 1 (IRL
Press, Oxford, UK 1991 )). The y1 isotype was chosen as it has been found to be the preferred human isotype for supporting ADCC and complement dependent cytotoxicity using matched sets of chimeric EBruggemanrv, M. et al.; J. Exp. Med. 166:1351-1361 (1987)) or humanized 25 antibodies (Riechmann; L. eral.; Nature 332:32-327 (1988)). The PCR-generated VL and VH
fragments (Fig. 1 ) were subsequently mutagenized so that they faithfully represent the soquence of muMAb4D5 determined at the protein level: VH Q1 E, VL V104L and tvariants are denoted by the -amino acid residue and number followed by the replacement amino acid). The human yl constant regions are identical to those reported by Ellison et al.
30 (Ellison, J. W. et al., Nucleic Acids Res. 13:4071-4079 (1982)) except for the mutations E359D and M361 L (Eu numbering, as in Kabat, E. A. et al., Sequences of Proteins of Immunologicallnterest (National Institutes of Health, Bethesda, MD, 1987)) which we installed to convert the antibody from the naturally rare A allotype vo the much more common non-A
allotypd (Tramont~no, A. et al., J. Mol: Biol. 215:175-182 (1990)). This was an attempt to Vd~ 92!22653 ~ ~ U ~ ~ J ~ PCIf/US92/OS126 reduce the risk of anti-allotype antibodies interfering with therapy.
Construction of Humanized Genes. Genes encoding chMAb4D5 light chain and heavy chain Fd fragment (VH and CH1 domains) were subcloned together into pUC119 (Vieira, J. &
Messing, J., Methods Enzymoi. ''53:3-11 (1987)) to create pAK1 and simultaneously S humanized in a single step rtFig. 2). Briefly, sets of 6 contiguous oligonucleotides were designed to humanize VM and V~ (Fig. 1 ). These oligonucleatides are 28 to 83 nucleotides in length, contain zero to 19 mismatches to the marine antibody template and are constrained to have 8 or 9 perfectly matched residues at each end to promote efficient annealing and iigation of adjacent oligonucleotides. The sets of VH and VL hurnanization oligonucleotides (5 pmol each) wars phosphorylated with either ATP or y-32P-ATP (Carter, P.
Methods Enzymol.
154:382-403 (1987)) and separately annealed with 3.7 pmol of pAK1 template in 40,u1 10 mM Tris-HCl (pH 8.0) and 10 mM MgCl2 by cooling from 100 ~C to room temperature over 30 min. The annealed oligonucleatides were joined by incubation with T4 DNA
ligase ( 12 units; New England Biolabs) in the prqsence of 2 NI 5 mM ATP and 2 /el 0.1 M
DTT for 10 min at 14 ~C. After electrophoresis on a 6°!° acrylamide sequencing get the assembled oligonucleotides were looted by autoradiography and recovered by electroelution. The assembled oligonucleotides ( -- 0.3 pmol each) were simultaneously annealed to 0.15 pmol single-stranded deoxyuridine-containing pAK1 prepared according to Kunkel et al. (Kunkel, T.
A. et aL, Methods Enzymol. 154:367-382 (1987)) in 10 pl 40 mM Tris-HCI (pH
7.5) and ~16 24 mM MgCl2 as above. He'teroduplex DNA was constructed by extending the primers with T7 DNA polymerase and transformed into E, coil 8MH 71-18 mutt as previously described (Carter; P., in Mutagenesis: A Practice! Approach, Chapter 1 (IRL Press, Oxford, UK 1991 )).
The resultant phag~iwid DNA pool was enriched first for huVL by restriction purification using 4_~
Xhol and then for huV~ key restriction selection using Stul as described in Carter, P., in Mutagene5is: A Practical Approach, Chapter 1 tIRL Press, Oxford, UK 1991 );
and in Wells, J. A. et al , Phil: Traps: R. Soc. Lond A 317:415-423 41986). Resultant clones containing both huVL and huVH genes were identified by nucleotide sequencing tSanger, F.
et al., Proc.
IVatl, aAcad. Sci. US~I 74:5463-5467 (19771) and designated pAK2. Additional humanize variants were generated by site-directed mutagenesis (Carter, P., in Mutagenesis: A Practice!
Approach, Chapter 1 (IRL Press, Oxford, UK 1991 )). The muMAb4D5 VL and VH
gene sbgme~nts in the transient expression vectors described above were then precisely replaced with their humanized versions.
Exlaression and Purification of IUlAb4D5 Variants. Appropriate MAb4D5 light and heavy chain cDNA expression vectors were co-transfected into an adenovirus transformed human .,.WO 92/22b53 ~ ~ ~ ~ ~ ~ ~ PGTIU~a9214S~~~
embryonic kidney cell line, 293 (Graham, F. L, et al.. J. Gen. Viro~ 36:68-72 f't 977)) using a high efficiency procedure IGarman, G. M. er al., DNA & Prot. Engin. Tech. 2:3-117 11990);
Gorman, C., in DNA Clanln9. val II, pp 143-'1 g0 (~. M. Glover, ed., IRL
Press, Oxford. UK
19$5?). Media were harvested daily for up to 5 days and the cells re-fed with serum free g madla. An'~bddigs were recovered from the media and affinity purified on protein a sepharose*
CL-4B IPharmacia) as described by the manufacturer. The eluted antibody was buffer-exchanged into phosphate-buffered saline by G25 gel filtration, concentrated by ultrafiltration (Cerrtriprep~i0 or ~er'atriao~i 00. Amiconi, sterile-filtered (Miliex~"sV, Millipore) and stored at 4 ~C. The concentration of antibody was determined by using bath total immunoglobuiin and antigen binding .ELISAs. The staruiard used was huMAb4D5-5, whose concentration had been rJetgrmined by amino acid composition analysis.
Cal! ProtifW"at~n Assay. The off8ct of MAb4D5 variants upon proliferation of the human mammary adenocarcinoma coil line, SK-BR-3, was investigated ss previousty.described ~IFendly, B. M. et al.: Cancer Res. 50:1554-'t 55$ I1 ~g0)f using saturating MAb4~5 rs concentrat;Qns.
AftINty Messuraments. The antigen binding affinity of MAb41~5 variants was determined using a sebrotad.form of the p185HER~ ECD prepared as described in Fendiy. ~.
. M..et al., J. 8iol. Rasp; INod.' 9:449~155.t't9941. Briefly, antibody and plg5HeR2 ECD were . incubated ~in so(ut(on until eqbilibriurh was found to be reached. The concentration of free antibody was th~dn determined'. by ,ELfSA .using immobilized p1$5HE~2 ECD and used to calouiata affinity tKd) according to Friguet et al. (Friguet. 8, et al. .t.
Immunal. Methods 77:305-319 I19135fi: ~ , .
.. , ,; ~. . ;
. . . ~ itF,SULTS
.a:5 , . 1 .. t~hrrhanixation tif'iinuMAb4iD5: Tha muMAb4a5 V~ arid vH gene segments ware first aloned~ by_' PC'R ~ and Sequoi~cBdi tFig. , .11. Ttie variable genes were xhan simultaneously . ,h~e~ized~by.:gene~avnvarsian_mutagenesis,usirip preassemblad ofigonucleotides tFig. xl. A
311 ~mer,: oiigoycleotide;~ontaining ~9 rniarria~chas to the template directed 24 simultaneous amino acid changes, required to humanize muMAb4D5 VL. Humanization of muMAb4D5 VH
requirad.32 amino acid .~char~ga~..~fuph were installed with a 361~mer containing 59 ~.rnismatches to the muN~Ab4D5 tbmplate: Two. out of 8 clones sequenced precisely encode huMAb4D~-5, although:~one of these clones cvittained a aingte nucleotide imporfectian. The 6.other clones were ess~ntialfy humamied but contained a small number of grrQrs_ ~ 3 nucleotide changes and ~ f~ single. nucleotides uelation per kilobe$e.
Additibnai humanized '*-trademarks ' WO 92!22653 ~ ~ ~ ~ ~ ''~ '~ PCTltJS92lg5126 .
!r 8 variants (Table 31 were constructed by site-directed mutagenesis of huMAb4D5-5.
Expression levels of huMAb4D5 variants were in the range of 7 to 15 pglml as judged by ELISA using immobilized p185HER2 ECD. Successive harvests of five 10 cm plates allowed 200 Ng to 500 mg of each variant to be produced in a week. Antibodies affinity purified on protein A gave a single band on a rCoomassie blue stained SDS polyacrylamide gel of mobility consistent with the expected Mr of -150 kDa. Electrophoresis under reducing conditions gave 2 bands consistent with the expected Mr of free heavy (48 kDa) and light (23 kDa) chains Inot shown). Amino terminal sequence analysis ( 10-cycles) gave the mixed sequence expected (see Fig. 1 ) from an equimolar combination of light and heavy chains (not shown).
huMAb4D5 Variants. In general, the FR residues were chosen from consensus human sequences (Kabat, E. A. ex al., Sequences of Proteins of lmmuno!pgica!
Interest (National Institutes of Health, Bethesda, MD, 1987)) and CDR residues Pram muMAb4D5.
Additional variants were constructed by replacing selected human residues in huMAb4D5-1 with their muMAb4D5 counterparts. These are VH residues ? 1, 73, 78, 93 plus 102 and VE
residues 55 plus 66 identified by our molecular modeling. VH residue 71 has previously been proposed by others (Tramontano, A. et al., J. Mol. Biol. 215:175-182 (1990)) to be critical to the conformation of VH-CnR2: Amino acid sequence differences between huMAb4D5 variant molecules aye shown in Table 3, together with their p185HER2 ECD binding affinity and 2tt maximal anti-proliferative activities against SK-BR-3 cells. Very similar Kd values were obtained for binding of MAb4D5 variants to either SK-BR-3 cells or to p185HER2 ECD (Table 3). However, Kd estimates derived from binding of MAb4D5 variants to p185HER2 ECD were more reproducible with smelter standard errors and consumed much smaller quantities of antibody than binding measurements with whole cells.
The most potent humanized variant designed by molecular modeling, huMAb4D5-8, contains S FR residues from muMAb4D5. This antibody binds the p185HER2 ECD 3-fold mare tightly than does muMAb4D5 itself (Table 3) and has comparable anti-proliferative activity with SK-BR-3 cells (Fig. 3).' In contrast; huMAb4D5-1 is the most humanized but least potent muMAb4D5 va'iant, created by simply installing the muMAb4D5 CDRs into the consensus human sequences. huMAb4D5-l binds the p185RER2 ECD 80-fold less tightly than does the murine antibody and has no detectable anti-proiiferative activity at the highest antibody concentration investigated (16 Ng/m)).
The anti-pPOliferative activity of huMAb4D5 variants against p185HER2 overexpressing SK-i3R-3 cells is not simply co~retated with their binding affinity for the p185HER2 ECD. For -~WO 92/22653 PCf/US92/~D5126 example, installation of three marine residues into the VH domain of huMAb4D5-2 (D73T, L78A and A93S) to create huMAb4D5-3 does not change the antigen binding affinity but does confer significant anti-proliferative activity (Table 3).
The importance of VH residue 71 (Tramontano, A. et el., J. M~!. Biol. 215:175-S (1990)) is supported b~> the observed 5-fold increase in affinity far p185HER2 ECD on .
replacement of R71 in huMAb4D5-1 with the corresponding marine residue, alanine (huMAb4D5-2). In contrast, replacing VH L78 in huMAb4D5-4 with the marine residue, alanine (huMAb4D5-5), does not significantly change the affinity for the p185HER2 ECD or change anti-proliferative activity, suggesting that residue 78 is not of critical functional significance to huMAb4D5 and its ability to interact properly with the extracellular domain of p185HERZ.
VL residue 66 is usually a glycine in human and marine K chain sequences (Kabat, E.
A. et al., Sequences of Proteins of lmmunological Inferest (National Institutes of Health, Bethesda, MD, 1987)) but an arginine occupies this position in the muMAb4D5 k light chain.
The side chain of residue 66 is likely to affect the conformation of VL-CDR1 and V~-CDR2 and the hairpin turn at 68-69 (Fig. 4). Consistent with the importance of this residue, the mutation VL G66R (huMAb4D5-3 --~ huMAb4D5-5) increases the affinity for the p185HER2 ECD by 4-fold with a concomitant increase in anti-proliferative activity.
From maPecular modeling it appears that the tyrosyl side chain of muMAb4D5 VL
residue 55 may either stabilize he conformation of VH-CDR3 or provide an interaction at the VL-V~ interface. The latter function may be dependent upon the presence of VH
Y102. In the context of huMAb4D5-5 the mutations VL E55Y (huMAb4D5-6) and VH V102Y
(huMAb4D5-7) individualty increase the affinity for p185HER2 ECD by 5-fold and 2-fold respectively,, whereas together thuMAb4D5-81 they increase the affinity by 11-fold. This is consistent with either proposed role of VL Y55-and VH Y102.
Secondary Immune Funcdorr of huMAb4D5-8: MuMAb4D5 inhibits the growth of human beast tumor cells which overexpress pl B~HER2 tHudziak, R. M. et el., Malec. Cell.
Biol. 9:1165-1172 (19891). The antibody, however, does not offer the possibility of direct termor cytotoxic effects: This possibility does arise in huMAb4D5-8 as a result of its high affinity (Kd _ 0.1 NM) and its human IgGl subtype. Table 4 compares the ADCC, mediated by huMAb4D5-8 with muMAb4D5 on a narrnal lung epithelial cell line, WI-38, which expresses a low level of p185HER2'and on SK-~R-3, which expresses a high level of p185HER2, The results demonstrate that: (1 D huMAb4D5 has a greatly enhanced ability to carry out ADCC as compared with its marine patent; and (2) that this activity may be selective for cell types WVtD 92!22653 ~ ~ ~ ~ '~ ~ PCg'lUS92l05126 ~0 which overexpress p185H~R2 DlSCUSStON
MuMAb4D5 is potentially useful for human therapy since it is cytostatic towards S human breast and ovarian tumor ~tir°tes overexpressing the /-?ERA-encoded p185RER2 receptor-like tyrosine kinase. Since both breast and ovarian carcinomas are chronic diseases it is anticipated that the optimal MAb4D5 variant molecule for therapy will have low immunogenicity and will be cytotoxic rather than solely cytostatic in effect.
Humanization of muMAb4D5 should accomplish these goals. We have identified 5 different huMAb4D5 variants which bind tightly to p185~ER2 ECD (Kd 5 1 nM) and which have significant anti-proliferative activity (Table 3). Furthermore huMAb4D5-8 but not muMAb4D5 mediates ADCC against human tumor cell lines overexpressing p185HER2 in the presence of human effector cells (Table 4) as anticipated for a human y1 isotype (Bruggemann, M.
et al., ,!. Exp.
Med. 166:1351-1361 (1987); Riechmann, ~.. et al., Nature 332:323-327 (1988)):
Rapid humanization of huMAb4D5 was facilitated by the gene conversion mutagenesis strategy developed here using long preassembled oligonucleotides. This method requires less than half the amount of synthetic DNA as does total gene synthesis and does not require convenient restriction sites in the target DNA. Our method appears to be simpler and more reliable than a variant protocol recently reported (Rostapshov, V. M. e? al., FEBS Gett.
249:379-382 (1989)). Transientexpression of huMAb4D5 in human embryonic kidney calls permitted the isolation of a few hundred micrograms of huMAb4D5 variants for rapid characterization by growth inhibition and antigen binding affinity assays.
Furthermore, different Combinations of light and heavy chain were readily tested by co-transfec~tion of corresponding cDNA expression erectors.
Z5 The crucial role of molecular modeling in the humanization of muMAb4D5 is illustrated by the designad variant huMAb4D5-8 which binds the p185HER2 ECt3 250-fold more tightly than the simple CDR I~op swap variant; huMAb4D5-1. It has previously been shown that the antigen binding affinity of a humanized antibody can be increased by mutagenesis based upon molecular modelling (Riedhmann, L: et~l., Na?ure 332:323-327 (1988); C~ueen, C. etal., Proc.
Natl. ~lcaa! Sci. USA 86:10029-10033 ( 1989)). Here we have extended this earlier work by others with a designed humanized antibody which binds its antigen 3-fold more tightly than the parent rodent antibody. While this result is gratifying, assessment of the success of the molecular modeling must await the outcome of X-ray structure determination.
From analysis of huMAb4D5 variants (Table 3) it is apparent that their anti-proliferative activity is not a .~JV~ 92/2265 ~ ~ ~ ~ ~ 7 ~ PCl"/US92JO5126 simple function of their binding affinity for p185HER2 ECD. I=or example the huMAb4D5-8 variant binds p185HER2 8-fold more tightly than muMAb4D5 but the humanized variant is slightly less potent in blocking the proliferation of SIB-BR-3 cells.
Additional huMAb4D5 variants are currently being constructed in an attempt to identity residues triggering the S anti-proliferative activity and in an attempt to enhance this activity.
In addition to retaining tight receptor binding and the ability to inhibit cell growth, the huMAb4D5-8 also confers a secondary immune function (ADCC). This allows for direct cytotoxic activity of the humanized molecule in the presence of human effector cells. The apparent selectivity of the cytotoxic activity for cell types which overexpress p185HER2 allows to for the evolution of a straightforward clinic approach to those human cancers characterized by overexpression of the HER2 protooncogene.
.... _ .. ~.: .. .,-. . ..

ewr~ ~zizz~s3 ~c~ius9zrossz~
~z Table 3. p185HEtt2 FCD binding affinity and anti-protiferative activities of MAb4D5 variants VH Residue° VL Residue°
MAb4D5 71 73 78 93 102 55 66 Rdt Relative cell Variant FR3 FR3 F"R3 FR3 CDR3 CDR2 FR3 nM
proliferationt i0 huMAb4D5-1 R D L A V E G 25 102 huMAb4D5-2 Ala D L A V E G 4.7 101 huMA,b4D5-3 Ala Thr Ala Ser V E G 4.4 66 huMAb4D5-4 Ala Thr L Ser V E Arg 0.82 56 huMAb4D5-S Ala Thr Ala Ser V E Arg 1.1 48 ~5 huMAb4D5-6 Ala Thr Ala Ser V Tyr Arg 0.22 51 huMAb4D5-7 Ala Thr Ala Ser Tyr E Arg 0.62 53 huMAb4D5-8 Ala Thr Ala Ser Tyr Tyr Arg 0.10 54 muMAb4D5 Ala Thr A1a Ser Tyr Tyr Arg 0.30 37 hluman and murine ~e~idues are shown in one letter and three letter amino acid code rd~pectiv~ly.
f Kd values for th~ ~185H~R2 EC~ vvere determined using the method of Friguet et aJ. t~3) and the standard error of each estimate is ~ ~ 1 ~°~.
t Proliferation of SK-8R-3 cells incubated for 98 hr with PVlAb4D5 ~rariants shown as a 25 percentage of the untreated control as described (Hudziak, R. M. et al., IVlulec. dell, Biol.
J:1 i 85-1172 X1989)). Data represent the maximal anti-proliferative effect for each ~rariant (see Fig: ~A) calculated as the mean of triplicate determinations at a A~Ab4D5 concentration of 8 yg/m!. Data are a!I taken from the same experiment with an estimated standard error of CA 02103059 2003-05-20 _..

coupling reaction by S100-HR (Pharmacial size exclusion chromatagraphy (2_5 cm x 100 cm) in the presence of PBS. The BsF/ab')2 samples were passed through a 0.2 mm filter flash frozen in liquid nitrogen and stored at -70' C.
Flow cytometric analysis of Flab' lsbindinp to Jurkat cells The Jurkat human acute T cell leukemia cell line was purchased from the American Type Cutture Collection (Rockville, MO) (ATCC TIB 152) and grown as recommended by the ATCC. Aliquots of 108 Juricat cells were incubated with appropriate concentrations of BsF(ab')z (anti-p185"~ / anti-CD3 variant) or control mono-specific anti-p185"E''~ F(ab')z in PBS plus 0.196 (w/v) bovine serum albumin and 10 mM sodium azide for 45 min at 4 ' C.
The cells were washed and then incubated with fluorescein-conjugated goat anti-human F(ab')z (Organon Teknika, West Chester, PA) for 45 min at 4 -C. Cells were washed and ' analyzed on a FACScari (Becton Dickinson and Co., Mountain View, CA). Cells (8 x 10') were acquired by list mode and gated by forward Light scatter versus side light scatter excluding dead cells and debris.
RESULTS
Design of humanized anti-CD3 variants The most potent humanized anti-CD3 variant previously identified, v1, differs from the marine parent antibody, UCHT1 at 19 out of 107 amino acid residues within V~
and at 37 out of 122 positions within V" (Shalaby et al.,supra) 1992). Here we recruited back additional marine residues into anti-CD3 v1 in an attempt to improve the binding affinity for CD3. The strategy chosen was a compromise between minimizing both the number of additional marine residues recruited and the number of anti-CD3 variants to be analyzed. We focused our attentions on a few CDR residues which were originally kept as human sequences in our minimalistic humanization regime. Thus human residues in V" CDR2 of anti-C03 v1 were replaced en bloc with their marine counterparts to give anti-CD3 v9:
'f57S:AGON:DGIQ:S62K:VG3F:GG_SD (SEQ ID NO: ~?0) (Fig. 5~ Similarly, the human residue E55 in V~ CDR2 of anti-CD3 vl was replaced with histidine from the marine anti-C:D3 antibody to generate anti-CD3 v 11. In addition, Vtc framework region (FR) residues 75 and 7G in anti-CD3 v1 were also replaced with their marine counterparts to create anti-CD3 v8: K75S:N7GS. Vtt residues75 and 7G are located in a loop close to Vti CDRI and CDR2 and therefore might influence antigen binding.
Additional variants created by combining mutations at these three sites are described helovv.
Preparation of BsFlab71 fra8ments Soluble and functional anti-p185"E'u and anti-CD3 Fab' fragments were recovered directly from corresponding E. colt fermentation pastes with the single hinge cysteine predominantly in the free thiol form (75-100 96 Fab'-SH) by affinity purification on Streptococcal protein G at pH 5 in the presence of EDTA (Carter et aL, 1992b, supra).
Thioether-Linked BsF(ab')~ fragments were then constructed by directed coupling using o-PDM
Si~i35~i 1 i ~J i:~ Sri~T

V'a'~ 92/226x3 ~ ~ Q ~ ~ 7 ~ P~'/1.JS92/05126 Table 4. Selectivity of antibody dependent tumor cell cytotoxicity mediated by huiVlAb4D5-8 WI-3$° SK-BR-3 E~fector:Target ratf,o'~ m~b4D5 huMAb4D5-8 m~a~3A'b4D5 huMAb4D5-8 A.t 25:1 <1.0 9.3 7.5 40.6 12.5:1 <1.0 11.1 4.7 36.8 6.25:1 <1.0 8.9 0.9 35.2 g0 3.13:1 <1.0 8.5 4.6 19.6 B. 25:1 <1.0 3.1 6.1 33.4 12.5:1 <1.0 1.7 5.5 26.2 6.25:1 1.3 2.2 2.0 21.0 3.13:1 <1.0 0.8 2.4 13.4 Sensitivity to ADCC of two human cell lines (WI-38, normal lung epithelium;
and SK-8R-3, human breast tumor cell line) are compared. WI-38 expresses a low level of p"185~ERZ 10.6 pg p~r pg cell protein) and SK-8Fi-3 expresses a high Devel of p185~ER2 !64 pg p185HER2 per pg cell protdin), as determined by ELISA lFendly et at., J. Biol. Reap. Mod.
9:449-455 (1.90)).
t ADCC assays were' carried out as described in l3rieggemann et al., J. Exp.
Med.
186:1851-1361 l1987D. Effector to target ratios were of 1!.-2 activated human peripheral blood lymphocytes to either WI-38 fibroblasts or SK-8R-8 tumor cells in 96-well microtiter plates for 4 hours at 3T QC. Values given represent percent specific cetl lysis as determined by '1Cr release. i"stimated standard error in these quadruplicate determinations was s t 1096.
t Monoclonal antibody concentrations used were 0.1 yg/ml !AD and 0.1 pg/ml lBi.

WU 92l22b53 '~ ~ ~ ~ ~ ~ ~ PGTlUS92/OSt2b ~5 EXAMPLE 2. Schematirt Method for Humanizinct an Antibody Seguence This example illustrates one stepwise elaboration of the methods for creating a humanised sequence described above. It will be understood that not all of these steps are essential to the claimed invention, and that steps may be taken in different order.
9 . ascertain a consensus human variable domain amino acid sequence and prepare from it a consensus structural model.
2. prepare model of import (the non-human domain to be humanized) variable domain sequences and note structural differences with respect ~o consensus human model.
3. identify CDR sequences in human and in import, both by using Kabat . (supra, 1 ~87> and crystal structure criteria. If there is any difference in CDR identity from the different criteria, use of crystal structure definition of the CDR, but retain the Kabat residues as important framework residues to impart.
4. substitute import CDR sequences for human CDR sequences to obtain initial "humanised" sequence.
5. compare import c~bn~CDR variabl~ domain sequence to the humanized sequence qnd note divergenGes.
6. Proceed through the following analysis for each amino acid residue where the import diverges from the humanized.
28 aIf the humanised residue represents a residue which is generally highly conserved across all species, use the residue in the humanized sequence. If the residue is not conserved across atl species; proceed with the analysis described in 6b.
b. If the residue is not generally conserved across all species, ask if the residue is generally conserved in humans.
i. If the residue is generally conserved in humans but the import ~esid~ae differs, examine the structural models of the i,~port and human sequences and determine if the import eesidue v~ould be likely to affect the binding or biological =,. ... ,,.., , ,:,: ;: ~ . -::- ;: , . , .., .,_ : , .... , . ... ,. ;. .. :......:
. , . >,. ,., .:: . .. , ..... ... ... , .

'6rVCD 92f22653 ~'CT/US92i05126 activity of the CDRs by considering 1 ) could it bind antigen directBy and 2) could it affect the conformation of the CDR.
If the conclusion is that an affect on the CDRs is likely, substitute the import residue. If the conclusion is that a CDR affect is unlikely, leave the humanized residue unchanged.
ii. If the residue is also not generally conserved in humans, examine the structural models of the import and human sequences and determine if the import residue would be likely to affect the binding or biological activity of the CDRs be considering 11 could it bind antigen directly and 2) could it affect the conformation of the CDR. If the conclusion is that an affect on the CDRs is likely, substitute the import residue. If the conclusion is that a CDR affect is unlikely, proceed to the next step.
a) examine the structural models of the import and human sequences and determine if the residue is exposed on the surface of the domain or is buried within. If th~ residue is exposed, use the residue in the humanized sequence. If the residua is buried, proceed to the next step.
(i) Examine the structural models of the impart and human sequences and determine if the residue is likely to affect the ~J~ - V~, interface. Residues involved with the ~interfac~ include; 34L, 36L, 38L, 43L: 33L: 36L, 85l., 87L, 89l., 91 L, 86L, 88L, X51°!, 3~'t~. 39FI, 43H, 45H, 4711, 60i~, 91 H; 93H~ 95H, 100H, and 103N. If no effect is likely, use the residue in the humanized sequence. If some affect is likely, substitute the import residue.
7. search the impot't sequence; the consensus sequence and the humanized sequence for gtycosylation sites outside the CDRs, and . determine if this gly~osylation site is likely to have any affect on . .".;' a%.. ..t,.~~~t ..'.y., .,...': . .:::. ....a....:. . .,:.:.
..,:.ar~. .''.'.: . ; ~:'. , ''...~.., , :',',:-.;.;: ~.~.:...~..;.,. ,,....
,...:.,.,.. , -:"'.y . :;.".~,. . ....' PCI'l1J892l05126 ~. ~VCD 92/22653 antigen binding andlor biological activity. If no effect is likely, use the human sequence at that site; if some affect is likely, eliminate the glycosylation site or use the import sequence at that site.
8. After completing the above analysis, determine the planned humanized sequence and prepare and test a sample. If the sample does not bind well to the target antigen, examine the particular residues listed below, regardless of the puestion of residue identity between the import and humanized residues.
a. Examine particular peripheral (note-CDR) variable domain residues that may, due to their position, possibly interact directly with a macromolecular antigen, including the following residues (where the " indicates residues which have been found to interact with antigen based on crystal structures):
i. Variable light domain: 36, 46, ~9°, 63-70 ii. Variable heavy domain: 2, 47°, 68, 70, 73-7.,.6.
b. Examine particular variable domain residues which could interact uvith, or otherwise affect, the conformation of variable domain CDRs, including the following (not including CDR residues themselves; since it is assumod that, because the CDRs interact with one mother, a~,y resis~ue in one CDR could potentially affect the c~nformation of another CDR residue) (L= LIGHT, H = HEAVY, residues appearing in b~Id are indicated to be structurally important according the Chothia et al., Mature .. ' 34~;1~77 (1989); and residues appearing in italic were altered ~5 during humanizati~n by Queen et al. (PDLD, Proc. Mall. Acad. Sci.
USA gg:10029 (1989) and Proc. Matl. Acad. 8ci, tJSA 88:2869 (1991 ):);
i. Variable tight domain:
aD CDR-1 (residues 24L-3~L): 2L, 4L, 66L-69L, 71 L
b) GDR-2 (residues 50L-56L): 35L, 46L, 47L, 48L, 49L, 58L, 62L. 64L-661:, 71 L, 73L
cl CDR-3 (residues 89L-97L): 2L, ~L, 36L, 98L, 37H, 45H, 47H, 58H, 6QH
ii. Variable heavy domain:

~.~,.,,,::..:, ., ,., :...
°~(~ 92/22b5~ ~ ~ ~ ~ ~ ~~ ~ PCI'/US92/05126 ,~,,>..;
a) CDR-1 (residues 26H-35H): 2H, 4H, 2~H, 36H, 71 H, 73H, 76H, 78H, g2H, ;94H
b) CDR-2 (residues 50H-55H): 49H, 69H, 69H, 7't H, 73H, 78H
c1 CDR-3 (residues 95H-102H): examine atl residues as possibl~~ interaction partners with this loop, because this loop varies in sire and conformation much more than the other CDRs.
9. If after step 8 the humanized variable~domain still is lacking in desired binding, repeat step 8. In addition, re-investigate any' buried residues which might affect the 'J~ -,/H interface (but ~rvhich would not directly affect CDR conformation). Additionally, evaluate the accessibility of non-CDR residues to solvent.

WO 92/22653 ~ 1 0 ~ ~ ~ ~ PCf'/US92/05126 EXAMPLE ~. En4ineering a Humanized Bist~ecific Ftab')2 Fragment This example demonstrates the construction of a humanized bispecific antibe:'y (BsF4ab')av1 by separate E, coii expression of each Fab' arm followed by directed chemical coupling in vitro. BsFlab')2 v1 ianti-CD3 anti-p185"ER2) was demonstrated to retarget the cytotoxic activity of human CD3+ CTL in vitro against the human breast tumor cell line, SK-BR-3, which overexpresses the p185"Epa product of the protooncogene HER2. This example demonstrates the minimalistic humanization strategy of installing as few murine residues as possible into a human antibody in order to recruit antigen-binding affinity and biological properties comparable to that of the murine parent antibody: This strategy proved very successful for the anti-p185"ERaarm of BsF(ab')2v1. tn contrast BsF(ab')2 v1 binds to T cells via its anti-CD3 arm much less efficiently than does the chimeric BsF(ab')Z
which contains the variable domains of the murine parent anti-CD3 antibody.
Here w~ have constructed additional BsF(ab)2 fragments containing variant anti-CD3 arms with selected murine residues restored in an attempt to improve antibody binding to T cells: One such variant, Bs Ftab')Z v9, was created by replacing six residues in the second hypervariable loop of the anti-CD3 heavy 2t? chain variable domain of BsFfab')a v1 with their counterparts from the murine parent anti-CD3 antibody. BsF4ab')Z v9 binds to T cel)s (Jurkat) much more efficiently than does BsF(ab')~ v1 and almost as efficiently as the chimeric BsFtab')2. This improvement in the efficiency of T cell binding of the humanized BsFtab'I~ is an important step in its development as a potential therapeutic agent for the treatment of p185"'ER~-overexpressing cancers.

Bispecefic antibodies tBsAbs) with specificities for tumor-associated antigens and surface markers on immune effector cells have proved effective for retargeting effector ;cells to kill tumor targets bath in vitro and in vivo treviewed by Fanger; M. W. et aJ., tmrrrunol. Today 10: 92-99 11989);

Fanger; M: W. et' al., lmmunol. Today 12: 51-54 (1991 ); and Nelson, H., Cancer Gells 3: 163-1 ?2 41991 )).' t3s~(ab') z fragments have often been used in preference to intact t3sAbs in retargeted cellular cytotoxicity to avoid the risk of killing innocent bystander cells binding to the Fc region of the antibody. An additional advantage of BsFtab')a over intact BsAbs is that they r~:~!:~'° ~ .:,,' . ;: ' : ,.~-r:, . . ;~ ' ~'~:':' ,::, ;;;. . , ..:v.. ,;.~:. .
W4 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT/U592/05126 ,....,.
$~
are generally much simpler to prepare free of contaminating monospecific molecules (reviewed by Songsivilai, S. and Lachmann, P. J., Clin. Exp.
Immunol. 79: 315-321 (1990) and Nolan, O. and O°Kennedy, R., Biochim.
Biophys. Acta 1040: 1-11 (1990)).
BsF(ab')Z fragments are traditionally constructed by directed chemical , coupling of Fab' fragrnents obtained by'limited proteolysis plus mild reduction of the parent rodent monoclonal Ab (Brennan, M. et al , Science 229, 81-83 (1985) and Glennie, M. J, etal.-',°J. lmmunol, 139: 2367-23?5 (1987)).
One such BsF(ab')a fragment (anti-glioma associated antigen / anti-CD3) was found to have clinical efficaoy in glioma patients (Nitta, T. etal., Lancet 335:
36$-371 (1990) and another BsF(ab')2 (anti-indium chelate ! anti-carcinoembryonic antigen) allowed clinical imaging of colorectal carcinoma (Stickney, D. R. etal:, Antibody, Imrrrunocanj. Radiapharm. 2: 1-13 (1989)).
Future BsFtab')2 destined for clinical applications are likely to be constructed from antibodies which are either human or at least "humanized" (Riechmann, L. etal., Nature 332: 323-327 (1988) to reduce their immunogenicity (Hale, G. et al.; Lancet i: 1394-1399 (1988)).
Recently a facile route to a fully humanized BsF(ab')x fragment designed for tumor immunatherapy has been demonstrated (Shalaby, M. R. et al., J.
Exp: Mea! 175: 217-225 (19921): This approach involves separate E. coli expression of each Fab' arm followed by traditional directed chemical coupling in vitro to form the BsF(ab')2. Orie aim of the BsF(ab')a was a humanized version (Carter, P. et al.; Proc. Natl. Acad Sci. USA ( 1992a) and -., Cartel, P., et al., BiolTechnology 10: 163-167 (1992b)) of the marine ~5 monoclonal Ab 4D5 which is directed against the p185"~R2 product of the p~rotooncogene HER2 (c-erbB-2D (Fendiy, B. M. et al.. Cancer Res. 50: 1550-1558 (1989)). The humanization of the antibody 4D5 is shown in Example 1 of this application. The second arm was a minimalistically humanized anti-CD3 antibody (Shalaby etal:'supra) which was created by installing the CDR
loops from the variable domains of the marine parent monoclonal Ab UCHT1 (Beverley; P: C. L. and Callard; R. E., Eur. J. lmmunol. 11: 329-334 (1981 )) into the humanized anti-p185"ERZ antibody. The BsF(ab')2 fragment containing the most potent humanized anti-CD3 variant (v1 ) was demonstrated by flow ' cytometry to bind specifically to a tumor target f . .. ,:~.~ . .v.,.,,. ".;....,. , ., : ~ ~,..:....'.,. :. . w.
. , WO 9Z/22653 ~ ~ tl ~3 ~ ~ ~ PCH'/US92/05126 .., ~I
overexpressing p185"ERZ and to hurnan peripheral blood mononuclear cells carrying CD3. in addition, Bs Flab' )z v1 enhanced the cytotoxic effects of activated human CTL 4-fold against SK-BR-3 tumor cells overexpressing p185'°~Z. The example descries efforts to improve the antigen binding affinity of the humanized anti-CD3 arm by the judicious recruitment of a smelt number of additional murine residues into the minimalistically humanized anti-CD3 variable domains.
MATERIALS AND METH~DS
C~nstruction of mutations in the anti-CD3 variable region ,genes.
The construction of genes encoding humanized anti-CD3 variant 1 (v1 ) variable light (V~) and heavy (V") chain damains in phagemid pUC119 has been described (Shalaby et al. supra): Additional anti-CD3 variants were generated using an efficient site-directed mutagenesis method 4Carter, P., Muta9enesis: a~ practical approach, dM. J. McPherson, Ed.), Chapter 1, IRL
Press, Oxfiord, UK ( 1991 )) using mismatched oligonucleotides which either install or remove unique restriction sites. f?ligonucleotides used are listed below using lowercase o indicate the targeted mutations. Corresponding ~24 coding changes are denoted by the starting amino acid in one letter code followed by the residue numbered acdording to Kabat, E. A. etal., SeQuences of Proteins of Immunplogicat Jnterest, 5'" edition, National Institutes of Health; Bethesda, MD; USA 11991 ); then the replacement amino acid and ~; 'f finally the identity of the anti-CD3 variant:
HX 11; 5' GTAGATAAATCCtctAACACAGCCTAtCTGCAAATG 3' (SEC~:ID. NO. 11 ) VH K75S, v6;
HX12; 5' GTAGATAAATCCAAAtctACAGCCTAtCTGCAAATG 3' 6SEQ.tD. NO. 12) V" N76S; .v7;
HX13, 5' GTA~ATAAATCCtcttctACAGCCTAtCTGCAAATG 3' i (SEQ.ID. NO. 13) V" K75S:N76S' v8;
X14, 5' CTTATAAAGGTGTTtCcACCTATaaCcAgAaatTCAA
GGatCGTTTCACgaTAtcCGTAGATAAATCC 3' (SEQ.ID.ND. 14) V" T5'?S:A6DN:D61 Q:S62K:V63F:G65D, v9;
LX6, 5' CTATACCTCCCGTCTgcatTCTGGAGTCCC 3' (SEQ.ID. NO. 15) ,.. .,~ '..:~:~ . :..' :'.~.., . :y., . . . ~.~.. . ,.
. a . :"f. . .
P
~cr/us~zeomz6 , .
WO lB/~~653 V~ E55H, v11.
Oligonucleotides HX11, HX12 and HX13 each remove a site for BspMl, whereas LX6 removes a site for Xhol and HX14 installs a site for Eco~3V
(bold). Anti-CD3 variant v10 was constructed from v9 by site-directed mutagenesis using oligonucleotide. HX13, Mutants were verified by dideoxynucleotide sequencing. (Sariger, F. et al., ProG. IVatl. .4cad. Sci.
PISA
74: 5463-5467 (1977)).
E, coli expression of Fab' fragrr~ents The expression plasmid, pAK19, for the co-secretion of tight chain and heavy chain Fd' fragment of the most preferred humanized anti-p185"ERz variant, HuMAb4D5-8; is described in Carter et al., 199~b, supra. Briefly, the Fab' expression unit is bicistronic with both chains under the transcriptional cantrof of the phoA promoter. Genes encoding humanized V~
and V" domains are precisely fused on their 5' side to a gene segment encoding the heat-stable enterotoxin II signet sequence and on their 3°
side to human k, C~ and IgG1 C"1 constant domain genes, respectively. The C"1 gene is immediately followed by a sequence encoding the hinge sequence CysAlaAla and followed by a b~cteriophage ~I to transcriptiona) terminator.
Fab' expression plasrv~ids for chimeric and humanized anti-CD3 variants (v1 to v4, Shalaby et at.aupra; v6 to v1 ~, this study) were created from pAK19 by precisely repBacing anti-p185"~Z V~ and V" gene segments with those .~
,~, encoding mursne and ct~rresponding humanized variants of the anti-CD3 ~5 antibody, respedtively; by sub-cloning and site-directed mutagenesis. The Fab' expressign ptasmid for the most potent humanized anti-CD3 variant identified in this study (v9) is designated pAK2~. The anti-p185"~2 Fab' fragment seas secreted fr~m ,~. coli K12 strain 25F2 containing plasmid pAK19 grown for 32 to~40 hr at, 37' C in an aerated 10 liter fermentor. The final cell densigy vvas 120-150 ODSSO and the titer of soluble and functional anti-pi 85"E'~2 Fab' was 1-2 g/titer as judged by antigen binding ELISA
(Carter et al., 199~b, supra). Anti-CD3 Fab' variants were secreted from E coli containing c~rresponding expression plasmids using very similar fermentation protocols. The highest expression titers of chimeric and O 92J22ba3 ~.~ o ~ ~ ~ ~ P~1~S92I051~b humanized anti-GD3 variants ware 2ta0 mgAiter arid 700 mgliiter, rsspeGtively, as judgBd bY total immunoglobulin LISA.
Cansrructlon of esF(ab'ls fragments Fab' fragments ware directly recovered from E. toll fermentation pastes in th0 free thiol form (Fab'-SH) by affinity pu~ificatiar~ on Streptococcal protein G at pH 5 in the presence of ~DTA (Carter et al., 199~b supra).
Thioether linked BsFtab'iz fragments (antnpf $5'~RZ J anti-CD3) were constructed by the procedure of Glannie'et al. supra with the following modifications. Anti-p 1 i35"~ Fob'-SH in t fl0 rriM 'Cris acetate. 8 mM SDTA
(pH ~,O) was reacted with O.t vol of 40 mM N.N'-1,2-phenylenedimatemide (o-PDM) in dinn~athy) lormamide for -'I.5 hr at 20 -C. ~xcass o-PDM was removed by protein G vurifiaation of the Fab' maioimide derivative (Fob'-mal) followed by buffer exchange into 24 rnM sodium acetate, 5 mM I:DTA (pH
5.~) Icoupllng buffer) using o~ntriprep-'~0 concentrators (AmiGOn). The total eoncentration of Fab' variants was estimated from the measured absorbents at 280 nm (Hu~b4D5-8 Fab° a°."' ° '1.56, Carter et al., 1992b, supra).
The free_ti~141 content of Fab' preparations was estimated by reaction with 5, 5'-dithiobis(2-nitrobenzoic ,acid) as desoribed by Creighton, T. E..
protein structura~ a praciical~apprvach, IT. E. Creighton, Ed.). Chapter 7, IRL Press.
Oxford, UK ( 1990), Fquimolar amounts of anti-p185"a" Fob'-ma) (assumivg ' quantitative, reaotlon of Fab'-SH with 4-PDM) and each anti-Ci7S Fab'-SH
variant werecoupled together at a combined concentration of 1 to 2.5 mgJrnl in the Goupl4rtg buffer for to to 48 hr at, 4 'C. The coupling reaction was ~'' ad ju~te~ td 4 mM cysteine ax IpH~ 7.0 and ~ incubated for 15 min at 20 ' C to reduce .any ~Wa~rted disulfide-linked Flab' )= formed. These reduction Gorrditians are sufficient to redi~Ge inter-heavy, chin disulfide bonds with virtually no' reduction of the disulfide between light and heavy chains. Any free thiol~ generated were their blacked with a0 mM iodaacetamida.
BsF(a~'Iz wss isolated f~bm the Coupling reaction by S 9 DO-HR IPharmaoia) 5iz9 eXC,lusion cnr'"omatogrsPhy -I2-5 crrr x 1 d0 Gm) in the presence of P~3S.
The BsFtab'l,.,samplqs ,were passed through a 0.2 mm filter flesh frozen in .
liquid nitrogen aryl stored at ~~-'~Q:'~~
*_.~rade.mark TOTRL P.20 5.& 19/12/20(71 16:23 X416 368 1645 - -_ Oreceived WO'~2/22653 ~ ~ ~ ~ ~ ~~ ~ P~f/US92fOS126 ,-FIoHr cyto~etric analysis of Flab' i?binding to Jurkat cells The Jurkat human acute T cell leukemia cell line was purchased from the American Type Culture Collection (Rockviile, MDD (ATCC TIB 152D and Brawn as recommended by the ATCC. Aliquots of 10~ Jurkat cells were incubated with appropriate concentrations of BsFfab'D2 tanti-p185"ER2 / anti-GD8 variantD or control mono-specific'~anti-p185"ER2 F(ab')2 in PBS plus 0.1 °~
~w/vD bovine serum albumin and.10 mM sodium azide for 45 min at 4 "C.
The cells were washed and than incubated with fluorescein-conjugated goat anti-human F(ab'DZ tOrganon Teknika, West Chester, PAD for 45 min at 4 ° C.
Cells were washed and analyzed on a FAGScan tBecton Dickinson and Go., Mountain View, CA1. Cells (8 x 10~D were acquired by list mode and Bated by forward light scatter versus side light scatter excluding dead cells and debris.
RESULTS
Design of humanized anti-CD3 variants The most potent humanized anti-CD3 variant previously identified, v1, differs from the marine parent antibody, UCHT1 at 19 out of 107 amino acid residues within V~ and at 37 out of 122 positions within VH ~Shalaby et ~l.,su~raD 1992D: Here we recruited back additional marine residues into anti-CD3 v1 in an attempt to improve the binding affinity for CD3. The strategy chosen was a compromise between minimizing both the number of additional marine «sidues recruited and the number of anti-CD3 variants to be analyzed. We focused our attentions on a few CDR residues which were ~rigina9ly kept as human sequences in our minimalistic humanization regime.
Thus human residues in VH CDR2 of anti-GD8 v1 were replaced en bloc with their marine counterparts to give anti-CD3 v9:
T57S:A60N:D61 Q:S62K:V63F:G65D (Fig. 5D. Similarly, the human residue E55 in VL CDR2 of anti~CD3 v1 was replaced with histidine from the marine anti-GD3 antibody to generate anti-CD3 v11. In addition, V" framework region tFRD resialues 75 and 76 in anti-CD3 v1 were also replaced with their marine counterparts to creqte anti-CD3 v8: K75S:N76S. VH residues 75 and 76 are located in a loop close to V,~ C~R 1 and CDR2 and therefore might ~.,.,,-.;.: .. .., . .
,...~,~V~ 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT/US92/OS126 sS
influence antigen binding. Additional variants created by combining mutations at these three sites are described below.
Preparation of BsF(ab°,12 fragments Soluble and functional anti-p185"~R~ and anti-CD3 Fab' fragments were recovered directly from corresponding E. Coli fermentation pastes with the single hinge cysteine predominantly in the free thioi form (75-100 % Fab'-SH) by affinity purification on Streptococcal protein G at pH
5 in the presence of EDTA (Carter et al., 1992b, supra). Thioether-linked BsF(ab')2 fragments were then constructed by directed coupling using o-PDM
as described by Glennie et al., supra. One arm was always the most potent humanized anti-p185"ERZ variant, HuMAb4D5--8 (Carter etal., 1992a, supra) and the other either a chimeric or humanized variant of the anti-CD3 antibody. Anti-p185"E"2 Fab'-SH was reacted with A-PDM to form the rnaleimide derivative (Fab'-mal) and then coupled to the Fab'-SH
for each anti-CD3 variant. F(ab')2 was then purified away from unreacted Fab' by size exclusion chromatography as shown for a representative preparation (BsF(ab')~ v8) in data not shown. The F(ab')Z fragment represents ~- 54~ of the total amount of antibody fragments (by mass) as judged by integration of the chromatograph peaks.

SDS-PAGE analysis of this BsF(ab')a v8 preparation under non-reducing conditions gave one major band with the expected mobility (M, -- 96 kDD as well as several very minor bands (dada not shown). Amino-terminal sequence ; ,~

analysis of the major band after efectroblotting on to polyvinyiidene difiuoride 26 membrane Mat~udaira, P:, J. .Biol. Chew. 282: 10035-10038 (198'7) gave the expected nnixed sequence from a stoichiometric 1:1 mixture of light and heavy chains (V~ l V": D/E, I/~J, QIQ, M/L, TIV, Q/E, S/S) expected for BsF(ab')2. The amino terminal region of both light chains are identical as are both heavy chains and correspond to donsensus human FFi sequences.
We have previously demonstrated that F(ab')2 constructed by directed chemical coup9in~ carry both anti-p185"~''2 and anti-CD3 antigen specificities (Shalaby et aL; supra). The level of contamination of the BsF(ab')2 with monospecific ~(ab' )2 is likely o be very low since mock coupling reactions with either anti-p185"E"2 Fib'-mal or anti-CD3 Fab'-SH alone did not yield detectable 2~~0~~;~~
CVO 92/22653 PC'I'/US92/d5126 - -w.
8 (~
quantities of Flab' )Z. Furthermore the coupling reaction was subjected to a mild reduction step followed by alkylation to remove trace amounts of disulfide-finked Flab' )2 that might be present. SDS-PAGE of the purified F(ab' )2 under reducing conditions gave two major bands with electrophoretic mobility and amino terminal sequence anticipated for free light chain and thioether-linked heavy chain dimers.
Scanning LASER dsnsitometry of a o-PDM coupled F(ab')Z preparation suggest that the minor species together represent --10°~ of the protein.
These minor contaminants were characterized by amino terminal sequence analysis and were tentatively identified on the basis of stoichiometry of light and heavy chain sequences and their electrophoretic mobility (data not shown). These data are consistent with the minor contaminants including imperfect Ftab' )z in which the disulfide bond between light and heavy chains is missing in ane or both arms, trace amounts of Fab' and heavy chain thioether-linked to tight chain.
finding of BsF(ab'Jz to Jurkat cells Binding of BsFtab')2 containing different anti-CD3 variants to Jurkat cells (human acute'T cell IeukemiaD was investigated by flow cytometry (data not shown). BsF(ab')a v9 binds much more efficiently to Jurkat cells than does our starting molecule; BsF(ab°)a v1, and almost as efficiently as the chimer'sc BsFtaka')2. Installation of additional marine residues into anti-CD3 v9 to create v10 (V" K75S:N76S) and v'l2 (V,~ K75S:N76S plus V~ E55H) did s: P
not farther improve, binding of corresponding BsF(ab°)2 to Jurkat cells. Nor did recruitment of these s°reurine residues into anti-CD3 v1 improve Jurkat binding: V~, K75S (v6): d/~ N76S tv7), V~, K75S:N7CS tvB), V' E55ii tv11 ) tnot shown). BsF(ab')2 v9 was chosen for future study since it is amongst the most efficient variants in binding to Jurkat cells and contains fewest marine residues in the humanized anti-CD3 arm. A monospecific anti-p1 B5~'~RZ Flab' )a did not show significant binding to Jurkat cells consistent with the interaqtion being mediated through the anti-CD3 arm.
DISCUSSI~N
A minima(istic strategy was chosen to humanize the anti-p1 B5"E~2 V1'~CD 92/22653 ~ ~ ~ ~ ~ ~ ~ PCTlUS92l0512G
(Carter efi al., 1992a, supra) and anti-CD3 arms (Shalaby et al., supra) of the BsF(ab')2 in this study in an attempt to minimize the potential immunogenicity of the resulting humanized antibody in the clinic. Thus we tried to install the minimum number of marine CDR and FR residues into the context of consensus human variable domain sequences as required to recruit antigen-binding affinity and biological properties comparable to the marine parent antibody. Molecular modeling was used firstly to predict the marine FR
residues which might be important to antigen binding and secondly to predict the marine CDR residues that might not be required. A small number of humanized variants were then constructed to test these predictions.
Our humanization strategy was very successful for the anti-p185"ERz antibody where one out of eight humanized variants (HuMAb4D5-8, IgG 1 ) was identified that bound the p185"~RZ antigen - 3-fold more tightly than the parent marine antibody (Carter at al., 1992a, supra). HuMAb4D5-8 contains a total of five marine FR residues and nine marine CDR residues, including V"
CDR2 residues 60-65, were discarded in favor of human counterparts. In contrast, BsF(ab')2 vl containing the most potent humanized anti-CD3 variant out of four originally constructed (Shalaby etal., supra) binds J6 cells with an affinity (/Cd) of 140 nM which is -- 70-fold weaker than that of the _ corresponding chimetic lBsF(ab')2.
Here we have rest~red T cell binding of the humanized anti-CD3 close to that of the chimeric variant by replacing six human residues in V" CDR2 with their marina aounte~parts: T57S:A60N:D61 C~:S62K:V6SF:G65D (anti,; $
CD3 v9; Fig. 5). It.appears rinore 6ikely that these marine residues enhance antigen binding indirectly by influencing the conformation of residues in the N-tarmirfal part of V" CDR2 rather than by directly contacting antigen.
Firstly, only N-terminal residues in V" CDR2 (50-58) have been found to contact antigen ih one or more of eight crystallographic structures of antibody/antigen complexes (Kabat et al., supra; and Mian, 1. S. at al., J.
lVfot. viol. - 2'! 7: 183-151 ( 1991 ): Fig. 5). Secondly, molecular modeling suggests that residues in the C-terminal part of V" CDR2 are at least partially buried tFig. 5). BsF(ab')a v9 binds to SK-BR-3 breast tumor cells with equal efficiency ~o BsF(ab°)2 v1 and chimeric BsF(ab')Z as anticipated since the anti-p185"ERa arm is identical in all of these molecules (Shalaby et al., supra, not W~O 92!22653 ~ ~ ~ ~ ~ ~j PCf'/US92/05126 shown).
Our novel approach to the construction of BsF(ab')2 fragments exploits an E. coli expression system which secretes humanized Fab' fragments at gram per titer titers and permits their direct recovery as Fab'-SH (Carter et al., 1992b, supra). Traditional vdirected chemical coupling of Fab'-SH
fragments is then used to form BsF(ab')2 in vitro (Brennan et al.,supra; and Glennie et al., supra). This route to Fab'-SH obviates problems which are inherent in their generation from intact antibodies: differences in susceptibility to proteolysis and nonspecific cleavage resulting in heterogeneity, low yield as well as partial reduction that is not completely selective for the hinge disulfide bonds. The strategy of using ~ co/i-derived Fab'-SH containing a single hinge cysteine abolishes some sources of heterogeneity in BsF~ab')2 preparation such as intra-hinge disulfide formation and contamination with intact parent antibody whilst greatly diminishes others, eg. formation of Flab' )3 fragments.
BsF(ab'l2 fragments constructed here were thioether-linked as originally described by Gteenie et a/., supra with future in vivo testing of these molecules in mind-. Thioether bonds, unlike disulfide bonds, are not susceptible'ta cleavage by trace amounts of thiot, which led to the proposal 2Q that thioether-linked Flab' )2 may be more stable than disulfide-(inked F(ab' )2 in vivo (Glennie et al., supra): This hypothesis is supported by our preliminary pharmecokinetic experiments in normal mice which suggest that thioether-finked BsF(ab')Z vl has a 3- fold longer plasma residence time than ~; ~
BsF(ab')2 v.1 iinked'by a single disulfide bond. Qisulfide and thioether-linked chime~ic BsF(ab')Z,were found to be indistinguishable in their efficiency of cell binding and in their retafgeting of CTL cytotoxicity, which suggests that o-PDM directed cou~ating does not compromise binding of the BsF(ab°)2 to either antigen (not shown). Nevertheless the nature of the linkage appears not to be critical since; a disulfide~lir~ked BsF(ab')2 (marine anti-p185"ERZ
i marine anti-CD3) was 'recently shown by others (Nishimura et al., lnt. J.
Cancer 50: 800-804 (192) to have potent anti-tumor activity in nude mice.
Our previous study (Shalaby et al.; supra! together with this one and that of Nishimura~ T. et al., supra improve the potential for using BsF(ab')a in targeted immunotherapy of ~pl g5"ERZ_overexpressing cancers in humans.

. . . ..
. :, . . ° y . . ', . . . .
W(~ 92/22653 ~ ~, Q ~ o ~~ 9 PCT/LJS92/05126 ~~
EXAMPLE 4. Humanization of an anti-CD18 antibody A marine antibody directed against the leukocyte adhesion receptor ~-chain (known as the H52 antibody) was humanized following the methods described above. Figures 6A and 6~ provide amino acid sequence comparisons for the marine and humanized antibody light chains and heavy chains.

... , : .. . .. , ;.
!~O 92/22653 ~ ~ Q ~ ~ y ~ ~ Q Pt.T/U~92/05126 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Genentech, Inc.

(ii) TITLE OF INVENTION: Imamunoglot~ulin Variants (iii) NUMBER OF SEQUENCES: 25 ~ . , , (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Genentech, Inc.

(B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco '95 (D) STATE: California (E) COUNTRY: USA

(F) ZIP: 94080 (v) COMPUTER READABLE FORM:

(A} MEDIUM TYPE: 5.25 inch, 360 K'~ floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: patin (Genentech) (vi) CURRENT APPLICATION DATA:

(.A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

3G1 (vii) PRIOR AP,PLICAT~ON DATA:

(A) APPLICATION NUMBER: 07/715272 (B) APPLICATION DATE: 14-JUN-1991 (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Adler, Carolyn R.

(B) REG1STRATION NUMBER: 32,324 (C) REF'ERENCE/DOCKET NUMBER: 709P1 , r; .~

(ix)- TELECOMMUNICATION TNFORMATION:

~() (A) TELEPkIONE: 415/225-2614 (B) TELEFAX: 415/952-9881 (C} TELEX: 910/371-7168 (2) INFORMATION
FOR SEQ
ID N0:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 109 amino acids (B} TYPE: amino acid (D) TOPOLOGY: linear ~ ~ ~
~ ~ '~
~

' .. ~'Vb'Q 92/22b53 T/US92/05125 P(.

(xi) SEQUENCE DESCRIPTION: SEQID
N0:1:

Asp Ile Gln Thr GlnSer ProSer SerLeu SerAla SerVal Met GIy Asp Arg Thr IleThr CysArg AlaSer GlnAsp ValAsn Val Thr Ala Va1 Trp TyrGln GlnLys ProGly LysAla ProLys A1a Leu Leu Ile Ser AlaSer FheLeu GluSer GlyVal ProSer Tyr Arg Fhe Ser Ser ArgSer GlyThr AspFhe ThrLeu ThrIle GIy Ser Ser Leu Pro GluAsp PheAla ThrTyr TyrCys GInGln G1n His Tyr Thr Pro ProThr PheGly G1nGly ThrLys ValGlu Thr 95 100 lOS

I1e Lys Arg Thr 2~a 109 ' (2) INFORMATION FOR
SEQ
ID
N0:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: acids 120 amino (B) TAPE: amino acid (D) 3,'OPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQID
N0:2:

Glu Val Gln Val GIuSer GlyG1y G1yLeu ValG1n FroGly Leu 1 5 10 15 ,~,~
~e GIy Ser Leu Leu SerCys AlaAla SerGly FheAsn IleLys Arg Asp Thr Tyr His TrpVa1 ArgGln AlaPro GlyLys G1yLeu Ile ~4~ Glu Trp Va1 Arg IleTyr ProThr AsnGly TyrThr ArgTyr Ala Ala Asp Ser Lys GIyArg PheThr IleSer A1aAsp ThrSer Val Lys Asn Thr Tyr LeuGln MetAsn SerLeu ArgAla GluAsp Ala 9~V(~ 92/22653 ~ ~ ~ ~ ~ .j ~ P~'/1JS92/05126 Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp G1y Phe Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Leu Va1 Thr Val Ser Ser (2) INFORMATION FOR SEQ ID N0:3:
1~ (i) SEQUENCE CHARACTERISTICS:
(Aj LENGTH: 109, amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
Asp Ile G1n Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val 24 Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys A1a Pro Lys Leu Leu Ile Tyr Ala A1a Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr I1e Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys G1n Gln 35 Tyr Asn Sex Leu Pro Tyr Thr Phe Gly GIn Gly Thr Lys Ua1 Glu Ile Lys Arg Thr 109 ' (2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 120 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
50 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val G1n Pro Gly GIy Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser ....' ,, , '..' ":'. . , ,.~ , .; ~.~'~... ..,;...~ , ,. ..... ' ... v ',:.'.~
. ...... ...
W~ 92/22653 ~ ~ ~ ~ ~ ~ ~ ~CI'/U~92/~5126 q 43 Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 35 . 40 45 Glu Trp Val Ala Val Ile Ser Glu Asn Gly Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser 65 ?0 ?5 1A Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp Gly Gly Asp Gly Phe Tyr 95 '100 105 A1a Met Asp Val Trp Gly G1n Gly Thr Leu Val Thr Val Ser Ser 2~0 (2) INFORMATIONFOR SEQ
ID N0:5:

( i) SEQUENCECHARACTERISTICS:

(A) LENGTH: acids 109 amino (B) TYPE: amino acid (D) TOPOLOGY:
linear (x i) SEQUENCEDESCRIPTION:SEQ ID
N0:5:

Asp Ile Val Thr Gln His LysPhe MetSer ThrSer Val Met Ser 3~ 1 5 10 15 Gly Asp Arg Ser Ile Cys LysAla SerGln AspVal Asn Val Thr ~5, Thr Ala Va1 Trp Tyr Gln LysPro G1yHis SerPro Lys Ala Gln 35 . 40 45 Lsu Leu Ile Ser Ala Phe ArgTyr ThrGly ValPro Asp Tyr Ser . 50 55 60 Arg Phe Thr Asn Arg Gly ThrAsp PheThr PheThr Ile Gly Ser ~,5 ?0 75 Ser Ser Val Ala Glu Leu A1aVal TyrTyr CysGln Gln Gln Asp ~5 80 85 90 His Tyr Thr Pro Pro Phe GlyGly GlyThr LysLeu Glu Thr Thr 95 ~ 100 105 50 Ile Lys Arg Ala V1~~ 92/22653 ~ ~ ~ ~ '~ ~ . F'C°T/6.JS92/AS126 {2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 120 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Leu Lys Leu Ser Gys Thr Ala Ser G1y Phe Asn Ile Lys ~ 25 30 Asp Thr Tyr Ile His Trp Val Lys G1n Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Asp Pro Lys Phe Gln Asp Lys A1a Thr Ile Thr A1a Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Val Ser Arg Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ser Arg Trp G..y Gly Asp G1y Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly Ala Ser Val Thr Val Ser Ser 110 11.5 120 (2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27.bases ' (B) TyPE:wucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:

(2) INFORMATION FOR SEQ ID N0:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 bases (B) TYPE: nucleic acid ~t'.~~p ~ . '=J . . . . ' i '~ ~s .~,......, . .. ,...~.:~;'.: .~ , ,:;~. ,m~,:~,.'. ' , .,, ' ~.: . ~ :
' :.'." . ~ . ';. ..,.. .
'WO 92122653 210 3 f~ ~ 9 p~T/US92/OS126 °I 5 (C) STRANDEDNESS: single (D) TOPOLOGX: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:

(2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 bases (B) TYPE: nucleic acid (Cj STRANDEDNESS: single (D) TOPOLOGY: linear (~ci) SEQUENCE DESCRIPTION: SEQ ID N0:9:

(2) INFORMATION
FOR SEQ
ID N0:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 bases 34 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (~y) TOPOLOGY: linear (~ci) SEQUENCE ~3ESCRIPTION: SEQ ID N0:10:

TGAGGAGACG GTGACCGTGG TCCCTTGGCC CCAG 34 , 4i (2) INFORMATION
EOTt SEQ
ID NO:11 (i) SEQUENCE CHARACTERISTICS:

(~) LENGTH: 36 bases ~5 (B) 'TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11;

;GTAGATAAAT ~CTCTAACAC AGCCTATCT~ CAAATG 36 YS;,x r.'. ''; :.~.'~ ..,.; ., . !.,'.'..... ;.:.: ~ ,;~:. .;'..~:".. :.,. ,~i -.."~ ;... ' ''.'.".
.7 ::~ ., . .
~''~ a- .:r. . ,t.-, t ...
!< ~,~.~.. '~ ~'%'~ .., '' .Y.....~ ..;9-, v , '.'.. .,.~. ., '' ' ~ .., :;, .. " .' .~, ;, ,;~ ;., 2~.fl~f~~~
WO 92122653 V '~' '~. PC.°T/US92/0~126 (2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear, (x~.) SEQUENCE DESCRIPTION: SEQ ID N0:12:
' (2) INFORMATION F'OR SEQ TD NO:13:
(i) SEQUENCE CHARACTERISTICS;
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS; single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:13:

GTAGATAAAT CCTCTTCTAC AGCCTATCTG CAAA1'G 36 (2) INFORt~tATION
FOR SEQ
LD N0:14:

(i) SEQUENCE CHARACTERISTICS:

(~,) ' ~;EN~TH: 68 bases ~5 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) T0P0LOGY: liner ,; r~

(xi) SEQUENCE'DESCRIPTION: SEQ ID N0:14:

CTTATAAAGG TGTTTCCACC TATAACCAGA AATTCAAGGA TCGTTTCACG

$5, ATATCCGTAG ATAAATCC 68 (2) INFORMATION
FOR SEQ
ID NO:15:

50 (i) SEQUENCE CHARACTERISTICS:

(Al LENGTH: 30 bass (g) TYPE: nucleic arid (C) STRANDEDNESS: singly (D) TOPOLOGY: linear k 'n. ,. ~ ..- ~,, .:. ~,' . ~ ~ .~ . , ,~., ,,~... -y... ~ ::. ,. ..... . ...
7 r..~:....,. . ~::; .mt.~ , ..:-... . .. ' . ~. ~ ,. . .... ~.~..'. ,... ~ ~.
-.w . ..
P~'/LJS92/05126 (xi)~SEQUENCE DESCRIPTION: SEQ ID N0:15:

(2) INFORMATION FOR SEQ ID N0:16:
( i) SEQUENCE CHE~RACTERISTICS
(A) LENGTH: 107 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESGRIPTION: SEQ ID N0:16:
Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Va1 Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pra Asp G1y Thr Va1 Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser G1y Val Pro Ser Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile ' 3~ 65 70 75 Ser Asn Leu Glu Gln Glu Asp Ile A1aThr TyrPhe CysG1n Gln Gly Asn Thr Leu Pro Trp Thr Phe AlaGly GlyThr LysLeu Glu 95 100 , 1,05 Ile Lys (2) INFORMATION FOR SEQ ID N0:17:

(i,) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 107 amino acids (B) APE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID,N0:17:

5~: Asp Ile Gln Met Thr Gln Ser Pro SprSer LeuSer AlaSer Val Gly Asp Arg Val Thr Ile Thr Cys ArgAla SerGln AspIle Arg . 20 25 30 WU 92/2263 ~ ~ ~ ~ PGT/LJ892/05126 ~ ~~ ~

B

Asn Tyr TrpTyr GlnGln LysPro GlyLys AlaPro Lys Leu Asn Leu Leu TyrThr SerArg LeuG1u SerGly ValPro Ser Ile Tyx Arg Phe SerGly SerGly ThrAsp TyrThr LeuThr I1e Ser Gly Ser Ser ProGlu AspPhe AlaThr TyrTyr CysGln Gln Leu Gln G1y Asn ProTrp ThxPhe GlyGln GlyThx LysVal Glu Thr Leu 95 '100 105 Ile Lys (2) INFORMATION SEQ
FOR ID
N0:18:

(i) SEQUENCE CHARACTERISTICS:

(A) acids LENGTH:
1.07 amino (B) amino TYPE: acid (D) linear TOPOLOGY:

(xi) SEQUENCE SE~QID
DESCRIPTION: N0:18:

Asp Ile ThrGln SexPro SerSer LeuSer AlaSer Val Gln Met Gly Asp Theale ThrCys ArgAla SerGln SerIle Ser ArE
Val Asn Tyr TrpTyr GlnG1n LysPro GlyLys AlaPro Lys Leu Ala 35 40 ~5 Leu Leu Ala'A1aSerSer LeuG1u SerGly ValPro Ser Ile Tyr 50 55 60 ~..a 4~ Arg Ptae SerGly SerGly ThrApp PheThr LeuThr Iie Ser Gly Ser Ser ProGlu AspPhi A1aThr TyrTyr GysG1n Gln Leu Gln Tyr Asn ProTxp ThrPhe GlyGln GlyThr LysVal Glu Ser Leu iii LyS

~.~~

V~iJ 92/22653 ~ ~ ~ c~! ~ ~ ~ PCTlUS92/~5126 (2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 129 amino acids (B) TYPE: amino acid (D) TOPOL(?GY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr ~ 25 30 Gly Tyr Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Met Gly Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr 20 50 55 fi0 Asn Gln Lys Phe Lys Asp Arg Phe Thr Ile Ser Lys Ala Thr Leu 25. Thr Val AspwLys Ser Ser Ser Thr Ala Tyr Leu Met Glu Leu Leu Asn Ser Leu Thr Ser Glu Asp Sex A1aVal TyrTyr CysAla Arg Ser Gly Tyr Tyr G1y Asp Ser Asp ~rpTyr PheAsp ValTrp Gly Ala Gly Thr Thr Val Thr Val Ser Ser (2),INFORMATION FOR SEQ ID ~:r N0:20:

(i),SEQUENCE CHARACTERISTICS:

(A) LENGTH: '122 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID
N0:20:

Glu Val Gln Leu Val Glu Ser Gly GlyGly LeuVa1 GlnPro Gly Gly Ser L~u Arg Leu Ser Cys -AlaAlaSer GlyTyr SerPhe Thr Gly Tyr~Thr Met Ann Trp Val Arg GlnAla ProGly LysGly Leu ~V~O X2/22653 ~ ~ ~ ~ ~ ~ ~ ~"~i'/11S~32/OS126 Glu Trp Val Ala Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr Asn Gln Lys Phe Lys Asp Arg Phe Thr IIe Ser Val Asp Lys Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala G1u Asp Thr Ala Va1 Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly Asp Sar Asp Trp Tyr Phe Asp Val Trp Gly Gln G1y Thr Leu Val Thr Val Ser Ser (2) INFORMATION FOR SEQ
ID N0:21:

~0 ( i} SEQUENCE CkIARACTERISTICS:

(A) LENGT~1: 122 aminoacids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE SEQ ID
DESCRIPTION: N0:21:

Glu Val Gln Leu Val Glu G1y GlyGly LeuVal GlnPro Gly Ser Gly Ser Leu Arg Leu Ser Ala AlaSer GlyPhe ThrPhe Ser Cys Ser Tyr Ala Met Ser Trp Arg GlnAla ProGly LysGly Leu Val G1u Trp Val Ser Val Ile Gly AspGly G1ySer ThrTyr Tyr Ser 40 Ala Asp Ser Val Lys Gly Phe ThrIle SerArg AspAsn Ser Arg Lys Asn Thr Leu Tyr Leu Met AsnSer LeuArg AlaGlu Asp Gln Thr A.la VaI Tyr Tyr Cys Arg G1yArg ValGly TyrSer Leu Ala Ser Gly Leu Tyr Asp Tyr GIy GlnGly ThrLeu ValThr Val Trp Ser Ser .

~v~ ~z~zzss~ 2 ~. 0 3 (~ ~ 0 ~c°°rius~zios'z6 (2) INFORMATION FOR SEQ ID N0:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 454 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRT:?TION: SEQ ID N0:22:
Gln Val G1n Leu Gln Gln Ser G1y Pro Glu Leu Val Lys Pro G1y Ala Ser Val Lys I1e Ser Cys Lys Thr,Ser G1y Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Met Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Phe Asn Pro Lys Asn G1y Gly Ser Ser His Asn Gln Arg Phe Met Asp Lys Ala Thr Leu Ala VaI Asp Lys Ser Thr Ser Thr A1a Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Gly Ile Tyr Tyr Cys Ala Arg Trp Arg Gly Leu Asn Tyr Gly Phe Asp ValArg TyrPhe AspVal TrpGly A1aGly ThrThr Val Thr Val SerSer AlaSer ThrLys GlyPro SerVal PhePro Leu AIa Pro SerSex Lys.Ser ThrSer GlyGly ThrAla AlaLeu Gly :140 145 150 Cys Leu ValLys AspTyr PhsPro GluPro ValThr Va1Ser Trp Asn Ser GlyAla LeuThr SerGly ValHis ThrPhe ProAla Val Leu G1n SerSer GlyLeu TyrSer LeuSer SerVal ValThr Val a 185 ~ 190 195 Pro Ser SerSer LeuGly ThrGln ThrTyr IleCys AsnVal Asn His Lys ProSer AsnThr LyrsVal AspLys LysVal GluPro Lys :,''... ...... ..... ,...= . ..:::.:;
i3'~ 92/22653 ~ ~ ~ ~ ~ ~ ~ PCT/US92105126 (~ Z
Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His~,Glu Asp Pro Glu Va1 Lys Phe Asn Trp Tyr 27~5~ 280 285 Val Asp GIy Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu '1'hr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Lle Ser Lys 2~ Ala Lys Gly Pro Arg Pro GlnVal TyrThr LeuPro Pro Gln Glu Ser Arg Glu Met Thr Asn GlnVal SerLeu ThrCys Leu Glu, Lys Val Lys Gly Ty~cPro Asp 'IleAla ValGlu TrpGlu Ser Phe Ser Asn Gly Gln Glu Asn Tyr LysThr ThrPro ProVa1 Leu Pro Asn Asp Ser Asp Ser Phe Leu TyxSer LysLeu ThrVal Asp ~-.e Gly Phe Lys Ser Arg GlriGln Asn Val~'heSerCys SerVal Met Trp Gly 4~5 430 435 Hia Glu Ala His Asn Tyr ~'hrG1n LysSex LeuSer Leu Leia His Ser Pro Gly , Lys (2) TNFORMATIONFOR SEQ :
ID
N0:23 ( j.) SEQUENCECHARACTERISTICS:

(A)' LENGTH: 57 aminoacids (~) TYPE: ami no acid (D)'TOPOLOGY: linear '~V~ 92/22653 ~ ~ ~ PC1'/U~92/0512~6 p o3 (xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:
His His Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe 1'hr Glu Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly Val His Ser Glu Val Gln Leu Val Glu Ser G1y Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Sex Cys Ala Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Met Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala G1y Ile Asn Pro Lys Asn Gly Gly Thr Ser His Asn Gln Arg Phe Met Asp Arg Phe 110 las 120 Thr Il.eSerVal AspLys SerThr SerThr A1a TyrMet GlnMet 3G Asn Ser LeuArg AlaGlu AspThr AlaVal Tyr TyrCys AlaArg Trp Arg GlyLeu AsnTyr GlyPhe AspVal Arg TyrPhe AspVal Trp Gly GlnGly ThrLeu Va1Thr ValSer Ser AlaSex ThrLys 170 1.75 180 G1y Pro SerVal Phe-Pro LeuAla PrnCys Ser ArgSer ThrSer Glu Sar ThxAla AlaiLeu GlyCys LeuVal Lys AspTyr PhePro 45- Glu Pro ValThr ValSer TrpAsn SerGly Ala LeuThr SerGly Val His ThrPhe ProAla ValLeu GlnSer Ser GlyLeu TyrSer Leu Ser SerVal ValThr Val'ThrSerSer Asn PheGly ThrGln ;:.r F:.:.., P ~
J.,,~, ~.~i,. :.., y 7 !3 >

Gu.
tG 7. .:: k 7 .
.. ~x I .:fin 1 , 4 4 ~0.' .A.-a., . ..>t d~'. ~ r 1 ' .~ 1 ~~.4r ~. , 7f , ,,. > . . ~, .' a"
:,:4" ...
:~ ;. , , F,.., . ...:;~ .;'~',t...y, ;.:. ,";'.~,;: ' .. ;.,.~.'~~o,> , ' m ", ..y'.. .., ' ,.. ' ..'...~~ ~ . .,. .~ , ',~;~ .... ,, ,. ~.:.;
r, . , ' ". . ~ ~ .;,.;~.~ . . ",. v:.,:. , . ;: , , . . ,..,. . ;. ,.. . ~
.~'~.. . ~.:.~.~ . :~ ~ ~ ' ~ .: , ~..,~. ..:.~ .,.
WCD 92/22653 ~ ~ ~ J ~ ~ ~ PC.TlUS92/05126 Ion Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Z'hr Val Glu Arg Lys Cys Cys Val Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly G1y Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 305 ~ 310 315 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 320 ~ 32S 330 Glu Cys Pro Pra Cys Pro Ala Pro Pro Val A1a G1y Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Sex Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Met Ghu Val Hi.s 380 385 ~390 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Va1 Ser Asn Lys Gly Leu Pro Ala Pxo Tle Glu Lys Thr Ile Sex Lys Thr Lys Gly Gln Pro Arg Glu 440 44S 450 ''~
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Va1 Ser Leu Thr Cys Leu Va1 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val.Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Ty~ Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Sir Lys Leu Thr Val Asp Lys Ser Arg Trp Gln G1n Gly ". :.
~V~ 92/22653 ~ ~ ~ ~ ~ ~ e~ PCT/LJS92i~15126 Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 'Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys (2) INFORMATION FOR SEQ ID N0:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 214 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESGRIPTION: SEQ ID N0:24:
Asp Va1 G1n Met Thr GIn Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg VaI Thr Ile Asn Cys Arg AlawSer GIn Asp Ile Asn Asn Tyr Leu Asn Trp Tyr GIn Gln Lys Pro Asn Gly Thr Val Lys Leu Leu IIe Tyr Tyr Thr Ser Thr Leu His Ser Gly Va1 Pro Ser Arg Phe Ser Gly Ser G1y Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Asp Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Al:a Ala Pro Ser Val Phe Ile Phe Pro Pro , 4~0 Ser Asp Glu Gln Leu Lys Ser Gly Thr AIa Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu GIn Ser G1y Asn Ser Gln Glu Ser Val Thr GIu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 50 170 ' 175 180 Leu Ser Lys AIa Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu ~~, r .,,...,.~. , ~ ,.. ~. ...::~., ., ,..: ,,:;... , . :~', '~';. . ' ::' ..
,~::. .....~'~.'y.:, ~,... ., ., ,~,.~:.:.. . .,~ ~,.... ' .;~. .. .
........:. . ;....
CVO 92/22653 ~ ~ ~ ~ ~ ~ ~ P~(:'1'/US92105126 . -~ bb Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Cys Glu (2) INFORMATION D
FOR SEQ N0:25:
I

(i) SEQUENCE
CHARACTERISTICS:

(A) acids LENGTH:

amino (P) amino TYPE: acid (D) linear TOPOLOGY:

(~i) SEQUENCE SEQ ID
DESCRIPTION: N0:25:

Met G1y Ser CysIle IleLeu PheLeu ValAla ThrAla Thr Trp Gly Val Ser AspIle GlnMet ThrGln SexPro SerSer Leu His Ser Ala Val GlyAsp ArgVal ThrIle ThrCys ArgAla Ser Ser Gln Asp Asn AsnTyr LeuAsn TrpTyr GlnGln LysPro Gly Ile Lys Ala Lys LeuLeu IleTyr TyrThr SerThr LeuHis Ser Pro Gly Val Ser ArgPhe SerGly SerGly SerGly ThrAsp Tyr Pro Thr Leu Ile SerSer LeuGln ProGlu AspPhe AlaThr Tyr Thr ~5 95 100 105 Tyr Cys Gln GlyAsn ThrLeu ProPro ThrPhe GlyGln Gly Gln Thr Lys G~LuIleLys ArgThr ValAla AlaPro SexVal Phe Val Ile Phe Pro SerAsp GluGln LeuLys SerGly ThrAla Ser Pro '6Ia1 Val Leu LeuAsn AsnPhe TyrPro ArgGlu AlaLys Val Cys Gln Trp Val AspAsn AlaLeu GlnSer GlyAsn SerGln Glu Lys Ser Va1 G1u GlnAsp SerLys AspSer ThrTyr SerLeu Ser Thr u~r~ :,, ,,.
. ~'~ ~zrzzs~3 ~ ~ o ~ ~ ~ ~ Pf'I'/1J~92/05126 lob Ser Thr heu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val . 200 205 210 Tyr Ala Cys Glu Val Thr His Gln G1y Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys

Claims (129)

WE CLAIM:
1. A method for making a humanized antibody comprising non-human, import Complementarity Determining Region (CDR)amino acid residues and human Framework Region (FR) amino acid residues, comprising the steps of:
(a) obtaining the amino acid sequences of an import variable domain and of a VH subgroup III consensus human variable domain;
(b) identifying CDR amino acid sequences in the import and the human variable domain sequences;
(c) substituting import CDRs for the corresponding human CDRs;
(d) aligning the amino acid sequences of a FR of the import antibody and the corresponding FR of the consensus variable domain;
(e) identifying import antibody FR residues in the aligned FR sequences that are non-homologous to the corresponding consensus variable domain residues;
(f) determining if the non-homologous import amino acid residue is expected to have at least one of the following effects:
(1) non-covalently binds antigen directly;
(2) interacts with a CDR; or (3) participates in the VL-VH interface;
(g) for any non-homologous import antibody amino acid residue which is expected to have at least one of these effects, substituting that residue for the corresponding amino acid residue in the consensus variable domain FR
sequence; and (h) preparing a humanized antibody which binds antigen, wherein the humanized antibody comprises an amino acid sequence determined according to the above steps.
2. The method of claim 1, having an additional step of determining if any such non-homologous residues are exposed on the surface of the domain or buried within it, and if the residue is exposed, retaining the consensus residue.
3. The method of claim 1, having the additional steps of searching the import variable domain sequence for glycosylation sites, determining if any such glycosylation site is expected to affect the antigen binding or affinity of the antibody, and if so, substituting the glycosylation site into the consensus sequence.
4. The method of claim 1, having the additional steps of searching the consensus variable domain sequence for glycosylation sites which are not present at the corresponding amino acid in the import sequence, and if the glycosylation site is not present in the import sequence, substituting the import amino acid residues for the amino acid residues comprising the consensus glycosylation site.
5. The method of claim 1, having an additional step which comprises aligning import antibody and consensus variable domain FR sequences, identifying import antibody FR
residues which are non- homologous with the aligned consensus FR sequence, and for each such non- homologous import antibody FR residue, determining if the corresponding consensus variable domain residue represents a residue which is highly conserved across all species at that site, and if it is so conserved, preparing a humanized antibody which comprises the consensus amino acid residue at that site.
6. The method of claim 1, wherein the corresponding consensus residues are selected from the group consisting of 4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91H, 92H, 93H, and 103H.
7. A method for making a humanized antibody comprising non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues, comprising providing an import, non-human antibody variable domain amino acid sequence having CDR
amino acid residues and FR amino acid residues; obtaining the amino acid sequence of a VH subgroup III consensus human antibody variable domain having CDR amino acid residues and FR amino acid residues; substituting non-human CDR amino acid residues for human CDR amino acid residues in the consensus human antibody variable domain; substituting an amino acid residue for the consensus amino acid residue at at least one of the following sites:
4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 91H, 92H, 93H.
and 103H; and preparing a humanized antibody which binds an antigen, wherein the humanized antibody comprises an amino acid sequence determined according to the above steps.
8. The method of claim 7, wherein the substituted residue is the residue found at the corresponding location of the non-human antibody.
9. A humanized antibody variable domain having a functional antigen binding region, said humanized antibody variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues incorporated into a VH subgroup III consensus human antibody variable domain, and further comprising an amino acid substitution at a site selected from the group consisting of:
4L, 35L, 36L, 38L, 43L, 44L, 46L, 58L, 62L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L, 87L, 98L, 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 68H, 69H, 70H, 73H, 74H, 75H, 76H, 78H, 92H, and 93H.
10. The humanized antibody variable domain of claim 9, wherein the substituted residue is the residue found at the corresponding location of the non-human antibody from which the non-human CDR amino acid residues are obtained.
11. The humanized antibody variable domain of claim 9, wherein no human (FR) Framework Region (FR) residue other than those set forth in the group has been substituted.
12. A method for making a humanized antibody comprising introducing Complementarity Determining Region (CDR) amino acid residues from an import antibody variable domain into a VH subgroup III consensus human antibody variable domain.
13. A humanized antibody variable domain having a functional antigen binding region, said humanized antibody variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues incorporated into a VH subgroup III consensus human antibody variable domain and further comprising a non-human import Framework Region (FR) residue, wherein the non-human import FR residue introduces a glycosylation site which affects the antigen binding or affinity of the humanized antibody variable domain.
14. A humanized antibody which binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity and comprises a heavy chain variable domain which comprises non-human import antibody Complementarity Determining Region (CDR) amino acid residues incorporated into a VH subgroup III consensus human variable domain.
15. A humanized variant of a non-human parent antibody, wherein the humanized variant comprises non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues, and:
(a) binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity:
(b) mediates specific cell lysis of SK-BR-3 calls in the presence of IL-2 activated human peripheral blood lymphocytes at least about four fold more effectively than the non-human parent antibody; and (c) mediates Antibody Dependent Cellular Cytotoxicity (ADCC) selective for cell types which overexpress p185HER2 at least about two fold more effectively than for cell types which express low levels of p185HER2.
16. The humanized variant of claim 15 which binds the HER2 receptor with an affinity of about 0.82 nM Kd or better affinity.
17. The humanized variant of claim 16 which binds the HER2 receptor with an affinity of about 0.10 nM Kd.
18. The humanized variant of claim 15 which inhibits proliferation of SK-BR-3 cells incubated for 96 hr with the antibody.
19. The humanized variant of claim 18 wherein the antibody inhibits proliferation of SK-BR-3 cells to about 66% of untreated control or greater inhibition.
20. A humanized variant of a non-human parent antibody, wherein the humanized variant comprises non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues, and;
(a) binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity; and (b) comprises a Framework Region (FR) amino acid substitution at a site selected from the group consisting of 73H, 78H, 93H and 66L, utilizing the numbering system set forth in Kabat.
21. The humanized variant of claim 20 which consists of about 1 to about 5 FR substitutions.
22. The humanized variant of claim 20 which comprises a FR substitution at site 73H.
23. The humanized variant of claim 20 which comprises a FR substitution at site 78H.
24. The humanized variant of claim 20 which comprises a FR substitution at site 93H.
25. The humanized variant of claim 20 which comprises a FR substitution at site 66L.
26. The humanized variant of claim 20 which further comprises a FR substitution at site 71H.
27. The humanized variant of claim 26 which comprises FR
substitutions at sites 71H, 73H, 78H, 93H and 66L.
28. A humanized variant of a non-human parent antibody, wherein the humanized variant comprises non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues; binds the HER2 receptor with better affinity than the non- human parent antibody; and comprises Framework Region (FR) amino acid substitutions at sites 71H, 73H, 78H, 93H and 66L, utilizing the numbering system set forth in Kabat.
29. An antibody which binds an antigen and comprises non-human heavy chain variable domain Complementarity Determining Region (CDR) amino acid residues which bind said antigen and VH subgroup III consensus human variable domain Framework Region (FR) amino acid residues; and further comprises non-human light chain variable domain CDR amino acid residues which bind said antigen.
30. The antibody of claim 29, further comprising VL kappa subgroup I consensus human variable domain FR amino acid residues.
31. A humanized antibody variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues which bind an antigen incorporated into a human antibody variable domain, and further comprising a Framework Region (FR) amino acid substitution at a site selected from the group consisting of: 4L, 38L, 43L, 44L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H and 92H, utilizing the numbering system set forth in Kabat.
32. The humanized variable domain of claim 31 wherein the substituted residue is the residue found at the corresponding location of the non-human antibody from which the non-human CDR amino acid residues are obtained.
33. The humanized variable domain of claim 31 wherein no human Framework Region (FR) residue other than those set forth in the group has been substituted.
34. The humanized variable domain of claim 31 wherein the human antibody variable domain is a consensus human variable domain.
35. The humanized variable domain of claim 31 wherein the residue at site 4L has been substituted.
36. The humanized variable domain of claim 31 wherein the residue at site 38L has been substituted.
37. The humanized variable domain of claim 31 wherein the residue at site 43L has been substituted.
38. The humanized variable domain of claim 31 wherein the residue at site 44L has been substituted.
39. The humanized variable domain of claim 31 wherein the residue at site 58L has been substituted.
40. The humanized variable domain of claim 31 wherein the residue at site 62L has been substituted.
41. The humanized variable domain of claim 31 wherein the residue at site 65L has been substituted.
42. The humanized variable domain of claim 31 wherein the residue at site 66L has been substituted.
43. The humanized variable domain of claim 31 wherein the residue at site 67L has been substituted.
44. The humanized variable domain of claim 31 wherein the residue at site 68L has been substituted.
45. The humanized variable domain of claim 31 wherein the residue at site 69L has been substituted.
46. The humanized variable domain of claim 31 wherein the residue at site 73L has been substituted.
47. The humanized variable domain of claim 31 wherein the residue at site 85L has been substituted.
48. The humanized variable domain of claim 31 wherein the residue at site 98L has been substituted.
49. The humanized variable domain of claim 31 wherein the residue at site 2H has been substituted.
50. The humanized variable domain of claim 31 wherein the residue at site 4H has been substituted.
51. The humanized variable domain of claim 31 wherein the residue at site 36H has been substituted.
52. The humanized variable domain of claim 31 wherein the residue at site 39H has been substituted.
53. The humanized variable domain of claim 31 wherein the residue at site 43H has been substituted.
54. The humanized variable domain of claim 31 wherein the residue at site 45H has been substituted.
55. The humanized variable domain of claim 31 wherein the residue at site 69H has been substituted.
56. The humanized variable domain of claim 31 wherein the residue at site 70H has been substituted.
57. The humanized variable domain of claim 31 wherein the residue at site 74H has been substituted.
58. The humanized variable domain of claim 31 wherein the residue at site 92H has been substituted.
59. An antibody comprising the humanized variable domain of claim 31.
60. An antibody which binds p185 HER2 and comprises a humanized antibody variable domain, wherein the humanized antibody variable domain comprises non-human Complementarity Determining Region (CDR) amino acid residues which bind p185 HER2 incorporated into a human antibody variable domain, and further comprises a Framework Region (FR) amino acid substitution at a site selected from the group consisting of:
4L, 38L, 43L, 44L, 46L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, 75H, 76H, 78H and 92H, utilizing the numbering system set forth in Kabat.
61. The antibody of claim 60 wherein the substituted residue is the residue found at the corresponding location of the non-human antibody from which the non-human CDR amino acid residues are obtained.
62. The antibody of claim 60 wherein no human Framework Region (FR) residue other than those set forth in the group has been substituted.
63. The antibody of claim 60 wherein the human antibody variable domain is a consensus human variable domain.
64. The antibody of claim 60 wherein the residue at site 4L has been substituted.
65. The antibody of claim 60 wherein the residue at site 38L has been substituted.
66. The antibody of claim 60 wherein the residue at site 43L has been substituted.
67. The antibody of claim 60 wherein the residue at site 44L has been substituted.
68. The antibody of claim 60 wherein the residue at site 46L has been substituted.
69. The antibody of claim 60 wherein the residue at site 58L has been substituted.
70. The antibody of claim 60 wherein the residue at site 62L has been substituted.
71. The antibody of claim 60 wherein the residue at site 65L has been substituted.
72. The antibody of claim 60 wherein the residue at site 66L has been substituted.
73. The antibody of claim 60 wherein the residue at site 67L has been substituted.
74. The antibody of claim 60 wherein the residue at site 68L has been substituted.
75. The antibody of claim 60 wherein the residue at site 69L has been substituted.
76. The antibody of claim 60 wherein the residue at site 73L has been substituted.
77. The antibody of claim 60 wherein the residue at site 85L has been substituted.
78. The antibody of claim 60 wherein the residue at site 98L has been substituted.
79. The antibody of claim 60 wherein the residue at site 2H has been substituted.
80. The antibody of claim 60 wherein the residue at site 4H has been substituted.
81. The antibody of claim 60 wherein the residue at site 36H has been substituted.
82. The antibody of claim 60 wherein the residue at site 39H has been substituted.
83. The antibody of claim 60 wherein the residue at site 43H has been substituted.
84. The antibody of claim 60 wherein the residue at site 45H has been substituted.
85. The antibody of claim 60 wherein the residue at site 69H has been substituted.
86. The antibody of claim 60 wherein the residue at site 70H has been substituted.
87. The antibody of claim 60 wherein the residue at site 74H has been substituted.
88. The antibody of claim 60 wherein the residue at site 75H has been substituted.
89. The antibody of claim 60 wherein the residue at site 76H has been substituted.
90. The antibody of claim 60 wherein the residue at site 78H has been substituted.
91. The antibody of claim 60 wherein the residue at site 92H has been substituted.
92. A humanized antibody variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues which bind an antigen incorporated into a consensus human variable domain, and further comprising an amino acid substitution at a site selected from the group consisting of:

4L, 38L, 43L, 44L, 46L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, 75H, 76H, 78H and 92H, utilizing the numbering system set forth in Kabat.
93. A humanized antibody which lacks immunogenicity compared to a non-human parent antibody upon repeated administration to a human patient in order to treat a chronic disease in that patient , wherein the humanized antibody comprises non-human Complementarity Determining Region (CDR) amino acid residues which bind an antigen incorporated into a human antibody variable domain, and further comprises an amino acid substitution at a site selected from the group consisting of:
4L, 38L, 43L, 44L, 46L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 36H, 39H, 43H, 45H, 69H, 70H, 74H, 75H, 76H, 78H and 92H, utilizing the numbering system set forth in Kabat.
94. A humanized variant of a non-human parent antibody which binds an antigen and comprises a human variable domain comprising the most frequently occurring amino acid residues at each location in all. human immunoglobulins of a human heavy chain immunoglobulin subgroup wherein amino acid residues forming Complementarity Determining Regions (CDRs) thereof comprise non-human antibody amino acid residues, and further comprises a Framework Region (FR) substitution where the substituted FR residue: (a) noncovalently binds antigen directly; (b) interacts with a CDR; (c) introduces a glycosylation site which affects the antigen binding or affinity of the antibody; or (d) participates in the VL-VH interface by affecting the proximity or orientation of the VL and VH regions with respect to one another.
95. The humanized variant of claim 94 which binds the antigen up to 3-fold more in the binding affinity than the parent antibody binds antigen.
96. A humanized antibody heavy chain variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues which bind antigen incorporated into a human antibody variable domain, and further comprising a Framework Region (FR) amino acid substitution at a site selected from the group consisting of: 24H, 73H, 76H, 78H, and 93H, utilizing the numbering system set forth in Kabat.
97. The humanized variable domain of claim 96 wherein the substituted residue is the residue found at the corresponding location of the non-human antibody from which the non-human CDR amino acid residues are obtained.
98. The humanized variable domain of claim 96 wherein no human Framework Region (FR) residue other than those set forth in the group has been substituted.
99. The humanized variable domain of claim 96 wherein the human antibody variable domain is a consensus human variable domain.
100. The humanized variable domain of claim 96 wherein the residue at site 24H has been substituted.
101. The humanized variable domain of claim 96 wherein the residue at site 73H has been substituted.
102. The humanized variable domain of claim 96 wherein the residue at site 76H has been substituted.
103. The humanized variable domain of claim 96 wherein the residue at site 78H has been substituted.
104. The humanized variable domain of claim 96 wherein the residue at site 93H has been substituted.
105. The humanized variable domain of claim 96 which further comprises an amino acid substitution at site 71H.
106. The humanized variable domain of claim 96 which further comprises amino acid substitutions at sites 71H
and 73H.
107. The humanized variable domain of claim 96 which further comprises amino acid substitutions at sites 71H, 73H and 78H.
108. An antibody comprising the humanized variable domain of claim 96.
109. A humanized variant of a non-human parent antibody which binds an antigen, wherein the humanized variant comprises Complementarity Determining Region (CDR) amino acid residues of the non-human parent antibody incorporated into a human antibody variable domain, and further comprises Framework Region (FR) substitutions at heavy chain positions 71H, 73H, 78H and 93H, utilizing the numbering system set forth in Kabat.
110. A humanized antibody variable domain comprising non-human Complementarity Determining Region (CDR) amino acid residues which bind an antigen incorporated into a human antibody variable domain, and further comprising a Framework Region (FR) amino acid substitution where the substituted FR residue:

(a) noncovalently binds antigen directly;
(b) interacts with a CDR; or (c) participates in the V L-V H interface by affecting the proximity or orientation of the V L and V H regions with respect to one another, and wherein the substituted FR
residue is at a site selected from the group consisting of: 4L, 38L, 43L, 44L, 58L, 62L, 65L, 66L, 67L, 68L, 69L, 73L, 85L, 98L, 2H, 4H, 24H, 36H, 39H, 43H, 45H, 69H, 70H, 73H, 74H, 76H, 78H, 92H and 93H, utilizing the numbering system set forth in Kabat.
111. The humanized variable domain of claim 110 wherein the substituted residue is the residue found at the corresponding location of the non-human antibody from which the non-human CDR amino acid residues are obtained.
112. The humanized variable domain of claim 110 wherein no human Framework Region (FR) residue other than those set forth in the group has been substituted.
113. A humanized antibody comprising the light chain variable domain sequence in SEQ ID NO: 17.
114. A humanized antibody comprising the heavy chain variable domain sequence in SEQ ID NO: 20.
115. A humanized anti-CD3 antibody comprising the amino acid sequences in SEQ ID NO: 17 and SEQ ID NO: 20.
116. A variable domain of a humanized antibody heavy chain comprising the variable domain sequence within SEQ
ID NO: 23.
117. A variable domain of a humanized antibody light chain comprising the variable domain sequence within SEQ
ID NO: 25.
118. A humanized anti-CD18 antibody comprising the heavy chain variable domain sequence within SEQ ID NO: 23 and the light chain variable domain sequence within SEQ ID
NO: 25.
119. A polypeptide comprising the following amino acid sequence:

GVPSRFS
GSX2SGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK, wherein X1 is E or Y and X2 is R or G.
120. A polypeptide comprising the following amino acid sequence:
EVQLVESGGGLVQPGGSLRLSCMSGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYT
RYADS

SS, wherein X3 is A or R, X4 is T or D, X5 is A or L, X6 is S
or A and X7 is V or Y.
121. The polypeptide of claim 119 comprising the amino acid sequence:
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG
VPSRFSG
SRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK.
122. The polypeptide of claim 120 comprising the amino acid sequence:
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGY
TRYADS

VKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
123. A humanized antibody comprising the heavy chain variable domain sequence:
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGY
TRYADSV

wherein X1 is V or Y, and wherein the humanized antibody binds p185HER2 more tightly than the non-human import antibody from which the CDR amino acid residues of the humanized antibody are derived.
124. The humanized antibody of claim 123 further comprising the light chain variable domain sequence:
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG
VPSRFSG
SRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK.
125. A humanized anti-HER2 antibody which comprises the light chain variable domain amino acid sequence:
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG
VPSRFSGS
RSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK
and the heavy chain variable domain amino acid sequence:
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGY
TRYADSV
KGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS.

CLAIMS:
126. A humanized IgG1 antibody comprising the variable domains of Claim 125.
127. A humanized IgG1 antibody comprising human gamma 1 heavy chain constant domains, human light chain constant domains, and the variable domains of Claim 125.
128. A humanized IgG1 antibody comprising human gamma 1 heavy chain constant domains, human kappa 1 light chain constant domains, and the variable domains of Claim 125.
129. A humanized IgG1 antibody comprising human gamma non-A allotype heavy and light chain constant domains and the variable domains of claim 125.
CA002103059A 1991-06-14 1992-06-15 Method for making humanized antibodies Expired - Lifetime CA2103059C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002481259A CA2481259A1 (en) 1991-06-14 1992-06-15 Method for making humanized antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71527291A 1991-06-14 1991-06-14
US07/715,272 1991-06-14
PCT/US1992/005126 WO1992022653A1 (en) 1991-06-14 1992-06-15 Method for making humanized antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002481259A Division CA2481259A1 (en) 1991-06-14 1992-06-15 Method for making humanized antibodies

Publications (2)

Publication Number Publication Date
CA2103059A1 CA2103059A1 (en) 1992-12-15
CA2103059C true CA2103059C (en) 2005-03-22

Family

ID=24873346

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002103059A Expired - Lifetime CA2103059C (en) 1991-06-14 1992-06-15 Method for making humanized antibodies

Country Status (14)

Country Link
US (4) US6407213B1 (en)
EP (3) EP0940468A1 (en)
JP (4) JP4124480B2 (en)
AT (1) ATE255131T1 (en)
AU (1) AU675916B2 (en)
CA (1) CA2103059C (en)
CY (2) CY2500B1 (en)
DE (2) DE122004000008I1 (en)
DK (1) DK0590058T3 (en)
ES (1) ES2206447T3 (en)
GE (1) GEP20074141B (en)
LU (1) LU91067I2 (en)
NL (1) NL300145I1 (en)
WO (1) WO1992022653A1 (en)

Families Citing this family (3495)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5948647A (en) * 1990-10-29 1999-09-07 Chiron Corporation Nucleic acids encoding antigen-binding sites specific for cancer antigens
US5849877A (en) * 1990-10-29 1998-12-15 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5811267A (en) * 1990-10-29 1998-09-22 Chiron Corporation Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (en) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US6329509B1 (en) * 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
US6685939B2 (en) 1991-08-14 2004-02-03 Genentech, Inc. Method of preventing the onset of allergic disorders
DE69233204T2 (en) * 1991-12-13 2004-07-15 Xoma Corp., Berkeley METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
EP0578515A3 (en) * 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
ES2112431T3 (en) * 1992-08-21 1998-04-01 Genentech Inc PROCEDURE FOR THE TREATMENT OF AN LFA-1 MEDIATED DISORDER.
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
EP0804235A4 (en) * 1993-05-04 2001-09-19 Aeres Biomedical Ltd Antibodies to p-selectin and their uses
US20040067157A1 (en) * 1993-07-22 2004-04-08 Clearant, Inc. Methods for sterilizing biological materials
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
AU3545795A (en) * 1994-09-08 1996-03-27 Chiron Corporation A method of improved production of insulin-like growth factor
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US7803904B2 (en) * 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
EP0831880A4 (en) * 1995-06-07 2004-12-01 Imclone Systems Inc Antibody and antibody fragments for inhibiting the growth of tumors
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
CA2245835A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
BR9609743A (en) 1995-07-27 1999-03-02 Genentech Inc Stable reconstituted formulation method for the preparation of a manufactured article formulation and use of the formation
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
WO1997046589A2 (en) 1996-06-07 1997-12-11 Neorx Corporation Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
AU3359497A (en) * 1996-07-11 1998-02-09 Takara Shuzo Co., Ltd. Method for effecting site-directed mutagenesis
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US7371376B1 (en) * 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA982371B (en) * 1997-03-21 1998-09-28 Sankyo Co Humanized anti-human fas antibody
US7083786B2 (en) * 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
BRPI9809387B8 (en) * 1997-04-07 2021-05-25 Genentech Inc humanized anti-human vascular endothelial growth factor antibody and composition comprising it
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
WO1998045332A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Humanized antibodies and methods for forming humanized antibodies
ES2263205T3 (en) * 1997-04-30 2006-12-01 Hans Klingemann NATURAL CYTOLITIC CELLULAR STRETCHES AND METHODS OF USE.
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE69841204D1 (en) 1997-06-04 2009-11-12 Oxford Biomedica Ltd Tumor targeted vector
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US20020192659A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030092002A1 (en) * 1997-09-17 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1027437T3 (en) 1997-10-29 2008-11-24 Genentech Inc Use of the WNT-1 induced secreted polypeptide WISP-1
IL135607A0 (en) 1997-10-29 2001-05-20 Genentech Inc Wnt-1 inducible genes
WO1999027964A1 (en) * 1997-12-01 1999-06-10 Cfy Biomedicals, Inc. Multivalent recombinant antibodies for treating hrv infections
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
EP1064382B1 (en) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
EP1308456B1 (en) * 1998-05-06 2007-08-22 Genentech, Inc. Antibody purification by ion exchange chromatography
ES2261589T3 (en) 1998-05-06 2006-11-16 Genentech, Inc. ANTI-HER2 ANTIBODY COMPOSITION.
AU2003200708B2 (en) * 1998-05-06 2007-01-04 Genentech, Inc. Protein purification
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
WO2000023082A1 (en) * 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
WO2000029431A1 (en) * 1998-11-17 2000-05-25 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
DE69938054T2 (en) * 1998-11-18 2009-02-12 Genentech, Inc., South San Francisco ANTIBODY VARIANTS HAVING HIGHER BINDING SAFFINITIES COMPARED TO PARENTAL ANTIBODIES
WO2000029447A1 (en) * 1998-11-19 2000-05-25 Smithkline Beecham Corporation Rhamm antagonist antibodies
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EA004590B1 (en) 1999-01-15 2004-06-24 Байоджен, Инк. Method for blocking the development or treating or reducing the severity or effects of "transplant against patients" disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
IL145674A0 (en) * 1999-04-06 2002-06-30 Genentech Inc USE OF ERbB RECEPTOR LIGANDS IN TREATING DIABETES
WO2000069460A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
CA2373815A1 (en) * 1999-05-14 2000-11-23 Imclone Systems Incorporated Treatment of refractory human tumors with epidermal growth factor receptor antagonists
TR200103432T2 (en) 1999-06-01 2002-10-21 Biogen, Inc. Blocking monoclonal VLA-1 antibody and its use in the treatment of inflammatory diseases.
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
BR0012195A (en) * 1999-06-25 2002-07-23 Genentech Inc Method for treating prostate cancer in a human, article of manufacture and use of an antibody that binds erbb2
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
CN100482281C (en) 1999-06-25 2009-04-29 基因技术股份有限公司 Method of treatment using anti-ErbB antibody-maytansinoid conjugates
PL204629B1 (en) 1999-06-25 2010-01-29 Genentech Inc Humanized antibodies of anti-ERBB2 and treatment with antibodies of anti-ERBB2
US20020068066A1 (en) * 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
MXPA02002037A (en) * 1999-08-27 2002-10-31 Genentech Inc DOSAGES FOR TREATMENT WITH ANTI ErbB2 ANTIBODIES.
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU1290001A (en) 1999-11-18 2001-05-30 Oxford Biomedica (Uk) Limited Antibodies
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
ATE337403T1 (en) * 1999-12-24 2006-09-15 Genentech Inc METHOD AND COMPOUNDS FOR EXTENSING THE HALF-LIFE TIMES IN THE EXCRETION OF BIOACTIVE COMPOUNDS
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU4574501A (en) 2000-03-17 2001-10-03 Millennium Pharm Inc Method of inhibiting stenosis and restenosis
EP1272647B1 (en) * 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
PT1283214E (en) 2000-04-21 2007-03-30 Fuso Pharmaceutical Ind Novel collectins
US20020009444A1 (en) * 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
PT1282443E (en) 2000-05-19 2009-12-04 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
AU2001268363B2 (en) 2000-06-20 2006-08-17 Biogen Idec Inc. Treatment of B cell associated diseases
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2077276A1 (en) 2000-06-23 2009-07-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
WO2002018583A2 (en) * 2000-09-01 2002-03-07 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
US20030017491A1 (en) * 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
SI1324776T2 (en) 2000-10-12 2018-06-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2427820A1 (en) * 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
WO2002048675A2 (en) * 2000-12-15 2002-06-20 Transderm Technologies, Llc Improved compositions and methods for producing antibodies to low molecular weight analytes
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7132510B2 (en) 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
EE05724B1 (en) 2001-01-05 2014-10-15 Pfizer Inc. Antibodies to insulin-like growth factor I receptor
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
WO2002060485A2 (en) 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
AU2002237972B2 (en) 2001-01-31 2007-11-29 Biogen Idec Inc. Use of CD23 antagonists for the treatment of neoplastic disorders
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CA2438513C (en) * 2001-02-19 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified anti-egfr antibodies with reduced immunogenicity
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2002247826A1 (en) * 2001-03-13 2002-09-24 University College London Specific binding members
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
EP1372717A2 (en) 2001-03-23 2004-01-02 Aphton Corporation Combination treatment of pancreatic cancer
US7638598B2 (en) 2001-04-06 2009-12-29 The Trustees Of The University Of Pennsylvania ErbB interface peptidomimetics and methods of use thereof
DE60236735D1 (en) 2001-04-13 2010-07-29 Biogen Idec Inc ANTIBODIES TO VLA-1
CA2444821C (en) 2001-04-24 2012-07-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-angiogenic agents and tnfa
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7132401B2 (en) 2001-05-22 2006-11-07 Merck & Co., Inc. Beta-secretase substrates and uses thereof
IL158921A0 (en) 2001-05-30 2004-05-12 Genentech Inc Anti-ngf antibodies for the treatment of various disorders
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
PT1399186E (en) 2001-06-13 2010-02-23 Armbruster Biotechnology Gmbh Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
DE50213368D1 (en) * 2001-06-13 2009-04-30 Immundiagnostik Ag DETERMINATION OF BONE-SIALOPROTEIN IN BODY FLUIDS FOR ONCOLOGICAL QUESTIONS
ATE440869T1 (en) 2001-06-20 2009-09-15 Fibron Ltd FGFR3 BLOCKING ANTIBODIES, METHOD FOR SCREENING THEREOF, AND USES THEREOF
CA2633413C (en) 2001-06-20 2012-08-21 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
CN1671416B (en) * 2001-07-12 2013-01-02 杰斐逊·富特 Super-humanized antibodies
CA2898314A1 (en) 2001-07-19 2003-07-31 Perian Therapeutics, Inc. Multimeric proteins and methods of making and using same
US20040078837A1 (en) * 2001-08-02 2004-04-22 Shannon Mark E. Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12
EA007984B1 (en) * 2001-08-03 2007-02-27 Дженентек, Инк. TACIs AND BR3 POLYPEPTIDES AND USE THEREOF
AU2002326531A1 (en) * 2001-08-03 2003-02-17 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
ATE382053T1 (en) * 2001-08-27 2008-01-15 Genentech Inc SYSTEM FOR ANTIBODIES EXPRESSION AND SYNTHESIS
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
CA2460120A1 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
AR037456A1 (en) 2001-11-30 2004-11-10 Biogen Inc ANTIBODIES AGAINST MONOCITARY CHEMOTHOTAL PROTEINS
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR20040096592A (en) * 2002-02-21 2004-11-16 와이어쓰 Follistatin domain containing proteins
RU2359697C2 (en) 2002-02-25 2009-06-27 Элан Фармасьютикалз, Инк. Injection of agents for inflammation treatment
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20070122406A1 (en) 2005-07-08 2007-05-31 Xencor, Inc. Optimized proteins that target Ep-CAM
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP2336185A1 (en) 2002-03-13 2011-06-22 Biogen Idec Inc. Anti- alpha v beta 6 antibodies
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
AU2003220439A1 (en) * 2002-03-19 2003-10-08 Abgenix, Inc. Methods for treating chronic obstructive pulmonary disease (copd)
CN103536916B (en) 2002-04-09 2016-08-17 比奥根Ma公司 For the method treating TWEAK associated conditions
DK1501856T3 (en) * 2002-04-10 2013-03-25 Genentech Inc Anti-HER2 antibody variants
JP2005536190A (en) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
US6916904B2 (en) * 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
JP3885658B2 (en) * 2002-05-13 2007-02-21 住友電気工業株式会社 Heterojunction bipolar transistor
ATE483466T1 (en) 2002-05-23 2010-10-15 Univ Pennsylvania FAS PEPTIDE MIMETICS AND THEIR USES
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
JP4753578B2 (en) * 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド Synthetic antibody phage library
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK1531791T3 (en) 2002-06-07 2010-11-01 Dyax Corp Prevention and restriction of ischemia
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP1551453A4 (en) * 2002-06-17 2007-04-25 Us Gov Health & Human Serv SPECIFICITY GRAFTING OF A WALL ANTIBODY ON A HUMAN CHARPENTE
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
ES2376165T3 (en) * 2002-07-15 2012-03-09 F. Hoffmann-La Roche Ag TREATMENT OF THE C�? NCER WITH THE ANTIBODY DIRECTED AGAINST ERBB2 RHUMAB 2C4.
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
KR101215701B1 (en) 2002-07-19 2012-12-26 베스 이스라엘 데코니스 메디칼 센터 Methods of diagnosing and treating pre-eclampsia or ecalmpsia
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
JP2005533863A (en) * 2002-07-25 2005-11-10 ジェネンテック・インコーポレーテッド TACI antibodies and their uses
AU2003263964C1 (en) * 2002-07-31 2010-08-19 Seagen Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
PT1534335E (en) 2002-08-14 2012-02-28 Macrogenics Inc Fcgammariib-specific antibodies and methods of use thereof
EP1542710B1 (en) * 2002-08-28 2012-09-26 Dyax Corp. Methods for preserving organs and tissues
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
JP2005538738A (en) * 2002-09-16 2005-12-22 エリューシス セラピューティクス,インコーポレーテッド Bispecific molecule comprising an anti-CR1 antibody cross-linked to an antigen-binding antibody fragment
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
PT1556083E (en) * 2002-10-08 2011-03-17 Rinat Neuroscience Corp Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
AU2003276084B2 (en) 2002-10-10 2009-07-09 Merck Patent Gmbh Bispecific anti-Erb-B antibodies and their use in tumor therapy
EP2301965B1 (en) 2002-10-16 2015-02-25 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7608429B2 (en) 2002-10-31 2009-10-27 Genentech, Inc. Methods and compositions for increasing antibody production
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2008103472A2 (en) 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20040229785A1 (en) * 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
US20040258685A1 (en) * 2002-11-21 2004-12-23 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
US20070048301A1 (en) * 2002-11-26 2007-03-01 Bodary-Winter Sarah C Compositions and methods for the treatment of immune related diseases
US7888479B2 (en) * 2002-11-27 2011-02-15 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactric proteins
SG2013036975A (en) * 2002-12-16 2016-07-28 Genentech Inc Immunoglobulin variants and uses thereof
KR101086660B1 (en) * 2002-12-17 2011-11-24 메르크 파텐트 게엠베하 Fusion of Mouse 14.18 Antibody That Binds to WD2 with Humanized Antibody (H14.18) and its IL-2
ATE431157T1 (en) * 2002-12-23 2009-05-15 Rinat Neuroscience Corp METHOD FOR TREATING TAXOL-INDUCED SENSORY NEUROPATHY
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CN102746399B (en) * 2002-12-24 2016-03-02 里纳特神经系统学公司 Anti-ngf antibodies and using method thereof
CA2510003A1 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7488475B2 (en) 2003-01-21 2009-02-10 Arius Research, Inc. Antibody therapy of tumors
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
KR20050114212A (en) 2003-01-24 2005-12-05 엘란 파마슈티칼스, 인크. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
ZA200505782B (en) * 2003-02-01 2006-09-27 Neuralab Ltd Active immunization to generate antibodies to soluble A-beta
JP3803790B2 (en) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ Novel diabody-type bispecific antibody
JP2006525960A (en) 2003-02-19 2006-11-16 ライナット ニューロサイエンス コーポレイション Nerve growth factor agonists and NSAIDs and methods for treating pain by administration of compositions comprising them
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
AU2004219592C1 (en) 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
EP1620127A4 (en) * 2003-03-20 2007-04-04 Rinat Neuroscience Corp Methods for treating taxol-induced gut disorder
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
WO2004087059A2 (en) 2003-03-26 2004-10-14 The University Of Texas Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding
CA2520381A1 (en) * 2003-03-26 2004-10-14 Sudhir Paul Proteolytic and covalent antibodies
WO2004087738A2 (en) * 2003-03-27 2004-10-14 The University Of Texas Lupus antibodies for passive immunotherapy of hiv/aids
AU2004225437B2 (en) * 2003-03-28 2010-05-13 Cancer Advances, Inc. Gastrin hormone immunoassays
JP4869064B2 (en) 2003-04-04 2012-02-01 ジェネンテック, インコーポレイテッド High concentration antibody and protein preparation
CA2519870A1 (en) * 2003-04-09 2004-10-28 Genentech, Inc. Use of rituximab intravenous compositions to treat rheumatoid arthritis
EP1613273B1 (en) 2003-04-11 2012-06-13 MedImmune, LLC Recombinant il-9 antibodies and uses thereof
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7321065B2 (en) 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7189694B2 (en) * 2003-04-18 2007-03-13 University Of Florida Research Foundation, Inc. Inhibitors of autophosphorylation protein kinases
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
SI2374819T1 (en) 2003-05-12 2017-09-29 Helion Biotech Aps Antibodies to MASP-2
CN100387301C (en) * 2003-05-12 2008-05-14 佛罗里达大学研究基金公司 Immunization materials and methods against FIV infection
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DK2361928T3 (en) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CA2526080A1 (en) * 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
JP2007536896A (en) * 2003-06-05 2007-12-20 ジェネンテック・インコーポレーテッド BLYS antagonists and their uses
CN1279056C (en) * 2003-06-06 2006-10-11 马菁 Specific antibody of tumor-associated antigen SM5-1 and use thereof
WO2005003175A2 (en) 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
WO2005000086A2 (en) * 2003-06-30 2005-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
US20050266009A1 (en) * 2003-06-30 2005-12-01 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
KR100945327B1 (en) 2003-07-08 2010-03-08 제넨테크, 인크. IL-173A / F heterologous polypeptide and its therapeutic use
EP1644408A1 (en) * 2003-07-15 2006-04-12 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
US20050058658A1 (en) * 2003-07-15 2005-03-17 Barros Research Institute Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
MXPA06000508A (en) * 2003-07-18 2006-04-05 Amgen Inc Specific binding agents to hepatocyte growth factor.
EP1648940B1 (en) 2003-07-28 2016-04-27 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP2128270B1 (en) 2003-08-08 2012-10-03 Genenews Inc. Osteoarthritis biomarkers and uses thereof
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1660186B1 (en) * 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
JP2007528723A (en) * 2003-08-22 2007-10-18 メディミューン,インコーポレーテッド Antibody humanization
US20050152894A1 (en) * 2003-09-05 2005-07-14 Genentech, Inc. Antibodies with altered effector functions
GB2406094B (en) * 2003-09-17 2007-06-06 Antisoma Plc Modified antibody comprising an amino acid substitution mutation which confers increased stability
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US20050176028A1 (en) * 2003-10-16 2005-08-11 Robert Hofmeister Deimmunized binding molecules to CD3
JP4948174B2 (en) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト Multispecific deimmunized CD3-binding agent
KR101438983B1 (en) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. Monomethylvaline compounds capable of conjugation to ligands
AR046833A1 (en) * 2003-11-10 2005-12-28 Schering Corp ANTI-INTERLEUQUINA ANTIBODIES-10
WO2005048938A2 (en) 2003-11-13 2005-06-02 California Pacific Medical Center Anti-pecam therapy for metastasis suppression
PT2161283E (en) 2003-11-17 2014-08-29 Genentech Inc Compositions comprising antibodies against cd79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
EP1689783B1 (en) 2003-11-25 2010-05-19 The Government Of The United States, As Represented by The Secretary Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc Methods of generating variant proteins with increased host string content and compositions thereof
US20060003412A1 (en) * 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
US20070249809A1 (en) * 2003-12-08 2007-10-25 Xencor, Inc. Protein engineering with analogous contact environments
JP4332558B2 (en) 2003-12-09 2009-09-16 エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド Targeted gene delivery to non-phagocytic mammalian cells via intact minicells from bacteria
ES2384569T3 (en) * 2003-12-19 2012-07-09 Genentech, Inc. Fragments of monovalent antibodies useful as therapeutic agents
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
US7968690B2 (en) * 2003-12-23 2011-06-28 Rinat Neuroscience Corp. Agonist anti-trkC antibodies and methods using same
ITRM20030601A1 (en) * 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
EP1709080B1 (en) * 2004-01-09 2011-03-09 Pfizer Inc. ANTIBODIES TO MAdCAM
CA2554729A1 (en) * 2004-01-27 2005-08-11 University Of Southern California Polymer-bound antibody cancer therapeutic agent
PT1718338E (en) 2004-02-02 2015-09-21 Engeneic Molecular Delivery Pty Ltd Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
JP5155564B2 (en) 2004-02-03 2013-03-06 ディアデクサス インコーポレーテッド Method for detecting Lp-PLA2 activity
CN1965082A (en) * 2004-02-06 2007-05-16 尼莫克斯股份有限公司 Humanized antibody
WO2005079479A2 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
ATE452147T1 (en) 2004-02-19 2010-01-15 Genentech Inc ANTIBODIES WITH CORRECTED CDR
US7875598B2 (en) 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
AU2005221187B2 (en) * 2004-03-10 2011-09-01 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
US7273608B2 (en) * 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
DK1735348T3 (en) * 2004-03-19 2012-07-16 Imclone Llc Human anti-epidermal growth factor receptor antibody
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
MXPA06011199A (en) 2004-03-31 2007-04-16 Genentech Inc Humanized anti-tgf-beta antibodies.
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
ES2665758T3 (en) * 2004-04-07 2018-04-27 Rinat Neuroscience Corp. Bone cancer pain treatment procedures by administration of a neuronal growth factor antagonist antibody
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20060034840A1 (en) * 2004-04-08 2006-02-16 Agus David B ErbB antagonists for pain therapy
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060002930A1 (en) * 2004-04-16 2006-01-05 Genentech, Inc. Treatment of disorders
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
KR20070012408A (en) * 2004-04-16 2007-01-25 제넨테크, 인크. 방법 How to increase cell depletion
EP2286844A3 (en) * 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
CA2566979A1 (en) 2004-06-04 2005-12-15 Genentech, Inc. Use of a cd20 antibody in treatment of multiple sclerosis
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (en) * 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
SV2006002143A (en) * 2004-06-16 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
EP1773391A4 (en) * 2004-06-25 2009-01-21 Medimmune Inc Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
JP2008505174A (en) 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド Optimized Fc variant
PT1771474E (en) 2004-07-20 2010-05-03 Genentech Inc Inhibitors of angiopoietin-like 4 protein, combinations, and their use
KR20110050567A (en) * 2004-07-22 2011-05-13 제넨테크, 인크. HER2 antibody composition
CN101072587B (en) 2004-07-26 2012-12-26 比奥根艾迪克Ma公司 Anti-cd154 antibodies
EA016357B1 (en) 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Antibodies directed against amyloid-beta peptide and methods using same
ATE465181T1 (en) * 2004-08-05 2010-05-15 Genentech Inc HUMANIZED ANTI-CMET ANTAGONISTS
MX2007001469A (en) 2004-08-06 2007-03-26 Genentech Inc Assays and methods using biomarkers.
AU2005271249A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
EA013752B1 (en) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Prevention and treatment of synucleinopathic and amyloidogenic disease
CN101052654A (en) * 2004-08-19 2007-10-10 健泰科生物技术公司 Polypeptide variants with altered effector function
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
WO2006021894A2 (en) 2004-08-26 2006-03-02 Engeneic Gene Therapy Pty Limited Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
CN101052653A (en) * 2004-09-02 2007-10-10 健泰科生物技术公司 Anti-Fc-gamma RIIB receptor antibody and uses therefor
JP2008511337A (en) * 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド Heteromultimeric molecule
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
RU2453558C2 (en) 2004-09-03 2012-06-20 Дженентек, Инк. Humanised anti-beta 7 antagonistic antibodies and use thereof
WO2006031994A2 (en) * 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
EP3073267A1 (en) 2004-09-21 2016-09-28 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8158128B2 (en) 2004-09-22 2012-04-17 Cancer Advances, Inc. Monoclonal antibodies to progastrin
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
SI1791565T1 (en) 2004-09-23 2016-08-31 Genentech, Inc. Cysteine engineered antibodies and conjugates
MX2007003522A (en) 2004-09-24 2007-06-11 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy.
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
RU2418004C2 (en) 2004-10-04 2011-05-10 Дженентек, Инк. Modulators of hepatocyte growth factor activator
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
KR20070073886A (en) * 2004-10-05 2007-07-10 제넨테크, 인크. Toxic Drugs
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
DK1802334T3 (en) 2004-10-21 2012-10-15 Genentech Inc Method of treating intraocular neovascular diseases
JP2008518023A (en) 2004-10-27 2008-05-29 メディミューン,インコーポレーテッド Regulation of antibody specificity by altering affinity for cognate antigens
AU2005302312A1 (en) * 2004-10-29 2006-05-11 Elusys Therapeutics, Inc. Use of CR1-binding molecules in clearance and induction of immune responses
JP2008519863A (en) * 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Auristatin having an aminobenzoic acid unit at the N-terminus
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20060222653A1 (en) * 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
EP2808033A1 (en) 2004-11-19 2014-12-03 Biogen Idec MA Inc. Treatment for multiple sclerosis
GB0425713D0 (en) * 2004-11-23 2004-12-22 Baker Matthew Immunogencity testing and antibody selection methods
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
US20070134243A1 (en) * 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
EP1833509A4 (en) * 2004-12-03 2008-12-03 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis
RU2007125644A (en) * 2004-12-07 2009-01-20 Дженентек Инк. (Us) SELECTION OF PATIENTS FOR THERAPY WITH HER INHIBITOR
ES2434732T3 (en) 2004-12-15 2013-12-17 Janssen Alzheimer Immunotherapy Humanized beta-amyloid antibodies for use in improving cognition
WO2006066171A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid βετα antibodies for use in improving cognition
WO2006066049A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
EP2290087A3 (en) 2004-12-22 2011-06-15 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
WO2006073846A2 (en) * 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
RU2393483C2 (en) * 2004-12-23 2010-06-27 Ф.Хоффманн-Ля Рош Аг Detection of therapeutic antibody in experimental animal
CN101137673B (en) 2005-01-05 2013-12-04 比奥根艾迪克Ma公司 Cripto binding molecules
EP2230517A1 (en) 2005-01-07 2010-09-22 Diadexus, Inc. OVR110 antibody compositions and methods of use
AU2006204791A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc Antibodies and Fc fusion proteins with altered immunogenicity
MX2007008218A (en) * 2005-01-13 2007-08-17 Genentech Inc Treatment method.
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
BRPI0606480A (en) 2005-01-21 2008-03-11 Astex Therapeutics Ltd pharmaceutical compounds
UA94899C2 (en) * 2005-01-21 2011-06-25 Дженентек, Инк. Fixed dosing of her antibodies
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN113952459B (en) 2005-02-03 2025-02-11 综合医院公司 Methods for treating gefitinib-resistant cancer
KR101385886B1 (en) 2005-02-03 2014-04-24 안티토페 리미티드 Human antibodies and proteins
CN101115773B (en) 2005-02-07 2015-06-10 罗氏格黎卡特股份公司 Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
CA2599589A1 (en) 2005-02-07 2006-08-17 Genenews,Inc. Mild osteoarthritis biomarkers and uses thereof
LT1850873T (en) 2005-02-08 2019-04-10 Genzyme Corporation Antibodies to tgfbeta
CA2595395A1 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
WO2006088950A2 (en) 2005-02-14 2006-08-24 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
ES2550621T3 (en) 2005-02-15 2015-11-11 Duke University Anti-CD19 antibodies and uses in oncology
CA2597945C (en) 2005-02-17 2016-07-12 Biogen Idec Ma Inc. Treating neurological disorders
MX2007009889A (en) 2005-02-23 2007-09-07 Genentech Inc Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor.
US20060193849A1 (en) * 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
EP2251037B1 (en) 2005-03-02 2015-01-14 Biogen Idec MA Inc. KIM-1 antibodies for treatment of TH1/TH2-mediated conditions
US8211430B2 (en) * 2005-03-04 2012-07-03 Curedm Group Holdings, Llc Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
CA2600929A1 (en) * 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
AU2006226192A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
JP2008537488A (en) * 2005-03-23 2008-09-18 ワイス Detection of GDF-8 modulating substances
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
EP2674165B1 (en) 2005-03-31 2016-10-12 The General Hospital Corporation Hepatocyte growth factor receptor agonist for increasing lymphangiogenesis
ES2833948T3 (en) 2005-04-04 2021-06-16 Biogen Ma Inc Methods for evaluating an immune response to a therapeutic agent
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
AR054260A1 (en) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp METHODS OF TREATMENT OF DISEASES OF THE LOWER MOTOR NEURONE AND COMPOSITIONS USED IN THE SAME
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
WO2006117782A2 (en) 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
WO2006121852A2 (en) 2005-05-05 2006-11-16 Duke University Anti-cd19 antibody therapy for autoimmune disease
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
DK1879573T3 (en) 2005-05-10 2013-02-25 Incyte Corp MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE AND METHODS FOR USING IT
US8088908B2 (en) * 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
JP2008545712A (en) * 2005-05-25 2008-12-18 キュアーディーエム、インク. Peptides, derivatives and analogs thereof, and methods of using them
PT1888113E (en) * 2005-05-27 2014-09-04 Biogen Idec Inc Tweak binding antibodies
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
ITRM20050290A1 (en) 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
DK2390267T3 (en) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stable and soluble antibodies that inhibit TNF (alpha)
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
JP5372500B2 (en) 2005-06-17 2013-12-18 トレラクス リクイデーティング トラスト ILT3-binding molecules and uses thereof
EP1893647A2 (en) 2005-06-23 2008-03-05 MedImmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
CN102875681A (en) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 Anti-alpha v beta 6 antibodies and uses thereof
PE20070207A1 (en) * 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
US7456259B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
ZA200800970B (en) 2005-08-15 2009-10-28 Genentech Inc Gene disruptions, compositions and methods relating thereto
BRPI0616005A2 (en) 2005-08-16 2011-05-31 Genentech Inc method for predicting the sensitivity of a cell or tissue sample, method for inducing apoptosis in a cell or tissue sample, and method of treating a dysfunction
AU2006283725B2 (en) * 2005-08-19 2012-02-16 The Trustees Of The University Of Pennsylvania Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
WO2007027906A2 (en) * 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090105138A1 (en) * 2005-09-06 2009-04-23 Trinity Therapeutics, Inc. Methods for treating immune mediated neurological diseases
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
EP1931709B1 (en) * 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
EP1951757B1 (en) 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
JP5686953B2 (en) 2005-10-11 2015-03-18 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー Compositions comprising cross-species-specific antibodies and uses of the compositions
ATE518007T1 (en) 2005-10-21 2011-08-15 Genenews Inc METHOD AND APPARATUS FOR CORRELING LEVELS OF BIOMARKER PRODUCTS WITH DISEASES
PE20070796A1 (en) * 2005-10-24 2007-08-15 Wyeth Corp PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS
CA2903896A1 (en) 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007056411A2 (en) * 2005-11-08 2007-05-18 Genentech, Inc. Method of producing pan-specific antibodies
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP2009515552A (en) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α4β7 integrin-reactive humanized immunoglobulin
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
EP1951892A4 (en) 2005-11-22 2009-01-14 Univ Pennsylvania ANTIBODY TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
JP6088723B2 (en) * 2005-11-23 2017-03-01 ジェネンテック, インコーポレイテッド Compositions and methods for B cell assays.
ES2388932T3 (en) * 2005-12-02 2012-10-19 Genentech, Inc. Binding polypeptides and uses thereof
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
DOP2006000277A (en) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp ANTI MN ANTIBODIES AND METHODS FOR USE
AR057237A1 (en) 2005-12-15 2007-11-21 Genentech Inc METHODS AND COMPOSITIONS TO ACT ON POLYUBIQUITINE
PT1976880T (en) 2005-12-21 2016-09-28 Amgen Res (Munich) Gmbh Pharmaceutical compositions with resistance to soluble cea
US20090214541A1 (en) * 2006-01-04 2009-08-27 L'instut National De La Sante Et De La Recherche Medicale Combination Therapy Using Anti-EGFR and Anti-HER2 Antibodies
AU2007248444B2 (en) 2006-01-05 2012-10-25 Genentech, Inc. Anti-EphB4 antibodies and methods using same
KR20080087164A (en) 2006-01-18 2008-09-30 더 제너럴 하스피탈 코포레이션 How to increase lymph function
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
WO2009051846A2 (en) 2007-10-18 2009-04-23 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
US20070175313A1 (en) * 2006-01-31 2007-08-02 Kevin Vandervliet MP3 player holder assembly
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
TWI417301B (en) 2006-02-21 2013-12-01 Wyeth Corp Antibodies against human il-22 and uses therefor
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
WO2007100711A2 (en) * 2006-02-24 2007-09-07 Investigen, Inc. Methods and compositions for detecting polynucleotides
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
KR20140057635A (en) 2006-03-15 2014-05-13 알렉시온 파마슈티칼스, 인코포레이티드 Treatment of Patients with Paroxysmal Nocturnal Hemorrhage as an Incompatible Substance
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc ANTIBODIES OF EGFL7 AND METHODS OF USE
AR059900A1 (en) 2006-03-17 2008-05-07 Genentech Inc ANTI-TAT226 ANTIBODIES AND IMMUNOCATE PLAYERS
DK1989231T3 (en) 2006-03-21 2015-08-24 Genentech Inc COMBINATION THERAPY INVOLVING ALFA5BETA1 antagonists
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
WO2007108152A1 (en) 2006-03-23 2007-09-27 Tohoku University High functional bispecific antibody
EP2004221A2 (en) 2006-03-23 2008-12-24 Novartis Pharma AG Anti-tumor cell antigen antibody therapeutics
JP4419976B2 (en) 2006-03-24 2010-02-24 オンキヨー株式会社 Speaker diaphragm and speaker
AR059922A1 (en) * 2006-04-01 2008-05-07 Galaxy Biotech Llc HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS
EP2614839A3 (en) 2006-04-05 2015-01-28 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
ES2643469T3 (en) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Antibodies that bind to the human tyrosine phosphatase beta protein (HPTP-beta) and uses thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
AU2007297565A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20090298093A1 (en) * 2006-04-27 2009-12-03 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
US20070292936A1 (en) * 2006-05-09 2007-12-20 Genentech, Inc. Binding polypeptides with optimized scaffolds
US7745584B2 (en) 2006-05-22 2010-06-29 California Institute Of Technology Antibodies to sulfated carbohydrates
AU2007267579B2 (en) * 2006-05-25 2013-05-30 Biogen Ma Inc. Methods of treating stroke
MX2008015132A (en) 2006-05-30 2008-12-10 Genentech Inc Antibodies and immunoconjugates and uses therefor.
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
AU2007258694B2 (en) * 2006-06-06 2011-12-22 Glaxo Group Limited Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
CA2654304A1 (en) * 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
AR061246A1 (en) * 2006-06-06 2008-08-13 Genentech Inc ANTI-DILL4 ANTIBODIES AND METHODS THAT USE THEM
AU2007258473B2 (en) * 2006-06-07 2012-08-23 Altrubio Inc. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
EP2037961B1 (en) 2006-06-14 2015-11-11 MacroGenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
AU2007345745C1 (en) * 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
ES2458498T3 (en) 2006-06-23 2014-05-05 Engeneic Molecular Delivery Pty Ltd. Targeted administration of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells by means of intact dead bacterial cells
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2008000079A1 (en) 2006-06-26 2008-01-03 The University Of British Columbia Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
PL2029173T3 (en) 2006-06-26 2017-04-28 Macrogenics, Inc. Fc riib-specific antibodies and methods of use thereof
US7749772B1 (en) 2006-06-29 2010-07-06 Varian, Inc. Antibody and immunoassays for determining the presence of Δ9-Tetrahydrocannabinol
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
US20080003230A1 (en) 2006-07-03 2008-01-03 Adair Charles D Composition for modulating the expression of cell adhesion molecules
SG173364A1 (en) 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
HUE038454T2 (en) 2006-08-04 2018-10-29 Medimmune Ltd Human antibodies to erbb 2
EP2520935A3 (en) 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
EP2056709A4 (en) 2006-08-11 2013-05-01 Univ New Jersey Med LUMINESCENT COMPOUNDS CONTAINING TWO SENSITIZERS, CONJUGATED, AND USES THEREOF
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
SI2059536T1 (en) 2006-08-14 2014-06-30 Xencor, Inc. Optimized antibodies that target cd19
EP2441472B1 (en) 2006-08-21 2015-06-10 F. Hoffmann-La Roche AG Tumor therapy with an anti-VEGF antibody
CA2661782C (en) 2006-08-28 2019-04-16 La Jolla Institute For Allergy And Immunology Antagonistic human light-specific human monoclonal antibodies
US10118970B2 (en) * 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
DK2594586T3 (en) 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
KR101503540B1 (en) 2006-09-05 2015-03-17 알렉시온 파마슈티칼스, 인코포레이티드 Methods and compositions for the treatment of antibody mediated neuropathy
AU2007292221B2 (en) 2006-09-06 2013-08-29 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
CL2007002567A1 (en) 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US20100008910A1 (en) 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
WO2008042941A2 (en) * 2006-10-04 2008-04-10 Medimmune, Llc Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
SG175596A1 (en) * 2006-10-11 2011-11-28 Antitope Ltd T cell epitope databases
AU2007324135B2 (en) 2006-10-12 2013-06-27 Genentech, Inc. Antibodies to lymphotoxin-alpha
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (en) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド Compound drug
EP2076287A2 (en) * 2006-10-12 2009-07-08 Wyeth Methods and compositions with reduced opalescence
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101687031B (en) * 2006-10-27 2014-05-14 勒帕斯公司 Compositions and methods for treating ocular diseases and conditions
ES2636089T3 (en) 2006-10-27 2017-10-05 Genentech, Inc. Antibodies and immunoconjugates and uses for them
ES2524059T3 (en) 2006-10-27 2014-12-03 Lpath, Inc. Compositions and procedures of binding to sphingosine-1-phosphate
AR063760A1 (en) 2006-11-02 2009-02-18 Genentech Inc ANTI-FACTOR D HUMANIZED ANTIBODIES AND USES OF THE SAME
ES2541546T3 (en) * 2006-11-03 2015-07-21 Wyeth Llc Substances that inhibit glycolysis in cell culture
US8129502B2 (en) * 2006-11-13 2012-03-06 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
WO2008058380A1 (en) * 2006-11-13 2008-05-22 Arius Research Inc. Cancerous disease modifying antibodies
BRPI0718609A8 (en) * 2006-11-13 2015-09-29 Arius Res Inc CANCER DISEASE MODIFYING ANTIBODIES.
EP2514439A1 (en) * 2006-11-15 2012-10-24 Functional Genetics, Inc. Anti-TSG101antibodies and their uses for treatment of viral infections
WO2008064306A2 (en) * 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
KR20090110295A (en) 2006-11-22 2009-10-21 에드넥서스, 어 브리스톨-마이어스 스퀴브 알&디 컴파니 Targeted Therapeutics Based on Engineered Proteins for Tyrosine Kinase Receptors Including IGF-IR
US8444971B2 (en) 2006-11-27 2013-05-21 Diadexus, Inc. OVR110 antibody compositions and methods of use
PL2662091T3 (en) 2006-12-01 2019-05-31 Novartis Ag Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
US8945565B2 (en) 2006-12-01 2015-02-03 Selexys Pharmaceuticals Corporation Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
US20110212096A1 (en) 2006-12-01 2011-09-01 Scott Rollins Anti-p-selectin antibodies and methods of their use and identification
US8288110B2 (en) * 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
EP2687232A1 (en) 2006-12-06 2014-01-22 MedImmune, LLC Methods of treating systemic lupus erythematosus
KR101546441B1 (en) * 2006-12-20 2015-08-24 엠엠알글로벌, 인코포레이티드 Antibodies and methods for making and using them
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
NO2740744T3 (en) 2007-01-09 2018-08-25
WO2008092041A2 (en) 2007-01-24 2008-07-31 Carnegie Mellon University Optical biosensors
US20100119526A1 (en) * 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
AU2008216495A1 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-Robo4 antibodies and uses therefor
DK2125889T3 (en) 2007-02-21 2014-04-14 Univ Massachusetts HUMAN ANTIBODIES AGAINST HEPATITIS C VIRUS (HCV) AND APPLICATIONS THEREOF
US7771947B2 (en) * 2007-02-23 2010-08-10 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
HUE043966T2 (en) 2007-02-23 2019-09-30 Prothena Biosciences Ltd Prevention and treatment of synucleinopathic and amyloidogenic disease
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
JP2010521154A (en) 2007-03-13 2010-06-24 アムゲン インコーポレイティッド K-ras mutation and B-raf mutation and anti-EGFr antibody therapy
WO2008112269A2 (en) 2007-03-13 2008-09-18 Amgen Inc. K-ras mutations and anti-egfr antibody therapy
WO2008112988A2 (en) 2007-03-14 2008-09-18 Novartis Ag Apcdd1 inhibitors for treating, diagnosing or detecting cancer
CN101668540A (en) * 2007-03-22 2010-03-10 英克隆有限责任公司 Stable antibody formulations
DK2125894T3 (en) 2007-03-22 2019-03-18 Biogen Ma Inc BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, SPECIFICALLY BINDING CD154 AND APPLICATIONS THEREOF
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP1975184A3 (en) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serine or threonine phosphorylation sites
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
US20100291024A1 (en) * 2007-03-30 2010-11-18 Xuebin Qin Methods and compositions for the treatment of proliferative and pathogenic diseases
CA2682170A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Antibodies with decreased deamidation profiles
WO2009027830A2 (en) 2007-03-30 2009-03-05 Engeneic Molecular Delivery Pty Ltd. Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
HRP20120759T1 (en) * 2007-04-03 2012-10-31 Amgen Research (Munich) Gmbh Cross-species-specific bispecific binders
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP2145902A3 (en) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
CN101977935A (en) * 2007-04-23 2011-02-16 惠氏公司 Methods and compositions for treating and monitoring treatment of il-13-associated disorders
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
ES2540807T3 (en) 2007-05-04 2015-07-13 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Variable domains of rabbit antibodies modified by genetic engineering and uses thereof
EP2737907A3 (en) 2007-05-07 2014-11-05 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
PL3072525T3 (en) 2007-05-14 2018-07-31 Astrazeneca Ab Methods of reducing basophil levels
JP2010530359A (en) 2007-05-17 2010-09-09 ジェネンテック, インコーポレイテッド Crystal structures of neuropilin fragments and neuropilin-antibody complexes
SI2164514T1 (en) 2007-05-21 2017-04-26 Alderbio Holdings Llc Antibodies to il-6 and use thereof
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
ES2585702T3 (en) 2007-05-30 2016-10-07 Lpath, Inc Compositions and methods for lysophosphatidic acid binding
PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
KR20150055103A (en) 2007-06-12 2015-05-20 에이씨 이뮨 에스.에이. Humanized antibodies to amyloid beta
EA020456B1 (en) 2007-06-14 2014-11-28 Байоджен Айдек Ма Инк. Pharmaceutical composition comprising vla-4 binding antibody for subcutaneous or intramuscular administration
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
HRP20150007T8 (en) 2007-06-15 2015-08-14 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts TUMOR TREATMENT ASSISTED IN SPECIFIC ANTI-L1 ANTIBODIES
PL2158221T3 (en) 2007-06-21 2019-02-28 Macrogenics, Inc. Covalent diabodies and uses thereof
CL2008001887A1 (en) 2007-06-29 2008-10-03 Amgen Inc PROTEINS OF UNION TO ANTIGEN THAT JOIN THE RECEPTOR ACTIVATED BY PROTEASES 2 (PAR-2); NUCLEIC ACID THAT CODES THEM; VECTOR AND GUEST CELL; METHOD OF PRODUCTION; AND COMPOSITION THAT UNDERSTANDS THEM.
SG10202005450PA (en) 2007-07-09 2020-07-29 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
WO2009012175A1 (en) 2007-07-13 2009-01-22 Ventana Medical Systems, Inc. Antibodies specific for the c-terminal regulatory domain of egfr and their use
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
KR20100058509A (en) 2007-07-31 2010-06-03 메디뮨 엘엘씨 Multispecific epitope binding proteins and uses thereof
EP2185594B1 (en) * 2007-08-13 2016-04-06 VasGene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
AU2008289442A1 (en) 2007-08-21 2009-02-26 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2009025846A2 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
AU2013203261B2 (en) * 2007-08-29 2016-07-14 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their use
PL2195023T3 (en) 2007-08-29 2018-08-31 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2570431A3 (en) 2007-08-30 2013-05-01 CureDM Group Holdings, LLC Compositions and methods of using proislet peptides and analogs thereof
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8323647B2 (en) 2007-09-13 2012-12-04 Delenex Therapeutics Ag Humanized antibodies against the β-amyloid peptide
KR102119108B1 (en) 2007-09-26 2020-06-04 추가이 세이야쿠 가부시키가이샤 Modified antibody constant region
SG10202100638XA (en) 2007-10-02 2021-02-25 Theranos Ip Co Llc Modular Point-Of-Care Devices And Uses Thereof
AU2008311366B2 (en) 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US20110212076A1 (en) * 2007-10-15 2011-09-01 King's College London Viral Therapeutic
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009055074A2 (en) * 2007-10-25 2009-04-30 Wyeth Erbb2 binding proteins and use thereof
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
AR069097A1 (en) 2007-10-30 2009-12-30 Genentech Inc PURIFICATION OF ANTIBODIES BY CATIONIC EXCHANGE CHROMATOGRAPHY
US20100330097A1 (en) 2007-11-01 2010-12-30 Hageman Gregory S Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
RU2530561C2 (en) 2007-11-05 2014-10-10 Медиммун, Ллк Method of treating scleroderma
KR101620642B1 (en) 2007-11-07 2016-05-12 제넨테크, 인크. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
EA201692127A1 (en) 2007-11-07 2017-08-31 Селлдекс Терапьютикс Инк. ANTIBODIES CONNECTING WITH HUMAN DEC-205
WO2010008411A1 (en) 2007-11-09 2010-01-21 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
PT2220116E (en) * 2007-11-12 2012-12-07 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of influenza
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
US20110053865A1 (en) * 2007-11-27 2011-03-03 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US8912149B1 (en) 2007-11-28 2014-12-16 California Institute Of Technology Glycosaminoglycan mimetics
JP5490714B2 (en) * 2007-11-28 2014-05-14 メディミューン,エルエルシー Protein preparation
TWI468417B (en) 2007-11-30 2015-01-11 Genentech Inc Anti-vegf antibodies
SI2796466T1 (en) 2007-12-07 2018-01-31 Zymogenetics, Inc. Humanized antibody molecules specific for IL-31
PT2222706E (en) 2007-12-14 2014-07-28 Novo Nordisk As Antibodies against human nkg2d and uses thereof
KR101499278B1 (en) 2007-12-17 2015-03-06 화이자 리미티드 Treatment of interstitial cystitis
HUE026846T2 (en) 2007-12-18 2016-08-29 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
CN102046658B (en) 2007-12-21 2015-01-07 米迪缪尼有限公司 Binding members for interleukin-4 receptor alpha (IL-4Ralpha) - 173
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
JP2011508738A (en) * 2007-12-26 2011-03-17 バイオテスト・アクチエンゲゼルシヤフト Method and agent for improving targeting of CD138 expressing tumor cells
CN101932333A (en) * 2007-12-26 2010-12-29 瓦西尼斯公司 Anti-C35 Antibody Combination Therapies and Methods
WO2009080829A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Agents targeting cd138 and uses thereof
WO2009080830A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Immunoconjugates targeting cd138 and uses thereof
HUE044466T2 (en) 2007-12-26 2019-10-28 Xencor Inc Fc variants with altered binding to FcRn
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
WO2009088805A2 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
ES2613963T3 (en) 2008-01-18 2017-05-29 Medimmune, Llc Cysteine manipulated antibodies for site specific conjugation
WO2009092805A1 (en) 2008-01-24 2009-07-30 Novo Nordisk A/S Humanized anti-human nkg2a monoclonal antibody
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
CL2009000062A1 (en) 2008-01-31 2010-05-14 Genentech Inc Humanized anti-cd79b antibody; with free tank modifications; immunoconjugate containing said antibody and a drug; polynucleotide encoding the antibody; vector, host cell; pharmaceutical composition and use of said composition to treat cancer, preferably lymphomas.
EP3048115B1 (en) 2008-02-01 2019-05-01 Her Majesty The Queen In Right of Canada as represented by The Minister of Health Monoclonal antibodies for ebola and marburg viruses
US9131671B2 (en) 2008-02-01 2015-09-15 Entogenetics, Inc. Methods, compositions and systems for production of recombinant spider silk polypeptides
BRPI0906387A2 (en) 2008-02-05 2015-07-07 Bristol Myers Squibb Co Alpha 5 - beta 1 antibodies and their uses
CA2713981C (en) 2008-02-08 2016-11-01 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
CN106110321A (en) 2008-03-04 2016-11-16 莱布瑞斯生物公司 The method for the treatment of inflammatory pain
CN101959528A (en) 2008-03-04 2011-01-26 辉瑞有限公司 Approaches to Treating Chronic Pain
JP2011513432A (en) * 2008-03-06 2011-04-28 ジェネンテック, インコーポレイテッド Combination therapy of c-met and HER antagonist
CN102015766B (en) 2008-03-10 2014-07-16 特罗科隆科学有限公司 Compositions and methods for the therapy and diagnosis of cytomegalovirus
CA2727792C (en) * 2008-03-14 2017-07-25 Obschestvo S Ogranichennoi Otvetstvennostyu "Initium-Pharm" Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action
EP3269366B1 (en) 2008-03-18 2020-01-15 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and lapatinib, and methods of use
AU2009228158B2 (en) 2008-03-27 2014-02-27 Zymogenetics, Inc. Compositions and methods for inhibiting PDGFRbeta and VEGF-A
JP5555223B2 (en) * 2008-04-02 2014-07-23 マクロジェニクス,インコーポレーテッド HER2 / neu specific antibody and method of use thereof
AU2009234389B2 (en) 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
WO2009131702A2 (en) 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
CR20170001A (en) 2008-04-28 2017-08-10 Genentech Inc ANTI FACTOR D HUMANIZED ANTIBODIES
KR20110014607A (en) 2008-04-29 2011-02-11 아보트 러보러터리즈 Dual Variable Domain Immunoglobulins and Uses thereof
EP2439212B1 (en) 2008-05-02 2016-12-21 Novartis AG Improved fibronectin-based binding molecules and uses thereof
CN102099373A (en) 2008-05-22 2011-06-15 百时美施贵宝公司 Multivalent fibronectin based scaffold domain proteins
EP3384919A1 (en) 2008-06-02 2018-10-10 Dana Farber Cancer Institute, Inc. Cs1 peptides
MX2010013236A (en) 2008-06-03 2011-02-24 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2133433A1 (en) 2008-06-09 2009-12-16 Centre Georges François Leclerc A method for predicting responsiveness to a treatment with an anti-HER2 antibody
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
ES2431355T3 (en) 2008-06-17 2013-11-26 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
RU2588467C3 (en) 2008-06-25 2021-10-20 Новартис Аг STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF
EP3628686B1 (en) 2008-06-25 2021-07-21 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
PT2307457T (en) 2008-06-25 2018-10-16 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies inhibiting tnf
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
KR101847107B1 (en) 2008-07-08 2018-04-10 인사이트 홀딩스 코포레이션 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
DK2318832T3 (en) 2008-07-15 2014-01-20 Academia Sinica Glycan arrays on PTFE-like aluminum coated slides and related methods
PE20110571A1 (en) 2008-07-15 2011-08-29 Genentech Inc CONJUGATES DERIVED FROM ANTHRACICLINE, AS ANTITUMORAL COMPOUNDS
CN102159231B (en) * 2008-07-18 2016-06-15 三一治疗公司 The method treating the ADE of immune-mediated dengue infection and dengue infection (including dengue hemorrhagic fever and dengue shock syndrome)
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
SG10201702382RA (en) 2008-08-04 2017-05-30 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
PE20150222A1 (en) 2008-09-03 2015-03-02 Genentech Inc MULTI-SPECIFIC ANTIBODIES
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CN102264763B (en) 2008-09-19 2016-04-27 米迪缪尼有限公司 Antibody being oriented to DLL4 and uses thereof
EP2344180A2 (en) 2008-09-23 2011-07-20 Wyeth LLC Methods for predicting production of activating signals by cross-linked binding proteins
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
PL2356153T3 (en) 2008-10-01 2016-11-30 Cross-species-specific psmaxcd3 bispecific single chain antibody
EP2349329A4 (en) 2008-10-14 2012-10-31 Dyax Corp Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
WO2010045193A1 (en) 2008-10-14 2010-04-22 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2347038A4 (en) * 2008-10-14 2013-06-12 Janssen Biotech Inc Methods of humanizing and affinity-maturing antibodies
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
CN102264765B (en) * 2008-10-28 2016-01-20 盐野义制药株式会社 Anti-MUC1 antibody
CN102272154A (en) 2008-10-29 2011-12-07 惠氏有限责任公司 Methods for purification of single domain antigen binding molecules
JP5823867B2 (en) 2008-10-29 2015-11-25 アブリンクス エン.ヴェー. Formulation of single domain antigen binding molecule
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010051502A2 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
PL2350304T3 (en) 2008-10-31 2017-06-30 Janssen Biotech, Inc Toll-like receptor 3 antagonists
JP5693460B2 (en) * 2008-11-12 2015-04-01 セラクローン サイエンシーズ, インコーポレイテッド Human M2e peptide immunogen
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
US8309306B2 (en) * 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
AU2009323007B2 (en) 2008-11-25 2016-01-28 H. Lundbeck A/S. Antagonists of IL-6 to prevent or treat thrombosis
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US8211434B2 (en) 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2370092A1 (en) 2008-12-03 2011-10-05 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
KR101370797B1 (en) 2008-12-05 2014-03-14 아브락시스 바이오사이언스, 엘엘씨 Albumin binding peptide-mediated disease targeting
AU2009322185A1 (en) * 2008-12-05 2011-07-21 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
MX2011005967A (en) 2008-12-05 2011-06-30 Abraxis Bioscience Llc Sparc binding peptides and uses thereof.
NZ717213A (en) 2008-12-09 2017-10-27 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2747248A1 (en) 2008-12-17 2010-07-15 Sharookh Kapadia Hepatitis c virus combination therapy
PT2786762T (en) 2008-12-19 2019-05-28 Macrogenics Inc Covalent diabodies and uses thereof
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
EP2382234A2 (en) 2008-12-23 2011-11-02 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
CA2748757A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN102271710A (en) 2009-01-06 2011-12-07 国家健康与医学研究院 B cell depleting agents for the treatment of atherosclerosis
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
EP2387584A1 (en) 2009-01-14 2011-11-23 IQ Therapeutics BV Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2394159B1 (en) 2009-02-04 2018-09-26 Molecular Innovations Assays for detecting prorenin, and antibodies used therein
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
EP2396652B1 (en) 2009-02-11 2017-12-13 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin
PT2881402T (en) 2009-02-12 2017-08-23 Cell Signaling Technology Inc Mutant ros expression in human liver cancer
WO2010096388A2 (en) 2009-02-18 2010-08-26 Carnegie Mellon University Quenched dendrimeric dyes for bright detection
JP5861223B2 (en) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. Proprotein and its use
WO2010098863A1 (en) * 2009-02-26 2010-09-02 Lpath, Inc. Humanized platelet activating factor antibody design using anti-lipid antibody templates
US20100248265A1 (en) * 2009-02-27 2010-09-30 The Salk Institute For Biological Studies Compositions and methods for diagnosis and treatment of cancer
SI3260136T1 (en) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv) -neutralizing antibodies
CN104447995A (en) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
PE20160553A1 (en) 2009-03-20 2016-05-18 Amgen Inc ANTIBODY SPECIFIC ANTAGONIST FOR ALPHA-4-BETA-7 HETERODIMER
US8242248B2 (en) * 2009-03-23 2012-08-14 Nodality, Inc. Kits for multiparametric phospho analysis
AU2010229479B2 (en) 2009-03-25 2013-03-28 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof
JP5725508B2 (en) 2009-03-25 2015-05-27 国立大学法人東北大学 LH type bispecific antibody
LT3702371T (en) 2009-03-25 2023-01-10 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
MX2011010264A (en) 2009-04-01 2011-10-11 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use.
AU2010232692C1 (en) 2009-04-01 2017-06-01 Genentech, Inc. Treatment of insulin-resistant disorders
SG175004A1 (en) 2009-04-02 2011-11-28 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
ES2363358B1 (en) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al THERAPEUTIC AGENTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AN INDESEABLE CELLULAR PROLIFERATION.
JP5992325B2 (en) 2009-04-06 2016-09-14 ワイス・エルエルシー Treatment plans utilizing neratinib for breast cancer
SG175080A1 (en) * 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
EP2419446A4 (en) * 2009-04-17 2013-01-23 Lpath Inc Humanized antibody compositions and methods for binding lysophosphatidic acid
CN102573907A (en) * 2009-04-17 2012-07-11 比奥根艾迪克Ma公司 Compositions and methods to treat acute myelogenous leukemia
CA2758523C (en) 2009-04-18 2019-03-12 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
US8609101B2 (en) * 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
HUE028021T2 (en) 2009-04-29 2016-11-28 Janssen Biotech Inc Toll-like receptor 3 antagonists
EP2799453B1 (en) 2009-04-29 2019-04-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ERG2 monoclonal antibodies and their therapeutic use
TW201825115A (en) 2009-05-13 2018-07-16 美商建新公司 Anti-human cd52 immunoglobulins
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
EP2432803A2 (en) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2010138839A2 (en) 2009-05-28 2010-12-02 Abraxis Bioscience, Llc Use of 2 anti-sparc antibodies to predict response to chemotherapy
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
TWI513465B (en) 2009-06-25 2015-12-21 Regeneron Pharma Method of treating cancer with dll4 antagonist and chemotherapeutic agent
EP2448593B1 (en) 2009-07-03 2020-11-25 Bionor Immuno AS Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
WO2011000054A1 (en) 2009-07-03 2011-01-06 Avipep Pty Ltd Immuno-conjugates and methods for producing them
WO2011004899A1 (en) 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
CA2766737A1 (en) 2009-07-07 2011-01-13 Genentech, Inc. Diagnosis and treatment of autoimmune demyelinating diseases
SG177583A1 (en) 2009-07-09 2012-02-28 Hoffmann La Roche In vivo tumor vasculature imaging
MX2012000620A (en) 2009-07-13 2012-01-27 Genentech Inc Diagnostic methods and compositions for treatment of cancer.
EP2454368A4 (en) 2009-07-17 2013-01-09 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
EP3404044A1 (en) 2009-07-24 2018-11-21 F. Hoffmann-La Roche AG Optimizing the production of antibodies
DE202010018640U1 (en) 2009-07-24 2019-11-14 F. Hoffmann-La Roche Ag stirrer system
AR077595A1 (en) 2009-07-27 2011-09-07 Genentech Inc COMBINATION TREATMENTS
KR20120089253A (en) 2009-07-31 2012-08-09 제넨테크, 인크. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2010278959A1 (en) 2009-07-31 2012-02-02 Amgen Inc. Polypeptides that bind tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods
SG178276A1 (en) 2009-08-06 2012-03-29 Genentech Inc Method to improve virus removal in protein purification
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
US20110038871A1 (en) 2009-08-11 2011-02-17 Veena Viswanth Ccr2 inhibitors for treating conditions of the eye
CN102498206A (en) 2009-08-11 2012-06-13 弗·哈夫曼-拉罗切有限公司 Production of proteins in glutamine-free cell culture media
EP3381937A3 (en) 2009-08-13 2018-10-31 The Johns Hopkins University Methods of modulating immune function
CN102575298A (en) 2009-08-14 2012-07-11 霍夫曼-拉罗奇有限公司 Biological markers for monitoring patient response to VEGF antagonists
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2011022472A2 (en) 2009-08-18 2011-02-24 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
CA2771186C (en) 2009-08-28 2018-01-02 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
RU2012112550A (en) 2009-09-01 2013-10-10 Эбботт Лэборетриз IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DK2473522T3 (en) 2009-09-02 2016-11-28 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
JP5996429B2 (en) 2009-09-03 2016-09-21 ジェネンテック, インコーポレイテッド Method for treatment, diagnosis and monitoring of rheumatoid arthritis
US8936792B2 (en) 2009-09-11 2015-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with reduced immunogenicity
BR112012005315A2 (en) 2009-09-11 2016-03-22 Genentech Inc method for identifying a patient likely to respond to an anticancer agent, method for identifying a patient who has an increased likelihood of metastasis, method for monitoring the effectiveness of anticancer therapy, and method for dose optimization of a anticancer agent
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
CN102712696A (en) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 Coiled coil and/or tether containing protein complexes and uses thereof
BR112012005670A2 (en) 2009-09-17 2017-01-10 Hoffmann La Roche '' method for identifying a cancer patient who may benefit from antiagiogenic therapy, method for predicting a cancer patient's responsiveness to antiangiogenic therapy, use of an anti-vegf antibody to improve the effect of treating a cancer patient, method or use, useful kit for performing the method, use of a protein or usom kit useful for performing the method, use of a protein or oligonucleotide or polynecleotide matrix to determine the level of bfgf expression in a method and kit or use
JP2013505268A (en) 2009-09-18 2013-02-14 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Use of the SPARC microenvironment signature in the treatment of cancer
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
PL2483305T3 (en) 2009-10-01 2017-03-31 F.Hoffmann-La Roche Ag Multistep final filtration of immunoglobulin
UY32914A (en) 2009-10-02 2011-04-29 Sanofi Aventis ANTIBODIES SPECIFICALLY USED TO THE EPHA2 RECEIVER
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
ES2666372T3 (en) 2009-10-11 2018-05-04 Biogen Ma Inc. Trials related to anti-VLA-4
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
PE20121531A1 (en) 2009-10-15 2012-12-22 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN
EP2488873B1 (en) 2009-10-16 2015-08-05 Novartis AG Biomarkers of tumor pharmacodynamic response
DK2488203T3 (en) * 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
MX2012002013A (en) * 2009-10-19 2012-03-16 Genentech Inc Modulators of hepatocyte growth factor activator.
JP5814925B2 (en) 2009-10-22 2015-11-17 ジェネンテック, インコーポレイテッド Anti-hepsin antibody and method of use thereof
ES2564207T3 (en) 2009-10-22 2016-03-18 F. Hoffmann-La Roche Ag Methods and compositions for modulating hepsin activation of macrophage stimulating protein
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
CN102905727B (en) 2009-10-30 2016-12-07 詹森生物科技公司 IL-17A Antagonist
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
PT2496698T (en) 2009-11-03 2019-04-18 Hope City TRUNCED EPIDERMAL GROWTH FACTOR RECEIVER (EGFRT) FOR SELECTION OF TRANSDUCED T CELLS
US8932588B2 (en) 2009-11-05 2015-01-13 Teva Pharmaceuticals Australia Pty. Ltd. Treatment of cancer involving mutated KRAS or BRAF genes
WO2011062112A1 (en) 2009-11-18 2011-05-26 国立大学法人東北大学 Highly-functional mutant of humanized anti-egfr antibody variable region
LT2504364T (en) 2009-11-24 2017-11-10 Medimmune Limited Targeted binding agents against b7-h1
KR101884028B1 (en) 2009-11-30 2018-08-01 제넨테크, 인크. Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2)
CA2782007C (en) * 2009-11-30 2018-07-24 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
TW201129380A (en) * 2009-12-04 2011-09-01 Genentech Inc Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
US10584181B2 (en) 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
US20120321619A1 (en) 2009-12-09 2012-12-20 Bayer Intellectual Property Gmbh Anti-c4.4a antibodies and uses thereof
EP2509409B1 (en) 2009-12-10 2016-07-27 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
US8937159B2 (en) * 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
RU2559542C2 (en) 2009-12-23 2015-08-10 Дженентек, Инк. Anti-bv8 antibodies and using them
WO2011079283A1 (en) * 2009-12-23 2011-06-30 Bioalliance C.V. Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
AU2010336029B2 (en) 2009-12-23 2011-10-13 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
ES2905545T3 (en) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins
US9221759B2 (en) 2010-01-13 2015-12-29 Rutgers, The State University Of New Jersey Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency
EP2523687B1 (en) 2010-01-15 2017-08-02 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for diagnosis and treatment of cutaneous T cell lymphomas using the NKp46 receptor
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
CA2787755A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
US9023997B2 (en) 2010-01-20 2015-05-05 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
AU2011218125A1 (en) 2010-02-18 2012-07-19 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
CA2787657A1 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN102167742B (en) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 A fully human anti-HER2 monoclonal antibody, its preparation method and use
WO2011106723A2 (en) * 2010-02-26 2011-09-01 Lpath, Inc. Anti-paf antibodies
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
PL2542590T5 (en) 2010-03-05 2020-08-10 The Johns Hopkins University Compositions and Methods for Target Immunomodulatory Antibodies and Fusion Proteins
CN102858362A (en) 2010-03-11 2013-01-02 阿布拉西斯生物科学有限责任公司 SPARC angiogenic domain and methods of use
RU2584232C2 (en) 2010-03-22 2016-05-20 Дженентек, Инк. Compositions and methods used for stabilisation of protein-containing finished forms
WO2011119661A1 (en) 2010-03-24 2011-09-29 Genentech, Inc. Anti-lrp6 antibodies
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011119979A2 (en) 2010-03-26 2011-09-29 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
EP2552947A4 (en) 2010-03-26 2013-11-13 Dartmouth College VISTA, A T-LYMPHOCYTE REGULATORY MEDIA PROTEIN, VISTA BINDING AGENTS AND USE THEREOF
ES2665592T3 (en) 2010-03-31 2018-04-26 Boehringer Ingelheim International Gmbh Anti-CD40 antibodies
TWI653333B (en) 2010-04-01 2019-03-11 安進研究(慕尼黑)有限責任公司 Cross-species specific PSMAxCD3 bispecific single chain antibody
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
BR112012025728B1 (en) 2010-04-09 2022-01-11 Critical Care Diagnostics, Inc ISOLATED ANTIBODIES OR FRAGMENTS THAT BIND TO SOLUBLE HUMAN ST2, HYBRIDOMA, KIT, AS WELL AS METHODS FOR QUANTIFICATION OF A LEVEL OF HUMAN SOLUBLE ST2 IN A SAMPLE FROM AN INDIVIDUAL, AND FOR PREDICTING THE RISK OF DEATH WITHIN ONE YEAR IN AN INDIVIDUAL
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
CN105669865A (en) 2010-04-13 2016-06-15 塞尔德克斯医疗公司 Antibodies that bind human CD27 and uses thereof
CA2796180A1 (en) 2010-04-15 2011-10-20 Alper Biotech, Llc Monoclonal antibodies against her2 antigens, and uses therefor
LT3202789T (en) 2010-04-16 2020-06-10 Biogen Ma Inc. Anti-vla-4 antibodies
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
JP2013531474A (en) * 2010-04-30 2013-08-08 エスペランス ファーマシューティカルズ, インコーポレイテッド Soluble peptide-Her2 / neu (human epidermal growth factor receptor 2) ligand conjugate and method of use thereof
WO2011139985A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
RU2012151500A (en) 2010-05-03 2014-06-10 Дженентек, Инк. COMPOSITIONS AND METHODS SUITABLE FOR REDUCING VISCOSITY OF PROTEIN-CONTAINING COMPOSITIONS
AU2011250970B2 (en) 2010-05-10 2016-12-15 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
PL3299380T3 (en) 2010-05-25 2024-12-16 F. Hoffmann-La Roche Ag Methods of purifying polypeptides
US9995679B2 (en) 2010-05-25 2018-06-12 Carnegie Mellon University Targeted probes of cellular physiology
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
KR20130098165A (en) 2010-06-03 2013-09-04 제넨테크, 인크. Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
KR20130086546A (en) 2010-06-03 2013-08-02 아브락시스 바이오사이언스, 엘엘씨 Use of SPARC Microenvironment Signature in Cancer Treatment
BR112012030311A2 (en) 2010-06-08 2017-01-24 Genentech Inc antibody
AR081434A1 (en) * 2010-06-10 2012-08-29 Lilly Co Eli ANTIBODY OF THE PEPTIDE RELATED TO THE CALCITONINE GENE (CGRP), PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE OF THE ANTIBODY TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT PAIN OR MIGRANE PAIN AND ANOGEN ANOGEN FRAGMENT
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
EP2582729A4 (en) 2010-06-18 2014-05-28 Hoffmann La Roche ANTI-AXL ANTIBODIES, AND METHODS OF USE.
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011163401A2 (en) 2010-06-22 2011-12-29 Neogenix Oncology, Inc. Colon and pancreas cancer specific antigens and antibodies
HRP20191878T1 (en) 2010-06-24 2019-12-27 F. Hoffmann - La Roche Ag Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
PH12013500064A1 (en) 2010-07-09 2013-03-11 Exelixis Inc Combinations of kinase inhibitors for the treatment of cancer
JP2013539962A (en) 2010-07-09 2013-10-31 ジェネンテック, インコーポレイテッド Anti-neuropilin antibodies and methods of use
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CA2805572A1 (en) 2010-07-16 2012-01-19 Martin Hegen Modified single domain antigen binding molecules and uses thereof
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
BR112013003646B1 (en) 2010-07-29 2021-09-08 Eleven Biotherapeutics, Inc. ISOLATED PROTEIN THAT COMPRISES A DOMAIN OF CYTOKINE OF THE INTERLEUKIN-1 (IL-1) CHIMERIC FAMILY, ITS METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND USES, AS WELL AS, NUCLEIC ACID, VECTOR, AND HOST CELL
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
JP6092773B2 (en) 2010-07-30 2017-03-08 ノバルティス アーゲー Fibronectin cradle molecule and its library
CA2807127C (en) 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
RU2013106216A (en) 2010-08-03 2014-09-10 Ф. Хоффманн-Ля Рош Аг BIOMARKERS OF CHRONIC Lymphocytic Leukemia
BR112013002578A2 (en) 2010-08-03 2019-05-14 Abbvie Inc. double variable domain immunoglobins and their uses
KR20140016230A (en) 2010-08-04 2014-02-07 시즐 바이오테크놀로지 리미티드 Methods and compounds for the diagnosis and treatment of
EP2600898A1 (en) 2010-08-05 2013-06-12 F.Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
JP2012034668A (en) 2010-08-12 2012-02-23 Tohoku Univ Fragment of humanized anti-egfr antibody substituted-lysine variable region, and use thereof
CA2807664A1 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
BR112013003279A2 (en) 2010-08-13 2016-06-14 Genentech In "Methods for treating a disease, method for neutralizing or blocking il-1ß and / or il-18 activity, antibody, uses of an antibody and uses of a monoclonal antibody"
BR112013002444A2 (en) 2010-08-13 2016-05-24 Roche Glycart Ag isolated antibody, polynucleotide and polypeptide, composition, vector, host cell, antibody conjugate, pharmaceutical formulation, use of the antibody, methods of producing an antibody, treating an individual, inducing cell lysis of a tumor cell and diagnosing a disease in an individual
UA113712C2 (en) 2010-08-13 2017-02-27 FAP ANTIBODY AND METHODS OF ITS APPLICATION
KR20140005864A (en) 2010-08-16 2014-01-15 암젠 인코퍼레이티드 Antibodies that bind myostatin, compositions and methods
KR101566090B1 (en) 2010-08-17 2015-11-13 에프. 호프만-라 로슈 아게 ANTI-HUMAN IgG1 ANTIBODY
PL3333188T3 (en) 2010-08-19 2022-05-09 Zoetis Belgium S.A. Anti-ngf antibodies and their use
JP5758004B2 (en) 2010-08-24 2015-08-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Bispecific antibodies comprising Fv fragments stabilized by disulfides
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
US11077212B2 (en) 2010-08-24 2021-08-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
EP2609117B1 (en) 2010-08-25 2015-09-16 F.Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2612151B1 (en) 2010-08-31 2017-08-09 Genentech, Inc. Biomarkers and methods of treatment
WO2012030904A2 (en) 2010-08-31 2012-03-08 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
CA3182320A1 (en) 2010-09-23 2012-03-29 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
AR083044A1 (en) 2010-09-27 2013-01-30 Regeneron Pharma ANTI-CD48 ANTIBODIES AND USES OF THE SAME
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
JP5974012B2 (en) 2010-10-05 2016-08-23 ジェネンテック, インコーポレイテッド Mutant smoothened and method of using the same
UY33679A (en) 2010-10-22 2012-03-30 Esbatech STABLE AND SOLUBLE ANTIBODIES
EP3214442A1 (en) 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a
AU2011323820A1 (en) 2010-10-25 2013-05-23 Biogen Ma Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels
CA2816950C (en) 2010-11-04 2018-11-27 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
CA2816763A1 (en) 2010-11-05 2012-05-10 Transbio Ltd Markers of endothelial progenitor cells and uses thereof
PH12013500933A1 (en) 2010-11-10 2017-08-23 Genentech Inc Methods and compositions for neural disease immunotherapy
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Antibody and alaninyl-maitansinol conjugates
PE20180249A1 (en) 2010-11-19 2018-02-02 Eisai Randd Man Co Ltd NEUTRALIZING ANTIBODIES ANTI-CCL20
WO2012071554A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
US8728473B2 (en) 2010-12-01 2014-05-20 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
ES2719548T3 (en) 2010-12-06 2019-07-11 Seattle Genetics Inc Humanized antibodies to liv-1 and use them to treat cancer
UA112170C2 (en) 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
EA201790664A1 (en) 2010-12-20 2017-07-31 Дженентек, Инк. ANTIBODIES AGAINST MEZOTELINE AND IMMUNOCONJUGATES
WO2012084829A1 (en) 2010-12-21 2012-06-28 F. Hoffmann-La Roche Ag Isoform enriched antibody preparation and method for obtaining it
ES2524897T3 (en) 2010-12-21 2014-12-15 F. Hoffmann-La Roche Ag Chromatography equipment characterization
JP2014511106A (en) 2010-12-22 2014-05-08 ジェネンテック, インコーポレイテッド Anti-PCSK9 antibody and method of use
EP2655414B1 (en) 2010-12-23 2018-08-29 Roche Diagniostics GmbH Bispecific binding agent
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-CD38 . antibody
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012093068A1 (en) 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
CN111982829A (en) 2011-01-21 2020-11-24 拉布拉多诊断有限责任公司 Systems and methods for maximizing sample usage
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
EP2670422B1 (en) 2011-02-02 2018-10-17 Emory University Antagonism of the vip signaling pathway
MX2013008833A (en) 2011-02-02 2013-12-06 Amgen Inc Methods and compositons relating to inhibition of igf-1r.
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
RU2013140685A (en) 2011-02-04 2015-03-10 Дженентек, Инк. OPTIONS Fc, METHODS FOR PRODUCING THEM
HRP20182017T4 (en) 2011-02-08 2021-08-20 Medimmune, Llc ANTIBODIES SPECIFICALLY BINDING STAPHYLOCOCCUS AUREUS ALPHAS TOXIN AND METHODS OF ADMINISTRATION
KR20130118941A (en) 2011-02-10 2013-10-30 로슈 글리카트 아게 Improved immunotherapy
SI3075745T1 (en) 2011-02-10 2018-12-31 Roche Glycart Ag Mutant interleukin-2 polypeptides
BR112013020743A2 (en) 2011-02-14 2016-10-18 Theraclone Sciences Inc compositions and methods for influenza therapy and diagnosis
MX353143B (en) 2011-02-28 2017-12-20 Genentech Inc Biological markers and methods for predicting response to b-cell antagonists.
MX342034B (en) 2011-02-28 2016-09-12 Hoffmann La Roche Monovalent antigen binding proteins.
AR085404A1 (en) 2011-02-28 2013-09-25 Hoffmann La Roche PROTEINS OF UNION TO ANTIGEN
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
CN103619876A (en) 2011-03-10 2014-03-05 Hco抗体股份有限公司 Bispecific three-chain antibody-like molecules
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
AU2012229188A1 (en) 2011-03-15 2013-09-26 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CN107840894A (en) 2011-03-25 2018-03-27 格兰马克药品股份有限公司 Heterodimer immunoglobulin
EP2691417B2 (en) 2011-03-29 2024-10-30 Roche Glycart AG Antibody fc variants
JP6130350B2 (en) 2011-03-30 2017-05-17 アブリンクス エン.ヴェー. Methods of treating immune disorders with single domain antibodies against TNFα
MY189494A (en) 2011-03-31 2022-02-16 Genentech Inc Methods of administering beta7 integrin antagonists
SG194048A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
JP2014516511A (en) 2011-04-07 2014-07-17 ジェネンテック, インコーポレイテッド Anti-FGFR4 antibody and method of use
US20140010886A1 (en) 2011-04-07 2014-01-09 Georgia Tech Research Corporation Compositions comprising saccharide binding moieties and methods for targeted therapy
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR20210021101A (en) 2011-04-08 2021-02-24 유니버시티 오브 레스터 Methods for treating conditions associated with masp-2 dependent complement activation
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
PL2699264T3 (en) 2011-04-20 2018-08-31 Medimmune, Llc Antibodies and other molecules that bind b7-h1 and pd-1
WO2012142662A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
UA116189C2 (en) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. COMPOSITION OF ANTI-α4β7 ANTIBODY
CN108969469A (en) 2011-05-02 2018-12-11 米伦纽姆医药公司 The preparation of 4 β of anti alpha, 7 antibody
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
JP6169561B2 (en) 2011-05-06 2017-07-26 ザ ガバメント オブ ザ ユナイテツド ステイツ オブ アメリカ アズ リプリゼンテツド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒユーマン サービシズ Recombinant immunotoxins targeting mesothelin
ES2567276T3 (en) 2011-05-12 2016-04-21 Genentech, Inc. LC-MS / MS method of monitoring multiple reactions to detect therapeutic antibodies in animal samples using frame-changing peptides
EA030462B1 (en) 2011-05-16 2018-08-31 Дженентек, Инк. Fgfr1 agonists and methods of use thereof
EA201990685A1 (en) 2011-05-17 2019-12-30 Дзе Рокфеллер Юниверсити NEUTRALIZING HUMAN IMMUNO DEFICIENCY VIRUS ANTIBODIES AND WAYS OF THEIR APPLICATION
PT3662932T (en) 2011-05-20 2021-05-14 H Lundbeck As Anti-cgrp compositions and use thereof
KR102128628B1 (en) 2011-05-20 2020-06-30 앨더바이오 홀딩스 엘엘씨 Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
CN107827982B (en) 2011-05-20 2021-07-06 H.伦德贝克公司 Use of anti-CGRP antibodies and antibody fragments for the prevention or inhibition of photophobia or photophobia in a subject in need thereof
KR102030531B1 (en) 2011-05-21 2019-10-10 마크로제닉스, 인크. Deimmunized serum-binding domains and their use for extending serum half-life
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2714741B1 (en) 2011-05-25 2019-10-30 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory disorders
SG195025A1 (en) 2011-06-02 2013-12-30 Dyax Corp Fc RECEPTOR BINDING PROTEINS
WO2012170071A1 (en) 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
CN104024275A (en) 2011-06-10 2014-09-03 科里木恩有限公司 BINDING COMPOUNDS TO HUMAN ss1-ADRENORECEPTOR (ss1-AR) AND THEIR USE IN THE MEASUREMENT OF AUTO-ANTI-ssA1-AR ANTIBODIES
US20140141020A1 (en) * 2011-06-14 2014-05-22 Mayo Foundation For Medical Education And Research Anti-cd3 therapies
CN103596984B (en) 2011-06-15 2016-04-13 霍夫曼-拉罗奇有限公司 The antibody of Anti-human EPO receptor and using method
MX354663B (en) 2011-06-22 2018-03-14 Hoffmann La Roche Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes.
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CA2840537C (en) 2011-06-28 2021-12-14 Oxford Biotherapeutics Ltd. Antibodies to adp-ribosyl cyclase 2
EP2726098A1 (en) 2011-06-30 2014-05-07 F.Hoffmann-La Roche Ag Anti-c-met antibody formulations
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
EP2739310B1 (en) 2011-08-05 2018-04-18 Research Development Foundation Improved methods and compositions for modulation of olfml3 mediated angiogenesis
JP6120848B2 (en) 2011-08-15 2017-04-26 メディミューン,エルエルシー Anti-B7-H4 antibody and use thereof
EP2744824A1 (en) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Neuregulin antibodies and uses thereof
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
AU2012299195B9 (en) 2011-08-19 2018-05-10 Regeneron Pharmaceuticals, Inc Anti-Tie2 antibodies uses thereof
RU2605390C2 (en) 2011-08-23 2016-12-20 Рош Гликарт Аг Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
CA2844141A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Anti-mcsp antibodies
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
CN103748114B (en) 2011-08-23 2017-07-21 罗切格利卡特公司 T cell activating bispecific antigen binding molecules
RU2617970C2 (en) 2011-08-23 2017-04-28 Рош Гликарт Аг ANTIBODIES WITHOUT Fc-FRAGMENT INCLUDING TWO FAB-FRAGMENT AND METHODS OF APPLICATION
PT2748202T (en) 2011-08-23 2018-10-08 Roche Glycart Ag Bispecific antigen binding molecules
MX2014002289A (en) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Tandem fc bispecific antibodies.
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
EP2751285B2 (en) 2011-08-31 2020-04-01 Genentech, Inc. Method for sensitivity testing of a tumour for a egfr kinase inhibitor
EA201490623A1 (en) 2011-09-12 2016-01-29 Янссен Байотек Инк. Antagonists of toll-like receptor 3 for the treatment of metabolic and cardiovascular diseases
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8435738B2 (en) 2011-09-25 2013-05-07 Theranos, Inc. Systems and methods for multi-analysis
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
CA2846083A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
CN103930111A (en) 2011-09-19 2014-07-16 霍夫曼-拉罗奇有限公司 Combination therapy comprising a C-MET antagonist and a B-RAF antagonist
WO2013043071A1 (en) 2011-09-23 2013-03-28 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
CA2846432A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
PT2750683T (en) 2011-10-03 2018-06-26 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
AU2012319150B2 (en) 2011-10-05 2017-08-17 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
KR20130036993A (en) * 2011-10-05 2013-04-15 삼성전자주식회사 Antibodies specifically binding to epitope in sema domain of c-met
JP6310394B2 (en) 2011-10-10 2018-04-11 ゼンコア インコーポレイテッド Methods for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
EP2766043A4 (en) 2011-10-13 2015-06-10 Aerpio Therapeutics Inc Methods for treating vascular leak syndrome and cancer
EP2766045B1 (en) 2011-10-13 2016-12-07 The Regents of The University of California Treatment of breast cancer with companion diagnostic
AR088322A1 (en) 2011-10-14 2014-05-28 Genentech Inc ANTI-HTRA1 ANTIBODIES AND METHODS OF USE
EP4234034A3 (en) 2011-10-14 2023-09-20 F. Hoffmann-La Roche AG Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
JP6254087B2 (en) 2011-10-15 2017-12-27 ジェネンテック, インコーポレイテッド SCD1 antagonists for treating cancer
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
US20140288279A1 (en) 2011-10-21 2014-09-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
CA2850034A1 (en) 2011-10-28 2013-05-02 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
WO2013063516A1 (en) 2011-10-28 2013-05-02 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
PT3257564T (en) 2011-11-02 2019-03-22 Hoffmann La Roche Overload and elute chromatography
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
AU2012335205A1 (en) 2011-11-11 2014-05-29 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
PT2780368T (en) 2011-11-14 2018-03-22 Regeneron Pharma Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
CN118515766A (en) 2011-11-16 2024-08-20 勃林格殷格翰国际有限公司 Anti-IL-36R antibodies
JP2014533700A (en) 2011-11-21 2014-12-15 ジェネンテック, インコーポレイテッド Purification of anti-c-MET antibody
AR088941A1 (en) 2011-11-23 2014-07-16 Bayer Ip Gmbh ANTI-FGFR2 ANTIBODIES AND THEIR USES
AU2012340766B2 (en) 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
RU2014124530A (en) 2011-11-23 2015-12-27 Идженика, Инк. ANTIBODIES TO CD98 AND WAYS OF THEIR APPLICATION
EP3763741A1 (en) 2011-11-28 2021-01-13 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
CN104271761B (en) 2011-11-30 2017-03-15 霍夫曼-拉罗奇有限公司 Erbb3 mutation in cancer
SG11201402737SA (en) 2011-12-05 2014-06-27 Hoffmann La Roche Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
WO2013087913A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
JP2015502165A (en) 2011-12-22 2015-01-22 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Expression vector construction, novel production cell generation methods, and their use for recombinant production of polypeptides
SG11201403445YA (en) 2011-12-22 2014-07-30 Hoffmann La Roche Full length antibody display system for eukaryotic cells and its use
RU2639519C2 (en) 2011-12-22 2017-12-21 Ф.Хоффманн-Ля Рош Аг Expression vector element combination, new methods for obtaining producer cells and their application for recombinant production of polypeptides
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2793941A1 (en) 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles of manufacture and methods for co-administration of antibodies
US20150030602A1 (en) 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2793944A4 (en) 2011-12-23 2015-09-02 Nicholas B Lydon IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
TWI443107B (en) 2011-12-29 2014-07-01 Ind Tech Res Inst Humanized anti-human cell surface antigen CD34 monoclonal antibody and application thereof
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
BR112014015851A2 (en) 2011-12-30 2019-09-24 Abbvie Inc double specific binding proteins directed against il-13 and / or il-17
CA2862979A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
WO2013104798A1 (en) 2012-01-12 2013-07-18 Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences Modulators of immune responses
CN104203268A (en) 2012-01-13 2014-12-10 霍夫曼-拉罗奇有限公司 Biological markers for identifying patients for treatment with vegf antagonists
KR20140116490A (en) 2012-01-18 2014-10-02 제넨테크, 인크. Anti-lrp5 antibodies and methods of use
CN104168920A (en) 2012-01-18 2014-11-26 霍夫曼-拉罗奇有限公司 Methods of using FGF19 modulators
MX360778B (en) 2012-01-27 2018-11-16 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein.
WO2013114245A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
SG11201404486QA (en) 2012-01-31 2014-11-27 Genentech Inc Anti-ig-e m1' antibodies and methods using same
WO2013113641A1 (en) 2012-01-31 2013-08-08 Roche Glycart Ag Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
CN104379601B (en) 2012-02-03 2021-04-09 霍夫曼-拉罗奇有限公司 Bispecific antibody molecules and antigen-transfected T-cells and their use in medicine
RU2644341C2 (en) 2012-02-10 2018-02-08 Дженентек, Инк. Single-chain antibodies and other heteromultimers
SG11201404703WA (en) 2012-02-11 2014-09-26 Genentech Inc R-spondin translocations and methods using the same
SI2814587T1 (en) 2012-02-15 2018-08-31 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
EP2814468B1 (en) 2012-02-16 2019-06-19 Santarus, Inc. Anti-vla1 (cd49a) antibody pharmaceutical compositions
TWI613215B (en) 2012-02-22 2018-02-01 再生元醫藥公司 Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
CN104220458B (en) * 2012-02-24 2018-08-14 阿特根公司 It is combined with the modification antibody of the motif containing cysteine residues, the modification antibody-drug conjugates containing the modification antibody and its manufacturing method
JP6407726B2 (en) 2012-03-01 2018-10-24 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH Long-life polypeptide binding molecule
MX2014010379A (en) 2012-03-02 2015-05-15 Roche Glycart Ag Predicitive biomarker for cancer treatment with adcc enhanced antibodies.
KR20170036142A (en) 2012-03-08 2017-03-31 할로자임, 아이엔씨 Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
SI2825558T1 (en) 2012-03-13 2019-08-30 F. Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
EP2638916A1 (en) 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
WO2013142299A1 (en) 2012-03-20 2013-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
RU2650770C2 (en) 2012-03-27 2018-04-17 Грин Кросс Корпорейшн Epitopes of epidermal growth factor receptor surface antigen and use thereof
CN104220457A (en) 2012-03-27 2014-12-17 霍夫曼-拉罗奇有限公司 Diagnosis and treatments relating to her3 inhibitors
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS
KR20140142719A (en) 2012-03-30 2014-12-12 제넨테크, 인크. Diagnostic methods and compositions for treatment of cancer
EP2833900B1 (en) 2012-04-01 2018-09-19 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
TWI619729B (en) 2012-04-02 2018-04-01 再生元醫藥公司 Anti-hla-b*27 antibodies and uses thereof
WO2013155346A1 (en) 2012-04-11 2013-10-17 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
PL2838998T3 (en) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
BR112014027166A2 (en) 2012-05-01 2017-06-27 Genentech Inc antibody, nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation, treatment method, proliferation inhibiting method and detection methods.
US11078265B2 (en) 2012-05-03 2021-08-03 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
US9441039B2 (en) 2012-05-07 2016-09-13 Amgen Inc. Anti-erythropoietin antibodies
KR101505157B1 (en) 2012-05-08 2015-03-24 주식회사 종근당 Anti-ErbB2 Antibody Variants
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
EP4053162A1 (en) * 2012-05-18 2022-09-07 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2013177470A1 (en) 2012-05-23 2013-11-28 Genentech, Inc. Selection method for therapeutic agents
CA2875624A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Hiv vaccine
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
JP5933830B2 (en) 2012-06-08 2016-06-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Variant selectivity and combination of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of cancer
CA2875989A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2861617A1 (en) 2012-06-15 2015-04-22 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
KR20150023711A (en) 2012-06-15 2015-03-05 제넨테크, 인크. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
CN104582736A (en) 2012-06-21 2015-04-29 印第安纳大学研究及科技有限公司 Incretin receptor ligand polypeptide Fc region fusion polypeptide and conjugate with altered Fc effector function
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CA2877533C (en) 2012-06-22 2022-08-16 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
TW201843172A (en) 2012-06-25 2018-12-16 美商再生元醫藥公司 anti-EGFR antibody and use thereof
HK1202334A1 (en) 2012-06-26 2015-09-25 霍夫曼-拉罗奇有限公司 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CA2871880A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
JP6445429B2 (en) 2012-06-27 2018-12-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Method and use thereof for selecting and generating tailor-made selective and multispecific therapeutic molecules comprising at least two different targeting entities
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
CA2871112C (en) 2012-07-04 2020-05-12 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
MX353951B (en) 2012-07-04 2018-02-07 Hoffmann La Roche Anti-theophylline antibodies and methods of use.
EP3339328A1 (en) 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
PL2870247T3 (en) 2012-07-05 2019-10-31 Hoffmann La Roche Expression and secretion system
AU2013288931A1 (en) 2012-07-09 2014-12-11 Genentech, Inc. Immunoconjugates comprising anti-CD22 antibodies
TW201408698A (en) 2012-07-09 2014-03-01 Genentech Inc Anti-CD79b antibodies and immunoconjugates
WO2014011518A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies
US20140030282A1 (en) 2012-07-09 2014-01-30 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
CA2876730A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
HUE056217T2 (en) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecific anti-VEGF / anti-ANG-2 antibodies and their use in the treatment of ophthalmic vascular diseases
ES2673847T3 (en) 2012-07-25 2018-06-26 Celldex Therapeutics, Inc. Anti KIT antibodies and uses thereof
MX2015000681A (en) 2012-08-02 2015-04-10 Hoffmann La Roche METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF.
JP6464085B2 (en) 2012-08-07 2019-02-06 ジェネンテック, インコーポレイテッド Combination therapy for the treatment of glioblastoma
CN104662045B (en) 2012-08-07 2019-04-05 罗切格利卡特公司 Include two kinds of engineered improved immunotherapies of composition at the antibody with effector functions reduce and raised
WO2014026033A1 (en) 2012-08-08 2014-02-13 University Of Florida Research Foundation, Inc. Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
JP2015530983A (en) 2012-08-08 2015-10-29 ロシュ グリクアート アーゲー Interleukin-10 fusion protein and use thereof
CN109705218B (en) 2012-08-09 2022-07-19 罗切格利卡特公司 ASGPR antibodies and uses thereof
FR2994390B1 (en) 2012-08-10 2014-08-15 Adocia METHOD FOR LOWERING THE VISCOSITY OF HIGH CONCENTRATION PROTEIN SOLUTIONS
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014028939A2 (en) 2012-08-17 2014-02-20 California Institute Of Technology Targeting phosphofructokinase and its glycosylation form for cancer
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
JP6211084B2 (en) 2012-08-21 2017-10-11 アカデミア シニカAcademia Sinica Benzocyclooctyne compounds and uses thereof
UA115789C2 (en) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Antibody formulations and uses thereof
ES2747836T3 (en) 2012-09-06 2020-03-11 Adelaide Research&Innovation Pty Ltd Methods and products to prevent and / or treat metastatic cancer
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
TWI595007B (en) 2012-09-10 2017-08-11 Neotope Biosciences Ltd Anti-mcam antibodies and associated methods of use
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
WO2014049003A1 (en) 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
EP2904106A4 (en) 2012-10-01 2016-05-11 Univ Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
UA118441C2 (en) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Antibodies recognizing alpha-synuclein
US10087250B2 (en) 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
EP2719706A1 (en) 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
US10093740B2 (en) 2012-10-15 2018-10-09 Universitat Zurich Bispecific HER2 ligands for cancer therapy
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
PT2908912T (en) 2012-10-18 2020-09-04 Univ Rockefeller Broadly-neutralizing anti-hiv antibodies
AU2013334583B2 (en) 2012-10-24 2018-09-13 Research Development Foundation JAM-C antibodies and methods for treatment of cancer
EP2911692B1 (en) 2012-10-26 2019-08-21 The University of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
US9492563B2 (en) 2012-10-30 2016-11-15 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
KR20190107184A (en) 2012-11-01 2019-09-18 애브비 인코포레이티드 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
EP2914278B1 (en) 2012-11-05 2021-06-02 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
US9725512B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. HER3 antibodies binding to the beta-hairpin of HER3
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
AR093446A1 (en) 2012-11-13 2015-06-10 Genentech Inc ANTIHEMAGLUTININE ANTIBODIES AND METHODS OF USE
TW201438736A (en) 2012-11-14 2014-10-16 Regeneron Pharma Methods of treating ovarian cancer with Dll4 antagonists
CN105051528A (en) 2012-11-15 2015-11-11 弗·哈夫曼-拉罗切有限公司 Ionic strength-mediated ph gradient ion exchange chromatography
WO2014078866A2 (en) 2012-11-19 2014-05-22 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
ES2778823T3 (en) 2012-11-20 2020-08-12 Sanofi Sa Anti-CEACAM5 antibodies and their uses
ES2701076T3 (en) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells
WO2014084508A1 (en) 2012-11-27 2014-06-05 (주)알테오젠 Composition for stabilizing fusion protein in which protein and fc domain are fused
BR112015012644A2 (en) 2012-11-30 2017-12-19 Hoffmann La Roche method for determining a cancer patient's need, cancer treatment method, pharmaceutical composition, use of a nucleic acid or antibody and kit;
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
UA118255C2 (en) 2012-12-07 2018-12-26 Санофі Compositions comprising anti-cd38 antibodies and lenalidomide
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
PT2928923T (en) 2012-12-10 2020-03-27 Biogen Ma Inc Anti-blood dendritic cell antigen 2 antibodies and uses thereof
RU2015129551A (en) 2012-12-19 2017-01-25 Эмплиммьюн, Инк. ANTIBODIES TO HUMAN B7-H4 AND THEIR APPLICATION
PL2935328T3 (en) 2012-12-21 2019-02-28 Hoffmann La Roche Disulfide-linked multivalent mhc class i comprising multi-function proteins
RU2650756C2 (en) 2012-12-21 2018-04-17 МЕДИММЬЮН, ЭлЭлСи Antibodies to h7cr
ES2871816T3 (en) 2012-12-27 2021-11-02 Sanofi Sa Anti-LAMP1 Antibodies and Antibody-Drug Conjugates, and Uses Thereof
EP3336104A1 (en) 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
JO3405B1 (en) 2013-01-09 2019-10-20 Regeneron Pharma ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
CN111044725B (en) 2013-01-20 2024-03-29 武田药品工业株式会社 Evaluation and treatment of bradykinin-mediated disorders
AU2014207409B2 (en) 2013-01-20 2019-12-19 Takeda Pharmaceutical Company Limited Evaluation, assays and treatment of pKal-mediated disorders
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson FUSION PROTEINS FOR MODULATING LYMPHOCYTES T REGULATORS AND EFFECTORS
CN105431455A (en) 2013-02-01 2016-03-23 圣塔玛丽亚生物疗法公司 Administration of an anti-activin-a compound to a subject
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
WO2014126198A1 (en) 2013-02-15 2014-08-21 株式会社ペルセウスプロテオミクス Anti-cdh3 humanized antibody, drug conjugate thereof, and utilization of same
EP3744736A1 (en) 2013-02-20 2020-12-02 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
CN105358576B (en) 2013-02-20 2020-05-05 诺华股份有限公司 Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors
BR112015018418A2 (en) 2013-02-22 2017-07-18 Hoffmann La Roche methods for treating cancer, for increasing the effectiveness of a treatment, for postponing and / or preventing cancer development, for increasing sensitivity to a targeted therapy, to extending the sensitivity period, to extending the response duration to a targeted therapy. and pharmaceutical
AR094873A1 (en) 2013-02-25 2015-09-02 Genentech Inc METHODS AND COMPOSITIONS TO DETECT AND TREAT MUTANTS OF AKT RESISTANT TO DRUGS
SG11201504497TA (en) 2013-02-26 2015-09-29 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
MX2015010843A (en) 2013-02-26 2016-04-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules.
RU2015140915A (en) 2013-02-26 2017-04-03 Роше Гликарт Аг BSPECIFIC ANTI-BINDING MOLECULES ACTIVATING T-CELLS
WO2014131715A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Anti-mcsp antibodies
CA2902505A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
CA2902263A1 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CA2904713A1 (en) 2013-03-11 2014-10-09 Amgen Inc. Protein formulations comprising darbepoetin
JP6445519B2 (en) 2013-03-13 2018-12-26 メドイミューン・リミテッドMedImmune Limited Pyrrolobenzodiazepine and its conjugates
SG11201506244VA (en) 2013-03-13 2015-09-29 Prothena Biosciences Ltd Tau immunotherapy
ES2731779T3 (en) 2013-03-13 2019-11-19 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2904630A1 (en) 2013-03-13 2014-10-02 Sanofi Compositions comprising anti-cd38 antibodies and carfilzomib
JO3532B1 (en) 2013-03-13 2020-07-05 Regeneron Pharma Anti-il-33 antibodies and uses thereof
SG11201507447PA (en) 2013-03-13 2015-10-29 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EA201591750A1 (en) 2013-03-14 2016-05-31 Дженентек, Инк. ANTIBODIES AGAINST B7-H4 AND IMMUNOCONJUGATES
ES2790420T3 (en) 2013-03-14 2020-10-27 Scripps Research Inst Conjugates of antibodies and targeting agents uses of the same
CA2903480A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
PE20151893A1 (en) 2013-03-14 2015-12-30 Parkash Gill TREATMENT OF CANCER USING ANTIBODIES THAT BIND GRP78 ON THE CELLULAR SURFACE
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
MX2015011444A (en) 2013-03-15 2015-12-16 Genentech Inc Compositions and methods for diagnosis and treatment of hepatic cancers.
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
ES2769574T3 (en) 2013-03-15 2020-06-26 Michael C Milone Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN105451767B (en) 2013-03-15 2019-10-18 泽恩格尼亚股份有限公司 Multivalence and monovalent polyspecific compound and application thereof
BR112015023262B8 (en) 2013-03-15 2024-02-06 Ac Immune Sa Isolated antibody, immunoconjugate, pharmaceutical formulation and uses of antibody
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
RS57393B1 (en) 2013-03-15 2018-09-28 Hoffmann La Roche Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
JP6448614B2 (en) 2013-03-15 2019-01-09 ベス イスラエル デアコネス メディカル センター インコーポレイテッド Methods and compositions for generation and use of conformation specific antibodies
KR102158924B1 (en) 2013-03-15 2020-09-22 제넨테크, 인크. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
JP6594855B2 (en) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド Heterodimeric protein
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
AR095199A1 (en) 2013-03-15 2015-09-30 Genzyme Corp ANTI-CD52 ANTIBODIES
JP6469644B2 (en) 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド Methods and compositions related to anti-CCR7 antigen binding proteins
MX2015012326A (en) 2013-03-15 2016-03-08 Genentech Inc Anti-crth2 antibodies and their use.
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
EP2970475A1 (en) 2013-03-15 2016-01-20 Biogen MA Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
JP2016522793A (en) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド Bispecific binding protein directed against IL-1β and / or IL-17
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh UNION MOLECULES FOR BCMA AND CD3
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
AU2014240101B2 (en) 2013-03-15 2018-05-17 Regeneron Pharmaceuticals, Inc. IL-33 antagonists and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
NZ712903A (en) 2013-03-18 2018-07-27 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
CA2904095A1 (en) 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
UA118028C2 (en) 2013-04-03 2018-11-12 Рош Глікарт Аг Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
BR112015024926A2 (en) 2013-04-16 2017-10-10 Genentech Inc compositions, article of manufacture, methods for treating a cancer patient, for evaluating a composition, for evaluating biological activity, for producing a composition and for evaluating the fragmentation of a composition and variant of pertuzumab
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
CN105324124A (en) 2013-04-19 2016-02-10 赛腾制药 Cytokine-derived therapy for reduced vascular leak syndrome
PE20190920A1 (en) 2013-04-29 2019-06-26 Hoffmann La Roche MODIFIED ANTIBODIES OF BINDING TO HUMAN FCRN AND METHODS OF USE
PE20151925A1 (en) 2013-04-29 2015-12-26 Hoffmann La Roche ANTI-IGF-1R ANTIBODIES WITH ABOLITION OF THE FCRN BINDING AND ITS USE IN THE TREATMENT OF VASCULAR EYE DISEASES
CA2904805A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
EP2992331A4 (en) 2013-04-30 2017-03-29 Université de Montréal Novel biomarkers for acute myeloid leukemia
US10239951B2 (en) * 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
KR101453462B1 (en) 2013-05-16 2014-10-23 앱클론(주) Antibodies Capable of Binding Specifically to HER2
PH12021550015A1 (en) 2013-05-20 2022-05-11 Genentech Inc Anti-transferrin receptor antibodies and methods of use
HK1232243A1 (en) 2013-05-24 2018-01-05 米迪缪尼有限公司 Anti-b7-h5 antibodies and their uses
DK3004174T3 (en) 2013-05-31 2019-07-22 Zymeworks Inc HEATER MULTIMATES WITH REDUCED OR DOWN-REGULATED EFFECTOR FUNCTION
CA2913011A1 (en) 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
HRP20200812T1 (en) 2013-05-31 2020-08-07 Genentech, Inc. ANTIBODIES AGAINST TEICHONIC ACID OF CELL WALL AND CONJUGATES
SG11201509982UA (en) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
AU2014280846B2 (en) 2013-06-13 2020-11-05 University Of South Australia Methods for detecting prostate cancer
PE20160716A1 (en) 2013-06-14 2016-08-11 Bayer Pharma AG ANTI-TWEAKR ANTIBODY AND ITS USES
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
EP3010548A1 (en) 2013-06-21 2016-04-27 Innate Pharma Enzymatic conjugation of polypeptides
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
JP6450381B2 (en) 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション Soluble MIC neutralizing monoclonal antibody for treating cancer
JP6546162B2 (en) 2013-07-05 2019-07-17 ゲンマブ エー/エス Humanized or chimeric CD3 antibodies
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
BR112016000231A8 (en) 2013-07-12 2019-12-31 Genentech Inc methods for identifying separation conditions with ion exchange chromatography and for analysis of polypeptide compositions
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
WO2015013671A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
TW201920262A (en) 2013-07-30 2019-06-01 美商再生元醫藥公司 Anti-activin A antibody and use thereof
WO2015015448A2 (en) 2013-07-31 2015-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates
KR102516152B1 (en) 2013-08-01 2023-03-31 파이브 프라임 테라퓨틱스, 인크. Afucosylated anti-fgfr2iiib antibodies
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
BR112016002685A2 (en) 2013-08-07 2018-01-30 Astute Medical Inc timp2 assays that perform better on biological samples
AU2014307080B2 (en) 2013-08-12 2018-06-07 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
DK3036320T4 (en) 2013-08-19 2024-05-06 Biogen Ma Inc CONTROL OF PROTEIN GLYCOSYRATION USING CULTURE MEDIA ADDITION AND CELL CULTURE PROCESS PARAMETERS
US20160237399A1 (en) 2015-02-18 2016-08-18 Biogen Ma Inc. Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
WO2015025054A1 (en) 2013-08-22 2015-02-26 Medizinische Universität Wien Dye-specific antibodies for prestained molecular weight markers and methods producing the same
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
MX2016002798A (en) 2013-09-05 2016-07-21 Genentech Inc Method for chromatography reuse.
JP6486368B2 (en) 2013-09-06 2019-03-20 アカデミア シニカAcademia Sinica Activation of human iNKT cells using glycolipids containing modified glycosyl groups
US11545241B1 (en) 2013-09-07 2023-01-03 Labrador Diagnostics Llc Systems and methods for analyte testing and data management
PT3041513T (en) 2013-09-08 2020-09-07 Kodiak Sciences Inc Factor viii zwitterionic polymer conjugates
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US9481729B2 (en) 2013-09-11 2016-11-01 The University Of Hong Kong Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
HK1226081A1 (en) 2013-09-12 2017-09-22 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
CN104193828B (en) * 2013-09-12 2017-04-05 北京韩美药品有限公司 The recombination fusion protein of HER2 and VEGFR signal paths is blocked simultaneously
BR112016004450A2 (en) 2013-09-17 2017-10-17 Genentech Inc methods for treating a disease, for increasing the effectiveness of a treatment, for postponing and / or preventing the development of recurrence and / or resistance of a disease, for increasing sensitivity to an inhibitor, for extending the sensitivity period for an inhibitor and for extend response time to an inhibitor
HK1222569A1 (en) 2013-09-17 2017-07-07 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
EP3903599A1 (en) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
EA036927B1 (en) 2013-10-11 2021-01-15 Оксфорд Биотерепьютикс Лтд Conjugated antibodies against ly75 for the treatment of cancer
CN105612182B (en) 2013-10-11 2019-12-10 豪夫迈·罗氏有限公司 Multispecific domain exchange consensus variable light chain antibodies
WO2015054670A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Nsp4 inhibitors and methods of use
CN111239415B (en) 2013-10-17 2024-03-26 综合医院公司 Methods of identifying subjects responsive to treatment for autoimmune diseases and compositions for treating the same
EP3057615B1 (en) 2013-10-18 2021-02-24 F.Hoffmann-La Roche Ag Anti-rspo antibodies and methods of use
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
JP6657098B2 (en) 2013-10-21 2020-03-04 ダイアックス コーポレーション Diagnosis and treatment of autoimmune diseases
SG11201603127WA (en) 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
JP2016538275A (en) 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ, エセ.アー. Production of T-cell retargeting heterodimeric immunoglobulins
CN104628846B (en) 2013-11-06 2019-12-06 三生国健药业(上海)股份有限公司 Method for purifying recombinant protein
KR102404285B1 (en) 2013-11-06 2022-05-31 아스튜트 메디컬 인코포레이티드 Assays for igfbp7 having improved performance in biological samples
EP3466445A1 (en) 2013-11-06 2019-04-10 Janssen Biotech, Inc. Anti-ccl17 antibodies
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
EP3068798B1 (en) 2013-11-12 2020-10-07 OGD2 Pharma Human igg1 derived antibody with pro-apoptotic activity
WO2015075635A2 (en) 2013-11-19 2015-05-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
EA201691027A1 (en) 2013-11-20 2016-12-30 Ридженерон Фармасьютикалз, Инк. APLNR MODULATORS AND THEIR APPLICATION
RS60882B1 (en) 2013-11-21 2020-11-30 Hoffmann La Roche Anti-alpha-synuclein antibodies and methods of use
KR102357906B1 (en) 2013-11-27 2022-02-03 자임워크스 인코포레이티드 Bispecific antigen-binding constructs targeting her2
AU2014363944B2 (en) 2013-12-09 2020-03-26 Allakos Inc. Anti-Siglec-8 antibodies and methods of use thereof
JP2017502002A (en) 2013-12-09 2017-01-19 ニューヨーク・ユニバーシティ Composition and method for phagocytic cell delivery of anti-staphylococcal agents
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
AU2014362238A1 (en) 2013-12-13 2016-06-09 Genentech, Inc. Anti-CD33 antibodies and immunoconjugates
CA2929565A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
AU2014364601A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies
KR102433591B1 (en) 2013-12-17 2022-08-18 제넨테크, 인크. Anti-cd3 antibodies and methods of use
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
JP2017501167A (en) 2013-12-17 2017-01-12 ジェネンテック, インコーポレイテッド Combination therapy comprising OX40 binding agonist and PD-1 axis binding antagonist
US20150174242A1 (en) 2013-12-19 2015-06-25 Mayo Foundation For Medical Education And Research Monovalent anti-cd3 adjuvants
WO2015095539A1 (en) 2013-12-20 2015-06-25 Genentech, Inc. Dual specific antibodies
JP6793902B2 (en) 2013-12-20 2020-12-02 ノバルティス アーゲー Adjustable chimeric antigen receptor
DK3083680T3 (en) 2013-12-20 2020-03-16 Hoffmann La Roche Humanized anti-Tau (pS422) antibodies and methods for use
US20160289633A1 (en) 2013-12-20 2016-10-06 Biogen Ma Inc. Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
KR20160099087A (en) 2013-12-20 2016-08-19 에프. 호프만-라 로슈 아게 Bispecific her2 antibodies and methods of use
TWI670283B (en) 2013-12-23 2019-09-01 美商建南德克公司 Antibodies and methods of use
MY182431A (en) 2013-12-24 2021-01-25 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
SG11201605215YA (en) 2013-12-25 2016-08-30 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
KR20160104628A (en) 2014-01-03 2016-09-05 에프. 호프만-라 로슈 아게 Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
KR102278429B1 (en) 2014-01-03 2021-07-16 에프. 호프만-라 로슈 아게 Covalently linked polypeptide toxin-antibody conjugates
WO2015101587A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
CN111057147B (en) 2014-01-06 2023-11-10 豪夫迈·罗氏有限公司 Monovalent blood brain barrier shuttle module
EP3094654B1 (en) 2014-01-14 2020-03-11 The Medical College of Wisconsin, Inc. Targeting clptm1l for treatment and prevention of cancer
MX382848B (en) 2014-01-15 2025-03-13 Hoffmann La Roche FC REGION VARIANTS WITH MODIFIED NEONATAL FC RECEPTOR (FCRN) BINDING AND MAINTAINED α-PROTEIN BINDING PROPERTIES.
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
AU2015209481C1 (en) 2014-01-21 2020-10-29 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
SI3097122T1 (en) 2014-01-24 2020-07-31 Ngm Biopharmaceuticals, Inc. Antibodies binding beta klotho domain 2 and methods of use thereof
US20170043034A1 (en) 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
KR102465042B1 (en) 2014-01-31 2022-11-09 다이이찌 산쿄 가부시키가이샤 Anti-her2 antibody-drug conjugate
US9840543B2 (en) 2014-01-31 2017-12-12 Boehringer Ingelheim International Gmbh Anti-BAFF antibodies
AU2015214264B2 (en) 2014-02-04 2018-12-20 Curis, Inc. Mutant Smoothened and methods of using the same
EA201992609A1 (en) 2014-02-06 2020-03-04 Ф.Хоффманн-Ля Рош Аг FILLED PROTEINS CONTAINING INTERLEUKIN-2 AND THEIR APPLICATIONS
US20150246963A1 (en) 2014-02-08 2015-09-03 Genentech, Inc. Methods of treating alzheimer's disease
TWI785472B (en) 2014-02-08 2022-12-01 美商建南德克公司 Methods of treating alzheimer's disease
EP3105253B1 (en) 2014-02-12 2018-06-27 F. Hoffmann-La Roche AG Anti-jagged1 antibodies and methods of use
KR20150097304A (en) 2014-02-18 2015-08-26 삼성전자주식회사 Anti-EGFR/Anti-HER2 Bispecific Antibodies With Anti-EGFR DARPins
SG11201606870XA (en) 2014-02-21 2016-09-29 Genentech Inc Anti-il-13/il-17 bispecific antibodies and uses thereof
WO2015130416A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
DK3110446T3 (en) 2014-02-28 2022-02-28 Allakos Inc Methods and compositions for treating Siglec-8-associated diseases
PT3122757T (en) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Charged linkers and their uses for conjugation
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ES2784749T3 (en) 2014-03-10 2020-09-30 Richter Gedeon Nyrt Immunoglobulin purification with the use of precleaning steps
RS59077B1 (en) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
TW201623331A (en) 2014-03-12 2016-07-01 普羅帝納生物科學公司 Anti-MCAM antibodies and associated methods of use
EP3116907A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
US10407506B2 (en) 2014-03-12 2019-09-10 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
EP3116906A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
WO2015136468A1 (en) 2014-03-13 2015-09-17 Prothena Biosciences Limited Combination treatment for multiple sclerosis
JP6722110B2 (en) * 2014-03-14 2020-07-15 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. Humanized antibody with increased stability
EP3116486B1 (en) 2014-03-14 2019-12-04 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
ES2897765T3 (en) 2014-03-14 2022-03-02 Hoffmann La Roche Methods and compositions for the secretion of heterologous polypeptides
EP3811970A1 (en) 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
TWI754319B (en) 2014-03-19 2022-02-01 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
LT3119431T (en) 2014-03-21 2024-03-12 Teva Pharmaceuticals International Gmbh ANTAGONISTIC ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS OF USE THEREOF
WO2015148531A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US11124760B2 (en) 2014-03-24 2021-09-21 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
CA2939246A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
EP3122768A2 (en) 2014-03-27 2017-02-01 Yeda Research and Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
KR20230022270A (en) 2014-03-28 2023-02-14 젠코어 인코포레이티드 Bispecific antibodies that bind to cd38 and cd3
CR20160500A (en) 2014-03-31 2016-12-14 Genentech Inc ANTI-OX40 ANTIBODIES AND METHODS OF USE
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
SG10202107077QA (en) 2014-04-02 2021-07-29 Hoffmann La Roche Method for detecting multispecific antibody light chain mispairing
MX395149B (en) 2014-04-07 2025-03-24 Novartis Ag COMBINATION THERAPIES INCLUDING A CHIMERALIC CD19 ANTIGEN RECEPTOR FOR CANCER.
JP6744856B2 (en) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド Blood-brain barrier shuttle containing antibody that recognizes α-synuclein
WO2015155976A1 (en) 2014-04-10 2015-10-15 第一三共株式会社 (anti-her2 antibody)-drug conjugate
RU2016144176A (en) 2014-04-11 2018-05-14 МЕДИММЬЮН, ЭлЭлСи SPECIFIC ANTIBODIES TO HER2
ES2910443T3 (en) 2014-04-16 2022-05-12 Biocon Ltd Stable protein formulations comprising a molar excess of sorbitol
ES2845650T3 (en) 2014-04-18 2021-07-27 Acceleron Pharma Inc Procedures to increase red blood cell levels and treat sickle cell disease
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
MX2016014007A (en) 2014-04-25 2017-01-11 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab.
JP6983511B2 (en) 2014-04-25 2021-12-17 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Methods and Compositions for Treating Metastatic Breast Cancer and Other Cancers in the Brain
US11602525B2 (en) 2014-04-25 2023-03-14 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
AP2016009564A0 (en) 2014-04-27 2016-11-30 Ccam Biotherapeutics Ltd Humanized antibodies against ceacam1
PT3137114T (en) 2014-04-30 2021-02-26 Pfizer Anti-ptk7 antibody-drug conjugates
CR20160561A (en) 2014-05-01 2017-05-03 Genentech Inc ANTI-FACTOR D ANTIBODY VARIATIONS AND THEIR USES
HUE063273T2 (en) 2014-05-06 2024-01-28 Hoffmann La Roche Production of heteromultimeric proteins using mammalian cells
WO2015173325A2 (en) 2014-05-16 2015-11-19 Ablynx Nv Improved immunoglobulin variable domains
WO2015179658A2 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
JP2017524371A (en) 2014-05-23 2017-08-31 ジェネンテック, インコーポレイテッド MIT biomarkers and methods of use
WO2015184004A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
AU2015267051B2 (en) 2014-05-27 2022-03-17 Academia Sinica Fucosidase from bacteroides and methods using the same
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CA2950440A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
TWI732738B (en) 2014-05-28 2021-07-11 中央研究院 Anti-tnf-alpha glycoantibodies and uses thereof
PT3148579T (en) 2014-05-28 2021-03-11 Ludwig Inst For Cancer Res Ltd ANTI-GITR ANTIBODIES AND METHODS OF THEIR USE
KR102366644B1 (en) 2014-05-30 2022-02-22 상하이 헨리우스 바이오테크, 인크. Anti-epidermal growth factor receptor (egfr) antibodies
WO2015191715A1 (en) 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
CN107073109B (en) 2014-06-11 2021-08-06 凯西·A·格林 Use of VISTA agonists and antagonists to inhibit or enhance humoral immunity
BR112016029226A2 (en) 2014-06-13 2017-10-17 Acceleron Pharma Inc methods and compositions for treating ulcers
JP2017517552A (en) 2014-06-13 2017-06-29 ジェネンテック, インコーポレイテッド Treatment and prevention of anticancer drug resistance
TWI713453B (en) 2014-06-23 2020-12-21 美商健生生物科技公司 Interferon alpha and omega antibody antagonists
AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
CA2947504A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016004370A1 (en) 2014-07-03 2016-01-07 Genentech, Inc. Polypeptide expression systems
EP3166688B1 (en) 2014-07-08 2024-08-21 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
KR102360693B1 (en) 2014-07-11 2022-02-08 벤타나 메디컬 시스템즈, 인코포레이티드 Anti-pd-l1 antibodies and diagnostic uses thereof
US9914774B2 (en) 2014-07-11 2018-03-13 Genentech, Inc. Notch pathway inhibition
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
WO2016009436A1 (en) 2014-07-15 2016-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Isolated polypeptides of cd44 and uses thereof
JP7054622B2 (en) 2014-07-21 2022-04-14 ノバルティス アーゲー Treatment of cancer with humanized anti-BCMA chimeric antigen receptor
US10568947B2 (en) 2014-07-21 2020-02-25 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
RU2747384C2 (en) 2014-07-21 2021-05-04 Новартис Аг Cancer treatment with chimeric cd33 antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (en) 2014-07-21 2017-09-28 ノバルティス アーゲー Low immunoenhancing dose of mTOR inhibitor and CAR combination
EP3708227A1 (en) 2014-07-22 2020-09-16 Sutro Biopharma, Inc. Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
US10487151B2 (en) 2014-07-23 2019-11-26 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
JP2017524359A (en) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Biomarkers useful for the treatment of IL-23A related diseases
US20160060360A1 (en) 2014-07-24 2016-03-03 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
BR112017001579A2 (en) 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable cd3 antibodies and methods of use
MX367787B (en) 2014-07-29 2019-09-06 Cellectis ROR1 (NTRKR1) CHEMERICAL ANTIGEN RECEPTORS SPECIFIC FOR CANCER IMMUNOTHERAPY.
EP3194432B1 (en) 2014-07-31 2019-04-10 Cellectis Ror1 specific multi-chain chimeric antigen receptor
WO2016016859A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
AR101669A1 (en) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
EP3174903B1 (en) 2014-07-31 2024-04-10 Amgen Research (Munich) GmbH Bispecific single chain antibody construct with enhanced tissue distribution
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
JP6692343B2 (en) 2014-08-01 2020-05-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Anti-CD45RC antibody for use as a drug
SI3177643T1 (en) 2014-08-04 2019-08-30 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
WO2016020856A2 (en) 2014-08-05 2016-02-11 MabQuest SA Immunological reagents
JP6919118B2 (en) 2014-08-14 2021-08-18 ノバルティス アーゲー Treatment of cancer with GFRα-4 chimeric antigen receptor
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
KR102616429B1 (en) 2014-08-19 2023-12-26 노파르티스 아게 Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
AU2015308818B2 (en) 2014-08-28 2021-02-25 Bioatla Llc Conditionally active chimeric antigen receptors for modified T-cells
ES2797754T3 (en) 2014-08-28 2020-12-03 Pfizer Stability-modulating linkers for use with drug-antibody conjugates
DK3189073T3 (en) 2014-09-04 2020-03-30 Cellectis TROPHOBLAST GLYCOPROTEIN (5T4, TPBG) -Specific Chimeric Antigen Receptors for Cancer Therapy
JP6899321B2 (en) 2014-09-08 2021-07-07 アカデミア シニカAcademia Sinica Activation of human iNKT cells using glycolipids
EP3191136A1 (en) 2014-09-08 2017-07-19 Michaela Arndt Construct for the delivery of a molecule into the cytoplasm of a cell
EP3191527B1 (en) 2014-09-10 2020-01-15 F.Hoffmann-La Roche Ag Galactoengineered immunoglobulin 1 antibodies
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
KR20170052600A (en) 2014-09-12 2017-05-12 제넨테크, 인크. Cysteine engineered antibodies and conjugates
CN114106185A (en) 2014-09-12 2022-03-01 基因泰克公司 anti-HER 2 antibodies and immunoconjugates
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
MA40579A (en) 2014-09-12 2016-03-17 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
US10059768B2 (en) 2014-09-12 2018-08-28 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP3194400A1 (en) 2014-09-17 2017-07-26 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
CN114621969A (en) 2014-09-17 2022-06-14 诺华股份有限公司 Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA2957148A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
WO2016044588A1 (en) 2014-09-19 2016-03-24 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
JP6694877B2 (en) 2014-09-23 2020-05-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Anti-IL-25 antibody and use thereof
SI3262071T1 (en) 2014-09-23 2020-07-31 F. Hoffmann-La Roche Ag Method of using anti-cd79b immunoconjugates
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
EP3201226A2 (en) 2014-10-03 2017-08-09 Massachusetts Institute of Technology Antibodies that bind ebola glycoprotein and uses thereof
US9921230B2 (en) 2014-10-08 2018-03-20 Rhode Island Hospital Methods for diagnosis and treatment of concussion or brain injury
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
KR20210013299A (en) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 Butyrylcholinesterase zwitterionic polymer conjugates
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
MA41685A (en) 2014-10-17 2017-08-22 Biogen Ma Inc COPPER SUPPLEMENT FOR THE REGULATION OF GLYCOSYLATION IN A MAMMAL CELL CULTURE PROCESS
US10040844B2 (en) 2014-10-22 2018-08-07 The Regents Of The University Of California Proteolytic release of cell surface antigens for phage biopanning
KR102781429B1 (en) 2014-10-31 2025-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Altering gene expression in modified t cells and uses thereof
MA40864A (en) 2014-10-31 2017-09-05 Biogen Ma Inc HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
WO2016070001A1 (en) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
US20160161485A1 (en) 2014-11-03 2016-06-09 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
WO2016073380A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
KR20170080675A (en) 2014-11-05 2017-07-10 제넨테크, 인크. Anti-fgfr2/3 antibodies and methods using same
US10066002B2 (en) 2014-11-05 2018-09-04 Genentech, Inc. Methods of producing two chain proteins in bacteria
BR112017009152A2 (en) 2014-11-05 2018-03-06 Genentech Inc Two-chain protein production methods in bacteria
CN107073126A (en) 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 Combination treatment comprising OX40 combinations activator and TIGIT inhibitor
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
HRP20191766T1 (en) 2014-11-06 2019-12-27 F. Hoffmann - La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
RU2713131C1 (en) 2014-11-06 2020-02-03 Ф. Хоффманн-Ля Рош Аг EMBODIMENTS OF Fc-REGION WITH MODIFIED BINDING PROPERTIES OF FcRn AND PROTEIN A
HK1243440A1 (en) 2014-11-10 2018-07-13 F. Hoffmann-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
JP2018500882A (en) 2014-11-10 2018-01-18 ジェネンテック, インコーポレイテッド Animal model of nephropathy and drug for treating it
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016075612A1 (en) 2014-11-12 2016-05-19 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
KR102588377B1 (en) 2014-11-14 2023-10-12 에프. 호프만-라 로슈 아게 Antigen binding molecules comprising a tnf family lignad trimer
US20160166685A1 (en) 2014-11-17 2016-06-16 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3221359B1 (en) 2014-11-17 2020-05-27 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
US10434177B2 (en) 2014-11-17 2019-10-08 Carnegie Mellon University Activatable two-component photosensitizers
DK3221349T3 (en) 2014-11-19 2021-01-04 Axon Neuroscience Se Humanized tau antibodies in Alzheimer's disease
EP3221364B1 (en) 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
CN107250158B (en) 2014-11-19 2022-03-25 基因泰克公司 Anti-transferrin receptor/anti-BACE 1 multispecific antibodies and methods of use
JP6779876B2 (en) 2014-11-19 2020-11-04 ジェネンテック, インコーポレイテッド Anti-transferrin receptor antibody and how to use it
HUE059632T2 (en) 2014-11-20 2022-12-28 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
RS60615B1 (en) 2014-11-20 2020-08-31 Hoffmann La Roche Common light chains and methods of use
CN107074955B (en) 2014-11-20 2021-06-22 豪夫迈·罗氏有限公司 T cell activating bispecific antigen binding molecules against FolR1 and CD3
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
EP3581585A1 (en) 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
WO2016086189A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
IL252467B (en) 2014-11-26 2022-06-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
US10208108B2 (en) 2014-11-28 2019-02-19 The Israel Institute of Biological Research (IIBR) Antibodies directed to ricin toxin
US10233256B2 (en) * 2014-11-28 2019-03-19 The Israel Institute of Biological Research (IIBR) Antibodies directed to ricin toxin
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
MX2017007055A (en) 2014-12-03 2017-11-08 Genentech Inc Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof.
JP6721590B2 (en) 2014-12-03 2020-07-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Multispecific antibody
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
WO2016090040A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
MA41119A (en) 2014-12-03 2017-10-10 Acceleron Pharma Inc METHODS OF TREATMENT OF MYELODYSPLASIC SYNDROMES AND SIDEROBLASTIC ANEMIA
AU2015358325A1 (en) 2014-12-05 2017-05-25 Genentech, Inc. Anti-CD79b antibodies and methods of use
WO2016090347A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
MX2017007491A (en) 2014-12-10 2018-05-04 Genentech Inc Blood brain barrier receptor antibodies and methods of use.
WO2016094837A2 (en) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
SMT202500043T1 (en) 2014-12-15 2025-03-12 Univ California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3234120A4 (en) 2014-12-15 2018-05-16 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
JP2018503368A (en) 2014-12-18 2018-02-08 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Assay methods and methods for determining antibodies that induce CDC
EP3945096A1 (en) 2014-12-19 2022-02-02 Regenesance B.V. Antibodies that bind human c6 and uses thereof
CN120271705A (en) 2014-12-19 2025-07-08 中外制药株式会社 Anti-myostatin antibodies, polypeptides comprising variant FC regions, and methods of use
KR20230044338A (en) 2014-12-19 2023-04-03 추가이 세이야쿠 가부시키가이샤 Anti-c5 antibodies and methods of use
IL284291B2 (en) 2014-12-19 2025-02-01 Lundbeck Seattle Biopharmaceuticals Inc Humanized anti-acth antibodies and use thereof
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CN107428823B (en) 2015-01-22 2021-10-26 中外制药株式会社 Combinations and methods of use of two or more anti-C5 antibodies
WO2016116626A1 (en) 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
EP3247281B1 (en) 2015-01-23 2020-12-02 The University of North Carolina at Chapel Hill Apparatuses, systems, and methods for preclinical ultrasound imaging of subjects
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
EP3248013B1 (en) 2015-01-24 2020-07-15 Academia Sinica Cancer markers and methods of use thereof
WO2016120220A1 (en) 2015-01-26 2016-08-04 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
TWI711631B (en) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
TWI781507B (en) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
TWI786505B (en) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
HK1245882A1 (en) 2015-01-28 2018-08-31 F. Hoffmann-La Roche Ag Gene expression markers and treatment of multiple sclerosis
WO2016123593A1 (en) 2015-01-30 2016-08-04 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN107636170A (en) 2015-02-04 2018-01-26 健泰科生物技术公司 Mutant Smoothened and How to Use It
AU2016215535B2 (en) 2015-02-04 2021-09-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
EP3816179A3 (en) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
JP6959869B2 (en) 2015-02-23 2021-11-05 シーガル セラピューティクス エスアーエス Non-natural semaphorins 3 and their medical use
CA2972099A1 (en) 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
DK3265123T5 (en) 2015-03-03 2024-09-16 Kymab Ltd ANTIBODIES, USES AND METHODS
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
HK1247936A1 (en) 2015-03-06 2018-10-05 F. Hoffmann-La Roche Ag Ultrapurified dsba and dsbc and methods of making and using the same
EP3267994A4 (en) 2015-03-09 2018-10-31 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2018511797A (en) 2015-03-16 2018-04-26 ジェネンテック, インコーポレイテッド IL-13 detection and quantification method and use in diagnosis and treatment of Th2-related diseases
JP6968698B2 (en) 2015-03-17 2021-11-24 メモリアル スローン ケタリング キャンサー センター Anti-MUC16 antibody and its use
EP3069734A1 (en) 2015-03-17 2016-09-21 Exiris S.r.l. Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
EA201992756A3 (en) 2015-03-18 2020-06-30 Сиэтл Дженетикс, Инк. ANTIBODIES AGAINST CD48 AND THEIR CONJUGATES
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
CN107530428B (en) 2015-03-23 2022-05-13 震动疗法股份有限公司 Antibodies to ICOS
KR102749339B1 (en) 2015-03-23 2025-01-03 바이엘 파마 악티엔게젤샤프트 Anti-CEACAM6 antibodies and their uses
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
MX2017012423A (en) 2015-03-30 2018-01-26 Dyax Corp Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack.
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
SG11201707490SA (en) 2015-04-03 2017-10-30 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof
HK1252957A1 (en) 2015-04-06 2019-06-06 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
MA41919A (en) 2015-04-06 2018-02-13 Acceleron Pharma Inc ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES
WO2016164308A1 (en) 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
KR20180002653A (en) 2015-04-07 2018-01-08 제넨테크, 인크. Antigen binding complexes having an agonistic activity activity and methods of use
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
JP6999421B2 (en) 2015-04-07 2022-02-04 アレクトル エルエルシー Anti-sortilin antibody and how to use it
LT3280729T (en) 2015-04-08 2022-08-10 Novartis Ag CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) EXPRESSING CELL
TWI787645B (en) 2015-04-13 2022-12-21 美商輝瑞股份有限公司 Cd3-specific antibodies, therapeutic bispecific antibodies and their uses
MX2017013156A (en) 2015-04-14 2018-02-21 Boehringer Ingelheim Int Methods of treating diseases.
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
HK1250236A1 (en) 2015-04-15 2018-12-07 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
MA53243A (en) 2015-04-17 2021-06-23 Bristol Myers Squibb Co COMPOSITIONS COMPRISING A COMBINATION OF IPILIMUMAB AND NIVOLUMAB
EA201792193A1 (en) 2015-04-17 2018-05-31 Эмджен Рисерч (Мьюник) Гмбх CONSTRUCTIONS OF BISPECIFIC ANTIBODIES FOR CDH3 AND CD3
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
KR20240093813A (en) 2015-04-24 2024-06-24 제넨테크, 인크. Multispecific antigen-binding proteins
PL3286315T3 (en) 2015-04-24 2021-11-02 F. Hoffmann-La Roche Ag METHODS OF IDENTIFICATION OF BACTERIA CONTAINING BINDING POLYPEPTIDES
US20160319009A1 (en) 2015-04-29 2016-11-03 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
EP3288584A2 (en) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
WO2016179003A1 (en) 2015-05-01 2016-11-10 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2016177833A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
US20160326234A1 (en) * 2015-05-07 2016-11-10 Andrew Hiatt Monoclonal antibody cocktails for treatment of ebola infections
TWI820377B (en) 2015-05-07 2023-11-01 美商艾吉納斯公司 Anti-ox40 antibodies and methods of use thereof
KR20180018525A (en) 2015-05-08 2018-02-21 젠코어 인코포레이티드 Heterozygous antibodies that bind CD3 and tumor antigens
EP4238994A3 (en) 2015-05-11 2024-02-07 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
JP7048319B2 (en) 2015-05-12 2022-04-05 ジェネンテック, インコーポレイテッド Treatment and diagnosis methods for cancer
US10906982B2 (en) 2015-05-15 2021-02-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
HUE051661T2 (en) 2015-05-18 2021-03-29 Tcr2 Therapeutics Inc Compositions and medical uses for tcr reprogramming using fusion proteins
AU2016263513A1 (en) 2015-05-20 2017-11-23 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
JP6688551B2 (en) 2015-05-21 2020-04-28 ハープーン セラピューティクス,インク. Trispecific binding proteins and methods of use
WO2016191750A1 (en) 2015-05-28 2016-12-01 Genentech, Inc. Cell-based assay for detecting anti-cd3 homodimers
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
ES2789500T5 (en) 2015-05-29 2023-09-20 Hoffmann La Roche Therapeutic and diagnostic procedures for cancer
CN107771182A (en) 2015-05-29 2018-03-06 豪夫迈·罗氏有限公司 Humanized anti-Ebola virus glycoprotein antibody and method of use
IL292708B2 (en) 2015-05-30 2024-08-01 Molecular Templates Inc Vaccine-free Shiga toxin A subunit scaffolds and cell-targeting molecules containing them
HRP20241134T1 (en) 2015-05-30 2024-11-22 F. Hoffmann-La Roche Ag METHODS OF TREATMENT OF HER2-POSITIVE PREVIOUSLY UNTREATED METASTATIC BREAST CANCER
WO2016196679A1 (en) 2015-06-02 2016-12-08 Genentech, Inc. Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
AU2016270858B2 (en) 2015-06-05 2022-04-28 Ac Immune Sa Anti-Tau antibodies and methods of use
WO2016200835A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
HK1252272A1 (en) 2015-06-08 2019-05-24 豪夫迈‧罗氏有限公司 Methods of treating cancer using anti-ox40 antibodies
CN116063499A (en) 2015-06-12 2023-05-05 艾利妥 anti-CD 33 antibodies and methods of use thereof
TW201709932A (en) 2015-06-12 2017-03-16 西雅圖遺傳學公司 CD123 antibody and its conjugate
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
HK1255483A1 (en) 2015-06-15 2019-08-16 基因泰克公司 Antibodies and immunoconjugates
PE20180330A1 (en) 2015-06-16 2018-02-13 Genentech Inc AFFINITY MATURED AND HUMANIZED ANTIBODIES FOR FCRH5 AND METHODS FOR THEIR USE
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
JP6996983B2 (en) 2015-06-16 2022-02-21 ジェネンテック, インコーポレイテッド Anti-CLL-1 antibody and how to use
AU2016278239B9 (en) 2015-06-17 2022-08-11 Allakos Inc. Methods and compositions for treating fibrotic diseases
CA2986592A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Anti-her2 antibodies and methods of use
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
WO2016207094A1 (en) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
PE20221007A1 (en) 2015-06-24 2022-06-15 Hoffmann La Roche ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH ENGINEERED AFFINITY
EP3313882B1 (en) 2015-06-24 2020-03-11 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
CN113929779B (en) 2015-06-24 2025-02-25 豪夫迈·罗氏有限公司 Humanized anti-Tau (pS422) antibodies and methods of use
WO2016207091A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
EP3514174B1 (en) 2015-06-29 2021-03-31 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
EP3313885A1 (en) 2015-06-29 2018-05-02 H. Hoffnabb-La Roche Ag Type ii anti-cd20 antibody for use in organ transplantation
CA2986796A1 (en) 2015-06-30 2017-01-05 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
EP3319994B1 (en) 2015-07-06 2024-02-07 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
LT3319995T (en) 2015-07-07 2019-07-10 F. Hoffmann-La Roche Ag COMPOUND TREATMENT WITH ANTI-HER-2 ANTIBODY-DRUG CONJUGATE AND BCL-2 INHIBITOR
CN108449940B (en) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 Conjugated bridging linkers to cell-binding molecules
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (en) 2015-07-13 2021-01-31 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究(慕尼黑)公司 Antibody constructs for flt3 and cd3
TW202346349A (en) 2015-07-31 2023-12-01 德商安美基研究(慕尼黑)公司 Antibody constructs for dll3 and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究(慕尼黑)公司 Antibody constructs for msln and cd3
TWI833685B (en) 2015-07-31 2024-03-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 Method of predicting the bioavailability of an antibody
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究(慕尼黑)公司 Antibody constructs for egfrviii and cd3
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究(慕尼黑)公司 Antibody constructs for cd70 and cd3
JOP20160154B1 (en) 2015-07-31 2021-08-17 Regeneron Pharma Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof
US10286080B2 (en) 2015-08-03 2019-05-14 Wayne State University IgA Fc-folate conjugates, pharmaceutical compositions and methods to treat cancer
KR102824235B1 (en) 2015-08-04 2025-06-25 악셀레론 파마 인코포레이티드 Methods for treating myeloproliferative disorders
HU231463B1 (en) 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Method for increasing the galactose content of recombinant proteins
WO2017024146A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
WO2017025458A1 (en) 2015-08-07 2017-02-16 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
CN108495641A (en) 2015-08-11 2018-09-04 塞勒克提斯公司 The cell for immunotherapy for targeting CD38 antigens and the engineering inactivated for CD38 genes
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
US10988528B2 (en) 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
FI3334761T3 (en) 2015-08-13 2023-08-14 Univ New York Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
US10852309B2 (en) 2015-08-25 2020-12-01 Prothena Biosciences Limited Methods for detecting phosphorylated alpha-synuclein
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide assembly and methods of making and using the same
EP3932953A1 (en) 2015-08-28 2022-01-05 F. Hoffmann-La Roche AG Anti-hypusine antibodies and uses thereof
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
KR20180039172A (en) 2015-09-01 2018-04-17 베링거 인겔하임 인터내셔날 게엠베하 Use of anti-CD40 antibodies for the treatment of lupus nephritis
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
WO2017041027A1 (en) 2015-09-04 2017-03-09 Obi Pharma, Inc. Glycan arrays and method of use
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
MX2018003005A (en) 2015-09-18 2018-04-11 Chugai Pharmaceutical Co Ltd Il-8-binding antibodies and uses thereof.
TWI811716B (en) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 Methods of treating inflammatory diseases
CA2999369C (en) 2015-09-22 2023-11-07 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
EA201890785A1 (en) 2015-09-23 2018-10-31 Ридженерон Фармасьютикалз, Инк. OPTIMIZED BISPECIFIC ANTI-CD3 ANTIBODIES AND THEIR APPLICATION
US11142565B2 (en) 2015-09-24 2021-10-12 Abvitro Llc Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
CA2994858C (en) 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
JP7628764B2 (en) 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド mod folkpon edge cargogo search carrier Signalsure procedure always Subaturch curl carrieresert match experiencesch suffer with Japan missed crgoc car
WO2017059132A1 (en) 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
MX2018003689A (en) 2015-09-29 2018-04-30 Celgene Corp Pd-1 binding proteins and methods of use thereof.
PE20181367A1 (en) 2015-09-30 2018-08-27 Janssen Biotech Inc AGONIST ANTIBODIES THAT SPECIFICALLY BIND HUMAN CD40 AND METHODS OF USE
AR106188A1 (en) 2015-10-01 2017-12-20 Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
US20180282410A1 (en) 2015-10-02 2018-10-04 Hoffmann-La Roche Inc. Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
EP3356410B1 (en) 2015-10-02 2021-10-20 F. Hoffmann-La Roche AG Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
CN108026179A (en) 2015-10-02 2018-05-11 豪夫迈·罗氏有限公司 With reference to mesothelin and the bispecific T cell activation antigen binding molecules of CD3
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
UA125962C2 (en) 2015-10-02 2022-07-20 Ф. Хоффманн-Ля Рош Аг Bispecific antibodies specific for a costimulatory tnf receptor
AR106199A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche T-CELL ACTIVATING ANTIGEN BINDING MOLECULES OF ANTIGEN
MY190297A (en) 2015-10-02 2022-04-12 Hoffmann La Roche Anti-pd1 antibodies and methods of use
JP6937746B2 (en) 2015-10-02 2021-09-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Bispecific anti-CD19 × CD3T cell-activating antigen-binding molecule
HRP20211357T1 (en) 2015-10-02 2021-11-26 F. Hoffmann - La Roche Ag Bispecific antibodies specific for pd1 and tim3
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
PE20181004A1 (en) 2015-10-02 2018-06-26 Hoffmann La Roche BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
KR20180075537A (en) 2015-10-06 2018-07-04 제넨테크, 인크. Methods for treating multiple sclerosis
US20170247467A1 (en) 2015-10-07 2017-08-31 Hoffmann-La Roche Inc. Bispecific antibodies with tetravalency for a costimulatory tnf receptor
WO2017064716A1 (en) 2015-10-13 2017-04-20 Rappaport Family Institute For Research Heparanase-neutralizing monoclonal antibodies
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201518675D0 (en) 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
JP2018534927A (en) 2015-10-22 2018-11-29 ジョンス セラピューティクス, インコーポレイテッド Gene signature that determines ICOS expression
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
US11267875B2 (en) 2015-10-28 2022-03-08 Yale University Humanized anti-DKK2 antibody and uses thereof
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
MX2018005036A (en) 2015-10-29 2018-08-01 Hoffmann La Roche Anti-variant fc-region antibodies and methods of use.
JP2018536650A (en) 2015-10-30 2018-12-13 ジェネンテック, インコーポレイテッド Anti-factor D antibody variant conjugates and uses thereof
CN116333125A (en) 2015-10-30 2023-06-27 银河生物技术有限责任公司 Antibodies that bind death receptor 4 and death receptor 5
PT3368578T (en) 2015-10-30 2021-05-06 H Hoffnabb La Roche Ag Anti-htra1 antibodies and methods of use thereof
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
EP3371206B1 (en) 2015-11-02 2021-04-14 F. Hoffmann-La Roche AG Methods of making fucosylated and afucosylated forms of a protein
US11235063B2 (en) 2015-11-03 2022-02-01 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
DK3370768T3 (en) 2015-11-03 2022-03-21 Janssen Biotech Inc ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND USES THEREOF
JP2019503985A (en) 2015-11-03 2019-02-14 グリコミメティクス, インコーポレイテッド Monoclonal antibodies, methods and compositions for the production of hematopoietic stem cells, and methods of using them
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
WO2017079746A2 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
CN118725134A (en) 2015-11-08 2024-10-01 豪夫迈·罗氏有限公司 Methods for screening multispecific antibodies
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
EP3377533A2 (en) 2015-11-19 2018-09-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
JP7072507B2 (en) 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド Methods for treating eye disorders
CN106729743B (en) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 anti-ErbB 2 antibody-drug conjugate, and composition, preparation method and application thereof
IL291926B2 (en) 2015-11-23 2024-06-01 Five Prime Therapeutics Inc FGFR2 inhibitors alone or in combination with immunostimulating agents in cancer treatment
TWI778491B (en) 2015-11-30 2022-09-21 美商輝瑞股份有限公司 Site specific her2 antibody drug conjugates
CN109415437B (en) 2015-12-02 2022-02-01 斯特库伯株式会社 Antibodies and molecules that immunospecifically bind to BTN1A1 and therapeutic uses thereof
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
EP3383497A4 (en) 2015-12-04 2019-06-12 The Regents of The University of California NEW ANTIBODIES FOR THE TREATMENT OF CANCERS
KR20180085800A (en) 2015-12-07 2018-07-27 젠코어 인코포레이티드 CD3 and heterodimeric antibodies that bind to PSMA
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
CN108290954B (en) 2015-12-09 2022-07-26 豪夫迈·罗氏有限公司 Use of type II anti-CD 20 antibodies to reduce anti-drug antibody formation
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
AU2016366521A1 (en) 2015-12-11 2018-06-21 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to EGFR and/or ErbB3 blockade
CN108602893A (en) 2015-12-11 2018-09-28 戴埃克斯有限公司 Inhibitors of plasma kallikrein and its purposes for the treatment of hereditary angioedema breaking-out
MY196756A (en) 2015-12-14 2023-05-03 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
NZ743713A (en) 2015-12-15 2020-01-31 Gilead Sciences Inc Human immunodeficiency virus neutralizing antibodies
MA44072A (en) 2015-12-17 2018-10-24 Janssen Biotech Inc ANTIBODIES SPECIFICALLY BINDING TO HLA-DR AND THEIR USES
BR112018009067A8 (en) 2015-12-18 2019-02-26 Chugai Pharmaceutical Co Ltd anti-c5 antibodies and methods of use
EA201891420A1 (en) 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся ANTIBODIES TO MYOSTATIN, POLYPEPTIDES, CONTAINING OPTIONS OF FC-REGIONS, AND METHODS OF THEIR APPLICATION
CN105646704B (en) * 2015-12-28 2019-11-15 广西医科大学 Anti-p185erbB2 human-mouse chimeric antibody ChAb26, mammary gland-specific expression vector, transgenic FVB mouse and preparation method thereof
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and conjugates thereof
CN107531795B (en) 2016-01-05 2021-01-19 江苏恒瑞医药股份有限公司 PCSK9 antibody, antigen-binding fragment thereof and medical application thereof
AR107303A1 (en) 2016-01-08 2018-04-18 Hoffmann La Roche METHODS OF TREATMENT OF POSITIVE CANCER FOR ACE USING ANTAGONISTS OF AXISION TO AXIS PD-1 AND ANTI-ACE / ANTI-CD3, USE, COMPOSITION, KIT
MX395252B (en) 2016-01-08 2025-03-25 Altrubio Inc Tetravalent anti-psgl-1 antibodies and uses thereof
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
BR112018014762A2 (en) 2016-01-20 2018-12-26 Genentech Inc method of treating (early) alzheimer's disease
JP2019506398A (en) 2016-01-21 2019-03-07 ファイザー・インク Epidermal growth factor receptor variant III and CD3 single and bispecific antibodies and their use
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
EP3964529B1 (en) 2016-01-22 2025-03-26 Mabquest SA Non-blocking pd1 specific antibodies
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
CN109073635A (en) 2016-01-25 2018-12-21 豪夫迈·罗氏有限公司 Method for measuring T cell dependence bispecific antibody
CA3011455A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
FI3411404T3 (en) 2016-02-03 2023-01-31 T CELL ACTIVATING PSMA AND CD3 BISPECIFIC ANTIBODY CONSTRUCTS
HUE057220T2 (en) 2016-02-03 2022-04-28 Amgen Res Munich Gmbh Bcma and cd3 bispecific t cell engaging antibody constructs
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
WO2017136558A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
EP3411069B1 (en) 2016-02-04 2024-07-10 The Scripps Research Institute Humanized anti-cd3 antibodies, conjugates and uses thereof
WO2017139417A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
BR112018016461A2 (en) 2016-02-12 2019-10-01 Janssen Pharmaceutica Nv antibodies and anti-sight fragments, their uses and their identification methods
CA3011900A1 (en) 2016-02-17 2017-08-24 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
GB201603291D0 (en) * 2016-02-25 2016-04-13 Binding Site Group The Ltd Antibodies
CA3015839A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System Connexin (cx)43 hemichannel-binding antibodies and uses thereof
WO2017147542A2 (en) 2016-02-26 2017-08-31 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
EP4155415A1 (en) 2016-02-29 2023-03-29 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US10941447B2 (en) 2016-02-29 2021-03-09 Rhode Island Hospital Diagnostics for pulmonary arterial hypertension and sudden cardiac death
AU2017228055B2 (en) 2016-03-01 2024-04-04 University Of Rijeka Faculty Of Medicine Antibodies specific to human poliovirus receptor (PVR)
MX2018010562A (en) 2016-03-02 2019-02-20 Eisai R&D Man Co Ltd ANTIBODY AND PHARMACO CONJUGATES BASED ON ERIBULIN AND METHODS FOR USE.
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
KR102355950B1 (en) 2016-03-04 2022-01-26 제이엔 바이오사이언시즈 엘엘씨 Antibodies to TIGIT
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
TW201808978A (en) 2016-03-08 2018-03-16 中央研究院 Methods for modular synthesis of N-glycans and arrays thereof
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
MX2018011169A (en) 2016-03-14 2018-12-06 Millennium Pharm Inc Method of preventing graft versus host disease.
MX2018011025A (en) 2016-03-14 2019-01-10 Millennium Pharm Inc Methods of treating or preventing graft versus host disease.
TWI759287B (en) 2016-03-15 2022-04-01 日商中外製藥股份有限公司 Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
EP3430172A4 (en) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center DIAGNOSTIC METHOD FOR CHRONIC INFLAMMATORY BOWEL DISEASE THROUGH T2 RNASE
MA43724B1 (en) 2016-03-22 2023-06-28 Hoffmann La Roche BI-SPECIFIC PROTEASE-ACTIVATED T-CELL MOLECULES
UA127308C2 (en) 2016-03-22 2023-07-19 Ф. Хоффманн-Ля Рош Аг Protease-activated t cell bispecific molecules
CN111363041B (en) 2016-03-23 2022-02-22 苏州创胜医药集团有限公司 Novel anti-PD-L1 antibodies
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
AU2017239018A1 (en) 2016-03-24 2018-08-16 Bayer As Radio-pharmaceutical complexes
WO2017165734A1 (en) 2016-03-25 2017-09-28 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
MY202022A (en) 2016-03-28 2024-03-29 Incyte Corp Pyrrolotriazine compounds as tam inhibitors
EP3436475A1 (en) 2016-03-29 2019-02-06 STCube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CA3018382A1 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
KR102367074B1 (en) 2016-03-29 2022-02-25 주식회사 에스티큐브 Dual function antibodies specific for glycosylated PD-L1 and methods of use thereof
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
KR101796277B1 (en) 2016-04-12 2017-11-13 앱클론(주) Antibodies Binding Specifically to HER2 with Improved Stability
WO2017180864A1 (en) 2016-04-14 2017-10-19 Genentech, Inc. Anti-rspo3 antibodies and methods of use
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
IL262366B2 (en) 2016-04-15 2024-07-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
EP3443008A1 (en) 2016-04-15 2019-02-20 Medimmune Limited ANTI-PrP ANTIBODIES AND USES THEREOF
SG11201808632YA (en) 2016-04-15 2018-10-30 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
ES2850428T3 (en) 2016-04-15 2021-08-30 Hoffmann La Roche Cancer monitoring and treatment procedures
EP3442999A2 (en) 2016-04-15 2019-02-20 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
WO2017181139A2 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
EP3443120A2 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Methods for monitoring and treating cancer
EP3560956A3 (en) 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
ES2944607T3 (en) 2016-04-15 2023-06-22 Novartis Ag Compositions and methods for the selective expression of chimeric receptors for the antigen
MA44723A (en) 2016-04-18 2019-02-27 Celldex Therapeutics Inc HUMAN CD40 BINDING AGONIST ANTIBODIES AND THEIR USES
JOP20170091B1 (en) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh Giving a bispecific formulation that binds to CD33 and CD3 for use in a modality for the treatment of myeloid leukemia
KR20230110820A (en) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 Cancer immunotherapy by immune activation or immune modulation via globo series antigens
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
US12054550B2 (en) 2016-04-28 2024-08-06 Biomunex Pharmaceuticals Bispecific antibodies targeting EGFR and HER2
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
HUE060258T2 (en) 2016-05-02 2023-02-28 Prothena Biosciences Ltd Tau immunotherapy
MX2018013342A (en) 2016-05-02 2019-05-09 Hoffmann La Roche The contorsbody - a single chain target binder.
SG11201809331RA (en) 2016-05-02 2018-11-29 Prothena Biosciences Ltd Antibodies recognizing tau
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
EP3241847A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2 binding antibodies
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP3455254B1 (en) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
CN109311987A (en) 2016-05-13 2019-02-05 生物蛋白有限公司 Anti- ROR2 antibody, antibody fragment and their immunoconjugates with and application thereof
KR102410778B1 (en) 2016-05-13 2022-06-21 더 제너럴 하스피탈 코포레이션 antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
MX2018014047A (en) 2016-05-17 2019-06-20 Genentech Inc Stromal gene signatures for diagnosis and use in immunotherapy.
EP4019019B1 (en) 2016-05-20 2024-02-07 Biohaven Pharmaceutical Holding Company Ltd. Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates
JP7267012B2 (en) 2016-05-27 2023-05-01 アジェナス インコーポレイテッド Anti-TIM-3 antibody and method of use thereof
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
EP3464375A2 (en) 2016-06-02 2019-04-10 Novartis AG Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
ES3008636T3 (en) 2016-06-02 2025-03-24 Immunocore Ltd Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CA3025995C (en) 2016-06-06 2023-08-08 F. Hoffmann-La Roche Ag Fusion proteins for ophthalmology with increased eye retention
AU2017277288B2 (en) 2016-06-09 2024-05-16 Omeros Corporation Monoclonal antibodies, compositions and methods for detecting mucin -like protein (MLP) as a biomarker for ovarian and pancreatic cancer
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
KR102495601B1 (en) 2016-06-10 2023-02-06 리제너론 파마슈티칼스 인코포레이티드 Anti-GITR Antibodies and Their Uses
MA45255A (en) 2016-06-14 2019-04-17 Xencor Inc BISPECIFIC CONTROL POINT INHIBITORS ANTIBODIES
EP3472197A1 (en) 2016-06-15 2019-04-24 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
SG11201810777WA (en) 2016-06-17 2018-12-28 Genentech Inc Purification of multispecific antibodies
BR112018073628A2 (en) 2016-06-17 2019-02-26 Chugai Seiyaku Kabushiki Kaisha antimiostatin antibodies and methods of use
US12071487B2 (en) 2016-06-17 2024-08-27 Life Technologies Corporation Site-specific crosslinking of antibodies
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. Cd3 binding antibodies
CN116143918A (en) 2016-06-24 2023-05-23 豪夫迈·罗氏有限公司 Anti-polyubiquitin multispecific antibodies
AU2017290086A1 (en) 2016-06-28 2019-01-24 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
EP3478714A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (en) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド Anti-transthyretin antibody
JP7017013B2 (en) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド Anti-transthyretin antibody
WO2018007314A1 (en) 2016-07-04 2018-01-11 F. Hoffmann-La Roche Ag Novel antibody format
PT3482210T (en) 2016-07-06 2021-07-28 Prothena Biosciences Ltd Assay for detecting total and s129 phosphorylated alpha-synuclein
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US20180008672A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
SG11201811015RA (en) 2016-07-12 2019-01-30 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
EP3484488B1 (en) 2016-07-12 2023-08-09 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
MX2018015853A (en) 2016-07-14 2019-08-21 Genmab As Multispecific antibodies against cd40 and cd137.
SG11201900344YA (en) 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
MA45674A (en) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co METHODS AND MATERIALS FOR EVALUATING A RESPONSE TO PLASMOBLAST AND PLASMOCYTE DEPLÉTION TREATMENTS
RS62011B1 (en) 2016-07-15 2021-07-30 Acceleron Pharma Inc Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018017673A1 (en) 2016-07-20 2018-01-25 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
WO2018017964A2 (en) 2016-07-21 2018-01-25 Emory University Ebola virus antibodies and binding agents derived therefrom
US10377833B2 (en) 2016-07-22 2019-08-13 Beijing Mabworks Biotech Co., Ltd. Bispecific anti-HER2 antibody
AU2017300040A1 (en) 2016-07-22 2019-01-24 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) TREM2 cleavage modulators and uses thereof
CN107446045A (en) 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 A kind of anti-HER2 antibody, its pharmaceutical composition and purposes
EP3487880A1 (en) 2016-07-25 2019-05-29 Biogen MA Inc. Anti-hspa5 (grp78) antibodies and uses thereof
CN110072545A (en) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 Immunogenicity/therapeutic glycan pool object and application thereof
EA201990226A1 (en) 2016-07-27 2019-08-30 Акселерон Фарма Инк. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOFIBROSIS
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
JP2019523301A (en) 2016-07-28 2019-08-22 ノバルティス アーゲー Combination therapy of chimeric antigen receptor and PD-1 inhibitor
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
CA3027018A1 (en) 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
WO2018023121A1 (en) 2016-07-29 2018-02-01 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
MX2019001184A (en) 2016-07-29 2019-09-26 Juno Therapeutics Inc Anti-idiotypic antibodies against anti-cd19 antibodies.
BR112019002035A2 (en) 2016-08-01 2019-05-14 Novartis Ag cancer treatment using a chimeric antigen receptor in combination with an inhibitor of a m2 pro-macrophage molecule
JP7109789B2 (en) 2016-08-02 2022-08-01 ティーシーアール2 セラピューティクス インク. Compositions and methods for TCR reprogramming using fusion proteins
KR20190036528A (en) 2016-08-03 2019-04-04 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Collapse of Fc receptor participation in macrophage enhancement efficacy of anti-SIRPalpha antibody therapy
US11046776B2 (en) 2016-08-05 2021-06-29 Genentech, Inc. Multivalent and multiepitopic antibodies having agonistic activity and methods of use
AU2017305073B2 (en) 2016-08-05 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Composition for prevention or treatment of IL-8 related diseases
JP7250674B2 (en) 2016-08-08 2023-04-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト CANCER TREATMENT AND DIAGNOSTIC METHOD
JP7093767B2 (en) 2016-08-11 2022-06-30 ジェネンテック, インコーポレイテッド Pyrrolobenzodiazepine prodrug and its antibody conjugate
EP3497120A1 (en) 2016-08-12 2019-06-19 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
JP7009448B2 (en) 2016-08-12 2022-02-10 ヤンセン バイオテツク,インコーポレーテツド Fc genetically engineered anti-TNFR superfamily member antibody with enhanced agonist activity and how to use it
CN109716127B (en) 2016-08-15 2022-06-14 豪夫迈·罗氏有限公司 Chromatographic method for quantifying nonionic surfactant in composition containing nonionic surfactant and polypeptide
AU2017313405B2 (en) 2016-08-17 2024-09-26 Compugen Ltd. Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
TWI764917B (en) 2016-08-22 2022-05-21 醣基生醫股份有限公司 Antibodies, binding fragments, and methods of use
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018042385A2 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US11168148B2 (en) 2016-09-07 2021-11-09 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
EP3512549A4 (en) 2016-09-14 2020-06-17 Teneobio, Inc. ANTIBODIES BINDING CD3
CA3037144A1 (en) 2016-09-16 2018-03-22 Shanghai Henlius Biotech, Inc. Anti-pd-1 antibodies
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EA201990747A1 (en) 2016-09-19 2019-10-31 METHODS FOR TREATING IMMUNE DISORDERS WITH APPLICATION OF PROTEINS BINDING PD – 1
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
EP3515932B1 (en) 2016-09-19 2023-11-22 F. Hoffmann-La Roche AG Complement factor based affinity chromatography
RU2759334C2 (en) 2016-09-21 2021-11-12 Нексткьюр, Инк. Antibodies against siglec-15 and their application methods
WO2018057802A1 (en) 2016-09-21 2018-03-29 Aptevo Research And Development Llc Cd123 binding proteins and related compositions and methods
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
KR102557643B1 (en) 2016-09-23 2023-07-20 제넨테크, 인크. Use of IL-13 antagonists to treat atopic dermatitis
SG10202102617QA (en) 2016-09-23 2021-04-29 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
CA3036632A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
JP7066691B2 (en) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Bispecific anti-MUC16-CD3 antibody and anti-MUC16 drug complex
ES3013602T3 (en) 2016-09-28 2025-04-14 Kite Pharma Inc Antigen binding molecules and methods of use thereof
ES2897217T3 (en) 2016-09-30 2022-02-28 Hoffmann La Roche Bispecific antibodies against p95HER2
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
JP2019529509A (en) 2016-10-05 2019-10-17 アクセレロン ファーマ インコーポレーテッド Compositions and methods for treating kidney disease
MX2019003934A (en) 2016-10-06 2019-07-10 Genentech Inc THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER.
BR112019006781A2 (en) 2016-10-07 2019-07-30 Novartis Ag chimeric antigen receptors for cancer treatment
IL302917A (en) 2016-10-07 2023-07-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
CN109789211A (en) 2016-10-07 2019-05-21 第一三共株式会社 Treatment based on the patience cancer that Anti-HER 2-drug conjugates are bestowed
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
MA46529A (en) 2016-10-11 2019-08-21 Agenus Inc ANTI-LAG-3 ANTIBODIES AND PROCESSES FOR USE
EP3526254A1 (en) 2016-10-12 2019-08-21 Sutro Biopharma, Inc. Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
EP3525815A2 (en) 2016-10-13 2019-08-21 Massachusetts Institute of Technology Antibodies that bind zika virus envelope protein and uses thereof
RU2019114175A (en) 2016-10-14 2020-11-16 Ксенкор, Инк. BISPECIFIC HETERODYMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA FC-FUSION PROTEINS AND ANTIBODY FRAGMENTS TO PD-1
EP4032906A1 (en) 2016-10-14 2022-07-27 Boehringer Ingelheim International GmbH Methods of treating diseases
MX2019004690A (en) 2016-10-19 2019-09-27 Invenra Inc ANTIBODY CONSTRUCTS.
TW202300515A (en) 2016-10-20 2023-01-01 法商賽諾菲公司 Anti-chikv antibodies and uses thereof
KR20190084264A (en) 2016-10-25 2019-07-16 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Monoclonal antibody that binds to the CD160 transverse soma
KR20240128132A (en) 2016-10-26 2024-08-23 세다르스-신나이 메디칼 센터 Neutralizing anti-tl1a monoclonal antibodies
AU2017348365A1 (en) 2016-10-28 2019-05-23 Astute Medical, Inc. Use of antibodies to TIMP-2 for the improvement of renal function
JP2019535250A (en) 2016-10-29 2019-12-12 ジェネンテック, インコーポレイテッド Anti-MIC antibody and method of use
WO2018085495A2 (en) 2016-11-02 2018-05-11 Board Of Regents, The University Of Texas System Dissolvable films and methods of their use
KR20190088480A (en) 2016-11-02 2019-07-26 조운스 테라퓨틱스, 인크. Antibodies to PD-1 and uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN109906030B (en) 2016-11-04 2022-03-18 安健基因公司 Genetically modified non-human animals and methods for producing heavy chain-only antibodies
CN110505880A (en) 2016-11-04 2019-11-26 基因泰克公司 Treatment of HER2-positive breast cancer
JP7045724B2 (en) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド Anti-Family 19, member A5 antibody with sequence similarity and its uses
EP3538539A2 (en) 2016-11-08 2019-09-18 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
WO2018086139A1 (en) 2016-11-14 2018-05-17 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
EP3541836A1 (en) 2016-11-15 2019-09-25 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
EP3541408B1 (en) 2016-11-15 2024-11-13 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
CA3042435A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
TW201829463A (en) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 anti-HLA-G antibody and use thereof
JOP20190100A1 (en) 2016-11-19 2019-05-01 Potenza Therapeutics Inc Anti-gitr antigen-binding proteins and methods of use thereof
KR102477612B1 (en) 2016-11-21 2022-12-14 쿠레아브 게엠베하 Anti-gp73 antibodies and immunoconjugates
TWI822055B (en) 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 Conjugated biological molecules, pharmaceutical compositions and methods
CN110177803A (en) 2016-11-22 2019-08-27 T细胞受体治疗公司 For using fusion protein to carry out the composition and method that TCR is reprogramed
CN110198955A (en) 2016-11-23 2019-09-03 哈普恩治疗公司 Prostate-specific membrane antigen conjugated protein
CA3044729A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
EA201900312A1 (en) 2016-11-29 2019-12-30 Регенерон Фармасьютикалз, Инк. METHODS OF TREATMENT OF PROLACTIN-RECEPTOR OF POSITIVE BREAST CANCER
TWI857389B (en) 2016-12-01 2024-10-01 美商再生元醫藥公司 Methods of treating inflammatory conditions
DK3551660T5 (en) 2016-12-07 2024-09-02 Agenus Inc ANTI-CTLA-4 ANTIBODIES AND METHODS OF USING THEREOF
CN118634323A (en) 2016-12-07 2024-09-13 艾吉纳斯公司 Antibodies and methods of use thereof
TW202328181A (en) 2016-12-07 2023-07-16 美商建南德克公司 Anti-tau antibodies and methods of use
EP3551655A2 (en) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of their use
CA3046293A1 (en) 2016-12-12 2018-06-21 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
CN110381997A (en) 2016-12-12 2019-10-25 茂体外尔公司 For treating and preventing the method and composition comprising gene-virus therapy and immunologic test point inhibitor of cancer and infectious diseases
BR112019011199A2 (en) 2016-12-12 2019-10-08 Genentech Inc method to treat an individual who has prostate cancer and kits
CA3047230A1 (en) 2016-12-15 2018-06-21 The National Institute for Biotechnology in the Negev Ltd. Anti-pcna monoclonal antibodies and use thereof
US11325968B2 (en) 2016-12-16 2022-05-10 H. Lundbeck A/S Alpha-synuclein antibodies
WO2018114754A1 (en) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
CN111868086B (en) 2016-12-19 2024-07-16 免疫医疗有限公司 Anti-LIF antibodies and uses thereof
WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
KR102692708B1 (en) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
MX2019007411A (en) 2016-12-21 2019-08-29 Hoffmann La Roche Re-use of enzymes in in vitro glycoengineering of antibodies.
JP6952115B2 (en) 2016-12-21 2021-10-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Methods for in vitro glycan engineering of antibodies
CN116284402A (en) 2016-12-21 2023-06-23 特尼奥生物股份有限公司 Heavy chain-only anti-BCMA antibodies
MX2019006266A (en) 2016-12-21 2019-08-21 Hoffmann La Roche In vitro glycoengineering of antibodies.
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JOP20190134A1 (en) 2016-12-23 2019-06-02 Potenza Therapeutics Inc Anti-neuropilin antigen-binding proteins and methods of use thereof
EP3562844A1 (en) 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
MA47200A (en) 2017-01-03 2019-11-13 Hoffmann La Roche BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING A 20H4.9 ANTI-4-1BB CLONE
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
TW201825515A (en) 2017-01-04 2018-07-16 美商伊繆諾金公司 Met antibodies and immunoconjugates and uses thereof
EP3565845A4 (en) 2017-01-06 2020-10-07 Biosion, Inc. ERBB2 ANTIBODIES AND THEIR USES
WO2018132597A1 (en) 2017-01-12 2018-07-19 Eureka Therapeutics, Inc. Constructs targeting histone h3 peptide/mhc complexes and uses thereof
BR112019012847A2 (en) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd antibody or antibody functional fragment, polynucleotide, expression vector, host cells, method for producing an antibody of interest or antibody functional fragment and for producing an antibody-drug conjugate, antibody-drug conjugate, pharmaceutical composition , antitumor drug; and, method of treating a tumor.
DK3570884T3 (en) 2017-01-17 2020-11-30 Genentech Inc Subcutaneous HER2 antibody formulations
MX2019008538A (en) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods.
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
SG10201908697XA (en) 2017-01-31 2019-10-30 Chugai Pharmaceutical Co Ltd A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
JOP20190189A1 (en) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
RU2771485C2 (en) 2017-02-10 2022-05-04 Дженентек, Инк. Antibodies against tryptase, their compositions and applications
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
WO2018152181A1 (en) 2017-02-14 2018-08-23 Kite Pharma, Inc. Cd70 binding molecules and methods of use thereof
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
BR112019017197A2 (en) 2017-02-20 2020-04-14 Dragonfly Therapeutics Inc proteins that bind to her2, nkg2d and cd16
WO2018156785A1 (en) 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
CN111148760A (en) 2017-02-27 2020-05-12 卡拉斯医疗有限公司 Antibody constructs and methods of treating cancer
JP2018139530A (en) 2017-02-27 2018-09-13 帝人ファーマ株式会社 Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US20200061031A1 (en) 2017-02-28 2020-02-27 Kinki University Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
KR20190134631A (en) 2017-03-01 2019-12-04 제넨테크, 인크. How to diagnose and treat cancer
FI3589661T3 (en) 2017-03-02 2024-01-31 Genentech Inc Adjuvant treatment of her2-positive breast cancer
BR112019017500A2 (en) 2017-03-03 2020-04-14 Rinat Neuroscience Corp anti-gitr antibodies and methods of using them
SI3592769T1 (en) 2017-03-09 2024-10-30 Genmab A/S Antibodies against pd-l1
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
EP3596126A4 (en) 2017-03-15 2021-03-03 Tsinghua University NOVEL ANTI-TRKB ANTIBODIES
EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
EP3596114A2 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
JOP20180021A1 (en) 2017-03-16 2019-01-30 Janssen Biotech Inc Anti-phf-tau antibodies and uses thereof
HRP20231382T1 (en) 2017-03-16 2024-02-16 Alpine Immune Sciences, Inc. PD-L1 VARIANT OF IMMUNOMODULATING PROTEINS AND THEIR USE
UA129242C2 (en) 2017-03-22 2025-02-26 Дженентек, Інк. OPTIMIZED ANTIBODY COMPOSITION FOR TREATMENT OF EYE DISEASES
CA3055985A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CN108623686A (en) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 Anti- OX40 antibody and application thereof
EA201992278A1 (en) 2017-03-27 2020-03-03 Селджин Корпорейшн METHODS AND COMPOSITIONS FOR REDUCING IMMUNOGENOUS
CA3056837A1 (en) 2017-03-27 2018-10-04 F. Hoffmann-La Roche Ag Improved antigen binding receptors
WO2018183173A1 (en) 2017-03-27 2018-10-04 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
CN110382542B (en) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 Bispecific antigen-binding molecules targeting co-stimulatory TNF receptors
EP3601345A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
JOP20190203A1 (en) 2017-03-30 2019-09-03 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
AU2018241252B2 (en) 2017-03-30 2024-09-19 The University Of Queensland Chimeric molecules and uses thereof
CN119285787A (en) 2017-03-31 2025-01-10 健玛保控股有限公司 Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
CA3058175A1 (en) 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor
PE20200010A1 (en) 2017-04-03 2020-01-06 Hoffmann La Roche ANTIBODIES THAT JOIN STEAP-1
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
EP3606947B1 (en) 2017-04-03 2022-12-21 F. Hoffmann-La Roche AG Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
BR112019020485A2 (en) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. PPARY AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
MX2019011770A (en) 2017-04-03 2020-01-09 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15.
TWI704158B (en) 2017-04-04 2020-09-11 瑞士商赫孚孟拉羅股份公司 Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
US11718682B2 (en) 2017-04-05 2023-08-08 Astute Medical, Inc. Assays for TIMP2 having improved performance in biological samples
JP6997212B2 (en) 2017-04-05 2022-02-04 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antibodies that specifically bind to PD1 and LAG3
EP3606954B1 (en) 2017-04-05 2022-07-20 F. Hoffmann-La Roche AG Anti-lag3 antibodies
MX2019012017A (en) 2017-04-07 2020-02-12 Juno Therapeutics Inc Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods.
KR102732040B1 (en) 2017-04-11 2024-11-21 인히브릭스 바이오사이언스, 인크. Multispecific polypeptide constructs with limited CD3 binding and methods using the same
CN108690138A (en) * 2017-04-12 2018-10-23 鸿运华宁(杭州)生物医药有限公司 It is a kind of can be with people CD19 or CD20 and people the CD3 bispecific antibody combined and its application
MX2019012187A (en) 2017-04-13 2019-11-25 Hoffmann La Roche An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer.
TWI842672B (en) 2017-04-13 2024-05-21 美商艾吉納斯公司 Anti-cd137 antibodies and methods of use thereof
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
SG11201909516VA (en) 2017-04-14 2019-11-28 Tollnine Inc Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
WO2018191660A1 (en) 2017-04-14 2018-10-18 Genentech, Inc. Diagnostic and therapeutic methods for cancer
RU2665790C1 (en) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Monoclonal pd-l1 antibody
JP2020517750A (en) * 2017-04-19 2020-06-18 エイピーエイ− アドバンスト・テクノロジーズ・リミテッドApa− Advanced Technologies Ltd. Fusogenic liposomes, compositions, kits and uses thereof for the treatment of cancer
KR20190141686A (en) 2017-04-21 2019-12-24 제넨테크, 인크. Use of KLK5 antagonists to treat diseases
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
IL319308A (en) 2017-04-26 2025-04-01 Eureka Therapeutics Inc ׂ A Delaware Corp Constructs specifically recognizing glypican 3 and uses thereof
CA3059468A1 (en) 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
EP3615052B1 (en) 2017-04-27 2023-01-25 The University of Hong Kong Use of hcn inhibitors for treatment of cancer
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
TWI805582B (en) 2017-05-01 2023-06-21 美商艾吉納斯公司 Anti-tigit antibodies and methods of use thereof
CU24636B1 (en) 2017-05-02 2022-12-12 Prothena Biosciences Ltd ANTIBODIES RECOGNIZING TAU IN RESIDUES 257-271 OR 320-334 OF SEQ ID NO: 1
JP2020518638A (en) 2017-05-05 2020-06-25 アラコス インコーポレイテッド Methods and compositions for treating allergic eye diseases
MA48763A (en) 2017-05-05 2020-04-08 Amgen Inc PHARMACEUTICAL COMPOSITION INCLUDING BISPECIFIC ANTIBODY CONSTRUCTIONS FOR IMPROVED STORAGE AND ADMINISTRATION
JP7161494B2 (en) 2017-05-06 2022-10-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods of treating eye diseases with APLNR antagonists and VEGF inhibitors
EP3401328A1 (en) 2017-05-10 2018-11-14 Bayer Pharma Aktiengesellschaft One step antibody humanization by golden gate based germline framework region shuffling
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
EP3625251A1 (en) 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
TW202504644A (en) 2017-05-15 2025-02-01 日商第一三共股份有限公司 Use of antibody-drug conjugates
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
WO2018213304A1 (en) 2017-05-16 2018-11-22 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
CN110944718A (en) 2017-05-18 2020-03-31 里珍纳龙药品有限公司 Cyclodextrin protein drug conjugates
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
US20200079850A1 (en) 2017-05-24 2020-03-12 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
CA3064869A1 (en) 2017-05-26 2018-11-29 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
CN111010867B (en) 2017-05-30 2023-05-12 俄克拉何马大学董事会 Anti-doublecortin-like kinase 1 antibodies and methods of use thereof
CA3065300A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
EP3630835A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CA3064331A1 (en) 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
CN118772278A (en) 2017-06-02 2024-10-15 辉瑞公司 FLT3 specific antibodies and uses thereof
KR20200014304A (en) 2017-06-02 2020-02-10 에프. 호프만-라 로슈 아게 Type II anti-CD20 antibodies and anti-CD20 / anti-CD3 bispecific antibodies for the treatment of cancer
CR20190550A (en) 2017-06-05 2020-04-05 Janssen Biotech Inc ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE
JP2020522562A (en) 2017-06-06 2020-07-30 ストキューブ アンド シーオー., インコーポレイテッド Methods of treating cancer with antibodies and molecules that bind to BTN1A1 or BTN1A1 ligand
WO2018226861A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
US20210079057A1 (en) 2017-06-13 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
KR102772810B1 (en) 2017-06-15 2025-02-28 캔서 어드밴시스 아이엔씨 Compositions and methods for inducing humoral and cellular immunity against tumors and cancers
MX2019015563A (en) 2017-06-20 2020-07-28 Teneoone Inc Anti-bcma heavy chain-only antibodies.
KR102742528B1 (en) 2017-06-20 2024-12-16 테네오바이오, 인코포레이티드 Anti-BCMA heavy chain-only antibody
EA201992502A1 (en) 2017-06-20 2020-04-22 Эмджен Инк. METHOD FOR TREATING OR REDUCING THE INTENSITY OF METABOLIC DISORDERS WITH APPLICATION OF PROTEINS BINDING THE GASTROINhibitor PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GL 1 AGONISTS
EP3641830A1 (en) 2017-06-23 2020-04-29 Velosbio Inc. Ror1 antibody immunoconjugates
WO2019005756A1 (en) 2017-06-28 2019-01-03 The Rockefeller University Anti-mertk agonistic antibody-drug conjugates and uses thereof
EP3645122A1 (en) 2017-06-30 2020-05-06 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
CU20200002A7 (en) 2017-07-14 2020-11-30 Pfizer ANTIBODIES AGAINST MADCAM
CN111094334A (en) 2017-07-19 2020-05-01 美国卫生与公众服务部 Antibodies and methods for diagnosis and treatment of hepatitis B virus infection
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
EP3655034A1 (en) 2017-07-21 2020-05-27 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CN111448210B (en) 2017-07-26 2024-05-14 四十七公司 Anti-SIRP-α antibodies and related methods
WO2019020606A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
WO2019025299A1 (en) 2017-07-31 2019-02-07 F. Hoffmann-La Roche Ag Three-dimensional structure-based humanization method
CA3057447A1 (en) 2017-08-03 2019-02-07 Alector Llc Anti-cd33 antibodies and methods of use thereof
CN116333131A (en) 2017-08-04 2023-06-27 健玛保 Binding agents that bind to PD-L1 and CD137 and uses thereof
CA3070297A1 (en) 2017-08-11 2019-02-14 Genentech, Inc. Anti-cd8 antibodies and uses thereof
EP3444275A1 (en) 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
CA3073383C (en) 2017-08-23 2023-10-31 Daiichi Sankyo Company, Limited Antibody-drug conjugate preparation and lyophilization for same
AU2018323470B2 (en) 2017-08-28 2025-04-24 Angiex, Inc. Anti-TM4SF1 antibodies and methods of using same
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
KR20200045520A (en) 2017-09-07 2020-05-04 오거스타 유니버시티 리서치 인스티튜트, 인크. Antibodies to programmed cell death protein 1
MX2020002802A (en) 2017-09-13 2020-10-12 Teneobio Inc Heavy chain antibodies binding to ectoenzymes.
US11464784B2 (en) 2017-09-15 2022-10-11 The Regents Of The University Of California Inhibition of aminocylase 3 (AA3) in the treatment of cancer
CA3075087A1 (en) 2017-09-18 2019-03-21 Sutro Biopharma, Inc. Anti- folate receptor alpha antibody conjugates and their uses
EP3684413A1 (en) 2017-09-20 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
EP3684803A1 (en) 2017-09-22 2020-07-29 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
AU2018341454B2 (en) 2017-09-26 2023-09-28 The Regents Of The University Of California Compositions and methods for treating cancer
PE20210002A1 (en) 2017-09-27 2021-01-05 Incyte Corp SALTS OF PYRROLOTRIAZINE DERIVATIVES USEFUL AS TAM INHIBITORS
JP2021502955A (en) 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド Administration regimen for the treatment of synuclein disease
CR20210381A (en) 2017-09-29 2021-09-09 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
MX2020003125A (en) 2017-09-29 2020-10-01 Daiichi Sankyo Co Ltd ANTIBODY-DERIVATE PYRROLOBENZODIAZEPINE CONJUGATE.
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
CA3076632A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
RU2698048C2 (en) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" Monoclonal antibody to il-5rα
EA039662B1 (en) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Antibodies specific to cd47 and pd-l1
CN118497126A (en) 2017-10-04 2024-08-16 赫斯佩瑞克斯股份公司 Articles and methods for personalized cancer therapy
PE20210042A1 (en) 2017-10-06 2021-01-08 Prothena Biosciences Ltd METHODS TO DETECT TRANSTIRETIN
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
JP2020536967A (en) 2017-10-12 2020-12-17 イミュノウェイク インコーポレイテッド VEGFR-antibody light chain fusion protein
CN118978600A (en) 2017-10-13 2024-11-19 哈普恩治疗公司 Trispecific proteins and methods of use
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
JP2020536894A (en) 2017-10-15 2020-12-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Tumor treatment
CN111712515A (en) 2017-10-18 2020-09-25 高山免疫科学股份有限公司 Variant ICOS ligand immunomodulatory proteins and related compositions and methods
MX2020003497A (en) 2017-10-20 2020-07-22 Hoffmann La Roche Method for generating multispecific antibodies from monospecific antibodies.
WO2019084427A1 (en) 2017-10-27 2019-05-02 Kite Pharma, Inc. T cell receptor antigen binding molecules and methods of use thereof
AU2018358883A1 (en) 2017-10-30 2020-04-23 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
SG11202003980PA (en) 2017-10-31 2020-05-28 Staten Biotechnology B V Anti-apoc3 antibodies and methods of use thereof
CA3076027A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Bispecific 2+1 contorsbodies
WO2019086497A2 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Combination therapy with targeted ox40 agonists
JP7092881B2 (en) 2017-11-01 2022-06-28 エフ.ホフマン-ラ ロシュ アーゲー TriFab Contour Body
CN111246884A (en) 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 Novel Antigen Binding Molecules Containing Trimers of TNF Family Ligands
CN111295392A (en) 2017-11-01 2020-06-16 豪夫迈·罗氏有限公司 Compbody – multivalent target conjugate
PL3707510T3 (en) 2017-11-06 2024-09-30 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for cancer
MX2020004691A (en) 2017-11-07 2020-08-20 Regeneron Pharma Hydrophilic linkers for antibody drug conjugates.
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20200085828A (en) 2017-11-08 2020-07-15 젠코어 인코포레이티드 Bispecific and monospecific antibodies using novel anti-PD-1 sequences
EP3708589A4 (en) 2017-11-08 2021-08-11 Kyowa Kirin Co., Ltd. BIS SPECIFIC ANTIBODY BINDING TO CD40 AND EPCAM
AU2018369784B2 (en) 2017-11-14 2023-06-01 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CN111655732B (en) * 2017-11-14 2023-09-12 Gc细胞治疗 anti-HER 2 antibodies or antigen binding fragments thereof and chimeric antigen receptors comprising same
US11730763B2 (en) 2017-11-14 2023-08-22 Arcellx, Inc. Multifunctional immune cell therapies
IL274652B1 (en) 2017-11-14 2025-04-01 Arcellx Inc D-domain containing polypeptides and uses thereof
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN111433223B (en) 2017-11-29 2024-08-27 诺和诺德A/S(股份有限公司) Lyophilized preparation of anti-transthyretin monoclonal antibody
KR102791781B1 (en) 2017-12-01 2025-04-09 화이자 인코포레이티드 Anti-CXCR5 antibodies and compositions and uses thereof
MX2020005640A (en) 2017-12-01 2020-08-20 Seattle Genetics Inc Humanized anti-liv1 antibodies for the treatment of breast cancer.
AR113862A1 (en) 2017-12-01 2020-06-17 Seattle Genetics Inc ANTI-CD47 ANTIBODIES AND THEIR USES TO TREAT CANCER
EP3724229A1 (en) 2017-12-11 2020-10-21 Amgen Inc. Continuous manufacturing process for bispecific antibody products
WO2019118266A1 (en) 2017-12-12 2019-06-20 Macrogenics Inc. Bispecific cd 16-binding molecules and their use in the treatment of disease
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
PE20201339A1 (en) 2017-12-19 2020-11-25 Univ Rockefeller HUMAN IGG HR DOMAIN VARIANTS WITH IMPROVED EFFECTIVE FUNCTION
IL319982A (en) 2017-12-19 2025-05-01 Akouos Inc Aav-mediated delivery of therapeutic antibodies to the inner ear
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
CA3084105A1 (en) 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Antibodies binding to hla-a2/wt1
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
KR102823263B1 (en) 2017-12-22 2025-06-24 테네오바이오, 인코포레이티드 Heavy chain antibody binding to CD22
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
JP7391868B2 (en) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス, インク. Antibody against LILRB2
CN115925943A (en) 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 Anti-PD-L1 antibodies and uses thereof
KR20200104364A (en) 2017-12-27 2020-09-03 테네오바이오, 인코포레이티드 CD3-delta/epsilon heterodimer specific antibody
WO2019129136A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anti-pd-l1 antibody and uses thereof
WO2019129137A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anti-lag-3 antibody and uses thereof
WO2019133902A2 (en) 2017-12-28 2019-07-04 Astute Medical, Inc. Antibodies and assays for ccl14
JP7314146B2 (en) 2017-12-28 2023-07-25 中外製薬株式会社 Cytotoxicity-inducing therapeutic agent
AU2018396964C1 (en) 2017-12-28 2024-10-03 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against PD-L1
JP7369127B2 (en) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー,リミテッド Single domain antibodies against TIGIT and variants thereof
TW201940518A (en) 2017-12-29 2019-10-16 美商安進公司 Bispecific antibody construct directed to MUC17 and CD3
EP3731864A1 (en) 2017-12-29 2020-11-04 F. Hoffmann-La Roche SA Anti-vegf antibodies and methods of use
EP3732193A1 (en) 2017-12-29 2020-11-04 Alector LLC Anti-tmem106b antibodies and methods of use thereof
BR112020013236A2 (en) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. immunomodulatory proteins from multiple domains and methods of their use
EP3735271A4 (en) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
SG11202006348VA (en) 2018-01-05 2020-07-29 Ac Immune Sa Misfolded tdp-43 binding molecules
AU2019205542A1 (en) 2018-01-08 2020-07-16 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
US20200339686A1 (en) 2018-01-16 2020-10-29 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
US20190225689A1 (en) 2018-01-22 2019-07-25 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-pd-1 antibodies
US11402380B2 (en) 2018-01-25 2022-08-02 Emory University Assays for detecting antibodies capable of mediating antibody-dependent cell-mediated cytotoxicity
BR112020013405A2 (en) 2018-01-25 2020-12-01 Acm Biolabs Pte Ltd. polymerosomes comprising a soluble encapsulated antigen, as well as methods of its manufacture and use
KR20200115546A (en) 2018-01-26 2020-10-07 제넨테크, 인크. IL-22 Fc fusion protein and method of use
MX2020007628A (en) 2018-01-26 2020-10-12 Genentech Inc Compositions and methods of use.
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
BR112020015641A2 (en) 2018-02-01 2021-01-05 Pfizer Inc. SPECIFIC ANTIBODIES FOR CD70 AND ITS USES
SG11202006883QA (en) 2018-02-01 2020-08-28 Pfizer Chimeric antigen receptors targeting cd70
TWI860665B (en) 2018-02-01 2024-11-01 大陸商信達生物製藥(蘇州)有限公司 Full-human anti-b cell mature antigen (bcma) single chain antibody and use thereof
CN118772288A (en) 2018-02-08 2024-10-15 豪夫迈·罗氏有限公司 Bispecific antigen binding molecules and methods of use
UY38080A (en) 2018-02-08 2019-08-30 Amgen Inc LOW PH PHARMACEUTICAL FORMULATION
BR112020016190A2 (en) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. ANTIBODY VARIABLE DOMAINS DIRECTING THE NKG2D RECEIVER
TWI829667B (en) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 Antibodies binding to gprc5d
CA3226165A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
SG11202006583VA (en) 2018-02-09 2020-08-28 Genmab As Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses
US20220211805A1 (en) 2018-02-09 2022-07-07 Acceleron Pharma Inc. Methods for treating heterotopic ossification
US11591399B2 (en) 2018-02-14 2023-02-28 Abba Therapeutics Ag Anti-human PD-L2 antibodies
US20200377609A1 (en) 2018-02-14 2020-12-03 Kite Pharma, Inc. Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
CN111787949A (en) 2018-02-15 2020-10-16 宏观基因有限公司 Variant CD3-binding domains and their use in combination therapy for the treatment of disease
MX2020008502A (en) 2018-02-21 2020-09-25 Genentech Inc DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS.
WO2019161439A1 (en) 2018-02-23 2019-08-29 Cartherics Pty. Ltd. T cell disease treatment targeting tag-72
CN111836831A (en) 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 Administration for Anti-TIGIT Antagonist Antibody and Anti-PD-L1 Antagonist Antibody Therapy
CR20230030A (en) 2018-02-27 2023-03-10 Incyte Corp Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
MX387358B (en) 2018-02-28 2025-03-18 Pfizer IL-15 VARIANTS AND THEIR USES
MA52417A (en) 2018-03-01 2021-01-06 Regeneron Pharma BODY COMPOSITION MODIFICATION PROCESSES
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
CN112105639B (en) 2018-03-05 2024-09-27 詹森药业有限公司 Anti-PHF-tau antibodies and uses thereof
US12180301B2 (en) 2018-03-06 2024-12-31 Imcare Biotech, Llc Serine protease inhibitor kazal (SPIK) compositions and methods
BR112020017701A2 (en) 2018-03-12 2020-12-29 Zoetis Services Llc ANTI-NGF ANTIBODIES AND METHODS OF THE SAME
CA3093745A1 (en) 2018-03-12 2019-09-19 Genmab A/S Antibodies
AU2019236372B2 (en) 2018-03-13 2024-06-20 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
TWI841551B (en) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 Combination therapy with targeted 4-1bb (cd137) agonists
PT3765525T (en) 2018-03-13 2023-10-03 Zymeworks Bc Inc Anti-her2 biparatopic antibody-drug conjugates and methods of use
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP4183804A1 (en) 2018-03-14 2023-05-24 Boehringer Ingelheim International GmbH Use of il-36r antibodies for treatment of inflammatory bowel disease
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
CN112119090B (en) 2018-03-15 2023-01-13 中外制药株式会社 Anti-dengue virus antibodies cross-reactive to Zika virus and methods of use
EP3768698B1 (en) 2018-03-19 2025-02-12 MultiVir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
PE20210665A1 (en) 2018-03-23 2021-03-31 Bristol Myers Squibb Co ANTIBODIES AGAINST MICA AND / OR MICB AND ITS USES
HUE062414T2 (en) 2018-03-26 2023-10-28 Glycanostics S R O Means and methods for glycoprofiling of a protein
US11993658B2 (en) 2018-03-26 2024-05-28 Sutro Biopharma, Inc. Anti-BCMA antibodies and treatment methods
EP3775184A1 (en) 2018-03-29 2021-02-17 F. Hoffmann-La Roche AG Modulating lactogenic activity in mammalian cells
PE20211235A1 (en) 2018-03-29 2021-07-08 Univ California VARIANTS OF LFA3 AND THE COMPOSITIONS AND USES OF THEM
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
JP2021519771A (en) 2018-03-30 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company How to treat a tumor
JP7104458B2 (en) 2018-04-02 2022-07-21 上海博威生物医薬有限公司 Lymphocyte activation gene-3 (LAG-3) -binding antibody and its use
TW202011029A (en) 2018-04-04 2020-03-16 美商建南德克公司 Methods for detecting and quantifying FGF21
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
US10654944B2 (en) 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
US20190330366A1 (en) 2018-04-11 2019-10-31 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
MA52231A (en) 2018-04-12 2021-02-17 Fundacio Privada Inst Catalana De Recerca I Estudis Avancats COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN THE TREATMENT OF CANCER
MX2020010732A (en) 2018-04-13 2020-11-09 Hoffmann La Roche Her2-targeting antigen binding molecules comprising 4-1bbl.
US11648317B2 (en) 2018-04-13 2023-05-16 Genentech, Inc. Stable anti-CD79B immunoconjugate formulations
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
KR20210010862A (en) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-fusion protein and PD-1 targeting heterodimer fusion protein containing PD-1 antigen binding domain and uses thereof
AU2019256529A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
AR114789A1 (en) 2018-04-18 2020-10-14 Hoffmann La Roche ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
AR115052A1 (en) 2018-04-18 2020-11-25 Hoffmann La Roche MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM
WO2019209952A2 (en) 2018-04-23 2019-10-31 Emory University Vip antagonists and uses in treating cancer
MA52366A (en) 2018-04-25 2021-03-03 Prometheus Biosciences Inc OPTIMIZED ANTI-TL1A ANTIBODIES
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
EP3784274A1 (en) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
CA3097711A1 (en) 2018-04-30 2019-11-07 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
BR112020022035A2 (en) 2018-04-30 2021-02-02 Takeda Pharmaceutical Company Limited type 1 (cb1) cannabinoid receptor binding proteins and uses thereof
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
WO2019213384A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
US12324841B2 (en) 2018-05-07 2025-06-10 Genmab A/S Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
IL278400B2 (en) 2018-05-07 2024-03-01 Genmab As Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
JP7590871B2 (en) 2018-05-09 2024-11-27 レゲネロン ファーマシューティカルス,インコーポレーテッド Anti-MSR1 antibodies and methods of use thereof
JP2021522801A (en) 2018-05-09 2021-09-02 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド Antibodies specific for humannectin 4
US11970532B2 (en) 2018-05-10 2024-04-30 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2019214624A1 (en) 2018-05-11 2019-11-14 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing same, and use thereof
EP3794031A2 (en) 2018-05-14 2021-03-24 MedImmune Limited Antibodies against lif and dosage forms thereof
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
SG11202010493XA (en) 2018-05-18 2020-11-27 Glycotope Gmbh Anti-muc1 antibody
MA52940A (en) 2018-05-18 2021-04-28 Incyte Corp FUSION PYRIMIDINE DERIVATIVES USED AS A2A / A2B INHIBITORS
WO2019226829A1 (en) 2018-05-22 2019-11-28 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
KR102584675B1 (en) 2018-05-23 2023-10-05 화이자 인코포레이티드 Antibodies specific for GUCY2c and their uses
ES2984950T3 (en) 2018-05-23 2024-10-31 Pfizer CD3-specific antibodies and their uses
KR102822623B1 (en) 2018-05-23 2025-06-20 싱가포르국립대학교 Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11202011270QA (en) 2018-05-24 2020-12-30 Janssen Biotech Inc Anti-cd3 antibodies and uses thereof
EP3802607A2 (en) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Monospecific and multispecific anti-tmeff2 antibodies and there uses
EA202092839A1 (en) 2018-05-24 2021-02-12 Янссен Байотек, Инк. PSMA LINKING AGENTS AND THEIR APPLICATIONS
SG11202011082UA (en) 2018-05-25 2020-12-30 Alector Llc Anti-sirpa antibodies and methods of use thereof
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
JP7441165B2 (en) 2018-05-28 2024-02-29 第一三共株式会社 Treatment of HER2 mutant cancer by anti-HER2 antibody-drug conjugate administration
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
US12172986B2 (en) 2018-06-01 2024-12-24 Eisai R&D Management Co., Ltd Splicing modulator antibody-drug conjugates and methods of use
WO2019232484A1 (en) 2018-06-01 2019-12-05 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
KR20210056288A (en) 2018-06-01 2021-05-18 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 Compositions for treating diseases or conditions and uses thereof
CN112867394B9 (en) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 Anti-VLA-4 antibodies with reduced effector function
WO2019235426A1 (en) 2018-06-04 2019-12-12 中外製薬株式会社 Antigen-binding molecule showing changed half-life in cytoplasm
TWI851577B (en) 2018-06-07 2024-08-11 美商思進公司 Camptothecin conjugates
JP7438988B2 (en) 2018-06-13 2024-02-27 ノバルティス アーゲー BCMA chimeric antigen receptor and its use
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
JP7511308B2 (en) 2018-06-18 2024-07-05 ユーリカ セラピューティックス, インコーポレイテッド Prostate-specific membrane antigen (psma) targeting constructs and uses thereof
JP2021529516A (en) 2018-06-18 2021-11-04 アンウィタ バイオサイエンシス, インク. Cytokine fusion protein and its use
MA52300A (en) 2018-06-18 2021-04-21 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTI-NEOPLASICS AGENTS FOR USE IN THE TREATMENT OF CANCER
KR20210030366A (en) 2018-06-20 2021-03-17 인사이트 코포레이션 Anti-PD-1 antibodies and uses thereof
MY205387A (en) 2018-06-21 2024-10-18 Regeneron Pharma Bispecific anti-psma x anti-cd28 antibodies and uses thereof
JP2021528435A (en) 2018-06-22 2021-10-21 ゲンマブ エー/エス A method for producing a controlled mixture of two or more different antibodies
US12275797B2 (en) 2018-06-22 2025-04-15 Genmab Holding B.V. Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
MX2020014091A (en) 2018-06-23 2021-05-27 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor.
TWI853822B (en) 2018-06-27 2024-09-01 台灣浩鼎生技股份有限公司 Glycosynthase variants for glycoprotein engineering and methods of use
JP7504808B2 (en) 2018-06-29 2024-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-CD40 antibodies for use in the treatment of autoimmune diseases
EP3813800B1 (en) 2018-06-29 2025-05-07 Incyte Corporation Formulations of an axl/mer inhibitor
SG11202010990TA (en) 2018-06-29 2020-12-30 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
US11884729B2 (en) 2018-06-29 2024-01-30 ApitBio, Inc Anti-L1CAM antibodies and uses thereof
CR20210047A (en) 2018-07-02 2021-05-21 Amgen Inc ANTI-STEAP1 ANTIGEN BINDING PROTEIN
JP7554742B2 (en) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス,インコーポレーテッド Anti-TCR antibody molecules and uses thereof
CN112424228B (en) 2018-07-04 2024-08-09 豪夫迈·罗氏有限公司 Novel bispecific agonistic 4-1BB antigen binding molecules
MA53097A (en) 2018-07-05 2021-05-12 Incyte Corp MERGED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN119552251A (en) 2018-07-13 2025-03-04 艾利妥 Anti-sortilin antibodies and methods of use thereof
WO2020018556A1 (en) 2018-07-16 2020-01-23 Amgen Inc. Method of treating multiple myeloma
CN112839644A (en) 2018-07-18 2021-05-25 豪夫迈·罗氏有限公司 Methods of treating lung cancer with PD-1 axis binding antagonists, antimetabolites and platinum agents
TWI838389B (en) 2018-07-19 2024-04-11 美商再生元醫藥公司 BISPECIFIC ANTI-BCMAxANTI-CD3 ANTIBODIES AND USES THEREOF
JP2021531007A (en) 2018-07-20 2021-11-18 ピエール、ファーブル、メディカマン Receptor for VISTA
TWI841577B (en) 2018-07-20 2024-05-11 美商表面腫瘤學公司 Anti-cd112r compositions and methods
SG11202011597RA (en) 2018-07-20 2020-12-30 Teneobio Inc Heavy chain antibodies binding to cd19
CN112789294A (en) 2018-07-24 2021-05-11 印希比股份有限公司 Multispecific polypeptide constructs containing constrained CD3 binding domains and receptor binding regions and methods of use thereof
US20210283269A1 (en) 2018-07-25 2021-09-16 Daiichi Sankyo Company, Limited Effective method for manufacturing antibody-drug conjugate
KR20210040059A (en) 2018-07-27 2021-04-12 다이이찌 산쿄 가부시키가이샤 Protein Recognizing the Drug Site of an Antibody-Drug Conjugate
WO2020025532A1 (en) 2018-07-30 2020-02-06 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
WO2020027100A1 (en) 2018-07-31 2020-02-06 第一三共株式会社 Treatment of metastatic brain tumor by administration of antibody-drug conjugate
SG11202013248YA (en) 2018-07-31 2021-02-25 Amgen Inc Pharmaceutical formulations of masked antibodies
TWI701041B (en) 2018-08-01 2020-08-11 日商中外製藥股份有限公司 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CN110790840A (en) 2018-08-01 2020-02-14 三生国健药业(上海)股份有限公司 Antibodies that bind to human HER2, methods of making and uses thereof
JOP20210022A1 (en) 2018-08-03 2021-01-28 Amgen Inc Antibody constructs for CLDN18.2 and CD3
EP3831854A4 (en) 2018-08-03 2022-05-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
AU2019320336B2 (en) 2018-08-06 2025-06-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and tubulin inhibitor
EA202091888A1 (en) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
UA128584C2 (en) 2018-08-10 2024-08-21 Чугаі Сейяку Кабусікі Кайся Anti-cd137 antigen-binding molecule and utilization thereof
KR20210043618A (en) 2018-08-10 2021-04-21 제넨테크, 인크. Cell culture strategies to modulate protein glycosylation
AU2019321490A1 (en) 2018-08-13 2021-02-18 Inhibrx Biosciences, Inc. Ox40-binding polypeptides and uses thereof
US12103968B2 (en) 2018-08-16 2024-10-01 The Johns Hopkins University Antibodies to human ZnT8
TW202021618A (en) 2018-08-17 2020-06-16 美商23與我有限公司 Anti-il1rap antibodies and methods of use thereof
EP3836966A4 (en) 2018-08-17 2022-06-08 Ab Studio Inc. CATALYTIC ANTIBODIES AND METHODS OF USE THEREOF
JP7481255B2 (en) 2018-08-23 2024-05-10 第一三共株式会社 Antibody-drug conjugate sensitivity markers
EA202190601A1 (en) 2018-08-23 2021-07-14 Ридженерон Фармасьютикалз, Инк. ANTI-Fc ANTIBODIES EPSILON-R1 ALPHA (FCER1A), BISPECIFIC ANTIGEN-BINDING MOLECULES BINDING FCΕR1Α AND CD3 AND THEIR APPLICATION
WO2020043670A1 (en) 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
EP3844188A1 (en) 2018-08-28 2021-07-07 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
CN113056304A (en) 2018-08-30 2021-06-29 戴埃克斯有限公司 Plasma kallikrein inhibitors for the treatment of hereditary angioedema episodes and uses thereof
MX2021002225A (en) 2018-08-30 2021-07-16 Tcr2 Therapeutics Inc COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING THROUGH THE USE OF FUSION PROTEINS.
AU2019331024A1 (en) 2018-08-31 2021-03-18 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
AU2019331018A1 (en) 2018-08-31 2021-03-11 Alector Llc Anti-cd33 antibodies and methods of use thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
BR112021003472A2 (en) 2018-09-06 2021-05-18 Daiichi Sankyo Company, Limited cyclic dinucleotide derivative and antibody-drug conjugate thereof
SG11202100888WA (en) 2018-09-07 2021-02-25 Pfizer Anti-avb8 antibodies and compositions and uses thereof
AU2019337759A1 (en) 2018-09-10 2021-03-11 Legend Biotech Ireland Limited Single-domain antibodies against CD33 and constructs thereof
EP3623383A1 (en) 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
KR20210082444A (en) 2018-09-11 2021-07-05 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 Improved anti-FLT3 antigen binding protein
EP3849600A1 (en) 2018-09-12 2021-07-21 ACM Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
WO2020056170A1 (en) 2018-09-12 2020-03-19 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
BR112021004982A2 (en) 2018-09-17 2021-06-08 Biocontac Co., Ltd. antibody, polynucleotide, expression vector, transformed cell, methods to produce an antibody, to prevent or inhibit cancer and cancer metastasis, to diagnose cancer or cancer metastasis, to treat a disease and to diagnose a disease, pharmaceutical composition, compositions for diagnosis and composition for prevention or treatment of a disease and use of the antibody
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
US20210371537A1 (en) 2018-09-18 2021-12-02 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
EP3853251A1 (en) 2018-09-19 2021-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
EP3853611A1 (en) 2018-09-19 2021-07-28 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for bladder cancer
US20220177587A1 (en) 2018-09-19 2022-06-09 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
CN112912109A (en) 2018-09-20 2021-06-04 第一三共株式会社 Treatment of HER 3-mutated cancer by administration of anti-HER 3 antibody-drug conjugates
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3853249A4 (en) * 2018-09-21 2022-06-22 The University of North Carolina at Chapel Hill SYNTHETIC BINDERS TO LIMIT PERMEATION BY SLIME
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
CN112839959A (en) 2018-09-21 2021-05-25 特尼奥生物股份有限公司 Method for purifying heterodimeric multispecific antibodies
EP3857230B1 (en) 2018-09-21 2023-06-07 F. Hoffmann-La Roche AG Diagnostic methods for triple-negative breast cancer
CN120058958A (en) 2018-09-24 2025-05-30 视点制药公司 Multispecific antibodies targeting HPTP-beta (VE-PTP) and VEGF
EP3856343A1 (en) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
IL297931B2 (en) 2018-09-25 2025-03-01 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
CA3113541A1 (en) 2018-09-26 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
KR20210086619A (en) 2018-09-27 2021-07-08 셀진 코포레이션 SIRPα binding protein and methods of use thereof
US11208487B2 (en) 2018-09-27 2021-12-28 Tizona Therapeutics Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
TW202028239A (en) 2018-09-28 2020-08-01 美商安進公司 Antibodies against soluble bcma
US20210380675A1 (en) 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
JP2022511396A (en) 2018-10-01 2022-01-31 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antigen-binding molecule with trivalent binding to CD40
AU2019355252A1 (en) 2018-10-01 2021-04-01 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-FAP clone 212
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
AU2019352017A1 (en) 2018-10-03 2021-05-06 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
BR112021006055A2 (en) 2018-10-04 2021-07-20 Genmab Holding B.V. pharmaceutical composition, use of the pharmaceutical composition, and, methods for inducing cell death or for inhibiting the growth and/or proliferation of a tumor cell and for treating an individual.
US20220010020A1 (en) 2018-10-05 2022-01-13 Five Prime Therapeutics, Inc. Anti-FGFR2 Antibody Formulations
CN112823168A (en) 2018-10-08 2021-05-18 苏黎世大学 Tetrameric polypeptide that binds HER2
US20200109200A1 (en) 2018-10-09 2020-04-09 Genentech, Inc. Methods and systems for determining synapse formation
JP7644706B2 (en) 2018-10-11 2025-03-12 アムジエン・インコーポレーテツド Downstream processing of bispecific antibody constructs
EP3864044A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
CA3115285A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
WO2020076992A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
JP7627210B2 (en) 2018-10-15 2025-02-07 ジェネンテック, インコーポレイテッド Methods of treating residual breast cancer with trastuzumab emtansine
JP2022512744A (en) 2018-10-18 2022-02-07 ジェネンテック, インコーポレイテッド Diagnosis and treatment for sarcomatoid kidney cancer
MA53933A (en) 2018-10-21 2021-08-25 Slsg Ltd Llc MULTI-IMMUNOTHERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
CN113056287A (en) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 Conjugated chemical degradation inducers and methods of use
WO2020086328A1 (en) 2018-10-25 2020-04-30 The Medical College Of Wisconsin, Inc. Targeting clptm1l for treatment and prevention of cancer
AU2019367218A1 (en) 2018-10-26 2021-06-03 TeneoFour, Inc. Heavy chain antibodies binding to CD38
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
TWI844571B (en) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
EP3873944A1 (en) 2018-10-31 2021-09-08 Bayer Aktiengesellschaft Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
RU2724469C2 (en) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds to cd20
EP3877407A1 (en) 2018-11-05 2021-09-15 F. Hoffmann-La Roche AG Methods of producing two chain proteins in prokaryotic host cells
EP3877413A1 (en) 2018-11-06 2021-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
JP7527281B2 (en) 2018-11-06 2024-08-02 ジェンマブ エー/エス Antibody preparations
HU231514B1 (en) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell culture
BR112021008624A2 (en) 2018-11-08 2021-09-28 Prothena Biosciences Limited ANTIBODIES THAT RECOGNIZE TAU
CA3118966A1 (en) 2018-11-15 2020-05-22 Byondis B.V. Humanized anti-sirpa antibodies
WO2020102555A1 (en) 2018-11-16 2020-05-22 Memorial Sloan Kettering Cancer Center Antibodies to mucin-16 and methods of use thereof
AU2019385497A1 (en) 2018-11-20 2021-06-17 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
EP3884276A2 (en) 2018-11-23 2021-09-29 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
PE20211786A1 (en) 2018-11-26 2021-09-09 Forty Seven Inc HUMANIZED ANTIBODIES AGAINST C-KIT
WO2020112870A1 (en) 2018-11-28 2020-06-04 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
KR20210135987A (en) 2018-11-30 2021-11-16 알파인 이뮨 사이언시즈, 인코포레이티드 CD86 variant immunomodulatory protein and uses thereof
IL283522B2 (en) 2018-12-03 2025-03-01 Agensys Inc Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
EP3891186A1 (en) 2018-12-05 2021-10-13 MorphoSys AG Multispecific antigen-binding molecules
AU2018451747A1 (en) 2018-12-06 2021-06-17 F. Hoffmann-La Roche Ag Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
WO2020118293A2 (en) 2018-12-07 2020-06-11 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
US20200207812A1 (en) 2018-12-07 2020-07-02 Coherus Biosciences, Inc. Methods for producing recombinant proteins
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
BR112021011119A2 (en) 2018-12-11 2022-01-25 Daiichi Sankyo Co Ltd pharmaceutical composition
MX2021005878A (en) 2018-12-13 2021-07-16 Eisai R&D Man Co Ltd Herboxidiene splicing modulator antibody-drug conjugates and methods of use.
IL283890B1 (en) 2018-12-14 2025-07-01 Boehringer Ingelheim Io Canada Inc Anti-periostin antibodies and uses thereof
EP3894543A1 (en) 2018-12-14 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
US20220025055A1 (en) 2018-12-18 2022-01-27 Boehringer Ingelheim Io Canada, Inc. Flt3 agonist antibodies and uses thereof
EP3898688A1 (en) 2018-12-18 2021-10-27 Catapult Therapeutics B.V. The use of anti-ccr7 mabs for the prevention or treatment of graft-versus-host disease (gvhd)
EA202191580A1 (en) 2018-12-19 2021-11-01 Ридженерон Фармасьютикалз, Инк. SPECIFIC ANTI-CD28 X ANTI-CD22 ANTI-BODIES AND THEIR APPLICATION
KR20210104758A (en) 2018-12-19 2021-08-25 리제너론 파아마슈티컬스, 인크. Bispecific anti-MUC16 X anti-CD28 antibodies and uses thereof
AR117327A1 (en) 2018-12-20 2021-07-28 23Andme Inc ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM
CA3124356A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
WO2020132230A2 (en) 2018-12-20 2020-06-25 Genentech, Inc. Modified antibody fcs and methods of use
WO2020130125A1 (en) 2018-12-21 2020-06-25 第一三共株式会社 Combination of antibody-drug conjugate and kinase inhibitor
AR117728A1 (en) 2018-12-21 2021-08-25 Hoffmann La Roche CD28 ANTIGEN BINDING SUPERAGONIST MOLECULES WITH TUMOR TARGET
EP3897845A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional molecule directed against human pd-1
CA3123338A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
AR117468A1 (en) 2018-12-21 2021-08-11 Hoffmann La Roche ANTIBODY JOINING VEGF AND IL-1b AND METHODS OF USE
AU2019403404B2 (en) 2018-12-21 2025-05-29 Regeneron Pharmaceuticals, Inc. Rifamycin analogs and antibody-drug conjugates thereof
EA202191763A1 (en) 2018-12-21 2022-03-10 Озе Иммьюнотерапьютикс BIFUNCTIONAL ANTI-PD-1/SIRP MOLECULE
CN111349162A (en) 2018-12-21 2020-06-30 神州细胞工程有限公司 Humanized anti-PD-1 antibodies and uses thereof
SG11202102859TA (en) 2018-12-21 2021-04-29 Hoffmann La Roche Antibodies binding to cd3
MX2021007320A (en) 2018-12-21 2021-07-07 Hoffmann La Roche Tumor-targeted agonistic cd28 antigen binding molecules.
CN113454113A (en) 2018-12-21 2021-09-28 23与我公司 Antibodies to IL-36 and methods of use thereof
SG11202106116QA (en) 2018-12-21 2021-07-29 Genentech Inc Methods of producing polypeptides using a cell line resistant to apoptosis
US20220064301A1 (en) 2018-12-26 2022-03-03 Xilio Development, Inc. Anti-ctla4 antibodies and methods of use thereof
WO2020141145A1 (en) 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Anti-rabbit cd19 antibodies and methods of use
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
TWI874345B (en) 2019-01-07 2025-03-01 美商因荷布瑞克斯生物科學公司 Polypeptides comprising modified il-2 polypeptides and uses thereof
TWI852977B (en) 2019-01-10 2024-08-21 美商健生生物科技公司 Prostate neoantigens and their uses
US20220112283A1 (en) 2019-01-13 2022-04-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human nectin-2
TW202515617A (en) 2019-01-14 2025-04-16 美商建南德克公司 Rna molecules for use in cancer therapies
CN111434692B (en) 2019-01-15 2021-12-31 浙江道尔生物科技有限公司 Anti-CLD18A2 Nanobody and Its Application
CN113645953B (en) 2019-01-17 2025-03-25 英美偌科有限公司 Formulations
CN113330030A (en) 2019-01-17 2021-08-31 拜耳公司 Method for determining whether a subject is suitable for treatment with an agonist of soluble guanylate cyclase (sGC)
BR112021014276A2 (en) 2019-01-22 2021-09-28 Genentech, Inc. ISOLATED IGA ANTIBODIES, ISOLATED IGG-IGA FUSION MOLECULES, ISOLATED NUCLEIC ACID, HOST CELL, METHOD FOR PRODUCING AN ANTIBODY, TO TREAT AN INDIVIDUAL, TO INCREASE THE EXPRESSION OF DIMERS, TRIMERS OR TETRAMERS, TO INCREASE THE PRODUCTION OF POLYMERS, TO INCREASE The production of dimers, to increase the production of a polymer, to decrease the production of polymers, to increase the transient expression of an antibody, to express dimers of fusion molecules, to express dimers, trimers or tetramers, to purify an antibody, TO PURIFY AN OLIOMER STATE OF AN ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF THE ANTIBODY
CN120248098A (en) 2019-01-23 2025-07-04 豪夫迈·罗氏有限公司 Method for producing multimeric proteins in eukaryotic host cells
JP7538130B2 (en) 2019-01-23 2024-08-21 タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド Anti-PD-L1 diabodies and uses thereof
EP3914616A1 (en) 2019-01-23 2021-12-01 Encefa Cd31 competitors and uses thereof
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
WO2022080481A1 (en) 2020-10-16 2022-04-21 日本メジフィジックス株式会社 Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
EP3915581A4 (en) 2019-01-24 2023-03-22 Chugai Seiyaku Kabushiki Kaisha Novel cancer antigens and antibodies of said antigens
AU2020216295A1 (en) 2019-01-28 2021-09-09 Maple Biotech Llc PSMP antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
JP2020117502A (en) 2019-01-28 2020-08-06 ファイザー・インク Method of treating signs and symptoms of osteoarthritis
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
JP2022519273A (en) 2019-02-05 2022-03-22 シージェン インコーポレイテッド Anti-CD228 antibody and antibody drug conjugate
CN113412121A (en) 2019-02-12 2021-09-17 瑞泽恩制药公司 Compositions and methods for binding complement and target antigens using bispecific antibodies
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN113423730B (en) 2019-02-15 2024-01-05 上海药明合联生物技术有限公司 Method for preparing antibody-drug conjugates with improved homogeneity
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
TWI857009B (en) 2019-02-15 2024-10-01 大學健康網絡 Fcmr-binding molecules and uses thereof
EP3927430A1 (en) 2019-02-18 2021-12-29 Pfizer Inc. Method of treatment of chronic low back pain
EP3927371A1 (en) 2019-02-22 2021-12-29 Novartis AG Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
AU2020228033A1 (en) 2019-02-26 2021-09-16 Inspirna, Inc. High-affinity anti-MERTK antibodies and uses thereof
KR20210133237A (en) 2019-02-27 2021-11-05 제넨테크, 인크. Dosing for treatment with anti-TIGIT and anti-CD20 or anti-CD38 antibodies
MX2021010441A (en) 2019-03-01 2021-09-21 Allogene Therapeutics Inc CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS DIRECTED TO DLL3.
MX2021010390A (en) 2019-03-01 2021-11-17 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3.
CA3131953A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
CN111670201A (en) 2019-03-01 2020-09-15 荣昌生物制药(烟台)股份有限公司 Her2 concomitant diagnosis immunohistochemical detection antibody and application thereof
CN113544149B (en) 2019-03-03 2024-11-15 普罗塞纳生物科学有限公司 Antibodies that recognize tau
KR20210138588A (en) 2019-03-08 2021-11-19 제넨테크, 인크. Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
EP3938396A1 (en) 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
CR20210467A (en) 2019-03-14 2021-10-07 Genentech Inc Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
WO2020186132A1 (en) 2019-03-14 2020-09-17 Dyax Corp. Treating hereditary angioedema attack with reduced dosage of antibodies binding to human plasma kallikrein
KR20210144679A (en) 2019-03-21 2021-11-30 알로젠 테라퓨틱스 인코포레이티드 How to Improve TCRαβ+ Cell Depletion Efficiency
WO2020196475A1 (en) 2019-03-25 2020-10-01 第一三共株式会社 Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
TWI856078B (en) 2019-03-25 2024-09-21 日商第一三共股份有限公司 Antibody-pyrrolobenzodiazepine derivative conjugate, preparation method thereof and use thereof
US20220168438A1 (en) 2019-03-27 2022-06-02 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
KR20220047536A (en) 2019-04-01 2022-04-18 레이크파르마, 인코퍼레이티드 BTLA-binding (CD272) antibody for modulation of immune response and treatment of disease
HU231498B1 (en) 2019-04-04 2024-05-28 Richter Gedeon Nyrt Development of affinity chromatography of immunoglobulins using pre-binding flocculation
AU2020252556A1 (en) 2019-04-05 2021-10-21 Teneobio, Inc. Heavy chain antibodies binding to PSMA
JP7301155B2 (en) 2019-04-12 2023-06-30 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antigen-binding molecules containing lipocalin muteins
US20220218785A1 (en) 2019-04-17 2022-07-14 Alpine Immune Sciences, Inc. Methods and uses of variant icos ligand (icosl) fusion proteins
JP2022528804A (en) 2019-04-18 2022-06-15 ジェネンテック, インコーポレイテッド Antibody titer test
US20220143094A1 (en) 2019-04-19 2022-05-12 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor that recognizes engineered site in antibody
WO2020214937A1 (en) 2019-04-19 2020-10-22 Allogene Therapeutics, Inc. Antibodies against 4g7-derived chimeric antigen receptors
CN113747944A (en) 2019-04-19 2021-12-03 詹森生物科技公司 Methods of treating prostate cancer with anti-PSMA/CD 3 antibodies
BR112021020867A2 (en) 2019-04-19 2022-01-04 Genentech Inc Antibodies, nucleic acid, vector, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, uses of the antibody, method of treating an individual with cancer, and method of reducing clearance
RU2734432C1 (en) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds gitr
JP7650818B2 (en) 2019-04-26 2025-03-25 アロジーン セラピューティクス,インコーポレイテッド Methods for Producing Allogeneic CAR T Cells
CN113728003A (en) 2019-04-30 2021-11-30 吉加根公司 Recombinant polyclonal proteins and methods of use thereof
CA3134918A1 (en) 2019-05-03 2020-11-12 John Lee Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same
CN114269376A (en) 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 Methods of treating cancer with anti-PD-L1 antibodies
EP3962951A1 (en) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
CN114040926A (en) 2019-05-04 2022-02-11 印希比股份有限公司 Polypeptides that bind CD123 and uses thereof
WO2020227072A1 (en) 2019-05-04 2020-11-12 Inhibrx, Inc. Cd33-binding polypeptides and uses thereof
KR20220004751A (en) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a binding polypeptides and uses thereof
JP2022531894A (en) 2019-05-09 2022-07-12 ゲンマブ ビー.ブイ. Administration regimen of anti-DR5 antibody combination for use in the treatment of cancer
EP3966239A1 (en) 2019-05-09 2022-03-16 Boehringer Ingelheim International GmbH Anti-sema3a antibodies and their uses for treating eye or ocular diseases
US20220409734A1 (en) 2019-05-10 2022-12-29 Yutaka Nishimoto Antibody drug conjugates
WO2020231954A1 (en) 2019-05-10 2020-11-19 The University Of North Carolina At Chapel Hill Office Of Technology Commercialization Methods, systems, and computer readable media for generating images of microvasculature using ultrasound
BR112021022815A2 (en) 2019-05-14 2021-12-28 Genentech Inc Methods to treat follicular lymphoma, kits, immunoconjugates and polatuzumab vedotin
PH12021552831A1 (en) 2019-05-20 2023-01-16 Servier Lab Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP3959293B1 (en) 2019-05-20 2024-11-13 NIRvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
BR112021023048A2 (en) 2019-05-21 2022-04-19 Novartis Ag cd19 binding molecules and uses thereof
TWI762925B (en) 2019-05-21 2022-05-01 美商基利科學股份有限公司 Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
SG11202112453TA (en) 2019-05-23 2021-12-30 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
WO2020238730A1 (en) 2019-05-24 2020-12-03 三优生物医药(上海)有限公司 Novel cldn18.2 binding molecule
JP7313730B2 (en) * 2019-05-29 2023-07-25 ヘッジホッグ,インコーポレイテッド Antibody with improved endothelin receptor A binding ability
AR119264A1 (en) 2019-06-05 2021-12-09 Genentech Inc METHOD FOR REUSE OF CHROMATOGRAPHY
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CA3142440A1 (en) 2019-06-07 2020-12-10 Amgen Inc. Bispecific binding constructs
KR20220031616A (en) 2019-06-11 2022-03-11 알렉터 엘엘씨 Anti-Sortilin Antibodies for Use in Therapy
JP7580406B2 (en) 2019-06-13 2024-11-11 アロジーン セラピューティクス,インコーポレイテッド Anti-TALEN Antibodies and Uses Thereof
KR20220034784A (en) 2019-06-13 2022-03-18 볼트 바이오테라퓨틱스 인코퍼레이티드 Aminobenzazepine compounds, immunoconjugates, and uses thereof
WO2020252442A1 (en) 2019-06-13 2020-12-17 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
CR20210622A (en) 2019-06-14 2022-06-27 Teneobio Inc Multispecific heavy chain antibodies binding to cd22 and cd3
EP3986933A1 (en) 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
JP2022537269A (en) 2019-06-21 2022-08-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Use of Bispecific Antigen Binding Molecules that Bind MUC16 and CD3 in Combination with 4-1BB Costimulation
MX2021015888A (en) 2019-06-26 2022-03-22 Hoffmann La Roche Fusion of an antibody binding cea and 4-1bbl.
TWI877179B (en) 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 Anti-angpt2 antibodies
JP7354306B2 (en) 2019-06-27 2023-10-02 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Novel ICOS antibodies and tumor-targeting antigen-binding molecules containing them
MX2021015694A (en) 2019-06-28 2022-03-11 Genentech Inc COMPOSITION AND METHODS FOR STABILIZING LIQUID PROTEIN FORMULATIONS.
BR112021026410A2 (en) 2019-07-01 2022-02-08 Tonix Pharma Ltd Anti-cd154 antibodies and uses thereof
JP2022538139A (en) 2019-07-02 2022-08-31 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Immune complex comprising mutant interleukin-2 and anti-CD8 antibody
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
WO2021007338A1 (en) 2019-07-08 2021-01-14 Imcare Biotech, Llc. Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
AU2020309958A1 (en) 2019-07-10 2021-12-23 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
WO2021005232A1 (en) 2019-07-11 2021-01-14 Umc Utrecht Holding B.V. Intranasal administration of neutralising antiviral antibodies
AR119382A1 (en) 2019-07-12 2021-12-15 Hoffmann La Roche PRE-TARGETING ANTIBODIES AND METHODS OF USE
JPWO2021010326A1 (en) 2019-07-12 2021-01-21
AR119393A1 (en) 2019-07-15 2021-12-15 Hoffmann La Roche ANTIBODIES THAT BIND NKG2D
US20220273809A1 (en) 2019-07-19 2022-09-01 Genmab A/S Axl antibody-drug conjugates for use in treating cancer
EP4043490A4 (en) 2019-07-19 2023-08-16 Sinocelltech Ltd. HUMANIZED ANTI-VEGF FAB ANTIBODY FRAGMENT AND USE THEREOF
EP4001306A4 (en) 2019-07-19 2023-11-15 Sinocelltech Ltd. Humanized anti-vegf monoclonal antibody
US20210030885A1 (en) 2019-07-22 2021-02-04 Seagen Inc. Humanized anti-liv1 antibodies for the treatment of cancer
WO2021016598A1 (en) 2019-07-25 2021-01-28 Immunowake Inc. Methods of measuring cell-mediated killing by effectors
CA3148591A1 (en) 2019-07-26 2021-02-04 Amgen Inc. Anti-il13 antigen binding proteins
BR112022001492A2 (en) 2019-07-26 2022-03-22 Sinocelltech Ltd Humanized anti-il17a antibody and use thereof
CN112300279A (en) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 Methods and compositions directed to anti-CD 73 antibodies and variants
MX2022001049A (en) 2019-07-26 2022-05-03 Janssen Biotech Inc PROTEINS COMPRISING DOMAINS BINDING TO THE KALLYCHREIN-RELATED PEPTIDASE 2 ANTIGEN AND THEIR USES.
KR20220038415A (en) 2019-07-26 2022-03-28 벤더르빌트 유니버시티 Human monoclonal antibody to enterovirus D68
US20230374130A1 (en) 2019-07-30 2023-11-23 Qlsf Biotherapeutics, Inc. Bispecific anti lrrc15 and cd3epsilon antibodies
AU2020319677A1 (en) 2019-07-31 2022-01-06 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab
JP2022543551A (en) 2019-07-31 2022-10-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Antibody that binds to GPRC5D
WO2021022083A2 (en) 2019-07-31 2021-02-04 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
EP4003409A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
JP2022543553A (en) 2019-07-31 2022-10-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Antibody that binds to GPRC5D
PH12022550246A1 (en) 2019-08-01 2023-06-26 Incyte Corp A dosing regimen for an ido inhibitor
TWI832183B (en) 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 Antibodies that bind to pathological tau species and uses thereof
WO2021023860A1 (en) 2019-08-07 2021-02-11 Db Biotech, As Improved horseradish peroxidase polypeptides
KR20220116575A (en) 2019-08-12 2022-08-23 비온드 바이오로직스 엘티디 Antibodies against ilt2 and use thereof
AU2020328507A1 (en) 2019-08-12 2022-03-17 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
MX2022001882A (en) 2019-08-12 2022-05-30 Aptevo Res & Development Llc 4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40.
CN114555118A (en) 2019-08-15 2022-05-27 健玛保 Pharmaceutical compositions comprising bispecific antibodies against CD3 and CD20 and uses thereof
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2020335928A1 (en) 2019-08-30 2022-02-17 Agenus Inc. Anti-CD96 antibodies and methods of use thereof
US20220313835A1 (en) 2019-09-03 2022-10-06 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
KR20220084033A (en) 2019-09-04 2022-06-21 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Antibodies specific for IL20-RB and use thereof for treating acute exacerbation of chronic obstructive pulmonary disease
US20220332799A1 (en) 2019-09-04 2022-10-20 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
EP4028416A1 (en) 2019-09-10 2022-07-20 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
US20240043512A1 (en) 2019-09-11 2024-02-08 Imcare Biotech, Llc Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
US20230257479A1 (en) 2019-09-12 2023-08-17 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
WO2021050645A1 (en) 2019-09-12 2021-03-18 Genentech, Inc. Compositions and methods of treating lupus nephritis
KR20220064983A (en) 2019-09-18 2022-05-19 노파르티스 아게 NKG2D fusion protein and uses thereof
WO2021055577A2 (en) 2019-09-18 2021-03-25 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
RU2753282C2 (en) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
JP2022549218A (en) 2019-09-20 2022-11-24 ジェネンテック, インコーポレイテッド Anti-tryptase antibody medication
TWI859339B (en) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 Anti-nrp1a antibodies and their uses for treating eye or ocular diseases
TWI764291B (en) 2019-09-24 2022-05-11 財團法人工業技術研究院 Anti-tigit antibodies and methods of use
KR20220088428A (en) 2019-09-26 2022-06-27 주식회사 에스티큐브앤컴퍼니 Antibodies specific for glycosylated CTLA-4 and methods of use thereof
PE20221110A1 (en) 2019-09-27 2022-07-11 Genentech Inc DOSE ADMINISTRATION FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES
CN114746119A (en) 2019-09-27 2022-07-12 詹森生物科技公司 Anti-CEACAM antibodies and uses thereof
EP4036116A4 (en) 2019-09-27 2024-01-24 Nanjing GenScript Biotech Co., Ltd. Anti-vhh domain antibodies and use thereof
WO2021067242A1 (en) 2019-09-30 2021-04-08 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
US20220363753A1 (en) 2019-09-30 2022-11-17 Nekonal S.A.R.L. Anti-tirc7 antigen binding proteins
WO2021067863A2 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
US20210101982A1 (en) 2019-10-04 2021-04-08 Seattle Genetics, Inc. Anti-pd-l1 antibodies and antibody-drug conjugates
EP4037710A1 (en) 2019-10-04 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
BR112022006620A2 (en) 2019-10-08 2022-08-30 Nectin Therapeutics Ltd ANTIBODIES AGAINST POLYOVIRUS RECEPTOR (PVR) AND THEIR USES
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3152623A1 (en) 2019-10-11 2021-04-15 Richard D. Cummings Anti-tn antibodies and uses thereof
WO2021072210A1 (en) 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Methods of purifying ranibizumab or a ranibizumab variant
WO2021072182A1 (en) 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Methods for producing ranibizumab
MX2022004443A (en) 2019-10-18 2022-05-02 Genentech Inc Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma.
US20220396628A1 (en) 2019-10-23 2022-12-15 Kite Pharma, Inc. Anti-idiotypic antigen binding molecules and methods of use thereof
KR20220103721A (en) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Humanized Antibodies to TNF-Like Ligand 1A (TL1A) and Uses Thereof
TWI857167B (en) 2019-10-25 2024-10-01 美商博特生物治療公司 Thienoazepine immunoconjugates, and uses thereof
KR20220121792A (en) 2019-11-04 2022-09-01 씨젠 인크. Anti-CD30 antibody-drug conjugates and their use for the treatment of HIV infection
US20220378909A1 (en) 2019-11-05 2022-12-01 Jounce Therapeutics, Inc. Methods of Treating Cancer with Anti-PD-1 Antibodies
IL292757A (en) 2019-11-05 2022-07-01 Merck Patent Gmbh Tigit antibodies and their uses
CN115066613A (en) 2019-11-06 2022-09-16 基因泰克公司 Diagnostic and therapeutic methods for treating hematologic cancers
TW202131954A (en) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
US20230027495A1 (en) 2019-11-07 2023-01-26 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
MX2022005676A (en) 2019-11-13 2022-10-27 Amunix Pharmaceuticals Inc Barcoded xten polypeptides and compositions thereof, and methods for making and using the same.
EP4058485A1 (en) 2019-11-13 2022-09-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
CN114945369A (en) 2019-11-15 2022-08-26 思进公司 Method of combining tucatinib and anti-HER2 antibody-drug conjugates for the treatment of HER2-positive breast cancer
BR112022008172A2 (en) 2019-11-15 2022-07-12 Hoffmann La Roche STABLE AQUEOUS COMPOSITION, METHOD TO OBTAIN A PHARMACEUTICAL COMPOSITION AND DOSAGE FORM
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
EP4069736A1 (en) 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
CN115335399A (en) 2019-12-06 2022-11-11 朱诺治疗学股份有限公司 Anti-idiotype antibodies directed against GPRC5D target binding domains and related compositions and methods
EP4069741A1 (en) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
WO2021113701A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
CR20220329A (en) 2019-12-13 2022-11-23 Alector Llc Anti-mertk antibodies and methods of use thereof
CR20230210A (en) 2019-12-13 2023-06-14 Genentech Inc Anti-ly6g6d antibodies and methods of use
WO2021124073A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
US11987632B2 (en) 2019-12-18 2024-05-21 Hoffmann-La Roche Inc. Antibodies binding to HLA-A2/MAGE-A4
EP4077391A1 (en) 2019-12-18 2022-10-26 Teneofour, Inc. Heavy chain antibodies binding to cd38
JP2023506956A (en) 2019-12-20 2023-02-20 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト IL-37 fusion proteins and uses thereof
IL293626A (en) 2019-12-20 2022-08-01 Pfizer Treatment with antibody-drug conjugates specific for the her2 site
AR120832A1 (en) 2019-12-20 2022-03-23 Amgen Inc MULTISPECIFIC ANTIBODY CONSTRUCTS CD40 AGONISTS TARGETING MESOTHELIN FOR THE TREATMENT OF SOLID TUMORS
CN114828895A (en) 2019-12-23 2022-07-29 卫材R&D管理有限公司 Method for preparing eribulin-based antibody-drug conjugates
CA3165504A1 (en) 2019-12-23 2021-07-01 Genentech, Inc. Apolipoprotein l1-specific antibodies and methods of use
CN113045655A (en) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 anti-OX 40 antibodies and uses thereof
KR20220119467A (en) 2019-12-27 2022-08-29 아피메트 게엠베하 Methods of making the bispecific FCYRIII X CD30 antibody construct
KR20240035914A (en) 2019-12-27 2024-03-18 추가이 세이야쿠 가부시키가이샤 Anti-ctla-4 antibody and use thereof
TWI877278B (en) 2019-12-30 2025-03-21 美商思進公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
US20210205311A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
CN114929278A (en) 2020-01-06 2022-08-19 瓦西尼斯公司 anti-CCR 8 antibodies and uses thereof
CN115243763A (en) 2020-01-08 2022-10-25 里珍纳龙药品有限公司 Treatment of fibrodysplasia ossificans progressiva
EP4087866A1 (en) 2020-01-09 2022-11-16 F. Hoffmann-La Roche AG New 4-1bbl trimer-containing antigen binding molecules
CN110818795B (en) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 anti-TIGIT antibodies and methods of use
JP2023510854A (en) 2020-01-13 2023-03-15 武田薬品工業株式会社 Plasma kallikrein inhibitors and their use for treating pediatric hereditary angioedema attacks
EP4090681A1 (en) 2020-01-17 2022-11-23 Biolegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
EP4093771A1 (en) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
WO2021148983A1 (en) 2020-01-24 2021-07-29 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CA3168832A1 (en) 2020-01-29 2021-08-05 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
EP4097143A1 (en) 2020-01-31 2022-12-07 The Cleveland Clinic Foundation Anti-müllerian hormone receptor 2 antibodies and methods of use
CA3169661A1 (en) 2020-01-31 2021-08-05 Celgene Corporation Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
CN115397459A (en) 2020-01-31 2022-11-25 基因泰克公司 Methods for Inducing Neoepitope-Specific T Cells Using PD-1 Axis Binding Antagonists and RNA Vaccines
EP4100059A1 (en) 2020-02-04 2022-12-14 Genmab A/S Antibodies for use in therapy
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
AU2021220887B2 (en) 2020-02-10 2024-11-21 Shanghai Escugen Biotechnology Co., Ltd. CLDN18.2 antibody and use thereof
EP4105238A4 (en) 2020-02-10 2024-03-27 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
IL295310A (en) 2020-02-11 2022-10-01 Univ Vanderbilt Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
TW202144395A (en) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 Anti-CD137 antigen-binding molecule for use in cancer treatment
TW202140012A (en) 2020-02-12 2021-11-01 比利時商健生藥品公司 Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma
TW202144388A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in ovarian cancer and their uses
TW202144389A (en) 2020-02-14 2021-12-01 美商健生生物科技公司 Neoantigens expressed in multiple myeloma and their uses
IL295023A (en) 2020-02-14 2022-09-01 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and their uses
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
JP2023527609A (en) 2020-02-21 2023-06-30 ハープーン セラピューティクス,インク. FLT3 binding proteins and methods of use
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
WO2021173844A1 (en) 2020-02-26 2021-09-02 Biograph 55, Inc. C19 c38 bispecific antibodies
WO2021170067A1 (en) 2020-02-28 2021-09-02 上海复宏汉霖生物技术股份有限公司 Anti-cd137 construct and use thereof
JP2023516941A (en) 2020-02-28 2023-04-21 上海復宏漢霖生物技術股▲フン▼有限公司 Anti-CD137 constructs, multispecific antibodies and uses thereof
CA3169523A1 (en) 2020-02-28 2021-09-02 Jaume Pons Transglutaminase-mediated conjugation
MX2022010860A (en) 2020-03-06 2022-12-02 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors.
CN115768465A (en) 2020-03-06 2023-03-07 Ona疗法有限公司 anti-CD 36 antibodies and their use to treat cancer
CA3168173A1 (en) 2020-03-06 2021-09-10 Robert Babb Anti-gitr antibodies and uses thereof
EP4118105A2 (en) 2020-03-09 2023-01-18 Pfizer Inc. Cd80-fc fusion protein and uses thereof
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
PE20240020A1 (en) 2020-03-13 2024-01-04 Janssen Biotech Inc MATERIALS AND METHODS FOR THE UNION OF SIGLEC-3/CD33
AU2021236306A1 (en) 2020-03-13 2022-09-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN115298221A (en) 2020-03-18 2022-11-04 健玛保 Antibodies that bind B7H4
WO2021188749A1 (en) 2020-03-19 2021-09-23 Genentech, Inc. Isoform-selective anti-tgf-beta antibodies and methods of use
CN115427454A (en) 2020-03-19 2022-12-02 安进公司 Antibodies against mucin 17 and uses thereof
BR112022018847A2 (en) 2020-03-24 2022-11-22 Genentech Inc ANTIBODIES, NUCLEIC ACID, HOST CELL, CONJUGATES, PHARMACEUTICAL COMPOSITION, LONG-ACTION DELIVERY DEVICE FOR OCULAR DELIVERY, METHOD FOR TREAT A DISORDER AND USE OF THE ANTIBODY
CA3176257A1 (en) 2020-03-26 2021-09-30 Seagen Inc. Methods of treating multiple myeloma
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
TW202202620A (en) 2020-03-26 2022-01-16 美商建南德克公司 Modified mammalian cells
PT4045533T (en) 2020-03-26 2024-02-14 Univ Vanderbilt Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
WO2021198034A1 (en) 2020-03-30 2021-10-07 F. Hoffmann-La Roche Ag Antibody that binds to vegf and pdgf-b and methods of use
WO2021202590A1 (en) 2020-03-31 2021-10-07 Alector Llc Anti-mertk antibodies and methods of use thereof
AR121706A1 (en) 2020-04-01 2022-06-29 Hoffmann La Roche OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES
US20230107644A1 (en) 2020-04-01 2023-04-06 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2021202948A2 (en) 2020-04-04 2021-10-07 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
US20230183342A1 (en) 2020-04-06 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
KR20210124867A (en) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
EP4132576A1 (en) 2020-04-09 2023-02-15 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
WO2021204998A1 (en) 2020-04-10 2021-10-14 Heidelberg Immunotherapeutics Gmbh Natural antibodies in prophylaxis and therapy
CA3168460A1 (en) 2020-04-15 2021-10-21 F. Hoffmann-La Roche Ag Immunoconjugates
US11701427B2 (en) 2020-04-16 2023-07-18 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
CN115843268A (en) 2020-04-17 2023-03-24 纽约大学 Therapeutic MuSK antibodies
CA3173134A1 (en) 2020-04-20 2021-10-28 Jounce Therapeutics, Inc. Compositions and methods for vaccination and the treatment of infectious diseases
AU2021259861A1 (en) 2020-04-24 2022-11-17 Genentech, Inc. Methods of using anti-CD79b immunoconjugates
WO2021222181A2 (en) 2020-04-27 2021-11-04 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
KR20230003114A (en) 2020-04-28 2023-01-05 사이노셀테크 엘티디. TGFβR2 extracellular domain truncated molecule, fusion protein of TGFβR2 extracellular domain truncated molecule and anti-EGFR antibody, and anti-tumor use of fusion protein
WO2021222167A1 (en) 2020-04-28 2021-11-04 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
MX2021015024A (en) 2020-04-28 2022-01-18 Univ Rockefeller Neutralizing anti-sars-cov-2 antibodies and methods of use thereof.
CN115715220A (en) 2020-04-29 2023-02-24 特尼奥生物股份有限公司 Multispecific heavy chain antibodies with modified heavy chain constant regions
UY39191A (en) 2020-04-29 2021-11-30 Teneobio Inc MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
CN115803057A (en) 2020-04-29 2023-03-14 特纳奥尼公司 Methods of treating multiple myeloma
CN116963782A (en) 2020-05-03 2023-10-27 联宁(苏州)生物制药有限公司 Antibody drug conjugates comprising anti-TROP-2 antibodies
JP2023524271A (en) 2020-05-08 2023-06-09 ボルト バイオセラピューティクス、インコーポレーテッド Elastase-substrate peptide linker immunoconjugates and uses thereof
CA3178885A1 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
AU2021267402A1 (en) 2020-05-08 2022-11-24 Genmab A/S Bispecific antibodies against CD3 and CD20
CN111995681B (en) 2020-05-09 2022-03-08 华博生物医药技术(上海)有限公司 anti-TIGIT antibody, preparation method and application thereof
CA3183602A1 (en) 2020-05-13 2021-11-18 Seagen Inc. Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021228917A1 (en) 2020-05-15 2021-11-18 F. Hoffmann-La Roche Ag Prevention of visible particle formation in parenteral protein solutions
EP4153633A1 (en) 2020-05-19 2023-03-29 Amgen Inc. Mageb2 binding constructs
CN115605185A (en) 2020-05-19 2023-01-13 豪夫迈·罗氏有限公司(Ch) Use of a chelating agent to prevent the formation of visible particles in parenteral protein solutions
HRP20241488T1 (en) 2020-05-26 2025-02-14 Boehringer Ingelheim International Gmbh ANTI-PD-1 ANTIBODIES
CA3184189A1 (en) 2020-05-27 2021-12-02 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
WO2021238886A1 (en) 2020-05-27 2021-12-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
TW202210101A (en) 2020-05-29 2022-03-16 美商安進公司 Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
AU2021281417A1 (en) 2020-05-29 2022-12-08 23Andme, Inc. Anti-CD200R1 antibodies and methods of use thereof
IL298538A (en) 2020-05-29 2023-01-01 Seagen Inc Methods for treating her2-positive cancer with tocatinib in combination with trastuzumab and oxaliplatin-based chemotherapy
BR112022024629A2 (en) 2020-06-02 2023-02-23 Dynamicure Biotechnology Llc ANTI-CD93 CONSTRUCTS AND THEIR USES
CN113754775A (en) * 2020-06-02 2021-12-07 三生国健药业(上海)股份有限公司 Bispecific antibody for resisting PD-L1 and HER2
CA3176246A1 (en) 2020-06-02 2021-12-09 Arcus Biosciences, Inc. Antibodies to tigit
CN116529260A (en) 2020-06-02 2023-08-01 当康生物技术有限责任公司 anti-CD 93 constructs and uses thereof
CN115803062A (en) 2020-06-03 2023-03-14 博泰康医药公司 Antibodies to trophoblast cell surface antigen 2 (TROP-2)
AU2021283933A1 (en) 2020-06-04 2023-01-05 Amgen Inc. Bispecific binding constructs
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
JP2023527918A (en) 2020-06-08 2023-06-30 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Anti-HBV antibody and method of use
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
CA3177152A1 (en) 2020-06-12 2021-12-16 David Scott Johnson Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2021252977A1 (en) 2020-06-12 2021-12-16 Genentech, Inc. Methods and compositions for cancer immunotherapy
CA3181143A1 (en) * 2020-06-12 2021-12-16 Heechung KWON Multi-targeting recombinant herpes simplex viruses and use thereof
CA3181820A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
AU2021292511A1 (en) 2020-06-17 2023-02-16 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells
JP2023531200A (en) 2020-06-18 2023-07-21 ジェネンテック, インコーポレイテッド Treatment with anti-TIGIT antibody and PD-1 axis binding antagonist
EP4168446A1 (en) 2020-06-19 2023-04-26 F. Hoffmann-La Roche AG Antibodies binding to cd3 and folr1
EP4168445A1 (en) 2020-06-19 2023-04-26 F. Hoffmann-La Roche AG Immune activating fc domain binding molecules
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
EP4168456A1 (en) 2020-06-19 2023-04-26 F. Hoffmann-La Roche AG Antibodies binding to cd3
CA3177239A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific antibodies
KR20230025672A (en) 2020-06-19 2023-02-22 에프. 호프만-라 로슈 아게 Antibodies that bind to CD3 and CD19
JP2023532234A (en) 2020-06-22 2023-07-27 イノベント バイオロジクス(スーチョウ)カンパニー,リミティド Anti-CD73 antibody and its use
WO2021259880A1 (en) 2020-06-22 2021-12-30 Almirall, S.A. Anti-il-36 antibodies and methods of use thereof
PH12022553167A1 (en) 2020-06-23 2024-03-04 Hoffmann La Roche Agonistic cd28 antigen binding molecules targeting her2
WO2021259227A1 (en) 2020-06-23 2021-12-30 江苏康缘药业股份有限公司 Anti-cd38 antibody and use thereof
US20230256110A1 (en) 2020-06-24 2023-08-17 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
US20230330243A1 (en) 2020-06-24 2023-10-19 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and atr inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2021260578A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and cdk9 inhibitor
CN116249717A (en) 2020-06-24 2023-06-09 普罗塞纳生物科学有限公司 Antibodies recognizing sortilin
IL299161A (en) 2020-06-24 2023-02-01 Genentech Inc Apoptosis resistant cell lines
EP4172203A1 (en) 2020-06-25 2023-05-03 F. Hoffmann-La Roche AG Anti-cd3/anti-cd28 bispecific antigen binding molecules
EP4172179A4 (en) 2020-06-25 2024-11-20 Amunix Pharmaceuticals, Inc. Her-2 targeted bispecific compositions and methods for making and using the same
MX2022015375A (en) 2020-06-29 2023-01-16 Genmab As Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer.
JP2023532122A (en) 2020-06-29 2023-07-26 ジェネンテック, インコーポレイテッド Fixed dose combination of pertuzumab plus trastuzumab
CA3189297A1 (en) 2020-06-30 2022-01-06 Nathan Trinklein Multi-specific antibodies binding to bcma
AU2021298632A1 (en) 2020-06-30 2023-01-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-CD70 antibody and application thereof
CA3184618A1 (en) 2020-07-02 2022-01-06 John C. Timmer Polypeptides comprising modified il-2 polypeptides and uses thereof
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN116390772A (en) 2020-07-07 2023-07-04 博泰康医药公司 Novel maytansine analogs as ADC payloads and their use in cancer treatment
JP2023532764A (en) 2020-07-07 2023-07-31 エフ. ホフマン-ラ ロシュ アーゲー Alternative surfactants as stabilizers for therapeutic protein formulations
CN116390771A (en) 2020-07-13 2023-07-04 瑞泽恩制药公司 Camptothecin analogs conjugated to glutamine residues in proteins and uses thereof
BR112023000707A2 (en) 2020-07-14 2023-01-31 Hoffmann La Roche BINDING ASSAY FOR A FIXED DOSE COMBINATION, PROTEIN, KITS, COMPOSITIONS AND METHODS FOR EVALUATING A FIXED DOSE COMPOSITION, MAKING A COMPOSITION AND FOR ANALYZING THE PROTEIN CONTENT OF A FIXED DOSE COMBINATION
PE20231093A1 (en) 2020-07-16 2023-07-18 Novartis Ag ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTISPECIFIC BINDING MOLECULES
EP4183799A4 (en) 2020-07-17 2025-02-26 Daiichi Sankyo Co Ltd Method for producing antibody-drug conjugate
EP4182346A1 (en) 2020-07-17 2023-05-24 Pfizer Inc. Therapeutic antibodies and their uses
MX2023000617A (en) 2020-07-17 2023-02-13 Genentech Inc Anti-notch2 antibodies and methods of use.
KR20230042055A (en) 2020-07-20 2023-03-27 다이이찌 산쿄 가부시키가이샤 Combinations of anti-HER2 antibody-drug conjugates with HER dimerization inhibitors
CR20230017A (en) 2020-07-21 2023-02-17 Genentech Inc Antibody-conjugated chemical inducers of degradation of brm and methods thereof
US20230293680A1 (en) 2020-07-23 2023-09-21 Genmab B.V. A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
US20230295274A1 (en) 2020-07-27 2023-09-21 Single Cell Technology, Inc. Anti-sars coronavirus-2 spike protein antibodies
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4188384A1 (en) 2020-07-29 2023-06-07 Seagen Inc. Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
KR20230133832A (en) 2020-07-29 2023-09-19 다이내믹큐어 바이오테크놀로지 엘엘씨 Anti-CD93 constructs and uses thereof
AU2021317111A1 (en) 2020-07-29 2023-03-30 Janssen Biotech, Inc. Proteins comprising HLA-G antigen binding domains and their uses
BR112023001740A2 (en) 2020-08-03 2023-02-28 Hoffmann La Roche ANTIGEN-BINDING RECEPTORS, TRANSDUCED T-CELL, ISOLATED POLYNUCLEOTIDE, VECTOR, KIT, METHOD FOR TREAT A DISEASE IN A SUBJECT AND INDUCE LYSIS OF A TARGET CELL AND USE OF ANTIGEN-BINDING RECEPTOR
TW202212354A (en) 2020-08-03 2022-04-01 美商健生生物科技公司 Materials and methods for multidirectional biotransportation in virotherapeutics
WO2022029080A1 (en) 2020-08-03 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
IL300388A (en) 2020-08-04 2023-04-01 Pfizer Treatment with site specific her2 antibody-drug conjugates
WO2022031652A1 (en) 2020-08-04 2022-02-10 Seagen Inc. Anti-cd228 antibodies and antibody-drug conjugates
WO2022031834A1 (en) 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof
EP4192868A1 (en) 2020-08-05 2023-06-14 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
WO2022029011A1 (en) 2020-08-06 2022-02-10 BioNTech SE Binding agents for coronavirus s protein
PE20230983A1 (en) 2020-08-07 2023-06-21 Genentech Inc LIGAND FUSION PROTEINS FOR FLT3 AND METHODS OF USE
MX2023001776A (en) 2020-08-12 2023-03-10 Biond Biologics Ltd Antibodies against ilt2 and use thereof.
AU2021326516A1 (en) 2020-08-13 2023-04-13 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
TW202221026A (en) 2020-08-14 2022-06-01 瑞士商Ac 免疫有限公司 Humanized anti-TDP-43 binding molecules and uses thereof
EP4199954A4 (en) 2020-08-18 2024-12-25 Omeros Corporation MONOCLONAL ANTIBODIES, COMPOSITIONS AND METHODS FOR DETECTION OF COMPLEMENT FACTOR D
KR20230048150A (en) 2020-08-21 2023-04-10 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. Antibodies that specifically bind to glycosylated CEACAM5
EP4204448A2 (en) 2020-08-27 2023-07-05 cureab GmbH Anti-golph2 antibodies for macrophage and dendritic cell differentiation
WO2022047243A1 (en) 2020-08-27 2022-03-03 Enosi Life Sciences Corp. Methods and compositions to treat autoimmune diseases and cancer
CN116648507A (en) 2020-08-28 2023-08-25 基因泰克公司 CRISPR/Cas9 multiple knockout of host cell proteins
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
JPWO2022044248A1 (en) 2020-08-28 2022-03-03
IL300835A (en) 2020-09-02 2023-04-01 Genmab As Antibody therapy
JP2023540526A (en) 2020-09-04 2023-09-25 ノヴァロック バイオセラピューティクス, リミテッド Nectin-4 antibody and its use
US20250122282A2 (en) 2020-09-04 2025-04-17 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
CN116782933A (en) 2020-09-10 2023-09-19 健玛保 Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
WO2022053656A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
MX2023002545A (en) 2020-09-10 2023-03-14 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma.
EP4210746A1 (en) 2020-09-10 2023-07-19 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
CA3190376A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
KR20230066392A (en) 2020-09-10 2023-05-15 젠맵 에이/에스 Bispecific antibodies to CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
WO2022054009A2 (en) 2020-09-12 2022-03-17 Astrazeneca Uk Limited A scoring method for an anti-her2 antibody-drug conjugate therapy
PE20231575A1 (en) 2020-09-14 2023-10-04 Ichnos Sciences SA ANTIBODIES THAT BIND IL1RAP AND USES OF THESE
JP7454106B2 (en) 2020-09-15 2024-03-21 バイエル・アクチエンゲゼルシヤフト Novel anti-A2AP antibodies and their uses
TW202227478A (en) 2020-09-15 2022-07-16 德商拜恩迪克公司 Agents and methods for targeted delivery to cells
KR20230070259A (en) 2020-09-18 2023-05-22 리제너론 파마슈티칼스 인코포레이티드 Antigen Binding Molecules That Bind to CD38 and/or CD28, and Uses Thereof
TW202229344A (en) 2020-09-21 2022-08-01 德商百靈佳殷格翰國際股份有限公司 Use of anti-cd40 antibodies for treatment of inflammatory conditions
CN116209680A (en) 2020-09-24 2023-06-02 莫佛塞斯公司 A novel human antibody that binds to human CD3ε
IL301404A (en) 2020-09-28 2023-05-01 Seagen Inc Human anti-LIV1 antibodies for cancer therapy
DE102020125465A1 (en) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidated peptides and their deamidated counterparts presented by non-HLA-A*02 molecules for use in immunotherapy against various types of cancer
TW202229312A (en) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers
DE102020125457A1 (en) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidated peptides and their deamidated counterparts presented by HLA-A*02 molecules for use in immunotherapy against various types of cancer
MX2023003749A (en) 2020-10-02 2023-04-24 Genmab As Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3.
IL301547A (en) 2020-10-05 2023-05-01 Genentech Inc Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
CN116568708A (en) 2020-10-07 2023-08-08 硕腾服务有限责任公司 anti-NGF antibodies and methods of use thereof
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
MX2023004047A (en) 2020-10-09 2023-04-27 Astrazeneca Uk Ltd Combination of antibody-drug conjugate and parp1 selective inhibitor.
EP4228693A4 (en) 2020-10-13 2024-12-18 Janssen Biotech, Inc. Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
CA3196940A1 (en) 2020-10-14 2022-04-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
US20240084014A1 (en) 2020-10-16 2024-03-14 Qlsf Biotherapeutics, Inc. Multispecific binding compounds that bind to pd-l1
EP4232040A1 (en) 2020-10-20 2023-08-30 F. Hoffmann-La Roche AG Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
WO2022084400A1 (en) 2020-10-20 2022-04-28 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
TW202233671A (en) 2020-10-20 2022-09-01 美商建南德克公司 Peg-conjugated anti-mertk antibodies and methods of use
KR20230110523A (en) 2020-10-22 2023-07-24 얀센 바이오테크 인코포레이티드 Proteins Comprising a Delta-Like Ligand 3 (DLL3) Antigen Binding Region and Uses Thereof
US20220127344A1 (en) 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
KR20230112632A (en) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. Fusion with CD8 antigen binding molecules to modulate immune cell function
US20230400467A1 (en) 2020-10-26 2023-12-14 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022090181A1 (en) 2020-10-28 2022-05-05 F. Hoffmann-La Roche Ag Improved antigen binding receptors
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
KR20230095113A (en) 2020-11-04 2023-06-28 제넨테크, 인크. Dosing for Treatment with Anti-CD20/Anti-CD3 Bispecific Antibodies and Anti-CD79B Antibody Drug Conjugates
JP2023548878A (en) 2020-11-04 2023-11-21 ザ ロックフェラー ユニバーシティー Neutralizing anti-SARS-COV-2 antibody
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
MX2023005130A (en) 2020-11-04 2023-05-25 Genentech Inc Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies.
KR20230104229A (en) 2020-11-06 2023-07-07 암젠 인크 Polypeptide constructs that bind CD3
CA3199976A1 (en) 2020-11-06 2022-05-12 Amgen Research (Munich) Gmbh Polypeptide constructs selectively binding to cldn6 and cd3
CA3198064A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
JP2023547506A (en) 2020-11-06 2023-11-10 ノバルティス アーゲー Combination therapy of anti-CD19 agents and B-cell targeting agents to treat B-cell malignancies
TW202233680A (en) 2020-11-06 2022-09-01 德商安美基研究(慕尼黑)公司 Multitargeting bispecific antigen-binding molecules of increased selectivity
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
AU2021377614B2 (en) 2020-11-11 2025-05-15 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
KR20230106645A (en) 2020-11-11 2023-07-13 다이이찌 산쿄 가부시키가이샤 Combination of antibody-drug conjugate with anti-SIRPα antibody
US20230398230A1 (en) 2020-11-12 2023-12-14 Daiichi Sankyo Company, Limited Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
CN116635062A (en) 2020-11-13 2023-08-22 诺华股份有限公司 Combination Therapies Using Cells Expressing Chimeric Antigen Receptors (CARs)
CN117916261A (en) 2020-11-16 2024-04-19 豪夫迈·罗氏有限公司 Combination therapy with FAP-targeted CD40 agonists
PE20231556A1 (en) 2020-11-16 2023-10-03 Hoffmann La Roche GLYCOFORMS FROM MANNOSE FACTORIES
AU2021383611A1 (en) 2020-11-17 2023-06-29 Peter Maccallum Cancer Institute Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
TW202233684A (en) 2020-11-18 2022-09-01 美商泰尼歐生物公司 Heavy chain antibodies binding to folate receptor alpha
CA3199589A1 (en) 2020-11-19 2022-05-27 Ping Li Long-acting nerve growth factor polypeptides and uses thereof
US11617767B2 (en) 2020-11-20 2023-04-04 Simcere Innovation, Inc. Armed dual CAR-T compositions and methods for cancer immunotherapy
CN116761635A (en) 2020-11-24 2023-09-15 诺华股份有限公司 BCL-XL inhibitor antibody drug conjugates and methods of use thereof
CN112480248B (en) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 Molecules that specifically bind to CLD18A2
CN114539418A (en) 2020-11-26 2022-05-27 上海华奥泰生物药业股份有限公司 Bispecific antibodies and uses thereof
TW202241436A (en) 2020-11-30 2022-11-01 美商英塞特公司 Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022119976A1 (en) 2020-12-01 2022-06-09 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
EP4255930A1 (en) 2020-12-02 2023-10-11 Alector LLC Methods of use of anti-sortilin antibodies
CN116783217A (en) 2020-12-03 2023-09-19 安进公司 Immunoglobulin constructs with multiple binding domains
IL303381A (en) 2020-12-04 2023-08-01 Hoffmann La Roche PH-dependent mutant interleukin-2 polypeptides
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use
IL303295A (en) 2020-12-07 2023-07-01 UCB Biopharma SRL Multispecific antibodies and antibody combinations
CA3200895A1 (en) 2020-12-07 2022-06-16 Ugur Sahin Antibody and taxane combination therapy
BR112023008265A2 (en) 2020-12-07 2024-02-06 UCB Biopharma SRL ANTIBODIES AGAINST INTERLEUKIN-22
TW202237639A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
TW202237638A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
US20240042050A1 (en) 2020-12-11 2024-02-08 Bolt Biotherapeutics, Inc. Anti-her2 immunoconjugates, and uses thereof
CN116744978A (en) 2020-12-11 2023-09-12 博尔特生物治疗药物有限公司 Anti-HER2 immunoconjugates and their uses
IL303502A (en) 2020-12-11 2023-08-01 Genentech Inc Combination therapies for the treatment of HER2 cancer
EP4259782A1 (en) 2020-12-14 2023-10-18 Allogene Therapeutics, Inc. Methods and reagents for characterizing car t cells for therapies
PE20240819A1 (en) 2020-12-17 2024-04-18 Hoffmann La Roche ANTI-HLA-G ANTIBODIES AND THEIR USE
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
FI4267105T3 (en) 2020-12-28 2025-06-17 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
KR20230157940A (en) 2020-12-29 2023-11-17 인사이트 코포레이션 Combination therapy comprising A2A/A2B inhibitors, PD-1/PD-L1 inhibitors and anti-CD73 antibodies
IL303992A (en) 2020-12-29 2023-08-01 Cemm Forschungszentrum F?R Molekulare Medizin Gmbh Anti-april antibodies and uses thereof
EP4271482A2 (en) 2020-12-31 2023-11-08 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
EP4274658A1 (en) 2021-01-06 2023-11-15 F. Hoffmann-La Roche AG Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
CA3207098A1 (en) 2021-01-06 2022-07-14 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
KR20230131205A (en) 2021-01-13 2023-09-12 에프. 호프만-라 로슈 아게 combination therapy
TW202241925A (en) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 Peptides displayed by hla for use in immunotherapy against different types of cancers
US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
KR20230147092A (en) 2021-01-22 2023-10-20 바이원큐어 테라퓨틱스, 인크. Anti-HER-2/TROP-2 constructs and uses thereof
AU2022213743A1 (en) 2021-01-28 2023-06-15 Nanjing Chempion Biotechnology Co., Ltd. Conjugate and use thereof
JP2024506831A (en) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Compositions and methods for treating cytokine release syndrome
US20240059789A1 (en) 2021-01-28 2024-02-22 Janssen Biotech, Inc. Psma binding proteins and uses thereof
TW202241454A (en) 2021-02-01 2022-11-01 日商第一三共股份有限公司 Novel method for producing antibody-immunostimulator conjugate
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
TW202245811A (en) 2021-02-03 2022-12-01 美商異基因治療有限公司 Formulations and processes for car t cell drug products
JP2024505987A (en) 2021-02-04 2024-02-08 イノベント バイオロジクス(スーチョウ)カンパニー,リミティド Anti-TNFR2 antibodies and their uses
JP2024505674A (en) 2021-02-05 2024-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-IL1RAP antibody
CA3206413A1 (en) 2021-02-11 2022-08-18 Pinchas TSUKERMAN Antibodies against cd112r and uses thereof
TW202302626A (en) 2021-02-15 2023-01-16 日商武田藥品工業股份有限公司 Cell therapy compositions and methods for modulating tgf-b signaling
CA3208060A1 (en) 2021-02-17 2022-08-25 Jessie-Farah Fecteau Anti-cd30l antibodies and uses thereof
WO2022178090A2 (en) 2021-02-19 2022-08-25 Theripion, Inc. Dnase fusion polypeptides and related compositions and methods
JP2024506931A (en) 2021-02-19 2024-02-15 インヒブルクス インコーポレイテッド Preparation of DR5-binding polypeptide
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US20240226162A9 (en) 2021-02-25 2024-07-11 Teneobio, Inc. Anti-psma antibodies and car-t structures
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
EP4298129A1 (en) 2021-02-26 2024-01-03 Teneobio, Inc. Anti-muc1-c antibodies and car-t structures
US20240124572A1 (en) 2021-02-26 2024-04-18 Bayer Aktiengesellschaft INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDING
US20220340662A1 (en) 2021-03-01 2022-10-27 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
TW202317612A (en) 2021-03-01 2023-05-01 美商艾希利歐發展股份有限公司 Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
CA3210069A1 (en) 2021-03-03 2022-09-09 Tong Zhu Antibody-drug conjugates comprising an anti-bcma antibody
TW202302646A (en) 2021-03-05 2023-01-16 美商當康生物科技有限公司 Anti-vista constructs and uses thereof
KR20230156051A (en) 2021-03-09 2023-11-13 에프. 호프만-라 로슈 아게 Combination therapy of PD-1-targeted IL-2 variant immunoconjugate and FAP/4-1BB binding molecule
EP4304724A1 (en) 2021-03-09 2024-01-17 F. Hoffmann-La Roche AG Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
CN117500830A (en) 2021-03-09 2024-02-02 根马布股份公司 Multispecific binding agents against CD40 and CD137 in therapy
IL305736A (en) 2021-03-09 2023-11-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cldn6
IL305758A (en) 2021-03-10 2023-11-01 Immunowake Inc Immunomodulatory compounds and their uses
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
CA3210971A1 (en) 2021-03-12 2022-09-15 Bart-Jan DE KREUK Non-activating antibody variants
CN117062839A (en) 2021-03-12 2023-11-14 基因泰克公司 anti-KLK 7 antibodies, anti-KLK 5 antibodies, multispecific anti-KLK 5/KLK7 antibodies, and methods of use
WO2022191313A1 (en) 2021-03-12 2022-09-15 第一三共株式会社 Glycan, and method for producing medicine containing glycan
AU2022238526A1 (en) 2021-03-15 2023-09-07 F. Hoffmann-La Roche Ag Compositions and methods of treating lupus nephritis
US20240174746A1 (en) 2021-03-18 2024-05-30 Alector Llc Anti-tmem106b antibodies and methods of use thereof
WO2022198231A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
EP4314814A1 (en) 2021-03-22 2024-02-07 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
AU2022244229A1 (en) 2021-03-22 2023-09-14 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
WO2022204274A1 (en) 2021-03-23 2022-09-29 Alector Llc Anti-tmem106b antibodies for treating and preventing coronavirus infections
JP2024512567A (en) 2021-03-23 2024-03-19 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) Diagnosis and treatment methods for T-cell lymphoma
KR20230160314A (en) 2021-03-24 2023-11-23 얀센 바이오테크 인코포레이티드 Antibodies targeting CD22 and CD79B
JP2024510777A (en) 2021-03-24 2024-03-11 ヤンセン バイオテツク,インコーポレーテツド Proteins containing CD3 antigen binding domain and uses thereof
US20240150466A1 (en) 2021-03-25 2024-05-09 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
WO2022201122A1 (en) 2021-03-26 2022-09-29 Janssen Biotech, Inc. Humanized antibodies against paired helical filament tau and uses thereof
EP4313162A1 (en) 2021-03-26 2024-02-07 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
CN117940168A (en) 2021-03-26 2024-04-26 博尔特生物治疗药物有限公司 2-amino-4-carboxamide-benzazepine immunoconjugate and its use
BR112023018061A2 (en) 2021-03-30 2023-10-03 Bayer Ag ANTI-SEMA3A ANTIBODIES AND USES THEREOF
EP4314032A1 (en) 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Protease-activated polypeptides
JP7624255B2 (en) 2021-03-31 2025-01-30 日本マイクロバイオファーマ株式会社 Method for producing antibody-drug conjugate and enzyme used therein
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202313681A (en) 2021-04-02 2023-04-01 美商安進公司 Mageb2 binding constructs
TW202304994A (en) 2021-04-02 2023-02-01 美商泰尼歐生物公司 Agonistic anti-il-2r antibodies and methods of use
JP2024514107A (en) 2021-04-06 2024-03-28 テネオバイオ, インコーポレイテッド Anti-CD19 antibody and CAR-T construct
WO2022214681A1 (en) 2021-04-09 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
TW202304524A (en) 2021-04-10 2023-02-01 美商普方生物製藥美國公司 Folr1 binding agents, conjugates thereof and methods of using the same
WO2022218957A1 (en) 2021-04-12 2022-10-20 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
AR125344A1 (en) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd ANTI-C1S ANTIBODY
KR20230171952A (en) 2021-04-16 2023-12-21 테네오바이오, 인코포레이티드 Anti-CD20 antibody and CAR-T structure
WO2022225880A1 (en) 2021-04-19 2022-10-27 Genentech, Inc. Modified mammalian cells
WO2022223651A1 (en) 2021-04-23 2022-10-27 F. Hoffmann-La Roche Ag Prevention or mitigation of nk cell engaging agent-related adverse effects
EP4326768A1 (en) 2021-04-23 2024-02-28 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202302649A (en) 2021-04-26 2023-01-16 大陸商江蘇恆瑞醫藥股份有限公司 Anti-nectin-4 antibody, anti-nectin-4 antibody-drug conjugate and medicinal use thereof
EP4329887A1 (en) 2021-04-28 2024-03-06 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
CN117545778A (en) 2021-04-30 2024-02-09 皮埃尔法布雷医药公司 Novel stable anti-VISTA antibodies
AU2021443863A1 (en) 2021-04-30 2023-10-26 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
EP4329818A1 (en) 2021-04-30 2024-03-06 Celgene Corporation Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi)
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
US20240254224A1 (en) 2021-05-03 2024-08-01 UCB Biopharma SRL Antibodies
US20240218057A1 (en) 2021-05-06 2024-07-04 The Rockefeller University Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
US20240384006A1 (en) 2021-05-06 2024-11-21 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
CN119236056A (en) 2021-05-07 2025-01-03 高山免疫科学股份有限公司 Administration and therapeutic methods using TACI-Fc fusion immunomodulatory proteins
AR125815A1 (en) 2021-05-07 2023-08-16 Genmab As PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES THAT BIND B7H4 AND CD3
TW202310876A (en) 2021-05-12 2023-03-16 美商建南德克公司 Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
BR112023023775A2 (en) 2021-05-14 2024-02-20 Genentech Inc METHODS FOR TREATING AN INDIVIDUAL WITH A CD20-POSITIVE CELL PROLIFERATIVE DISORDER AND FOR TREATING A POPULATION OF INDIVIDUALS WITH A CD20-POSITIVE CELL PROLIFERATIVE DISORDER
JP2024518545A (en) 2021-05-14 2024-05-01 ジェネンテック, インコーポレイテッド TREM2 agonists
CN115448917A (en) 2021-05-19 2022-12-09 上海迪诺医药科技有限公司 Nitrogen-containing compound, conjugate containing nitrogen-containing compound and application of conjugate
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
US20240366777A1 (en) 2021-05-19 2024-11-07 Sutro Biopharma, Inc. Anti-folate receptor conjugate combination therapy with bevacizumab
EP4341385A1 (en) 2021-05-21 2024-03-27 Genentech, Inc. Modified cells for the production of a recombinant product of interest
WO2022251311A1 (en) 2021-05-25 2022-12-01 Seagen Inc. Methods of quantifying anti-cd40 antibodies
AR126009A1 (en) 2021-06-02 2023-08-30 Hoffmann La Roche CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM
EP4155321A1 (en) 2021-06-04 2023-03-29 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
US11572412B2 (en) 2021-06-04 2023-02-07 Boehringer Ingelheim International Gmbh Anti-SIRP-alpha antibodies
EP4351633A1 (en) 2021-06-08 2024-04-17 Biontech Cell & Gene Therapies Gmbh Agents and methods for activation and targeting of immune effector cells
WO2022258600A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
AU2022293999A1 (en) 2021-06-14 2023-11-30 argenx BV Anti-il-9 antibodies and methods of use thereof
WO2022262959A1 (en) 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3
US20240279341A1 (en) 2021-06-16 2024-08-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
EP4355783A1 (en) 2021-06-16 2024-04-24 Alector LLC Monovalent anti-mertk antibodies and methods of use thereof
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
CN117794948A (en) 2021-06-18 2024-03-29 特里尼生物公司 Antibodies that bind to human fibrin or fibrinogen gamma C domain and methods of using the same
JP2024522234A (en) 2021-06-18 2024-06-11 アリゲーター・バイオサイエンス・アーベー Novel combination therapy and uses thereof
TW202315891A (en) 2021-06-21 2023-04-16 丹麥商珍美寶股份有限公司 Binding agent dosing schedule
MX2023014683A (en) 2021-06-22 2024-01-12 Regeneron Pharma Anti-egfrviii antibody drug conjugates and uses thereof.
WO2022269473A1 (en) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
CN117616123B (en) 2021-06-25 2024-11-08 中外制药株式会社 Anti-CTLA-4 antibodies
AR126236A1 (en) 2021-06-25 2023-10-04 Chugai Pharmaceutical Co Ltd USE OF THE ANTI-CTLA-4 ANTIBODY
CA3221281A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
EP4363450A1 (en) 2021-07-01 2024-05-08 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
JP2024527324A (en) 2021-07-01 2024-07-24 デナリ セラピューティクス インコーポレイテッド Oligonucleotide conjugates targeted to the transferrin receptor
WO2023279092A2 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
TW202320857A (en) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 Linkers, drug linkers and conjugates thereof and methods of using the same
TW202317633A (en) 2021-07-08 2023-05-01 美商舒泰神(加州)生物科技有限公司 Antibodies specifically recognizing tnfr2 and uses thereof
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
CN115812082A (en) 2021-07-14 2023-03-17 舒泰神(北京)生物制药股份有限公司 Antibody specifically recognizing CD40 and its application
IL309856A (en) 2021-07-14 2024-02-01 Genentech Inc Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
AU2022311053A1 (en) 2021-07-15 2023-12-14 BioNTech SE Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
TW202309102A (en) 2021-07-20 2023-03-01 美商英伊布里克斯公司 Cd8-targeted modified il-2 polypeptides and uses thereof
TW202321283A (en) 2021-07-20 2023-06-01 美商英伊布里克斯公司 Cd8-binding polypeptides and uses thereof
KR20240036570A (en) 2021-07-22 2024-03-20 에프. 호프만-라 로슈 아게 Heterodimeric Fc domain antibodies
WO2023004386A1 (en) 2021-07-22 2023-01-26 Genentech, Inc. Brain targeting compositions and methods of use thereof
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
WO2023007374A1 (en) 2021-07-27 2023-02-02 Pfizer Inc. Method of treatment of cancer pain with tanezumab
AU2022318255A1 (en) 2021-07-27 2024-01-18 Morphosys Ag Combinations of antigen binding molecules
MX2024001214A (en) 2021-07-28 2024-02-12 Hoffmann La Roche Methods and compositions for treating cancer.
JP2024529502A (en) 2021-07-30 2024-08-06 オーエヌエー セラピューティクス エセ.エレ. Anti-CD36 Antibodies and Their Use for Treating Cancer - Patent application
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
JP2024528217A (en) 2021-08-03 2024-07-26 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antibodies and methods of use
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2023019200A1 (en) 2021-08-11 2023-02-16 Viela Bio, Inc. Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
EP4384553A1 (en) 2021-08-13 2024-06-19 Genentech, Inc. Dosing for anti-tryptase antibodies
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
WO2023021055A1 (en) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Multivalent anti-variant fc-region antibodies and methods of use
CA3229139A1 (en) 2021-08-20 2023-02-23 Pavel Strop Nectin-4 antibodies and conjugates
AU2022332285A1 (en) 2021-08-23 2024-02-15 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
CA3228822A1 (en) 2021-08-26 2023-03-02 Jan Tkac Glycoprotein biomarkers for diagnosing cancer
EP4392454A1 (en) 2021-08-27 2024-07-03 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
WO2023028591A1 (en) 2021-08-27 2023-03-02 Genentech, Inc. Methods of treating tau pathologies
IL310885A (en) 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-cgrp antibodies
TW202325727A (en) 2021-08-30 2023-07-01 美商建南德克公司 Anti-polyubiquitin multispecific antibodies
EP4397762A1 (en) 2021-08-31 2024-07-10 Taisho Pharmaceutical Co., Ltd. Anti-growth hormone antibody
KR20240051162A (en) 2021-09-02 2024-04-19 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 Anti-CECAM6 antibody with reduced side effects
EP4399227A1 (en) 2021-09-06 2024-07-17 Genmab A/S Antibodies capable of binding to cd27, variants thereof and uses thereof
WO2023038548A1 (en) 2021-09-08 2023-03-16 Акционерное общество "БИОКАД" Bispecific antibody comprising a heterodimer based on mhc proteins
AU2022346688A1 (en) 2021-09-14 2024-04-04 Glycanostics S.R.O Use of lectins to determine mammaglobin-a glycoforms in breast cancer
CN118369344A (en) 2021-09-16 2024-07-19 阿博莱斯制药公司 Anti-human CD45RC binding domain and its use
TW202327650A (en) 2021-09-23 2023-07-16 美商思進公司 Methods of treating multiple myeloma
US20250019455A1 (en) 2021-09-24 2025-01-16 Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
CA3232382A1 (en) 2021-09-27 2023-03-30 Zoetis Services Llc Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof
JPWO2023053282A1 (en) 2021-09-29 2023-04-06
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
MX2024003797A (en) 2021-09-30 2024-06-19 Seagen Inc B7-h4 antibody-drug conjugates for the treatment of cancer.
TW202321308A (en) 2021-09-30 2023-06-01 美商建南德克公司 Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
US20250002600A1 (en) 2021-10-06 2025-01-02 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
CA3233512A1 (en) 2021-10-06 2023-04-13 Alexander Muik Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
TW202330610A (en) 2021-10-08 2023-08-01 丹麥商珍美寶股份有限公司 Antibodies binding to cd30 and cd3
CN116064598B (en) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 Nucleic acid vaccine for coronavirus
IL311956A (en) 2021-10-08 2024-06-01 Chugai Pharmaceutical Co Ltd Method for preparing a prefilled syringe formulation
AR127273A1 (en) * 2021-10-09 2024-01-03 Hutchmed Ltd BISPECIFIC ANTIBODIES THAT BIND SPECIFICALLY TO CD47 AND HER2 AND USES THEREOF
CN118139648A (en) 2021-10-14 2024-06-04 豪夫迈·罗氏有限公司 Alternative PD1-IL7v immunoconjugates for treating cancer
CN118215674A (en) 2021-10-14 2024-06-18 豪夫迈·罗氏有限公司 Novel interleukin-7 immunoconjugates
EP4419558A1 (en) 2021-10-19 2024-08-28 Alector LLC Anti-cd300lb antibodies and methods of use thereof
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
EP4422697A1 (en) 2021-10-29 2024-09-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
CN118451108A (en) 2021-10-29 2024-08-06 思进公司 Methods for treating cancer using a combination of anti-PD-1 antibody and anti-CD30 antibody-drug conjugate
KR20240102981A (en) 2021-11-02 2024-07-03 비스테라, 인크. FC variants with abolished binding to FCgammaR and C1Q
IL312060A (en) 2021-11-03 2024-06-01 Affimed Gmbh Bispecific CD16A binders
JP2024541058A (en) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. Specific conjugation of antibodies
AU2022381918A1 (en) 2021-11-03 2024-06-13 Affimed Gmbh Bispecific cd16a binders
KR20240099315A (en) 2021-11-05 2024-06-28 아메리칸 다이어그노스틱스 앤드 테라피, 엘엘씨 (에이디엑스알엑스) Monoclonal antibodies against carcinoembryonic antigens and uses thereof
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EP4180061A1 (en) 2021-11-10 2023-05-17 Nerviano Medical Sciences S.r.l. Anthracycline derivative linker reagents, antibody-drug conjugates and methods
CA3236006A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
CA3235206A1 (en) 2021-11-16 2023-05-25 Davide BASCO Novel molecules for therapy and diagnosis
US20250073346A1 (en) 2021-11-18 2025-03-06 Oxford Bio Therapeutics Ltd Pharmaceutical combinations
KR20240125925A (en) 2021-11-18 2024-08-20 아스트라제네카 유케이 리미티드 Combination of antibody-drug conjugates and PARP1 selective inhibitors
PE20241755A1 (en) 2021-11-19 2024-08-28 Mirobio Ltd ENGINEERED PD-1 ANTIBODIES AND THEIR USES
WO2023094413A1 (en) 2021-11-25 2023-06-01 F. Hoffmann-La Roche Ag Improved antigen binding receptors
CN118284625A (en) 2021-11-26 2024-07-02 豪夫迈·罗氏有限公司 Combination therapy of anti-TYRP 1/anti-CD 3 bispecific antibodies and TYRP 1-specific antibodies
WO2023100975A1 (en) 2021-12-01 2023-06-08 中外製薬株式会社 Method for preparing antibody-containing formulation
EP4440625A1 (en) 2021-12-01 2024-10-09 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
EP4441095A1 (en) 2021-12-01 2024-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing anti-cd95l monoclonal antibodies
EP4445911A1 (en) 2021-12-06 2024-10-16 Beijing SoloBio Genetechnology Co., Ltd. Bispecific antibody that specifically binds to klebsiella pneumoniae o2 and o1 antigens, and composition
AR127887A1 (en) 2021-12-10 2024-03-06 Hoffmann La Roche ANTIBODIES THAT BIND CD3 AND PLAP
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
US20250051440A1 (en) 2021-12-14 2025-02-13 Institut National de la Santé et de la Recherche Médicale Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
WO2023114829A1 (en) 2021-12-15 2023-06-22 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
CN118574849A (en) 2021-12-17 2024-08-30 上海复宏汉霖生物技术股份有限公司 Anti-OX 40 antibodies and methods of use
JP2024547020A (en) 2021-12-17 2024-12-26 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド Anti-OX40 antibodies, multispecific antibodies and methods of use thereof
CR20240246A (en) 2021-12-20 2024-07-19 Hoffmann La Roche AGONIST ANTI-LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES THAT INCLUDE THEM
CN119013293A (en) 2021-12-22 2024-11-22 因赛特公司 Therapeutic paradigm of anti-CD 19 antibody therapy
MX2024007543A (en) 2021-12-23 2024-07-04 Jiangsu Hengrui Pharmaceuticals Co Ltd Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody.
CA3240724A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atr inhibitor
US20250161305A1 (en) 2021-12-28 2025-05-22 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
TW202330619A (en) 2021-12-28 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Anti-ror1 antibody, anti-ror1 antibody-drug conjugate and the pharmaceutical use thereof
TW202334193A (en) 2022-01-05 2023-09-01 美商英伊布里克斯公司 Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof
US20250066477A1 (en) 2022-01-05 2025-02-27 Inhibrx Biosciences, Inc. Gamma Delta T-Cell-Binding Polypeptides and Uses Thereof
PE20242347A1 (en) 2022-01-07 2024-12-16 Johnson And Johnson Entpr Innovation Inc MATERIALS AND METHODS FOR IL-1 BETA BINDING PROTEINS
US20230287138A1 (en) 2022-01-12 2023-09-14 Regneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
US20230322958A1 (en) 2022-01-19 2023-10-12 Genentech, Inc. Anti-Notch2 Antibodies and Conjugates and Methods of Use
EP4471005A1 (en) 2022-01-24 2024-12-04 Beijing Chempion Biotechnology Co., Ltd. Conjugate and use thereof
AR128331A1 (en) 2022-01-26 2024-04-17 Genentech Inc CHEMICAL DEGRADATION INDUCTORS CONJUGATED WITH ANTIBODIES AND METHODS OF THESE
AR128330A1 (en) 2022-01-26 2024-04-17 Genentech Inc CHEMICAL DEGRADATION INDUCERS CONJUGATED WITH ANTIBODY AND METHODS OF THESE
EP4469159A1 (en) 2022-01-27 2024-12-04 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
MX2024008833A (en) 2022-01-28 2024-07-25 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma.
CN118647402A (en) 2022-01-28 2024-09-13 健玛保 Bispecific antibodies targeting CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
AU2023212994A1 (en) 2022-01-28 2024-08-08 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023148276A1 (en) 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery to cells
EP4472998A1 (en) 2022-02-02 2024-12-11 BioNTech SE Cyclic epitope tags
IL314538A (en) 2022-02-02 2024-09-01 BioNTech SE Agents and methods for targeted delivery of nucleic acids to cells
WO2023152581A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. Method of treating cancer with psmaxcd3 antibody
EP4475884A1 (en) 2022-02-09 2024-12-18 Janssen Biotech, Inc. Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
EP4479427A1 (en) 2022-02-16 2024-12-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer
WO2023156549A1 (en) 2022-02-16 2023-08-24 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
WO2023156587A1 (en) 2022-02-18 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
US20250163169A1 (en) 2022-02-25 2025-05-22 Institut National de la Santé et de la Recherche Médicale Antibodies for preventing the cleavage of cd95l by metalloproteases
TW202400228A (en) 2022-02-25 2024-01-01 美商再生元醫藥公司 Dosing regimens for mitigation of cytokine release syndrome
US20250207169A1 (en) 2022-03-02 2025-06-26 Daiichi Sankyo Company, Limited METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
CN119451982A (en) 2022-03-02 2025-02-14 拜奥穆尼克斯制药 Bispecific antibodies that bind to HER-3 and HER-2 or EGFR
EP4486769A1 (en) 2022-03-02 2025-01-08 Heidelberg ImmunoTherapeutics GmbH Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
KR20240155334A (en) 2022-03-09 2024-10-28 메르크 파텐트 게엠베하 Anti-GD2 antibodies, immunoconjugates and therapeutic uses thereof
WO2023170240A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
US20250205350A1 (en) 2022-03-10 2025-06-26 Vivasor, Inc. Antibody-Drug Conjugates and Uses Thereof
CN119173530A (en) 2022-03-11 2024-12-20 詹森药业有限公司 Multispecific antibodies and their uses
KR20240159846A (en) 2022-03-11 2024-11-06 얀센 파마슈티카 엔브이 Multispecific antibodies and uses thereof
KR20240168351A (en) 2022-03-11 2024-11-29 마브링크 바이오사이언스 Antibody-drug conjugates and uses thereof
CN119173532A (en) 2022-03-11 2024-12-20 詹森药业有限公司 Multispecific antibodies and their uses
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
IL314907A (en) 2022-03-15 2024-10-01 Yeda Res & Dev Antibodies against GITR and their uses
EP4493933A1 (en) 2022-03-16 2025-01-22 AstraZeneca UK Limited A scoring method for an anti-trop2 antibody-drug conjugate therapy
US20240103010A1 (en) 2022-03-18 2024-03-28 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
JP2025513714A (en) 2022-03-22 2025-04-30 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング CD3-specific deimmunized antibodies
US20230414750A1 (en) 2022-03-23 2023-12-28 Hoffmann-La Roche Inc. Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
EP4499708A1 (en) 2022-03-25 2025-02-05 Shanghai Henlius Biotech, Inc. Anti-msln antibodies and methods of use
AR128876A1 (en) 2022-03-28 2024-06-19 Hoffmann La Roche ENHANCED FOLR1 PROTEASE ACTIVATABLE T LYMPHOCYTE BISPECIFIC ANTIBODIES
JP2025511000A (en) 2022-03-28 2025-04-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Interferon gamma variants and antigen-binding molecules containing the same
JP2025510828A (en) 2022-04-01 2025-04-15 ジェネンテック, インコーポレイテッド Hydroxypropyl methylcellulose derivatives for stabilizing polypeptides
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
EP4504780A1 (en) 2022-04-01 2025-02-12 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN116925223A (en) 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 Anti-PD-1 monoclonal antibodies and their derivatives and uses
KR20250004721A (en) 2022-04-06 2025-01-08 마이로바이오 리미티드 Engineered CD200R antibodies and uses thereof
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
KR20250004725A (en) 2022-04-08 2025-01-08 인히브릭스 바이오사이언스, 인크. Combination therapy with DR5 agonist and PLK1 inhibitor or CDK inhibitor
AU2023250038A1 (en) 2022-04-08 2024-11-14 Ac Immune Sa Anti-tdp-43 binding molecules
WO2023198648A1 (en) 2022-04-11 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t-cell malignancies
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
JP2025512342A (en) 2022-04-13 2025-04-17 ジェネンテック, インコーポレイテッド Pharmaceutical compositions and methods of use of therapeutic proteins
EP4508081A1 (en) 2022-04-13 2025-02-19 F. Hoffmann-La Roche AG Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
WO2023203177A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
KR20250005335A (en) 2022-04-26 2025-01-09 추가이 세이야쿠 가부시키가이샤 Syringe with built-in filter containing pharmaceutical preparation
EP4514391A1 (en) 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
WO2023212675A1 (en) 2022-04-28 2023-11-02 Allogene Therapeutics Inc. Methods for donor cell analysis
EP4514389A1 (en) 2022-04-29 2025-03-05 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
EP4514845A1 (en) 2022-04-29 2025-03-05 Broadwing Bio LLC Bispecific antibodies and methods of treating ocular disease
CN119630698A (en) 2022-04-29 2025-03-14 博闻生物有限责任公司 Angiopoietin-related protein 7 specific antibody and its use
KR20250021400A (en) 2022-04-29 2025-02-12 브로드윙 바이오 엘엘씨 Complement factor H-related 4-specific antibodies and uses thereof
WO2023213814A1 (en) 2022-05-02 2023-11-09 Pierre Fabre Medicament New formulation of anti vista antibody
TW202406934A (en) 2022-05-03 2024-02-16 美商建南德克公司 Anti-ly6e antibodies, immunoconjugates, and uses thereof
EP4519311A1 (en) 2022-05-05 2025-03-12 Inhibrx Biosciences, Inc. Albumin-binding polypeptides and uses thereof
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
CN119487065A (en) 2022-05-09 2025-02-18 舒泰神(北京)生物制药股份有限公司 Antibodies specifically recognizing GDF15 and their applications
WO2023218378A1 (en) 2022-05-11 2023-11-16 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AR129268A1 (en) 2022-05-11 2024-08-07 Hoffmann La Roche ANTIBODY THAT BINDS TO VEGF-A AND IL6 AND METHODS OF USE
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
AU2023269546A1 (en) 2022-05-12 2024-11-14 BioNTech SE Binding agents capable of binding to cd27 in combination therapy
CN119451985A (en) 2022-05-12 2025-02-14 健玛保 BINDING AGENTS CAPABLE OF BINDING CD27 IN COMBINATION THERAPY
AU2023268600A1 (en) 2022-05-12 2024-11-07 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2023218099A1 (en) 2022-05-13 2023-11-16 argenx BV In utero treatment of a fetus having genetic disease/neuromuscular disease
WO2023222557A1 (en) 2022-05-17 2023-11-23 Bayer Aktiengesellschaft Radiopharmaceutical complexes targeting prostate-specific membrane antigen and its combinations
EP4279092A1 (en) 2022-05-17 2023-11-22 Bayer AG Radiopharmaceutical complexes targeting prostate-specific membrane antigen
IL316767A (en) 2022-05-18 2025-01-01 Regeneron Pharma Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
EP4525927A1 (en) 2022-05-20 2025-03-26 Novartis AG Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
TW202410919A (en) 2022-05-23 2024-03-16 美商英伊布里克斯公司 Dr5 agonist and iap antagonist combination therapy
JP2025517490A (en) 2022-05-26 2025-06-05 ファイザー・インク Anti-TNFR2 Antibodies and Methods of Use Thereof
CN119278051A (en) 2022-05-26 2025-01-07 康姆普根有限公司 Anti-TIGIT antibody preparations
CN119278212A (en) 2022-05-31 2025-01-07 辉瑞大药厂 Anti-BMP9 antibodies and methods of use thereof
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
IL317319A (en) 2022-06-02 2025-01-01 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
CN119856056A (en) 2022-06-07 2025-04-18 基因泰克公司 Methods for determining the efficacy of lung cancer treatment comprising anti-PD-L1 antagonists and anti-TIGHT antagonist antibodies
EP4536290A1 (en) 2022-06-08 2025-04-16 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
CN119343464A (en) 2022-06-09 2025-01-21 艾洛基治疗公司 Methods for detecting genomic abnormalities in cells
EP4536704A2 (en) 2022-06-10 2025-04-16 Horizon Therapeutics Ireland DAC Igf1r antibodies
AU2023283838A1 (en) 2022-06-11 2025-01-23 Inhibrx Biosciences, Inc. Fcrn-binding polypeptides and uses thereof
EP4536358A1 (en) 2022-06-13 2025-04-16 Genentech Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
CN120035602A (en) 2022-06-17 2025-05-23 辉瑞公司 IL-12 variants, anti-PD 1 antibodies, fusion proteins and uses thereof
WO2023247050A1 (en) 2022-06-23 2023-12-28 Alligator Bioscience Ab Combination therapies
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
MA71328A (en) 2022-06-30 2025-04-30 Sutro Biopharma, Inc. ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-ROR1 ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES
EP4554978A1 (en) 2022-07-13 2025-05-21 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4554619A1 (en) 2022-07-15 2025-05-21 Danisco US Inc. Methods for producing monoclonal antibodies
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
AU2023309556A1 (en) 2022-07-19 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
TW202417503A (en) 2022-07-19 2024-05-01 美商舒泰神(加州)生物科技有限公司 Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
AR129995A1 (en) 2022-07-22 2024-10-23 Genentech Inc ANTI-STEAP1 ANTIGEN BINDING MOLECULES AND THEIR USES
EP4558823A1 (en) 2022-07-22 2025-05-28 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
EP4558151A1 (en) 2022-07-22 2025-05-28 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
WO2024020579A1 (en) 2022-07-22 2024-01-25 Bristol-Myers Squibb Company Antibodies binding to human pad4 and uses thereof
GB202210957D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210965D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
AU2023313120A1 (en) 2022-07-28 2025-02-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof
MA71630A (en) 2022-07-29 2025-05-30 Alector Llc TRANSFERRIN RECEPTOR ANTIGEN-BINDING DOMAINS AND THEIR USES
TW202413424A (en) 2022-08-01 2024-04-01 美商旗艦先鋒創新有限責任(Vii)公司 Immunomodulatory proteins and related methods
KR20250034106A (en) 2022-08-03 2025-03-10 화이자 인코포레이티드 Anti-IL27R antibodies and methods of use thereof
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
CN120077064A (en) 2022-08-05 2025-05-30 詹森生物科技公司 Transferrin receptor binding protein for the treatment of brain tumors
CN120051495A (en) 2022-08-05 2025-05-27 詹森生物科技公司 CD98 binding constructs for the treatment of brain tumors
CN119654163A (en) 2022-08-09 2025-03-18 魁尔斯弗生物治疗股份有限公司 Antibodies that bind to CLEC12A
AU2023325086A1 (en) 2022-08-16 2025-01-09 Allogene Therapeutics Inc. In vitro method for inhibiting hhv-6 infection
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
IL319060A (en) 2022-08-18 2025-04-01 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
IL318702A (en) 2022-08-19 2025-03-01 Evive Biotechnology Shanghai Ltd Formulations comprising g-csf and uses thereof
IL319125A (en) 2022-08-22 2025-04-01 Abdera Therapeutics Inc Dll3 binding molecules and uses thereof
CN120153254A (en) 2022-09-01 2025-06-13 基因泰克公司 Methods for the treatment and diagnosis of bladder cancer
AU2023334858A1 (en) 2022-09-01 2025-03-20 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
CN120077071A (en) 2022-09-07 2025-05-30 当康生物技术有限责任公司 Anti-VISTA constructs and their uses
WO2024051804A1 (en) 2022-09-08 2024-03-14 江苏恒瑞医药股份有限公司 Anti-ilt4 antibody and pharmaceutical use thereof
JPWO2024053574A1 (en) 2022-09-09 2024-03-14
AU2023343470A1 (en) 2022-09-14 2025-02-06 Amgen Inc. Bispecific molecule stabilizing composition
CN119836438A (en) 2022-09-19 2025-04-15 艾洛基治疗公司 Anti-idiotype antibodies to B-cell maturation antigen (BCMA)
CN119894933A (en) 2022-09-20 2025-04-25 普米斯生物技术(珠海)有限公司 Antibodies and their use in anti-tumor
CN119894936A (en) * 2022-09-20 2025-04-25 普米斯生物技术(珠海)有限公司 Anti-HER 2 antibodies and uses thereof
WO2024067344A1 (en) 2022-09-27 2024-04-04 舒泰神(北京)生物制药股份有限公司 Antibody for specifically recognizing light and use thereof
US20240101718A1 (en) 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
WO2024068572A1 (en) 2022-09-28 2024-04-04 F. Hoffmann-La Roche Ag Improved protease-activatable t cell bispecific antibodies
CN119948048A (en) 2022-09-29 2025-05-06 豪夫迈·罗氏有限公司 Protease-activated polypeptides
EP4345113A1 (en) 2022-09-30 2024-04-03 SDS Optic Spolka Akcyjna Anti-her2 antibody, a nucleic acid molecule encoding the variable region of said antibody, a method of detecting her2 in a biological sample, an immuno-enzymatic elisa assay and use of said anti-her2 antibody or fragments therefof
WO2024067841A1 (en) 2022-09-30 2024-04-04 上海迪诺医药科技有限公司 Benzazepine derivative, conjugate containing same, and use thereof
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein
AU2023356984A1 (en) 2022-10-05 2025-03-20 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
US20240228620A1 (en) 2022-10-06 2024-07-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
CN119998323A (en) 2022-10-07 2025-05-13 基因泰克公司 Methods of treating cancer using anti-C motif chemokine receptor 8 (CCR 8) antibodies
TW202430211A (en) 2022-10-10 2024-08-01 瑞士商赫孚孟拉羅股份公司 Combination therapy of a gprc5d tcb and imids
TW202423970A (en) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Combination therapy of a gprc5d tcb and cd38 antibodies
AU2023358500A1 (en) 2022-10-10 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods for reducing alloantibody levels in subjects in need of solid organ transplantation
TW202423969A (en) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Combination therapy of a gprc5d tcb and proteasome inhibitors
WO2024079192A1 (en) 2022-10-12 2024-04-18 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies
GB202215115D0 (en) 2022-10-13 2022-11-30 Univ Nottingham VEGF antibodies
WO2024083790A1 (en) 2022-10-17 2024-04-25 Institut Gustave Roussy Cd207 dendritic cells as a biomarker for tumoural progression and therapeutic target
AU2023365454A1 (en) 2022-10-18 2025-04-03 Meiji Seika Pharma Co., Ltd. Therapeutic agent for t cell malignancies
WO2024083021A1 (en) 2022-10-20 2024-04-25 北京三诺佳邑生物技术有限责任公司 Antibody combination specifically binding to trail or fasl, and bispecific antibody
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
CN120112796A (en) 2022-10-25 2025-06-06 基因泰克公司 Methods for the treatment and diagnosis of multiple myeloma
WO2024094822A1 (en) 2022-11-02 2024-05-10 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
AU2023372538A1 (en) 2022-11-03 2025-05-01 Seagen Inc. Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody
WO2024097741A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
IL320029A (en) 2022-11-08 2025-06-01 Genentech Inc Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100200A1 (en) 2022-11-09 2024-05-16 Cis Pharma Ag Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024104933A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Antigen binding molecules
AU2023379743A1 (en) 2022-11-17 2025-07-03 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
AU2023381445A1 (en) 2022-11-17 2025-06-05 Polygon Therapeutics Anti-cd8 alpha depleting antibodies
TW202440623A (en) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
CN120282803A (en) 2022-11-30 2025-07-08 第一三共株式会社 Combination of antibody-drug conjugates and DNMT inhibitors
AU2023401158A1 (en) 2022-12-01 2025-05-29 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
CN119998314A (en) 2022-12-08 2025-05-13 长春百克生物科技股份公司 Antibodies that specifically bind RSV
WO2024129594A1 (en) 2022-12-12 2024-06-20 Genentech, Inc. Optimizing polypeptide sialic acid content
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
CN120265662A (en) 2022-12-14 2025-07-04 艾洛基治疗公司 CD70 anti-idiotype antibody
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024133052A1 (en) 2022-12-19 2024-06-27 Universität Basel Vizerektorat Forschung T-cell receptor fusion protein
US20240269308A1 (en) 2022-12-21 2024-08-15 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
TW202432187A (en) 2022-12-23 2024-08-16 美商建南德克公司 Cereblon degrader conjugates, and uses thereof
WO2024148232A2 (en) 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof
WO2024151515A2 (en) 2023-01-09 2024-07-18 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
AR131638A1 (en) 2023-01-18 2025-04-16 Genentech Inc MULTISPECIFIC ANTIBODIES AND THEIR USES
AR131636A1 (en) 2023-01-20 2025-04-16 Hoffmann La Roche Recombinant FC-domain polypeptides - IL2 variant and membrane-anchored antigen-binding polypeptide therapy
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
TW202436339A (en) 2023-01-31 2024-09-16 瑞士商赫孚孟拉羅股份公司 Use for treating cancer selected from non-small cell lung cancer or triple negative breast cancer
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024165146A1 (en) 2023-02-07 2024-08-15 Biontech Cell & Gene Therapies Gmbh Immune effector cells stably and transiently expressing nucleic acids
WO2024165045A1 (en) 2023-02-09 2024-08-15 Beigene, Ltd. Self-stabilizing linker conjugates
US20240327538A1 (en) 2023-02-10 2024-10-03 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen and methods for making and using the same
WO2024173384A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
US20240277844A1 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024186690A2 (en) 2023-03-03 2024-09-12 Enosi Therapeutics Corporation Oligo-trap fusion proteins (ofps) and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2024184287A1 (en) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
WO2024187062A1 (en) 2023-03-08 2024-09-12 Amgen Inc. Controlled-ice nucleation lyophilization process for bispecific molecules
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
US20240343820A1 (en) 2023-03-09 2024-10-17 Kite Pharma, Inc. Antigen binding molecules and methods of use
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof
WO2024191983A1 (en) 2023-03-13 2024-09-19 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with bispecific anti-cd22 x anti-cd28 molecules
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
AR132121A1 (en) 2023-03-14 2025-05-28 Odyssey Therapeutics Inc ANTI-CD25 ANTIGEN BINDING PROTEINS AND THEIR USES
WO2024188356A1 (en) 2023-03-16 2024-09-19 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Ilt7-targeting antibodies and uses thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
TW202440636A (en) 2023-03-21 2024-10-16 美商傳記55有限公司 Cd19/cd38 multispecific antibodies
TW202438114A (en) 2023-03-23 2024-10-01 瑞士商百濟神州瑞士有限責任公司 Bioactive conjugate, preparation method therefor and use thereof
WO2024200637A2 (en) 2023-03-29 2024-10-03 Boehringer Ingelheim International Gmbh Dosing schedule of a her2 inhibitor
TW202446789A (en) 2023-03-31 2024-12-01 美商建南德克公司 Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024208776A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag Agonistic split antibodies
WO2024208777A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag All-in-one agonistic antibodies
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
AR132290A1 (en) 2023-04-05 2025-06-11 Genmab As PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIBODIES THAT BIND TO CD30 AND CD3
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
WO2024213754A1 (en) 2023-04-13 2024-10-17 Genmab A/S Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
US20240343805A1 (en) 2023-04-14 2024-10-17 Incyte Corporation USE OF AN ANTI-TGFßR2/PD-1 BISPECIFIC ANTIBODY
WO2024216064A1 (en) 2023-04-14 2024-10-17 Twist Bioscience Corporation Compositions and methods related to dkk1 binders
US20240400696A1 (en) 2023-04-17 2024-12-05 Amunix Pharmaceuticals, Inc. Compositions targeting epidermal growth factor receptor and methods for making and using the same
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2024220256A1 (en) 2023-04-18 2024-10-24 Qlsf Biotherapeutics, Inc. Antibodies binding to ly6g6d
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024218260A1 (en) 2023-04-18 2024-10-24 Institut Gustave Roussy Detecting tumor-associated-macrophages in pancreatic cancer
WO2024218650A1 (en) 2023-04-19 2024-10-24 Pfizer Inc. Lilrb1 and lilrb2 antibodies and methods of use thereof
WO2024227154A1 (en) 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
GB202306345D0 (en) 2023-04-28 2023-06-14 Immunocore Ltd Binding molecules
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024231320A1 (en) 2023-05-08 2024-11-14 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
TW202509071A (en) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 Antibodies capable of binding to ox40, variants thereof and uses thereof
WO2024235870A1 (en) 2023-05-15 2024-11-21 Argenx B.V. Antibodies for use in agrin-deficient disorders
TW202509065A (en) 2023-05-16 2025-03-01 瑞士商赫孚孟拉羅股份公司 Pd-1-regulated il-2 immunoconjugates and uses thereof
WO2024238787A1 (en) 2023-05-17 2024-11-21 Syndax Pharmaceuticals, Inc. Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody
WO2024238790A1 (en) 2023-05-17 2024-11-21 Odyssey Therapeutics, Inc. Modified single-domain antibodies
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
WO2024243217A1 (en) 2023-05-25 2024-11-28 BioLegend, Inc. Ceacam6 binding antibodies and antigen-binding fragments thereof
TW202448933A (en) 2023-05-31 2024-12-16 美商建南德克公司 Methods of treating tgf beta-related disorders with anti-transforming growth factor beta 3 antibodies
TW202515604A (en) 2023-05-31 2025-04-16 瑞典商阿斯特捷利康公司 Methods, compositions, and combinations for the treatment of ovarian cancer
WO2024246086A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Immunostimulatory antigen binding molecules that specifically bind to bcma
TW202504918A (en) 2023-06-01 2025-02-01 瑞士商赫孚孟拉羅股份公司 Bispecific antibodies targeting bcma and cd28
WO2024254455A1 (en) 2023-06-08 2024-12-12 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
TW202510911A (en) 2023-06-14 2025-03-16 美商安進公司 T cell engager masking molecules
WO2024256623A1 (en) 2023-06-16 2024-12-19 Heidelberg Immunotherapeutics Gmbh Novel anti-hsv antibody
WO2024263710A1 (en) 2023-06-20 2024-12-26 Allogene Therapeutics, Inc. Methods of detection for engineered cells
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
TW202504929A (en) 2023-06-22 2025-02-01 美商建南德克公司 Methods and compositions for cancer treatment
US20250011450A1 (en) 2023-06-22 2025-01-09 Genentech, Inc. Antibodies and uses thereof
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024261733A1 (en) 2023-06-23 2024-12-26 H. Lundbeck A/S Combinational treatment
TW202500197A (en) 2023-06-29 2025-01-01 瑞士商百濟神州瑞士有限責任公司 Bioactive conjugates, preparation method and use thereof
WO2025006846A2 (en) 2023-06-29 2025-01-02 Odyssey Therapeutics, Inc. Anti-trailr2 antigen-binding proteins and uses thereof
TW202500198A (en) 2023-06-29 2025-01-01 瑞士商百濟神州瑞士有限責任公司 Bioactive conjugates, preparation method and use thereof
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025002410A1 (en) 2023-06-30 2025-01-02 Evive Biotechnology (Shanghai) Ltd G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025024334A1 (en) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025021277A1 (en) 2023-07-21 2025-01-30 BioNTech SE Agents and methods for targeted delivery of cytokines to immune cells
US20250051432A1 (en) 2023-07-23 2025-02-13 Incyte Corporation Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody
WO2025021118A1 (en) * 2023-07-25 2025-01-30 海南先声再明医药股份有限公司 Ligand-drug conjugate and linker for conjugation
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025026553A1 (en) 2023-08-02 2025-02-06 BioNTech SE Agents and methods for targeted delivery to cells
WO2025034715A1 (en) 2023-08-07 2025-02-13 Janssen Biotech, Inc. Gucy2c antibodies and uses thereof
WO2025032510A1 (en) 2023-08-07 2025-02-13 Janssen Biotech, Inc. Stabilized cd3 antigen binding agents and methods of use thereof
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025036892A1 (en) 2023-08-14 2025-02-20 Morphosys Ag Cycat halfbody molecules comprising sterically occluding moieties
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025038732A1 (en) 2023-08-15 2025-02-20 Gigagen, Inc. Recombinant polyclonal proteins targeting hepatitis b virus (hbv) and methods of use thereof
WO2025038736A1 (en) 2023-08-15 2025-02-20 Gigagen, Inc. Methods of analyzing recombinant polyclonal proteins
WO2025040567A1 (en) 2023-08-18 2025-02-27 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof
WO2025048887A1 (en) 2023-09-01 2025-03-06 Inhibrx Biosciences, Inc. Ox40 agonist therapy
WO2025048860A1 (en) 2023-09-01 2025-03-06 Inhibrx Biosciences, Inc. Ox40 agonist therapy
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025045250A1 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof
WO2025054320A1 (en) 2023-09-05 2025-03-13 Tizona Therapeutics Anti-ackr4 antibodies, compositions and uses thereof
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025059508A1 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Compositions and methods of reducing immunogenicity and improving stability of antibodies
WO2025068207A1 (en) 2023-09-25 2025-04-03 F. Hoffmann-La Roche Ag ANTIBODY THAT BINDS TO C3bBb
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025072313A1 (en) 2023-09-27 2025-04-03 BioLegend, Inc. Anti-gpc4 antibodies
US12122842B1 (en) 2023-09-27 2024-10-22 R&D Systems, Inc. Human CD30-specific binding proteins and uses thereof
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025076081A1 (en) 2023-10-03 2025-04-10 Absci Corporation Tl1a associated antibody compositions and methods of use
WO2025076389A1 (en) 2023-10-06 2025-04-10 Seagen Inc. Methods of treating advanced solid tumors with b7-h4 antibody-drug conjugates
WO2025074328A1 (en) 2023-10-06 2025-04-10 Boehringer Ingelheim International Gmbh Use of anti-sirp-alpha antibodies to treat cancer
WO2025074337A1 (en) 2023-10-06 2025-04-10 Boehringer Ingelheim International Gmbh Use of anti-sirp-alpha antibodies to treat a liver disease or disorder
US20250114469A1 (en) 2023-10-09 2025-04-10 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE
US20250122306A1 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025080751A2 (en) 2023-10-13 2025-04-17 Odyssey Therapeutics, Inc. Anti-cdh17 antigen-binding proteins and uses thereof
WO2025078699A1 (en) 2023-10-13 2025-04-17 Nanocell Therapeutics Holdings B.V. Means and methods for delivery of agents to immune effector cells
WO2025085489A1 (en) 2023-10-17 2025-04-24 Bristol-Myers Squibb Company Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025082870A1 (en) 2023-10-19 2025-04-24 Bayer Aktiengesellschaft Anti-gpc3 antibodies and radioconjugates thereof
WO2025088496A1 (en) 2023-10-24 2025-05-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
WO2025087681A1 (en) 2023-10-26 2025-05-01 Morphosys Ag Bispecific antibodies against cd3 and cd20
WO2025096626A1 (en) 2023-10-31 2025-05-08 Seagen Inc. Methods of treating cancers using anti-cd30 antibody-drug conjugates
EP4552657A1 (en) 2023-11-07 2025-05-14 Bayer Aktiengesellschaft Radiopharmaceutical complexes and combinations
WO2025101982A1 (en) 2023-11-10 2025-05-15 Pfizer Inc. Anti-migis-alpha antibodies and methods of use thereof
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
CN117224689B (en) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 The use of combined anti-HER2 antibodies and chemotherapeutic agents in the treatment of gastric cancer
WO2025106634A1 (en) 2023-11-17 2025-05-22 Genentech, Inc. Mcl-1 inhibitor compounds and use in antibody drug conjugates
US20250163168A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Novel antibodies and antibody conjugates for the treatment of metabolic disorders
WO2025117639A1 (en) 2023-11-27 2025-06-05 Profoundbio Us Co. Antibodies and methods for ptk7 detection
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy
WO2025114555A1 (en) 2023-11-30 2025-06-05 Oncospear Aps Anti-cd163 antibodies with improved adcc capabilities
EP4563596A1 (en) 2023-11-30 2025-06-04 OncoSpear ApS Anti-cd163 antibodies with improved adcc capabilities
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025120513A1 (en) 2023-12-05 2025-06-12 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
WO2025122745A1 (en) 2023-12-05 2025-06-12 Genentech, Inc. Combination therapies for treatment of her2 cancer
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025122695A1 (en) 2023-12-06 2025-06-12 Incyte Corporation Combination therapy comprising dgk inhibitors and pd-1/pd-l1 inhibitors
WO2025122885A1 (en) 2023-12-08 2025-06-12 Absci Corporation Anti-her2 associated antibody compositions designed by artificial intelligence and methods of use
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120583A2 (en) 2023-12-08 2025-06-12 Janssen Biotech, Inc. CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
WO2025125118A1 (en) 2023-12-11 2025-06-19 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
WO2025128839A1 (en) 2023-12-13 2025-06-19 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease with anti igf-1r antagonistic antibodies
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025129010A1 (en) 2023-12-14 2025-06-19 Genentech, Inc. Methods of structure determination using antibodies
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
WO2025137086A1 (en) 2023-12-20 2025-06-26 Genentech, Inc. Reducing alpha-gal
WO2025132522A1 (en) 2023-12-20 2025-06-26 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4845198A (en) 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
DE3689123T2 (en) 1985-11-01 1994-03-03 Xoma Corp MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
AU625613B2 (en) 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
JP2646007B2 (en) 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 Gene fragment encoding anti-HIV antibody variable region, anti-HIV chimeric antibody expressed using the same, and method for producing the same
DE68909441T2 (en) 1988-02-12 1994-02-10 British Tech Group Modified antibodies.
FI895955A7 (en) 1988-04-15 1989-12-13 Protein Design Labs Inc IL-2 receptor-specific "chimeric" antibodies
ATE119198T1 (en) 1988-04-16 1995-03-15 Celltech Ltd METHOD FOR PRODUCING PROTEINS USING RECOMBINANT DNA.
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
IE64966B1 (en) 1988-10-19 1995-09-20 Dow Chemical Co A novel family of high affinity modified antibodies for cancer treatment
ATE102631T1 (en) 1988-11-11 1994-03-15 Medical Res Council CLONING OF IMMUNOGLOBULIN SEQUENCES FROM THE VARIABLE DOMAINS.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JP3048632B2 (en) 1989-06-02 2000-06-05 ザ ジョーンズ ホプキンズ ユニヴァーシティ スクール オブ メディスン Monoclonal antibody against β-chain of leukocyte adhesion receptor, method for producing the antibody, and its application
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
DK0429242T3 (en) 1989-11-17 1995-10-16 Unilever Plc Specific binding agents
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
NZ236792A (en) 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
EP0438312A3 (en) 1990-01-19 1992-07-01 Merck & Co. Inc. Recombinant human anti-cd18 antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9019553D0 (en) 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
HU219537B (en) 1991-03-06 2001-05-28 Merck Patent Gmbh. Humanized and chimaeric monoclonal antibodies comprising of them pharmaceutical composition and the antibodies coding sequence containing of expression vectors, and process for the praparation of antibodies
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
EP0519596B1 (en) * 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2149529C (en) 1992-11-16 2006-05-02 Fernado J. R. Do Couto Peptides and anti-sense peptides with broad neoplastic specificity
WO1994012214A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
KR20010071271A (en) 1998-05-15 2001-07-28 존 비. 랜디스 Treatment of Human Tumors with Radiation and Inhibitors of Growth Factor Receptor Tyrosine Kinases

Also Published As

Publication number Publication date
WO1992022653A1 (en) 1992-12-23
ES2206447T3 (en) 2004-05-16
EP0590058A1 (en) 1994-04-06
CY2006001I2 (en) 2011-02-02
US5821337A (en) 1998-10-13
DE69233254T2 (en) 2004-09-16
JP2005000169A (en) 2005-01-06
US6639055B1 (en) 2003-10-28
CY2006001I1 (en) 2010-07-28
DE69233254D1 (en) 2004-01-08
US6719971B1 (en) 2004-04-13
CY2500B1 (en) 2005-09-02
EP0590058B1 (en) 2003-11-26
AU2250992A (en) 1993-01-12
CA2103059A1 (en) 1992-12-15
ATE255131T1 (en) 2003-12-15
JP4836147B2 (en) 2011-12-14
AU675916B2 (en) 1997-02-27
JP4124480B2 (en) 2008-07-23
EP0940468A1 (en) 1999-09-08
EP1400536A1 (en) 2004-03-24
DE122004000008I1 (en) 2005-06-09
NL300145I1 (en) 2004-06-01
GEP20074141B (en) 2007-07-10
JP2008291036A (en) 2008-12-04
JP2006083180A (en) 2006-03-30
DK0590058T3 (en) 2004-03-29
US6407213B1 (en) 2002-06-18
LU91067I2 (en) 2004-04-02
JPH06508267A (en) 1994-09-22

Similar Documents

Publication Publication Date Title
CA2103059C (en) Method for making humanized antibodies
US6800738B1 (en) Method for making humanized antibodies
US6054297A (en) Humanized antibodies and methods for making them
US5869619A (en) Modified antibody variable domains
JP4157160B2 (en) Methods for the preparation of modified antibody variable regions
Weiner Fully human therapeutic monoclonal antibodies
CN106029697B (en) Canine antibodies with modified CH2-CH3 sequences
US6506883B2 (en) Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
Jolliffe Humanized antibodies: enhancing therapeutic utility through antibody engineering
US20250154281A1 (en) Anti-steap1 antigen-binding protein
CA3019740A1 (en) Administration of a bispecific construct binding to cd33 and cd3 for use in a method for the treatment of myeloid leukemia
JP2016523264A (en) Antibodies against Toso
US20240209085A1 (en) Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
Hozumi et al. Recombinant antibody technology: its advent and advances
WO2001023431A1 (en) Derivatives of antibody against ganglioside gm2
Zettlitz et al. Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70)
HK1062916A (en) Method for making humanized antibodies
US20030229207A1 (en) Modified antibody variable domains
JP4808841B2 (en) LO-CD2a antibodies that inhibit T cell activation and proliferation and methods of use thereof
EP2402371A1 (en) Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
HK1050696B (en) Immunoglobulin variants for specific fc epsilon receptors
HK1050696A1 (en) Immunoglobulin variants for specific fc epsilon receptors

Legal Events

Date Code Title Description
EEER Examination request
FZDC Discontinued application reinstated
MKEX Expiry